0001558370-24-006203.txt : 20240430 0001558370-24-006203.hdr.sgml : 20240430 20240430080035 ACCESSION NUMBER: 0001558370-24-006203 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 92 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240430 DATE AS OF CHANGE: 20240430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 24894089 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 10-Q 1 hrmy-20240331x10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2024

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-39450

HARMONY BIOSCIENCES HOLDINGS, INC.

(Exact name of registrant as specified in its charter)


Delaware	82-2279923
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)


630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA	19462
(Address of principal executive offices)	(Zip Code)

(484) 539-9800

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange
on which registered

Common Stock, par value $0.00001 value per share

HRMY

The Nasdaq Stock Market LLC
(Nasdaq Global Market)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:



Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of April 26, 2024, there were 56,791,861 shares of the registrant’s common stock, par value $0.00001 value per share, outstanding.

Table of Contents

TABLE OF CONTENTS


	Page
Part I. Financial Information	3
Item 1. Financial Statements	3
Condensed Consolidated Balance Sheets (Unaudited)	3
Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)	4
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)	5
Condensed Consolidated Statements of Cash Flows (Unaudited)	6
Notes to Condensed Consolidated Financial Statements (Unaudited)	7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	22
Item 3. Quantitative and Qualitative Disclosures About Market Risk	35
Item 4. Controls and Procedures	36
Part II. Other Information	36
Item 1. Legal Proceedings	36
Item 1A. Risk Factors	38
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	38
Item 3. Defaults upon Senior Securities	38
Item 4. Mine Safety Disclosures	38
Item 5. Other Information	38
Item 6. Exhibits	39
Signatures	40

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)


	March 31,		December 31,
	2024		2023
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	332,981	$	311,660
Investments, short-term		39,369		41,800
Trade receivables, net		79,719		74,140
Inventory, net		5,857		5,363
Prepaid expenses		12,894		12,570
Other current assets		8,683		5,537
Total current assets		479,503		451,070
NONCURRENT ASSETS:
Property and equipment, net		213		371
Restricted cash		270		270
Investments, long-term		81,244		72,169
Intangible assets, net		131,147		137,108
Deferred tax asset		147,639		144,162
Other noncurrent assets		6,969		6,298
Total noncurrent assets		367,482		360,378
TOTAL ASSETS	$	846,985	$	811,448
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Trade payables	$	15,144	$	17,730
Accrued compensation		7,317		23,747
Accrued expenses		91,699		99,494
Current portion of long-term debt		15,000		15,000
Other current liabilities		25,093		7,810
Total current liabilities		154,253		163,781
NONCURRENT LIABILITIES:
Long-term debt, net		174,996		178,566
Other noncurrent liabilities		2,342		2,109
Total noncurrent liabilities		177,338		180,675
TOTAL LIABILITIES		331,591		344,456
COMMITMENTS AND CONTINGENCIES (Note 13)
STOCKHOLDERS’ EQUITY:
Common stock—$0.00001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 56,791,214 and 56,769,081 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively		1		1
Additional paid in capital		620,507		610,266
Accumulated other comprehensive (loss) income		(171)		2
Accumulated deficit		(104,943)		(143,277)
TOTAL STOCKHOLDERS’ EQUITY		515,394		466,992
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	846,985	$	811,448

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements

Table of Contents

HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED

STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(In thousands, except share and per share data)


	Three Months Ended March 31,
	2024		2023
Net product revenue	$	154,615	$	119,126
Cost of product sold		27,484		20,780
Gross profit		127,131		98,346
Operating expenses:
Research and development		22,189		13,289
Sales and marketing		27,233		22,572
General and administrative		25,676		22,062
Total operating expenses		75,098		57,923
Operating income		52,033		40,423
Other (expense) income, net		(141)		2
Interest expense		(4,535)		(5,731)
Interest income		4,428		3,086
Income before income taxes		51,785		37,780
Income tax expense		(13,451)		(8,295)
Net income	$	38,334	$	29,485
Unrealized (loss) income on investments		(173)		120
Comprehensive income	$	38,161	$	29,605
EARNINGS PER SHARE:
Basic	$	0.68	$	0.49
Diluted	$	0.67	$	0.48
Weighted average number of shares of common stock - basic		56,771,251		59,732,157
Weighted average number of shares of common stock - diluted		57,597,627		61,221,511

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements

Table of Contents

HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except share and per share data)


						Accumulated
				Additional		other				Total
	Common Stock			paid-in		comprehensive		Accumulated		stockholders’
	Shares	Amount		capital		(loss) income		deficit		equity
Balance as of December 31, 2023	56,769,081	$	1	$	610,266	$	2	$	(143,277)	$	466,992
Net income	—		—		—		—		38,334		38,334
Unrealized loss on investments	—		—		—		(173)		—		(173)
Exercise of options and restricted stock units	22,133		—		(153)		—		—		(153)
Stock-based compensation	—		—		10,394		—		—		10,394
Balance as of March 31, 2024	56,791,214	$	1	$	620,507	$	(171)	$	(104,943)	$	515,394


						Accumulated
				Additional		other				Total
	Common Stock			paid-in		comprehensive		Accumulated		stockholders’
	Shares	Amount		capital		(loss) income		deficit		equity
Balance as of December 31, 2022	59,615,731	$	1	$	675,118	$	(151)	$	(272,130)	$	402,838
Net income	—		—		—		—		29,485		29,485
Unrealized loss on investments	—		—		—		120		—		120
Exercise of stock options	338,887		—		3,395		—		—		3,395
Stock-based compensation	—		—		7,203		—		—		7,203
Balance as of March 31, 2023	59,954,618	$	1	$	685,716	$	(31)	$	(242,645)	$	443,041

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements

Table of Contents

HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands, except share and per share data)


	Three Months Ended March 31,
	2024		2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$	38,334	$	29,485
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation		163		103
Intangible amortization		5,961		5,961
Stock-based and employee stock purchase compensation expense		10,394		7,203
Stock appreciation rights market adjustment		40		(642)
Debt issuance costs amortization		180		416
Deferred taxes		(3,477)		(3,442)
Amortization of premiums and accretion of discounts on Investment securities		(594)		(636)
Other non-cash expenses		467		369
Change in operating assets and liabilities:
Trade receivables		(5,579)		2,165
Inventory		(494)		207
Prepaid expenses and other assets		(3,439)		592
Trade payables		(2,586)		2,628
Other liabilities		(8,229)		(1,850)
Net cash provided by operating activities		31,141		42,559
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of investment securities		(25,106)		(47,776)
Proceeds from maturities and sales of investment securities		18,925		45,986
Purchase of property and equipment		(5)		—
Net cash used in investing activities		(6,186)		(1,790)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal repayment of long term debt		(3,750)		(500)
Proceeds from exercised options		116		3,909
Net cash (used in) provided by financing activities		(3,634)		3,409
NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH		21,321		44,178
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH—Beginning of period		311,930		244,534
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH—End of period	$	333,251	$	288,712
Supplemental Disclosure of Cash Flow Information:
Cash paid during the year for interest	$	4,585	$	5,017

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements

Table of Contents

HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

The Company

Harmony Biosciences Holdings, Inc., and its consolidated subsidiaries (the “Company”) was founded in July 2017 as Harmony Biosciences II, LLC, a Delaware limited liability company. The Company converted to a Delaware corporation named Harmony Biosciences II, Inc. in September 2017 and, in February 2020, the Company changed its name to Harmony Biosciences Holdings, Inc. The Company’s operations are conducted in its wholly owned subsidiary, Harmony Biosciences, LLC (“Harmony”), and Zynerba Pharmaceuticals, Inc. The Company is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders as well as patients living with other neurological diseases who have unmet medical needs. The Company is headquartered in Plymouth Meeting, Pennsylvania.

On October 10, 2023, the Company completed a tender offer to acquire all of the outstanding shares of common stock of Zynerba Pharmaceuticals, Inc. (together with its subsidiary, Zynerba Pharmaceutical Pty, Ltd., “Zynerba”). Zynerba is a clinical-stage pharmaceutical company focused on innovative pharmaceutically produced transdermal cannabidiol therapies for orphan neuropsychiatric disorders, including Fragile X Syndrome.

2. LIQUIDITY AND CAPITAL RESOURCES

The unaudited condensed consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of $104,943 and $143,277, as of March 31, 2024, and December 31, 2023, respectively. As of March 31, 2024, the Company had cash, cash equivalents and investments of $453,594.

The Company believes that its existing cash, cash equivalents and investments on hand as of March 31, 2024, as well as additional cash generated from operating and financing activities will meet its operational liquidity needs and fund its planned investing activities for the next twelve months from the date of issuance of these unaudited condensed consolidated financial statements.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated balance sheet as of March 31, 2024, the unaudited condensed consolidated statements of cash flows for the three months ended March 31, 2024, and 2023, and the unaudited condensed consolidated statements of operations and comprehensive income and the unaudited condensed consolidated statements of shareholders’ equity for the three months ended March 31, 2024, and 2023, are unaudited. The balance sheet as of December 31, 2023, was derived from audited financial statements as of and for the year ended December 31, 2023. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements as of and for the year ended December 31, 2023, and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of March 31, 2024, and the results of

Table of Contents

its operations and its cash flows for the three months ended March 31, 2024, and 2023. The unaudited condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC’s rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

Reclassifications

Certain prior period amounts within the unaudited condensed consolidated statements of operations and comprehensive income have been reclassified to conform to current period presentation. In particular, interest expense and interest income were previously classified together as interest expense, net and are now separately classified as interest expense and interest income, respectively. The reclassification of these items had no impact on net income, earnings per share or accumulated deficit in current or prior periods.

Significant Risks and Uncertainties

The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to, clinical trial results of the Company’s product candidates; the Company’s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company’s products, if approved; the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its product candidates.

The Company currently has one commercially approved product, WAKIX, and there can be no assurance that the Company’s research and development efforts will result in successfully commercialized products in addition to WAKIX. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the unaudited condensed consolidated financial statements, including the notes thereto, and elsewhere in this report. Actual results may differ significantly from estimates, which include rebates due pursuant to commercial and government contracts, accrued research and development expenses, stock-based compensation expense and income taxes.

Operating Segments

The Company holds all its tangible assets, conducts its operations, and generates its revenue in the United States. Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Makers in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined it operates in a single operating segment and has one reportable segment.

Fair Value of Financial Instruments

The Company’s unaudited condensed consolidated financial statements include cash, cash equivalents, restricted cash, accounts payable, and accrued liabilities, all of which are short term in nature and, accordingly, approximate fair value.

Table of Contents

It is the Company’s policy to measure non-financial assets and liabilities at fair value on a nonrecurring basis. These non-financial assets and liabilities are not measured at fair value on an ongoing basis but are subject to fair value adjustments in certain circumstances (such as evidence of impairment), which, if material, are disclosed in the accompanying footnotes.

The Company measures certain assets and liabilities at fair value based on the fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value into three levels based on the source of inputs as follows:

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.

Money market funds are classified as Level 1 fair value instruments. Investments in available-for-sale debt securities are classified as Level 2 and carried at fair value, which we estimate utilizing a third-party pricing service. The pricing service utilizes industry standard valuation models whereby all significant inputs, including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, bids, offers, or other market-related data, are observable. We validate valuations obtained from third-party services by obtaining market values from other pricing sources. The Company did not classify any assets or liabilities as Level 3 as of March 31, 2024, or December 31, 2023.

Cash, Cash Equivalents and Restricted Cash

Cash and cash equivalents and restricted cash consist of cash and, if applicable, highly liquid investments with an original maturity of three months or less when purchased, including investments in Money Market Funds and debt securities that approximate fair value. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet and the statements of cash flows.


	As of
	March 31,		December 31,
	2024		2023
Cash and cash equivalents	$	332,981	$	311,660
Restricted cash		270		270
Total cash, cash equivalents, and restricted cash shown in the statements of cash flows	$	333,251	$	311,930

Restricted cash includes amounts required to be held as a security deposit in the form of letters of credit for the Company’s credit card program and the fleet program.

Investments

The Company’s investments consist of debt securities that are classified as available-for-sale. Short-term and long-term investments are carried at fair value and unrealized gains and losses are recorded as a component of accumulated comprehensive income in stockholders’ equity. Interest income earned on cash and investment balances, accretion of the discount on investments in debt securities, amortization of premiums and realized gains and losses, if any, are recorded in interest income on the unaudited condensed consolidated statement of operations and comprehensive income. Realized gains and losses that result from the sale of investments are determined on a specific identification basis.

Table of Contents

At each reporting period, the Company reviews any unrealized losses position to determine if the decline in the fair value of the underlying investments is a result of credit losses or other factors. If the assessment indicates that a credit loss exists, any impairment is recognized as an allowance for credit losses in our consolidated statement of operations.

Concentrations of Risk

Substantially all of the Company’s cash and money market funds are held in five financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. Deposits may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company believes that it is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.

The Company is subject to credit risk from its trade receivables related to its product sales. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored, and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. The Company monitors its exposure within accounts receivable and would record a reserve against uncollectible accounts receivable if necessary. As of March 31, 2024, three customers accounted for 100% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 41% of gross accounts receivable; Accredo Health Group, Inc. (“Accredo”), which accounted for 36% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 23% of gross accounts receivable. As of December 31, 2023, three customers accounted for 100% of gross accounts receivable; Accredo, which accounted for 39% of gross accounts receivable, CVS Caremark, which accounted for 32% of gross accounts receivable; and Pantherx, which accounted for 29% of gross accounts receivable.

For the three months ended March 31, 2024, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 42% of gross product revenue; Accredo accounted for 33% of gross product revenue; and Pantherx accounted for 25% of gross product revenue. For the three months ended March 31, 2023, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 35% of gross product revenue; Pantherx accounted for 33% of gross product revenue; and Accredo accounted for 32% of gross product revenue.

The Company depends on a single supplier for its product and a single supplier for its active pharmaceutical ingredient.

Share Repurchases

The Company accounts for share repurchases as constructive retirements, whereby it reduces common stock and additional paid-in capital by the amount of the original issuance, with any excess purchase price recorded as a reduction to retained earnings. Under this method, issued and outstanding shares of common stock are reduced by the amount of shares of common stock repurchased, and no treasury stock is recognized on the condensed consolidated financial statements.

Business Combinations

Business combinations and asset acquisitions are accounted for in accordance with FASB ASC 805 Business Combinations. Refer to Note 4, Acquisition, for a more detailed discussion of the Zynerba Acquisition.

Recently Issued Accounting Pronouncements

In November 2023, the FASB issued Accounting Standards Update (“ASU”) No. 2023-07, Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 is intended to improve

Table of Contents

reportable segment disclosures primarily through enhanced disclosure of reportable segment expenses and requires that a public entity that has a single reportable segment provide all the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280. This ASU is effective for annual reporting periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. ASU 2023-07 is required to be applied retrospectively to all prior periods presented in the financial statements. The Company has one reportable segment and is currently evaluating the impact that ASU 2023-07 will have on its condensed consolidated financial statements.

In December 2023, the FASB issued Accounting Standards Update (“ASU”) No 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” (“ASU 2023-09”). ASU 2023-09 expands disclosures in the rate reconciliation and requires disclosure of income taxes paid by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that ASU 2023-09 will have on its condensed consolidated financial statements.

4. ACQUISITION

In October 2023, the Company completed a tender offer to purchase the outstanding common stock of Zynerba (“Zynerba Common Stock”) for (i) $1.1059 per share of Zynerba Common Stock (the “Common Cash Amount”), the aggregate amount of which was $60,000 and was paid at closing, plus (ii) one contingent value right (each, a “CVR”) per share of Zynerba Common Stock (the “Common CVR Amount”), which represents the right to receive up to approximately $2.5444 per share of Zynerba Common Stock, subject to the achievement of certain clinical, regulatory and sales-based milestones. The Common CVR Amounts are to be paid in cash, subject to any applicable withholding of taxes and without interest. The aggregate amount of consideration to acquire Zynerba Common Stock was $60,000, excluding transaction related fees of $2,645 and was paid by the Company using cash on hand.

The Zynerba Acquisition was accounted for as an asset acquisition under ASC Topic 805, Business Combinations, because substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable IPR&D asset, ZYN002, Zynerba’s lead asset. ZYN002 is the first and only pharmaceutically manufactured, synthetic cannabidiol, a non-euphoric cannabidiol, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system and is currently in Phase III clinical trial for the potential treatment of Fragile X Syndrome. The Company recognized the acquired assets and assumed liabilities based on the consideration paid, including transaction costs, on a relative fair value basis, and after first allocating the preliminary excess of the fair value of net assets acquired over the purchase price consideration to certain qualifying assets, principally, the IPR&D asset.

5. INVESTMENTS

The carrying value and amortized cost of the Company’s available-for-sale debt securities, summarized by type of security, consisted of the following:


	March 31, 2024
		Amortized	Unrealized	Unrealized		Fair
		Cost	Gains	Losses		Value
Short-term:
Commercial paper	$	23,038	10	(7)	$	23,041
Corporate debt securities		16,316	16	(4)		16,328
Total short-term investments	$	39,354	26	(11)	$	39,369

Long-term:
Corporate debt securities		51,062	61	(50)		51,073
U.S. government securities		30,368	—	(197)		30,171
Total long-term investments	$	81,430	61	(247)	$	81,244

Table of Contents


	December 31, 2023
		Amortized	Unrealized	Unrealized		Fair
		Cost	Gains	Losses		Value
Short-term:
Commercial paper	$	23,832	36	(3)	$	23,865
Corporate debt securities		15,968	28	—		15,996
U.S. government securities		1,940	—	(1)		1,939
Total short-term investments	$	41,740	64	(4)	$	41,800

Long-term:
Commercial paper	$	744	—	—	$	744
Corporate debt securities		42,688	81	(28)		42,741
U.S. government securities		28,795	7	(118)		28,684
Total long-term investments	$	72,227	88	(146)	$	72,169

The Company classifies investments with an original maturity of less than one year as current and investments with an original maturity date of greater than one year as noncurrent on its unaudited condensed consolidated balance sheet. The investments classified as noncurrent have original maturity dates ranging from 1-2 years. The Company did not have any available-for-sale debt security investments in a continuous unrealized loss position of greater than 12 months as of March 31, 2024, and December 31, 2023, respectively.

6. FAIR VALUE MEASUREMENTS

The Company’s assets measured at fair value consisted of the following:


	March 31, 2024				December 31, 2023
		Total	Level 1	Level 2		Total	Level 1	Level 2
Assets
Cash equivalents	$	264,079	264,079	—	$	244,569	243,685	884
Commercial paper		23,041	—	23,041		24,609	—	24,609
Corporate debt securities		67,401	—	67,401		58,737	—	58,737
U.S. government securities		30,171	—	30,171		30,623	—	30,623
Total	$	384,692	264,079	120,613	$	358,538	243,685	114,853

Table of Contents

7. INVENTORY

Inventory, net consisted of the following:


	As of
	March 31,		December 31,
	2024		2023
Raw materials	$	1,009	$	1,060
Work in process		1,748		2,020
Finished goods		3,100		2,283
Total inventory, net	$	5,857	$	5,363

8. INTANGIBLE ASSETS

In August 2019, the Company received FDA approval of WAKIX® (pitolisant) for the treatment of excessive daytime sleepiness (“EDS”) in adult patients with narcolepsy. This event triggered a milestone payment of $75,000 under the provisions of the 2017 LCA (defined below) which the Company capitalized as an intangible asset. The Company determined a useful life of 10 years for such intangible asset, and, as of March 31, 2024, the remaining useful life was 5.5 years.

In October 2020, the Company received FDA approval for the New Drug Application (“NDA”) for WAKIX for the treatment of cataplexy in adult patients with narcolepsy. This event triggered a milestone payment of $100,000 under the provisions of the 2017 LCA which the Company capitalized as an intangible asset and paid in January of 2021. The Company determined a useful life of 9 years for such intangible asset, and, as of March 31, 2024, the remaining useful life was 5.5 years.

In February 2022, the Company attained $500,000 in life-to-date aggregate net sales of WAKIX in the United States. This event triggered a final $40,000 payment under the provisions of the 2017 LCA which the Company capitalized as an intangible asset and paid in March of 2022. The Company determined a useful life of 7.6 years for such intangible asset, and, as of March 31, 2024, the remaining useful life was 5.5 years.

Amortization expense was $5,961 for each of the three months ended March 31, 2024, and 2023 and is recorded in general and administrative expenses on the unaudited condensed consolidated statements of operations and comprehensive income.

The Company expects the future annual amortization expense for the unamortized intangible assets to be as follows:


Years ending December 31,
2024 (excluding the three months ended March 31, 2024)	$	17,884
2025		23,845
2026		23,845
2027		23,845
2028		23,845
Thereafter		17,883
Total	$	131,147

Table of Contents

The gross carrying amount and net book value of the intangible asset is as follows:


	As of
	March 31,		December 31,
	2024		2023
Gross Carrying Amount	$	215,000	$	215,000
Accumulated Amortization		(83,853)		(77,892)
Net Book Value	$	131,147	$	137,108

9. LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS

License Agreements

In July 2017, Harmony entered into a License Agreement (the “2017 LCA”) with Bioprojet Société Civile de Recherche (“Bioprojet”) whereby Harmony acquired the exclusive right to commercialize the pharmaceutical compound pitolisant for the treatment, and/or prevention, of narcolepsy, obstructive sleep apnea, idiopathic hypersomnia, and Parkinson’s disease as well as any other indications unanimously agreed by the parties in the United States and its territories. A milestone payment of $50,000 was due upon acceptance by the FDA of pitolisant’s NDA, which was achieved in February 2019 and was expensed within research and development for the year ended December 31, 2019. A milestone payment of $77,000, which included a $2,000 fee that is described below, was due upon FDA approval of WAKIX (pitolisant) for treatment of EDS in adult patients with narcolepsy, which was achieved in August 2019. The $2,000 payment and $75,000 milestone payment were paid in August and November 2019, respectively. In addition, a milestone payment of $102,000, which included a $2,000 fee was due upon the FDA approval of the NDA for WAKIX for the treatment of cataplexy in adult patients with narcolepsy. The $2,000 payment was paid in October 2020 and a $100,000 milestone payment was paid in January 2021. A final $40,000 milestone payment was paid to Bioprojet in March 2022 upon WAKIX attaining $500,000 in aggregate net sales in the United States. The 2017 LCA also requires a fixed trademark royalty and a tiered royalty based on net sales, which is payable to Bioprojet on a quarterly basis. The Company incurred $24,738 and $19,060 for the three months ended March 31, 2024, and 2023, respectively, for sales-based, trademark and tiered royalties recognized as cost of product sold. As of March 31, 2024, and December 31, 2023, the Company had accrued $24,738 and $40,419, respectively, for sales-based, trademark and tiered royalties.

In July 2022, Harmony entered into a License and Commercialization Agreement (the “2022 LCA”) with Bioprojet whereby Harmony obtained exclusive rights to manufacture, use and commercialize one or more new products based on pitolisant in the United States and Latin America, with the potential to add additional indications and formulations upon agreement of both parties. Harmony paid an initial, non-refundable $30,000 licensing fee in October 2022 and additional payments of up to $155,000 are potentially due under the 2022 LCA upon the achievement of certain future development and sales-based milestones. In addition, there are other payments due upon achievement of development milestones for new indications and formulations as agreed upon by both parties. The 2022 LCA also requires a fixed trademark royalty and a tiered royalty based on net sales upon commercialization, which will be payable to Bioprojet on a quarterly basis.

Agreement Related to Intellectual Property

In August 2021, the Company entered into an asset purchase agreement with ConSynance Therapeutics, Inc. (the “APA”) to acquire HBS-102 (formerly referred to as “CSTI-100”), a potential first-in-class molecule with a novel mechanism of action. Under the terms of the APA, the Company acquired full development and commercialization rights globally, with the exception of Greater China, for $3,500. The Company accounted for the transaction as an asset acquisition as substantially all of the fair value of the assets acquired was concentrated in a single identified asset. In March 2023, the Company achieved a preclinical milestone, which triggered a $750 payment under the provisions of the APA, which the Company recognized as an IPR&D charge recorded in research and development within the unaudited condensed consolidated statement of operations and comprehensive income for the three months ended March 31, 2023. There are

Table of Contents

additional payments due under the APA upon the achievement of certain milestones including $1,000 for preclinical milestones, $19,000 for development milestones, $44,000 for regulatory milestones and $110,000 for sales milestones.

10. ACCRUED EXPENSES

Accrued expenses consist of the following:


	As of
	March 31,		December 31,
	2024		2023
Royalties due to Bioprojet	$	24,738	$	40,419
Rebates and other sales deductions		48,165		38,842
Interest		3,125		3,354
Sales and marketing		2,999		2,354
Research and development		7,898		9,835
Professional fees, consulting, and other services		1,918		2,195
Other expenses		2,856		2,495
	$	91,699	$	99,494

11. DEBT

Term Loan A Credit Agreement

In July 2023, the Company entered into a Credit Agreement (the “TLA Credit Agreement”) with JPMorgan Chase Bank, N.A., as “Administrative Agent”, and certain lenders. The TLA Credit Agreement provides for a five-year senior secured term loan (the “TLA Term Loan”) in an aggregate principal amount of $185,000.

In September 2023, the Company entered into the First Incremental Amendment (the “First Incremental Amendment”) with the Administrative Agent and Bank of America, N.A., as incremental lender. The First Incremental Amendment provides for an incremental senior secured term loan (the “Incremental Term Loan”) in an aggregate principal amount of $15,000. The First Incremental Amendment amends the TLA Credit Agreement and provides that the Incremental Term Loan will have identical terms as the TLA Term Loan.

The repayment schedule for both the TLA Term Loan and the Incremental Term Loan (together, the “Term Loans”) consists of quarterly $3,750 principal payments, which commence on December 31, 2023, increasing to quarterly $5,000 principal payments beginning on December 31, 2025, with a $115,000 payment due on the maturity date of July 26, 2028. The Term Loans bear interest at a per annum rate equal to, at the Company’s option, (i) a base rate plus a specified margin ranging from 2.50% to 3.00%, based on the Company’s senior secured net leverage ratio (as defined in the TLA Credit Agreement) or (ii) Term SOFR plus a credit spread adjustment of 0.10% plus a specified margin ranging from 3.50% to 4.00%, based on the Company’s senior secured net leverage ratio.

The net cash received related to the Term Loans as a result of the transactions, less debt issuance costs of $2,997, was $197,003. The debt issuance costs related to the Term Loans will be amortized as additional interest expense over the loan term of the TLA Credit Agreement. The fair value of the Term Loans as of March 31, 2024, was $192,267.

Table of Contents

Long-term debt, net consists of the following:


	March 31,		December 31,
	2024		2023
Principal amount	$	192,500	$	196,250
Unamortized debt discount associated with debt financing costs		(2,504)		(2,684)
Total debt, net		189,996		193,566
Less current portion		(15,000)		(15,000)
Long-term debt, net	$	174,996	$	178,566

Future minimum payments relating to total debt, net as of March 31, 2024, for the periods indicated below consists of the following:


Years ending December 31,
2024 (excluding the three months ended March 31, 2024)	$	11,250
2025		16,250
2026		20,000
2027		20,000
2028		125,000
Thereafter		—
Total	$	192,500

Interest expense related to the Company’s long-term debt, net, is included in interest expense within the unaudited condensed consolidated statements of operations and comprehensive income and consists of the following:


	Three Months Ended
	March 31,
	2024		2023
Interest on principal balance	$	4,355	$	5,315
Amortization of deferred financing costs		180		416
Total term loan interest expense	$	4,535	$	5,731

12. LEASES

In June 2018, the Company entered into an operating lease for approximately fifteen thousand square feet of office space in Plymouth Meeting, PA, which expires in May 2024. The Company subsequently entered into two separate operating leases for additional office space in Plymouth Meeting, PA, which include approximately thirteen thousand square feet and seven thousand square feet of additional office space, respectively, and expire in May 2024. In March 2024, the Company amended its existing operating leases for office space in Plymouth Meeting to extend their terms through June 2025. The terms of the lease payments provide for rental payments on a monthly basis and on a graduated scale. The Company also leases a fleet of automobiles that are used by its sales representatives and are classified as operating leases.

Operating lease right-of-use assets and operating lease liabilities are recognized based on the present value of the future lease payments using our incremental borrowing rate. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Our leases have remaining lease terms of less than 1 year to 3 years, some of which may include the option to extend or terminate the leases.

The Company recorded operating lease costs of $509 and $378 for the three months ended March 31, 2024, and 2023, respectively.

Table of Contents

As of March 31, 2024, the weighted-average remaining lease term for operating leases was 1.8 years and the weighted-average discount rate for operating leases was 7.32%.

Supplemental balance sheet information related to operating leases was as follows:


Leases	Classification		March 31, 2024		December 31, 2023
Assets
Operating lease right-of-use assets	Other noncurrent assets	$	3,046	$	2,344
Liabilities
Operating lease liability, current portion	Other current liabilities	$	1,793	$	1,437
Operating lease liability, long-term	Other long-term liabilities		1,276		1,082
Total operating lease liabilities		$	3,069	$	2,519

Supplemental cash flow information related to operating leases was as follows:


		March 31, 2024		March 31, 2023
Operating cash flows from operating leases	$	561	$	428
Right of use assets obtained in exchange for operating lease obligations	$	1,198	$	526

Future payments under noncancelable operating leases with initial terms of one year or more as of March 31, 2024, consisted of the following:


Years ending December 31,
2024 (excluding the three months ended March 31, 2024)	$	1,564
2025		1,239
2026		473
2027		3
2028		-
Thereafter		-
Total lease payments		3,279
Less: imputed interest		(210)
Total lease liabilities	$	3,069

13. COMMITMENTS AND CONTINGENCIES

Litigation

From time to time, the Company is subject to claims and suits arising in the ordinary course of business. The Company accrues such liabilities when they are known, if they are deemed probable and can be reasonably estimated. As of March 31, 2024, there were no material claims or suits outstanding.

14. STOCKHOLDERS’ EQUITY

Common Stock

The holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of the Company’s stockholders. The holders of common stock do not have any cumulative voting rights. Holders of common stock are entitled to receive any dividends declared by the Company’s board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. The Company’s common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions.

Table of Contents

Share Repurchase Program

In October 2023, the Company’s Board of Directors approved a share repurchase program (the “October 2023 Repurchase Program”) providing for the repurchase of shares of common stock in an aggregate amount of up to $200,000, excluding commissions and transaction fees. The October 2023 Repurchase Program may be suspended, terminated, or modified at any time for any reason. During the three months ended March 31, 2024, and 2023, no shares of common stock were repurchased and cancelled by the Company. As of March 31, 2024 the remaining amount of common stock authorized for repurchases was $150,000.

15. STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION

2020 Stock Incentive Plan

In August 2020, the Company adopted, and its stockholders approved, the 2020 Incentive Award Plan (the “2020 Plan”), in order to facilitate the grant of cash and equity incentives to directors, employees (including the Company’s named executive officers) and consultants of the Company and its subsidiaries. The 2020 Plan provides for the grant of stock options, including incentive stock options (“ISOs”) and non-qualified stock options (“NSOs”), SARs, restricted stock, dividend equivalents, restricted stock units (“RSUs”) and other stock or cash-based awards.

Stock options and stock appreciation rights under the 2020 Plan have a 10-year contractual term and vest over the vesting period specified in the applicable award agreement, at achievement of a performance requirement, or upon change of control (as defined in the applicable plan). RSUs vest over the vesting period specified in the applicable award agreement, at achievement of a performance requirement, or upon change of control (as defined in the applicable plan). As of March 31, 2024, there were 7,890,232 shares of common stock available for issuance under the 2020 Plan. The number of shares that may be issued under the 2020 Plan automatically increases on January 1 of each year in an amount equal to the lesser of (i) 4.0% of the shares of the Company’s common stock outstanding on December 31 of the preceding year or (ii) an amount determined by the Company’s board of directors.

2017 Stock Incentive Plan

In August 2017, the Company adopted an equity incentive plan (the “2017 Plan”). Under the 2017 Plan, directors, officers, employees, consultants, and advisors of the Company can be paid incentive compensation measured by the value of the Company’s shares of common stock through grants of stock options, stock appreciation rights (“SARs”), or restricted stock. Following the adoption of the 2020 Plan, no further grants have been, or will be, made under the 2017 Plan. However, the 2017 Plan will continue to govern the terms and conditions of outstanding awards granted under it.

Stock Options

The following table summarizes stock option activity for the three months ended March 31, 2024:


				Weighted-
		Weighted-		Average
		Average		Remaining
	Number of	Exercise		Contractual
	Awards	Price		Term
Awards outstanding—December 31, 2023	6,316,422	$	32.47	7.17
Awards issued	1,071,750	$	30.69
Awards exercised	(14,120)	$	8.22
Awards forfeited	(11,529)	$	39.31
Awards outstanding—March 31, 2024	7,362,523	$	32.25	7.35

Table of Contents

Stock Appreciation Rights

The following table summarizes SARs activity for the three months ended March 31, 2024:


				Weighted-
		Weighted-		Average
		Average		Remaining
	Number of	Exercise		Contractual
	Awards	Price		Term
Awards outstanding—December 31, 2023	43,208	$	9.38	5.32
Awards issued	—	$	—
Awards exercised	—	$	—
Awards forfeited	—	$	—
Awards outstanding—March 31, 2024	43,208	$	9.38	5.08

Restricted Stock Units

The following table summarizes RSU activity for the three months ended March 31, 2024:



		Weighted-
		Average
	Number of	Grant Date
	Awards	Fair Value
Awards outstanding—December 31, 2023	330,000	$	31.53
Awards issued	387,500	$	30.69
Awards vested	(15,000)	$	29.03
Awards forfeited	(350)	$	30.69
Awards outstanding—March 31, 2024	702,150	$	31.08

As of March 31, 2024, and December 31, 2023, stock awards issued under the 2017 and 2020 Plans of 3,596,040 and 3,298,284 shares of common stock, respectively, were vested.

Value of Stock Options and SARs

The Company values options and SARs using the Black-Scholes option-pricing model. The Company lacks sufficient historical company-specific volatility information. Therefore, the Company estimates expected stock volatility based on historical volatility of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For options with service-based vesting conditions, the expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. For SARs, the expected term is based upon the weighting of certain future events. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for the time periods approximately equal to the expected term of the award. An expected dividend yield of 0% is based on the fact that the Company has never paid cash dividends and does not expect to do so in the foreseeable future.

The assumptions used to value the awards are summarized in the following table.


	As of
	March 31,		December 31,
	2024		2023
Dividend yield	0.00	%	0.00	%
Expected volatility	72.60 - 72.60	%	74.87 - 80.78	%
Risk-free interest rate	4.06 - 4.20	%	3.42 - 4.62	%
Lack of marketability discount	0.00	%	0.00	%
Expected term (years)	2.01 - 6.11		2.26 - 10.77

Table of Contents

Value of RSUs

The fair value of RSUs is equal to the value of the Company’s common stock on the grant date.

The weighted average per share fair value of awards issued under the 2017 Plan and 2020 Plan was $21.13 and $20.64 on March 31, 2024, and December 31, 2023, respectively.

Stock-Based Compensation Expense

Stock-based compensation expense for the three months ended March 31, 2024, and 2023, was recorded in the unaudited condensed consolidated statements of operations and comprehensive income in the following line items:


	Three Months Ended March 31,
	2024		2023
Research and development expense	$	1,371	$	976
Sales and marketing expense		1,994		1,073
General and administrative expense		7,069		4,512
	$	10,434	$	6,561

Stock-based compensation expense related to options and RSUs issued under the 2017 Plan and 2020 Plan is included in stockholder’s equity, and a liability for SARs is included in other non-current liabilities, in the Company’s unaudited condensed consolidated balance sheet. As of March 31, 2024, the total unrecognized stock-based compensation expense was $73,718 and $19,399 for stock options and RSUs, respectively. This amount will be recognized in the Company’s consolidated statement of operations over a weighted average period of 2.7 years.

Employee Stock Purchase Plan

The 2020 Employee Stock Purchase Plan (“ESPP”) was adopted by the Company’s Board of Directors on April 30, 2021. The ESPP permits eligible employees to purchase shares of the Company’s common stock at a 15% discount from the lesser of the fair market value per share of the Company’s common stock on the first day of the offering period or the fair market value of the Company’s common stock on the purchase date. Funds are collected from employees through after-tax payroll deductions. The total number of shares reserved for issuance under the ESPP was initially 629,805, which automatically increases on January 1 of each year in an amount equal to the lesser of (i) 1.0% of the shares of the Company’s common stock outstanding on December 31 of the preceding year or (ii) an amount determined by the Company’s board of directors. It is intended that the ESPP meet the requirements for an “employee stock purchase plan” under Section 423 of the Internal Revenue Code. There were no shares issued under the ESPP for the three months ended March 31, 2024, and 2023, respectively. The discount on the ESPP was $80 and $105 for the three months ended March 31, 2024, and 2023, respectively, and is recorded within stock-based compensation expense.

16. EARNINGS PER SHARE

Basic earnings per share is calculated by dividing net income by the weighted average number of shares of common stock outstanding. Diluted net income per share of common is computed under the treasury stock method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income, the potential dilutive effects of stock options, stock appreciation rights and restricted stock units.

Table of Contents

The following table sets forth the computation of basic and diluted net income per share:


	Three Months Ended March 31,
	2024		2023
Numerator
Net income	$	38,334	$	29,485
Denominator
Net income per share of common stock - basic	$	0.68	$	0.49
Net income per share of common stock- diluted	$	0.67	$	0.48
Weighted average number of shares of common stock - basic		56,771,251		59,732,157
Weighted average number of shares of common stock - diluted		57,597,627		61,221,511

Securities outstanding that were included in the computation above, utilizing the treasury stock method are as follows:

Potential shares of common stock issuable that were excluded from the computation of diluted weighted-average shares outstanding excluded from the numerator, are as follows:

17. INCOME TAXES

A reconciliation between the statutory federal income tax rate and the Company’s effective income tax rate for the three months ended March 31, 2024, and 2023 is as follows:


	Three Months Ended March 31,
	2024		2023
Federal income tax rate	21.0	%	21.0	%
Stock-based compensation	—		(2.8)
State taxes	5.1		6.3
Credits	(1.0)		(2.9)
Other	0.4		0.4
Valuation allowance	0.5		—
Total	26.0	%	22.0	%

18. RELATED-PARTY TRANSACTIONS

The Company was party to a management agreement for professional services provided by a related party, Paragon Biosciences, LLC (“Paragon”). Paragon is an entity that shares common ownership with the Company. In addition, the Chairman of the Company’s board of directors is the Founder, Chairman and CEO of Paragon. The Company is also party to a right of use agreement with Paragon whereby it has access to and the right to use certain office space leased by Paragon in Chicago, IL. The Company incurred $73 and $71 for the three months ended March 31, 2024, and 2023, respectively, in expenses to Paragon, which are included in general and administrative expense in the unaudited condensed consolidated statements of operations and comprehensive loss. As of March 31, 2024, and December 31, 2023, there were no amounts due to or due from related parties included in the unaudited condensed consolidated balance sheets.

Table of Contents

19. SUBSEQUENT EVENTS

On April 11, 2024, the Company announced that it entered into a sublicense agreement with Bioprojet for an orexin-2 receptor agonist (OX2R) (the “Licensed Compound”) to be evaluated for the treatment of narcolepsy and other potential indications (the “Sublicense”). Under the Sublicense, the Company obtained the exclusive right to develop, manufacture and commercialize the Licensed Compound in the United States and Latin American territories (the “Licensed Territories”), which are rights that Bioprojet originally licensed from Teijin Pharma, the innovator of the Licensed Compound. The Licensed Compound is currently in pre-clinical development with an Investigational New Drug application currently anticipated in the second half 2025. Under the Sublicense, the Company paid Bioprojet an upfront license fee of $25,500 and will also be obligated to pay up to $127,500 upon achievement of development and regulatory milestones and up to $240,000 upon achievement of sales-based milestones, as well as royalty rates in the mid-teens on any sales of product using the Licensed Compound in the Licensed Territories.

On April 30, 2024, the Company announced that its subsidiary, Zynerba, acquired all of the issued and outstanding capital stock of Epygenix Therapeutics, Inc., a Wyoming corporation (“Epygenix”), pursuant to the terms of a stock purchase agreement. In connection with the closing of the transaction, Zynerba paid the former stockholders of Epygenix up front consideration of $35,000 (which amount is subject to adjustment following the closing). In addition, Zynerba will also be obligated to pay up to $130,000 upon the achievement of development and regulatory milestones and up to $515,000 upon the achievement of certain sales-based milestones, in each case to Epygenix’s former stockholders. Epygenix has an exclusive license relating to the use of clemizole for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy, products, prospective products, product approvals, research and development costs, anticipated timing and likelihood of success of clinical trials, expected timing of the release of clinical trial data, the plans and objectives of management for future operations and future results of anticipated products, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, statements about:

●

our commercialization efforts and strategy for WAKIX;

●

the rate and degree of market acceptance and clinical utility of pitolisant in additional indications, if approved, and any other product candidates we may develop or acquire, if approved;

●

our research and development plans, including our plans to explore the therapeutic potential of pitolisant in additional indications;

●

our ongoing and planned clinical trials;

●

our ability to expand the scope of our license agreements with Bioprojet Société Civile de Recherche (“Bioprojet”);

Table of Contents

●

the availability of favorable insurance coverage and reimbursement for WAKIX;

●

the timing of, and our ability to obtain, regulatory approvals for pitolisant for other indications as well as any other product candidates;

●

our estimates regarding expenses, future revenue, capital requirements and additional financing needs;

●

our ability to identify, acquire and integrate additional products or product candidates with significant commercial potential that are consistent with our commercial objectives;

●

our commercialization, marketing and manufacturing capabilities and strategy;

●

significant competition in our industry;

●

our intellectual property position;

●

loss or retirement of key members of management;

●

failure to successfully execute our growth strategy, including any delays in our planned future growth;

●

our failure to maintain effective internal controls; and

●

the impact of government laws and regulations.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential”, or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the factors described under the section in our most recent Annual Report on Form 10-K entitled “Item 1A. Risk Factors” and the sections in this Quarterly Report on Form 10-Q titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.

Unless otherwise indicated, information contained in this Quarterly Report on Form 10-Q concerning our industry, including industry statistics and forecasts, competitive position and the markets in which we operate is based on information from independent industry and research organizations, other third-party sources and management estimates. Management estimates are derived from publicly available information released by independent industry analysts and other third-party sources, as well as data from our internal research, and are based on assumptions made by us upon reviewing such data, and our experience in, and knowledge of, such industry and markets, which we believe to be reasonable. In addition, projections, forecasts, assumptions and estimates of the future performance of the industry in which we operate and our future performance are necessarily subject to uncertainty and risk due to a variety of factors, including those described in “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements.” These and other factors could cause results to differ materially from those expressed and forecasts in the estimates made by the independent parties and by us.

Table of Contents

You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

As used herein, the terms “Harmony,” “we,” “us,” “our” and “the Company” refer to Harmony Biosciences Holdings, Inc., a Delaware corporation and our operating subsidiary, Harmony Biosciences, LLC.

Further, we have in-licensed from Bioprojet the registered trademark product name WAKIX® in the United States. We also have registered trademark protection in the United States for KNOW NARCOLEPSY®, REM AT THE WRONG TIME® and NON-REM AT THE WRONG TIME®, as well as our brand and logo HB®, HB HARMONY BIOSCIENCES® and HARMONY BIOSCIENCES®. This report also includes trademarks, service marks and trade names of other companies. Trademarks, service marks and trade names appearing in this Quarterly Report on Form 10-Q are the property of their respective owners.

Company Overview

We are a commercial-stage, pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Our product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action (“MOA”) specifically designed to increase histamine signaling in the brain by binding to H3 receptors. In August 2019, WAKIX was approved by the U.S. Food and Drug Administration (the “FDA”) for the treatment of excessive daytime sleepiness (“EDS”) in adult patients with narcolepsy, and its U.S. commercial launch was initiated in November 2019. In October 2020, WAKIX was approved by the FDA for the treatment of cataplexy in adult patients with narcolepsy. WAKIX is the first-and-only approved product for patients with narcolepsy that is not scheduled as a controlled substance by the U.S. Drug Enforcement Administration (the “DEA”).

We believe that pitolisant’s ability to regulate histamine gives it the potential to provide therapeutic benefit in other rare neurological diseases that are mediated through H₃ receptors and histamine signaling. We are taking a mechanism-based approach to managing the life cycle of pitolisant and identified idiopathic hypersomnia (“IH”), another central disorder of hypersomnolence like narcolepsy, as our next potential new indication for WAKIX, which received orphan drug designation by the FDA in September 2023 and Fast Track Designation in November 2023. In April 2022, we initiated a Phase 3 registrational trial, the INTUNE Study, to evaluate the efficacy and safety of pitolisant in adult patients with IH. We completed enrollment in the INTUNE study in May 2023 and we announced topline data in October 2023. While the primary endpoint did not meet statistical significance, we believe the totality of the data showed favorable numerical trends for pitolisant in the treatment of adult patients with IH and we met with the FDA in March 2024 to discuss the path forward for IH. Following our meeting with the FDA, we plan to submit a supplemental NDA (“sNDA”) for IH in the second half of 2024 based on the totality of the data obtained from the INTUNE study and from other sources. We are focusing our development efforts on other rare neurological disorders in which EDS is a prominent symptom, including Prader-Willi Syndrome (“PWS”) and myotonic dystrophy, otherwise known as dystrophia myotonica (“DM”). Based on the positive signals from the data from our Phase 2 proof-of-concept signal detection clinical trial to evaluate pitolisant for the treatment of EDS and other key symptoms in patients with PWS, an end-of-phase 2 meeting with the FDA was held in June 2023. We aligned with the FDA on the proposed Phase 3 registration study design to support further investigation of pitolisant as a potential treatment to address the unmet medical need for children, adolescents and adults with PWS experiencing EDS, for which there is currently no approved treatment. In October 2023, we received FDA alignment regarding the protocol for the Phase 3 TEMPO study in patients with PWS, which we believe will satisfy the requirements for both the registrational trial and one of the two requirements for pediatric exclusivity for pitolisant. In February 2024, the FDA granted Orphan Drug designation to pitolisant for the treatment of PWS. The Phase 3 registrational trial, the TEMPO study, was initiated in March 2024. In June 2021, we initiated a Phase 2 proof-of-concept signal

Table of Contents

detection clinical trial to evaluate pitolisant for the treatment of EDS, fatigue and cognitive dysfunction in adult patients with DM1 and announced topline results from this trial in the fourth quarter of 2023, in which clinically meaningful improvements were demonstrated in EDS and fatigue. The safety profile was consistent with the established safety profile of pitolisant.

Our partner, Bioprojet completed a Phase 3 trial in pediatric patients with narcolepsy and submitted the trial data to the European Medicines Agency (the “EMA”) seeking approval for a pediatric narcolepsy indication. In January 2023, Bioprojet received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) and in March 2023, the EMA granted approval for the marketing authorization of WAKIX for the treatment of narcolepsy in children 6 and older. Based on the data from the positive Phase 3 trial conducted by Bioprojet, we submitted an sNDA for pediatric narcolepsy in December 2023. On February 21, 2024, we announced that the FDA has granted priority review of our pediatric narcolepsy sNDA and has set a Prescription Drug User Fee Act, or target action date, of June 21, 2024.

We remain committed to obtaining pediatric exclusivity for WAKIX. The initiation of the PWS Phase 3 registrational trial, the TEMPO study, and pediatric narcolepsy sNDA are supportive of our efforts in obtaining pediatric exclusivity for WAKIX.

We also seek to expand our pipeline through the acquisition of additional assets that focus on addressing the unmet needs of patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. We are targeting assets that will allow us to further leverage the expertise and infrastructure that we have successfully built at Harmony so we can optimize the benefit of internal synergies. Consistent with this objective, in July 2022, we entered into a License and Commercialization Agreement (the “2022 LCA”) with Bioprojet whereby we obtained exclusive rights to manufacture, develop and commercialize one or more new products based on pitolisant in the United States and Latin America, with the potential to add additional indications and formulations upon the agreement of both parties. We have made progress in the development of two new formulations of pitolisant, Next Gen 1 (“NG1”) and Next Gen 2 (“NG2”). Both formulations entered clinical studies in the fourth quarter of 2023. We received data from the NG1 pilot bioequivalence study, which supports further development of NG1. We anticipate data from the NG2 pilot pharmacokinetics study in the second half of 2024. These formulations are expected to generate new IP to extend the pitolisant franchise out beyond 2040.

In addition, in October 2023, we completed the acquisition of Zynerba Pharmaceuticals, Inc. (together with its subsidiary, Zynerba Pharmaceutical Pty, Ltd., “Zynerba”), a clinical-stage pharmaceutical company focused on innovative pharmaceutically produced transdermal cannabidiol therapies for orphan neuropsychiatric disorders. Zynerba’s drug candidate is ZYN002, the first and only pharmaceutically-produced synthetic cannabidiol gel, devoid of THC, and formulated as a patent protected, permeation-enhanced gel for transdermal delivery. ZYN002 is currently in a pivotal Phase 3 trial, the RECONNECT study, for the treatment of Fragile X Syndrome (“FXS”). Topline data from this Phase 3 study is anticipated in mid-2025. ZYN002 has patent protection for the treatment of FXS until 2038.

In August 2021, we acquired HBS-102, a Melanin-concentrating hormone receptor 1 (MCHR1) antagonist previously developed as CSTI-100/ALB-127258(a)/ALB-127258 (the “Compound”), along with intellectual property and other assets related to the development, manufacture, and commercialization of the Compound from ConSynance Therapeutics, Inc. We acquired full development and commercialization rights for HBS-102 globally, but we have provided an indication-limited grant-back license to ConSynance for the development and commercialization of the Compound in Greater China. We are conducting a preclinical proof-of-concept study to assess the effect of HBS-102 on hyperphagia, weight gain and other metabolic parameters in a mouse model of PWS. We anticipate data from both studies in the first half of 2024. A 13-week toxicology study is completed and the preliminary results are encouraging.

Table of Contents

manufacture and commercialize the Licensed Compound in the United States and Latin American territories, which are rights that Bioprojet originally licensed from Teijin Pharma, the innovator of the Licensed Compound.

Pitolisant was developed by Bioprojet and approved by the EMA in 2016 for the treatment of narcolepsy in adult patients with or without cataplexy and in 2021 for the treatment of EDS in adult patients with obstructive sleep apnea. We acquired an exclusive license to develop, manufacture and commercialize pitolisant in the United States pursuant to our license agreement with Bioprojet (as amended, the “2017 LCA”) in July 2017. Pitolisant was granted Orphan Drug Designation for the treatment of narcolepsy by the FDA in 2010. It received Breakthrough Therapy designation for the treatment of cataplexy in patients with narcolepsy and Fast Track status for the treatment of EDS and cataplexy in patients with narcolepsy in April 2018.

Our operations are conducted by our wholly owned subsidiaries, Harmony Biosciences, LLC and Zynerba.

Commercial Performance Metrics

As of March 31, 2024, we continued to see growth in the number of unique healthcare professional (“HCP”) prescribers of WAKIX since it became available in November 2019. The average number of patients on WAKIX for the three months ended March 31, 2024, was approximately 6,300. Additionally, as of March 31, 2024, we have secured formulary access for more than 80% of all insured lives (Commercial, Medicare and Medicaid) in the United States. Within these covered lives, we have observed favorable access to WAKIX subsequent to the expanded approval of WAKIX for the treatment of cataplexy in adult patients with narcolepsy in October 2020.

Financial Operations Overview

Net Product Revenue

Net product revenue includes gross product shipments less provisions for sales discounts and allowances, which includes trade allowances, rebates to government and commercial entities, and other discounts. Although we expect net sales to increase over time, provisions for sales discounts and allowances may fluctuate based on the mix of sales to different customer segments and/or changes in our estimates.

Cost of Product Sales

Cost of product sales includes manufacturing and distribution costs, the cost of API, FDA program fees, royalties due to third parties on net product sales, freight, shipping, handling, storage costs and salaries of employees involved with oversight of production. We expect the cost of product sales to increase as we continue to ramp up production in order to meet future demand for WAKIX and diversify our supply chain for WAKIX.

The shelf life of WAKIX is three years from date of manufacture, with the earliest expiration of current inventory expected to be June 2025. We regularly review our inventory levels and expect write-offs from time to time. We will continue to assess inventory levels in future periods as demand for WAKIX and the rate of inventory turnover evolves. We currently have adequate supply of WAKIX to cover demand into the third quarter of 2025, with additional API on-hand inventory to support at least 36 months beyond this time frame.

Research and Development Expenses

Research and development expenses primarily include development programs for potential new indications for pitolisant in patients with IH, PWS, DM and the development of ZYN002 in patients with FXS. We also incur research and development expenses related to our team of Medical Science Liaisons (“MSLs”) who interact with key opinion leaders, with a focus on the science, the role of histamine in sleep-wake state stability and the novel mechanism of action of pitolisant. In addition, our MSLs support our market access team

Table of Contents

with the presentation of clinical data to payors upon request and our clinical development team to identify potential clinical trial sites. Research and development costs are expensed as incurred. We have significantly increased our research and development efforts as we advance our clinical programs and assess other product candidates to expand our pipeline. Research and development expenses also include:

●

employee-related expenses, such as salaries, share-based compensation, benefits and travel expenses for our research and development personnel;

●

direct third-party costs such as expenses incurred under agreements with CROs, and contract manufacturing organizations (“CMOs”);

●

manufacturing costs in connection with producing materials for use in conducting clinical trials;

●

costs related to packaging and labelling of clinical supplies;

●

other third-party expenses (e.g., consultants, advisors) directly attributable to the development of our product candidates;

●

acquired in-process research and development; and

●

amortization expense for assets used in research and development activities.

A significant portion of our research and development costs are external costs, such as fees paid to CROs and CMOs, central laboratories, contractors, and consultants in connection with our clinical development programs. Internal expenses primarily relate to personnel who are deployed across multiple programs.

Product candidates in later stages of clinical development generally have higher development costs in the current period than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials, milestone payments, and the cost of submitting an NDA to the FDA (and/or other regulatory authorities). We expect our research and development expenses to be significant over the next several years as we advance our current clinical development programs and prepare to seek regulatory approval for additional indications for pitolisant, complete the Phase 3 clinical trial for ZYN002, and advance NG1, NG2, ZYN002 and HBS-102 to develop toward new indications.

At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of any additional indications for pitolisant or other product candidates that we move forward for regulatory approval. There are numerous risks and uncertainties associated with developing product candidates, including uncertainty related to:

●

the duration, costs and timing of clinical trials of our current development programs and any further clinical trials related to new product candidates;

●

the sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;

●

the impact of the COVID-19 pandemic, including any future resurgence or new variants, on the ability to initiate new clinical trials and/or maintain the continuity of ongoing clinical trials, including our ability to access sleep labs in order to conduct objective sleep testing, that could be impacted by future shelter-in-place orders and needs of the health care system to focus on managing patients affected by COVID-19;

●

receiving Bioprojet’s consent to pursue additional indications for pitolisant;

Table of Contents

●

the acceptance of INDs for our planned clinical trials or future clinical trials;

●

the successful and timely enrollment and completion of clinical trials;

●

the successful completion of preclinical studies and clinical trials;

●

successful data from our clinical programs that support an acceptable risk-benefit profile of our product candidates in the intended populations;

●

the receipt and maintenance of regulatory and marketing approvals from applicable regulatory authorities;

●

establishing agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidate is approved;

●

the entry into collaborations to further the development of our product candidates;

●

obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates; and

●

successfully launching our product candidates and achieving commercial sales, if and when approved.

A change in the outcome of any of these variables with respect to the development of any of our programs or any product candidate we develop would significantly change the costs, timing and viability associated with the development and/or regulatory approval of such programs or product candidates.

Sales and Marketing Expenses

Our sales and marketing expenses primarily relate to the market development and commercialization activities of WAKIX for the treatment of EDS and cataplexy in adult patients with narcolepsy. Market development and commercial activities account for a significant portion of our operating expenses and are expensed as incurred. We expect our sales and marketing expenses to increase in the near- and mid-term to support WAKIX’s indications for the treatment of EDS or cataplexy in adult patients with narcolepsy and to expand our portfolio with the anticipated growth from potential additional indications.

Sales and marketing expenses include:

●

employee-related expenses, such as salaries, share-based compensation, benefits and travel expenses for our sales, marketing and market access personnel;

●

healthcare professional-related expenses, including marketing programs, healthcare professional promotional medical education, disease education, conference exhibits and market research;

●

patient-related expenses, including patient awareness and education programs, disease awareness education, patient reimbursement programs, patient support services and market research;

●

market access expenses, including payor education, specialty pharmacy programs and services to support the continued commercialization of WAKIX; and

●

secondary data purchases (i.e., patient claims and prescription data), data warehouse development and data management.

Table of Contents

In addition, sales and marketing expenses include external costs such as website development, media placement fees, agency fees for patient, medical education and promotional expenses, market research, analysis of secondary data, conference fees and consulting fees.

General and Administrative Expenses

General and administrative expenses consist primarily of employee-related expenses, such as salaries, share-based compensation, benefits and travel expenses for our personnel in executive, legal, finance and accounting, human resources, investor relations, and other administrative departments. General and administrative expenses also consist of office leases, and professional fees, including legal, tax and accounting and consulting fees.

We anticipate that our general and administrative expenses will increase in the future to support our continued commercialization efforts, ongoing and future potential research and development activities, and increased costs of operating as a public company. These increases will likely be driven by costs associated with the hiring of additional personnel and fees paid to outside consultants, lawyers and accountants, among other expenses. Additionally, we anticipate increased costs associated with being a public company, including expenses related to services associated with maintaining compliance with the requirements of Nasdaq and the SEC, insurance and investor relations costs. If any of our current or future indication expansion programs or new product candidates obtain U.S. regulatory approval, we expect that we would incur significantly increased expenses associated with building a sales and marketing team.

Paragon Agreement

We are party to a right-of-use agreement with Paragon Biosciences, LLC (“Paragon”) whereby we have access to and the right to use certain office space leased by Paragon in Chicago, Illinois. For the three months ended March 31, 2024, we paid fees of $0.1 million pursuant to this agreement.

Interest Expense

Interest expense consists primarily of interest expense on debt facilities, amortization of debt issuance costs and amortization of premiums on our debt securities.

Interest Income

Interest income consists primarily of cash interest earned on our cash and investment balances and accretion of the discount on our investments in debt securities.

Table of Contents

Results of Operations

The following table sets forth selected items in our unaudited condensed consolidated statements of operations for the periods presented:


	Three Months Ended March 31,
	2024		2023

	(In thousands)
Net product revenue	$	154,615	$	119,126
Cost of product sales		27,484		20,780
Gross profit		127,131		98,346
Operating expenses:
Research and development		22,189		13,289
Sales and marketing		27,233		22,572
General and administrative		25,676		22,062
Total operating expenses		75,098		57,923
Operating income		52,033		40,423

Other (expense) income, net		(141)		2
Interest expense		(4,535)		(5,731)
Interest income		4,428		3,086
Net income before provision for income taxes		51,785		37,780
Income tax (expense) benefit		(13,451)		(8,295)
Net income	$	38,334	$	29,485

Net Product Revenue

Net product revenue increased by $35.5 million, or 29.8%, for the three months ended March 31, 2024 compared to the same period in 2023. The increase was primarily due to a 28.3% increase in the number of units shipped, and the impact of a 7% price increase partially offset by higher rebates to commercial entities, which resulted in a decrease to net product revenue of approximately 4%. The price increase occurred in January 2024.

Cost of Product Sales

Cost of product sales increased by $6.7 million, or 32.3%, for the three months ended March 31, 2024, compared to the same period in 2023. Cost of product sales as a percentage of net product revenue was 17.8% for the three months ended March 31, 2024, compared to 17.4% for the three months ended March 31, 2023. The increase in cost of product sales in the period was due to higher sales of WAKIX.

Research and Development Expenses

The following table is a summary of our research and development expenses:


	Three Months Ended March 31,
	2024		2023		Change

	(in thousands)
Pitolisant	$	9,110	$	6,187	$	2,923
ZYN002		3,879		-		3,879
Other research and development		2,446		1,774		672
IPR&D		-		750		(750)
Personnel expenses		5,383		3,602		1,781
Stock-based compensation		1,371		976		395
Total	$	22,189	$	13,289	$	8,900

Table of Contents

Research and development expenses increased by $8.9 million, or 67.0%, for the three months ended March 31, 2024, compared to the same period in 2023. The increase for the three months ended March 31, 2024 was primarily driven by $3.9 million in research and development expenses for ZYN002, which did not have any expenses in the prior year, a $2.9 million increase in clinical development and regulatory work associated with pitolisant, driven by increases for PWS and DM indications, a $1.8 million increase in personnel costs associated with higher headcount and a $0.4 million increase in stock compensation associated with new awards, partially offset by a $0.8 million IPR&D charge related to preclinical milestones achieved for HBS-102 during the three months ended March 31, 2023.

Sales and Marketing Expenses

Sales and marketing expenses increased by $4.7 million, or 20.6%, for the three months ended March 31, 2024, compared to the same period in 2023. The increase for the three months ended March 31, 2024, was primarily due to a $2.7 million increase in patient engagement and marketing activities, a $0.9 million increase in personnel costs, and a $0.9 million increase in stock compensation associated with new awards. The increase in patient engagement and marketing activities for the period was driven by our continued growth of WAKIX and the increase in personnel costs for the period was related to increased headcount.

General and Administrative Expenses

General and administrative expenses increased by $3.6 million, or 16.4%, for the three months ended March 31, 2024, compared to the same period in 2023. The increase in the three months ended March 31, 2024, was primarily due to a $2.6 million increase in stock compensation associated with new awards and a $0.8 million increase in legal fees, primarily associated with patent lawsuits.

Interest Expense

Interest expense decreased by $1.2 million, or 20.9%, for the three months ended March 31, 2024, compared to the same period in 2023. The decrease for the three months ended March 31, 2024, was primarily due to lower interest rates as a result of refinancing into the TLA Credit Agreement (defined below).

Interest Income

Interest income increased by $1.3 million, or 43.5%, for the three months ended March 31, 2024, compared to the same period in 2023. The increase for the three months ended March 31, 2024, was primarily a result of having higher invested balances, and higher investment yields on those balances, compared to the prior year period.

Income Taxes

Income tax expense was $13.5 million, representing a 26.0% effective tax rate, for the three months ended March 31, 2024, compared to $8.3 million, representing a 22.0% effective tax rate, for the three months ended March 31, 2023. The increase in our effective tax rate was due to a 2.8% tax benefit from the exercise of stock options in the prior year period and a 1.9% benefit from estimated tax credits. The effective tax rate of 26.0% for the three months ended March 31, 2024, included 5.1% for state income taxes, partially offset by a 1.0% benefit from credits.

Table of Contents

Liquidity, Sources of Funding and Capital Resources

Overview

As of March 31, 2024, we had cash, cash equivalents, and investments of $453.6 million, outstanding debt of $192.5 million and an accumulated deficit of $104.9 million.

The unaudited condensed consolidated financial statements have been prepared as though we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.

We believe that our existing cash, cash equivalents and investments on hand as of March 31, 2024, will enable us to meet our operational liquidity needs and fund our planned investing activities for the next 12 months. We have based our liquidity and cash flow projections on assumptions that may prove to be incorrect, and we could use our capital resources sooner than we expect.

Term Loan A Credit Agreement

In July 2023, we entered into a Credit Agreement (the “TLA Credit Agreement”) with JPMorgan Chase Bank, N.A., as “Administrative Agent”, and certain lenders. The TLA Credit Agreement provides for a five-year senior secured term loan (the “TLA Term Loan”) in an aggregate principal amount of $185.0 million.

In September 2023, we entered into the First Incremental Amendment (the “First Incremental Amendment”) with the Administrative Agent and Bank of America, N.A., as incremental lender. The First Incremental Amendment provides for an incremental senior secured term loan (the “Incremental Term Loan”) in an aggregate principal amount of $15.0 million. The First Incremental Amendment amends the TLA Credit Agreement and provides that the Incremental Term Loan will have identical terms as the TLA Term Loan.

The repayment schedule for both the TLA Term Loan and the Incremental Term Loan (together, the “Term Loans”) consists of $3.8 million quarterly principal payments, which commence on December 31, 2023, increasing to $5.0 million quarterly principal payments beginning on December 31, 2025, with a $115.0 million payment due on the maturity date of July 26, 2028. The Term Loans bear interest at a per annum rate equal to, at our option, (i) a base rate plus a specified margin ranging from 2.50% to 3.00%, based on our senior secured net leverage ratio (as defined in the TLA Credit Agreement) or (ii) Term SOFR plus a credit spread adjustment of 0.10% plus a specified margin ranging from 3.50% to 4.00%, based on our senior secured net leverage ratio.

The TLA Credit Agreement contains customary affirmative and negative covenants, financial covenants, representations and warranties, events of default and other provisions. We were in compliance with all covenants as of March 31, 2024.

Share Repurchases

In October 2023, the Company’s Board of Directors approved a share repurchase program (the “October 2023 Repurchase Program”) providing for the repurchase of shares of common stock in an aggregate amount of up to $200,000, excluding commissions and transaction fees. The October 2023 Repurchase Program may be suspended, terminated, or modified at any time for any reason. During the three months ended March 31, 2024, the Company repurchased and cancelled no shares of common under the October 2023 Repurchase Program. As of March 31, 2024, the remaining amount of common stock authorized for repurchases was $150.0 million.

Table of Contents

Zynerba Acquisition

In October 2023, we completed a tender offer (the “Tender Offer”) to acquire all of the outstanding shares of common stock of Zynerba (“Zynerba Common Stock”).

Under the terms of the Tender Offer, we paid (i) $1.1059 per share of Zynerba Common Stock (the “Common Cash Amount”), the aggregate amount of which was $60,000 and was paid at closing, plus (ii) one contingent value right (each, a “CVR”) per share of Zynerba Common Stock (the “Common CVR Amount”), which represents the right to receive up to approximately $2.5444 per share of Zynerba Common Stock, subject to the achievement of certain clinical, regulatory and sales-based milestones. The Common CVR Amounts are to be paid in cash, subject to any applicable withholding of taxes and without interest. The aggregate consideration we paid to acquire the Zynerba Common Stock upon completion of the Tender Offer was $60 million, exclusive of transaction related fees. We financed the acquisition with cash on hand.

Asset Purchase Agreement

In August 2021, we entered into an asset purchase agreement with ConSynance Therapeutics, Inc. (the (APA”) to acquire HBS-102, a potential first-in-class molecule with a novel mechanism of action. Under the terms of the APA, we acquired full development and commercialization rights globally, with the exception of Greater China, for $3.5 million. Additionally, there are payments due upon the achievement of certain milestones below, including $1.0 million for additional preclinical milestones (see “Recent Milestone Payments”), $19.0 million for development milestones, $44.0 million for regulatory milestones and $110.0 million for sales milestones.

License Agreements

In April 2024, we entered into a sublicense agreement with Bioprojet for an orexin-2 receptor agonist (OX2R) (the “Licensed Compound”) to be evaluated for the treatment of narcolepsy and other potential indications (the “Sublicense”). Under the Sublicense, the Company obtained the exclusive right to develop, manufacture and commercialize the Licensed Compound in the United States and Latin American territories (the “Licensed Territories”), which are rights that Bioprojet originally licensed from Teijin Pharma, the innovator of the Licensed Compound. The Licensed Compound is currently in pre-clinical development with an Investigational New Drug application currently anticipated in the second half 2025. Under the Sublicense, the Company will pay Bioprojet an upfront license fee of $25.5 million and will also be obligated to pay up to $127.5 million upon achievement of development and regulatory milestones and up to $240.0 million upon achievement of sales-based milestones, as well as royalty rates in the mid-teens on potential sales in the Licensed Territories.

In July 2022, we entered into the 2022 LCA with Bioprojet whereby we obtained exclusive rights to manufacture, develop and commercialize one or more new products based on pitolisant in the United States and Latin America, with the potential to add additional indications and formulations upon the agreement of both parties. We paid an initial, non-refundable $30.0 million licensing fee in October 2022 and additional payments of up to $155.0 million are potentially due under the 2022 LCA upon the achievement of certain future development and sales-based milestones. In addition, certain payments will become due upon the achievement of development milestones for new indications and formulations as agreed upon by both parties. The 2022 LCA also includes a fixed trademark royalty and a tiered royalty based on net sales of any new products commercialized, which will be payable to Bioprojet on a quarterly basis.

Recent Milestone Payments

In March 2023, we achieved a preclinical milestone, which triggered a $0.8 million payment under the provisions of the APA, which was paid in April 2023.

Table of Contents

Cash Flows

The following table sets forth a summary of our cash flows for the three months ended March 31, 2024, and 2023:


	Three Months Ended March 31,
	2024		2023

Selected cash flow data	(In thousands)
Cash provided by (used in):
Operating activities	$	31,141	$	42,559
Investing activities		(6,186)		(1,790)
Financing activities		(3,634)		3,409

Operating Activities

Net cash provided by operating activities for the three months ended March 31, 2024, primarily consisted of net income of $38.3 million adjusted for non-cash items of $10.4 million related to stock-based compensation expense, $6.1 million related to intangible amortization and depreciation, and $3.5 million related to deferred tax assets. Net working capital excluding cash decreased by $20.3 million.

Net cash provided by operating activities of $42.6 million for the three months ended March 31, 2023, consisted of net income of $29.5 million adjusted for non-cash items of $3.4 million related to deferred tax assets, $6.1 million related to intangible amortization and depreciation and $6.6 million related to stock-based compensation expense. Net working capital excluding cash increased by $3.7 million.

Investing Activities

Net cash used in investing activities for the three months ended March 31, 2024, was $6.2 million, which was primarily attributable to $25.1 million in purchases of debt securities, partially offset by $18.9 million from maturities of investments.

Net cash used in investing activities for the three months ended March 31, 2023, was $1.8 million, which was primarily attributable to $47.8 million in purchases of debt securities, partially offset by $46.0 million from sales and maturities of investments.

Financing Activities

Net cash used in financing activities for the three months ended March 31, 2024, was $3.6 million, which primarily consisted of $3.7 million in principal payments associated with the TLA Credit Agreement, partially offset by $0.1 million in proceeds from the exercise of stock options.

Net cash provided by financing activities for the three months ended March 31, 2023, was $3.4 million, which primarily consisted of $3.9 million in proceeds from the exercise of stock options partially offset by a $0.5 million principal payment associated with the Blackstone Credit Agreement.

Critical Accounting Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the dates of the balance sheets and the reported amounts of expenses during the reporting periods. In accordance with GAAP, we evaluate our estimates and judgments on an ongoing basis.

Table of Contents

Significant estimates include assumptions used in the determination of the amount of revenue recognized on sales of WAKIX, costs incurred under services type agreements related to the performance of research and development activities, and the measurement of compensation expense pursuant to stock-based awards. We base our estimates on contractual terms, historical experience, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We define our critical accounting policies as those under GAAP that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. During the quarter covered by this report, there were no material changes to the accounting policies and assumptions previously disclosed, except as disclosed in Note 3 to the unaudited condensed consolidated financial statements contained herein.

Recent Accounting Pronouncements

See Note 3 to our unaudited condensed consolidated financial statements for recent accounting pronouncements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Interest Rate Fluctuation Risk

We are exposed to market risk related to changes in interest rates. We invest a portion of our cash in investment-grade, interest-bearing securities. The primary objectives of our investment activities are to preserve principal, maintain liquidity and maximize total return. In order to achieve these objectives, we invest in money market funds, U.S. government and agency securities, corporate bonds and commercial paper in accordance with our investment policy. Our investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of our investments to preserve principal and maintain liquidity. All investment securities have a credit rating of at least A-2/P-2/F2 from at least two National Recognized Statistical Rating Organizations. We do not have any direct investments in asset-backed securities, collateralized debt or loan obligations, or structured investment vehicles. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. Based on our $384.7 million of investments in money market funds, U.S. treasury notes, corporate bonds and municipal obligations as of March 31, 2024, an immediate 10% change in market interest rates would not have a material impact on the fair market value of our investment portfolio or on our financial position or results of operations.

As of March 31, 2024, we had $192.5 million in borrowings outstanding. The Term Loans bear interest at a per annum rate equal to, at our option, (i) a base rate plus a specified margin ranging from 2.50% to 3.00%, based on our senior secured net leverage ratio (as defined in the TLA Credit Agreement) or (ii) Term SOFR plus a credit spread adjustment of 0.10% plus a specified margin ranging from 3.50% to 4.00%, based on our senior secured net leverage ratio. Based on the $192.5 million of principal outstanding as of March 31, 2024, an immediate 10% change in the SOFR would not have a material impact on our debt-related obligations, financial position or results of operations.

Foreign Currency Fluctuation Risk

We are not currently exposed to significant market risk related to changes in foreign currency exchange rates; however, we have contracted with and may continue to contract with foreign vendors that are located in Europe. Our operations may be subject to fluctuations in foreign currency exchange rates in the future.

Table of Contents

Inflation Fluctuation Risk

Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations for each of the three months ended March 31, 2024, and 2023.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, including our principal executive officer and our principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of March 31, 2024. Based on that evaluation, our principal executive officer and principal financial officer concluded that, as of March 31, 2024, our disclosure controls and procedures were effective to provide reasonable assurance that the information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

Our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may become involved in litigation relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations or financial condition.

ANDA Litigation

On September 27, 2023, we and our licensor, Bioprojet, received notice from Lupin Limited (“Lupin”) pursuant to 21 U.S.C. § 355(j) et seq. and 21 C.F.R. § 314.95 et seq. (the “Lupin Notice Letter”) that Lupin has submitted ANDA No. 218846 (the “Lupin ANDA”) to the FDA and is seeking regulatory approval to market a generic version of WAKIX^® before the expiration of U.S. Patent Nos. 8,486,947 (“’947 patent”) and 8,207,197 (“’197 patent”). On September 27, 2023, we and Bioprojet received notice from Novugen Pharma Sdn. Bhd. (“Novugen”) pursuant to 21 U.S.C. § 355(j) et seq. and 21 C.F.R. § 314.95 et seq. (the “Novugen Notice Letter”) that Novugen has submitted ANDA No. 218834 (the “Novugen ANDA”) to the FDA and is seeking regulatory

Table of Contents

approval to market a generic version of WAKIX^® before the expiration of the ’947 patent and ’197 patent. The ’947 patent and the ‘197 patent are listed with respect to WAKIX^® in the FDA’s Orange Book and will expire in September 2029 and March 2030, respectively. The Lupin Notice Letter and the Novugen Notice Letter assert that their generic product will not infringe the ’947 patent and the ‘197 patent and/or that the ’947 patent and the ‘197 patent are invalid or unenforceable. On November 9, 2023, we, Bioprojet and Bioprojet’s wholly owned subsidiary, Bioprojet Pharma SAS (“Bioprojet Pharma”), filed a complaint for patent infringement of the ’947 patent and the ‘197 patent against Lupin, Novugen and certain of their affiliates and agents in the United States District Court for the District of Delaware in response to the filing of their respective ANDAs with the FDA.

On October 12, 2023, we and Bioprojet received notice from Novitium Pharma LLC (“Novitium”), pursuant to 21 U.S.C. § 355(j) et seq. and 21 C.F.R. § 314.95 et seq. (the “Novitium Notice Letter”), that Novitium has submitted ANDA No. 218495 (the “Novitium ANDA”) to the FDA and is seeking regulatory approval to market a generic version of WAKIX^® before the expiration of U.S. Patent No. 8,354,430 (the “’430 patent”), which is also listed with respect to WAKIX^® in the FDA’s Orange Book and will expire in February 2026, ’947 patent, and ’197 patent. On October 12, 2023, we and Bioprojet received notice from Zenara Pharma Pvt. Ltd. (“Zenara”), pursuant to 21 U.S.C. § 355(j) et seq. and 21 C.F.R. § 314.95 et seq. (the “Zenara Notice Letter”), that Zenara has submitted ANDA No. 218796 (the “Zenara ANDA”) to the FDA and is seeking regulatory approval to market a generic version of WAKIX^® before the expiration of the ’430 patent, ’947 patent and the ’197 patent. On October 14, 2023, we and Bioprojet received notice from AET Pharma US, Inc. (“AET”), pursuant to 21 U.S.C. § 355(j) et seq. and 21 C.F.R. § 314.95 et seq. (the “AET Notice Letter”), that AET has submitted ANDA No. 218892 (the “AET ANDA”) to the FDA and is seeking regulatory approval to market a generic version of WAKIX^® before the expiration of the ’947 patent and the ’197 patent. On October 16, 2023, we and Bioprojet received notice from Annora Pharma Private Limited (“Annora”), pursuant to 21 U.S.C. § 355(j) et seq. and 21 C.F.R. § 314.95 et seq. (the “Annora Notice Letter”), that Annora has submitted ANDA No. 218832 (the “Annora ANDA”) to the FDA and is seeking regulatory approval to market a generic version of WAKIX^® before the expiration of the ’430 patent, the ’947 patent and the ’197 patent. AET’s Notice Letter asserts that AET’s generic product will not infringe the ’947 patent and the ‘197 patent and/or that ’947 patent and the ‘197 patent are invalid or unenforceable. The Annora Notice Letter asserts that its generic product will not infringe the ‘430 patent, ’947 patent and the ‘197 patent and/or that the ‘430 patent, ’947 patent and the ‘197 patent are invalid or unenforceable. The Novitium Notice Letter asserts that its generic product will not infringe the ‘430 patent, ’947 patent and the ‘197 patent and/or that the ‘430 patent, ’947 patent and the ‘197 patent are invalid or unenforceable. The Zenara Notice Letter asserts that its generic product will not infringe the ‘430 patent, ’947 patent and the ‘197 patent and/or that the ‘430 patent, ’947 patent and the ‘197 patent are invalid or unenforceable. On November 21, 2023, we, Bioprojet and Bioprojet Pharma filed a complaint for patent infringement of the ’947 patent and the ‘197 patent against AET, Annora, Novitium and Zenara and certain of their affiliates and agents and for patent infringement of the ’430 patent against Annora, Novitium and Zenara and certain of their affiliates and agents in the United States District Court for the District of Delaware in response to their filing of their respective ANDAs with the FDA.

In October 2023, MSN Pharmaceuticals Inc. (“MSN Pharma”) sent correspondence to us and Bioprojet stating that MSN Pharma has submitted ANDA No. 218873 (the “MSN ANDA”) to the FDA and is seeking regulatory approval to market a generic version of WAKIX^®_.On December 8, 2023, MSN Laboratories Private Limited (“MSN”) filed a declaratory judgment action in the United States District Court for the Eastern District of Virginia against Bioprojet claiming that the ‘430 patent, the ’947 patent and the ‘197 patent will not be infringed by MSN’s generic version of WAKIX^®and that the ‘947 patent is invalid. On December 11, 2023, we, Bioprojet and Bioprojet Pharma filed a complaint in the United States District Court for the District of Delaware for patent infringement of the ‘430 patent, the ’947 patent and the‘197 patent against MSN and MSN Pharma. On January 12, 2024, the declaratory judgment action was transferred from the United States District Court for the Eastern District of Virginia to the United States District Court for the District of Delaware.

On April 15, 2024, the United States District Court for the District of Delaware issued a scheduling order consolidating the cases described above for all purposes up to and including trial (the “Scheduling Order”). The Scheduling Order set March 27, 2025 as the date for the hearing on claim construction and scheduled a four-day bench trial beginning on February 17, 2026.

Table of Contents

Item 1A. Risk Factors.

In addition to the other information included in this report, you should carefully consider the discussion of risk factors affecting the Company as set forth in Part I, Item 1A "Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2023, which could materially affect our business, financial condition or future results. The risks described in these reports are not the only risks facing the Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, and operating results.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

Rule 10b5-1 Trading Arrangements

On February 23, 2024, Jeffrey Dierks, Chief Commercial Officer of the Company, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 35,708 shares of the Company’s common stock related to the exercise of options beginning on July 1, 2024 and until December 31, 2024.

During the three months ended March 31, 2024, no director or officer of the Company terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Epygenix Acquisition

On April 30, 2024, the Company announced that its subsidiary Zynerba Pharmaceuticals, Inc. (“Zynerba”) acquired all of the issued and outstanding capital stock of Epygenix Therapeutics, Inc., a Wyoming corporation (“Epygenix”), pursuant to the terms of a stock purchase agreement. In connection with the closing of the transaction, Zynerba paid the former stockholders of Epygenix up front consideration of $35 million (which amount is subject to adjustment following the closing). In addition, Zynerba will also be obligated to pay up to $130 million upon the achievement of development and regulatory milestones and up to $515 million upon the achievement of certain sales-based milestones, in each case to Epygenix’s former stockholders. Epygenix has an exclusive license relating to the use of clemizole for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome.

Table of Contents

Item 6. Exhibits.

Exhibit		Incorporated by Reference
No.	Exhibit Description	Form	Date	Number
2.1+	Agreement and Plan of Merger, dated August 14, 2023, by and among Harmony Biosciences Holdings, Inc., Xylophone Acquisition Corp. and Zynerba Pharmaceuticals, Inc.	8-K/A	September 14, 2023	2.1
3.1	Amended and Restated Certificate of Incorporation of Harmony Biosciences Holdings, Inc.	8-K	August 21, 2020	3.1
3.2	Amended and Restated Bylaws.	8-K	August 21, 2020	3.2
10.1*	Amendment No. 1 to License and Commercialization Agreement, dated July 31, 2022, by and between Bioprojet Société Civile de Recherche and Harmony Biosciences, LLC.
10.2*	Amendment No. 2 to License and Commercialization Agreement, dated July 28, 2017, by and between Bioprojet Société Civile de Recherche and Harmony Biosciences, LLC.
31.1*	Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101*	The following financial statements from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023 formatted in Inline XBRL: (i) Balance Sheets, (ii) Statements of Operations, (iii) Statements of Stockholders’ Equity and (vi) Notes to Financial Statements, tagged as blocks of text and including detailed tags.
104*	Cover Page Interactive Date File (formatted as Inline XBRL and contained in Exhibit 101)

*	Filed herewith.

Furnished herewith. This certification is deemed furnished, and not filed, with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Harmony Biosciences Holdings, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934 for any schedules so furnished.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	HARMONY BIOSCIENCES HOLDINGS, INC.

	By:		/s/ Jeffrey M. Dayno
	Name:		Jeffrey M. Dayno
	Title:		President, Chief Executive Officer and Director (principal executive officer)
	Date:		April 30, 2024

	By:		/s/ Sandip Kapadia
	Name:		Sandip Kapadia
	Title:		Chief Financial Officer and Chief Administrative Officer (principal financial officer)
	Date:		April 30, 2024

EX-10.1 2 hrmy-20240331xex10d1.htm EX-10.1

AMENDMENT NO. 1

LICENSE AND COMMERCIALIZATION AGREEMENT

This Amendment No. 1, dated as of April 6, 2024 (this “First Amendment”), to the License and Commercialization Agreement, dated as of July 31, 2022, (the “Agreement”), is entered into between Bioprojet Société Civile de Recherche, an independent (privately) owned research company organized under the laws of France and having its principal place of business at 30, rue des Francs-Bourgeois, 75003 Paris, France (together with its Affiliates, including Bioprojet Pharma SAS and Bioprojet Europe Ltd., “Bioprojet”), and Harmony Biosciences, LLC, a limited liability company organized under the laws of Delaware and having its principal place of business at 630 W. Germantown Pike, Suite 215, Plymouth Meeting, Pennsylvania 19462 USA (“Partner”). Capitalized terms used, but not otherwise defined, in this First Amendment shall have the meanings ascribed to them in the Agreement. Bioprojet and Partner may be referred to herein, together, as the “Parties” and, individually, as a “Party.”

WHEREAS, the Parties have previously entered into the Agreement;

WHEREAS, the Parties have agreed to expand their collaboration by entering into a co-development agreement with respect to an orexin program in-licensed from Teijin; and

WHEREAS, in accordance with the Agreement, the Parties desire to further amend the Agreement, upon the terms and subject to the conditions set forth herein.

NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the adequacy and receipt of which hereby are acknowledged, the Parties hereby agree as follows:

1. The Parties hereby agree that Section 1.41 (“Field Products”) of the Agreement is hereby deleted in its entirety.

2. The Parties hereby agree that Section 8.3 (“Exclusivity of Efforts - Harmony”) of the Agreement is hereby deleted in its entirety.

3. This First Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Signatures to this First Amendment delivered by facsimile or similar electronic transmission will be deemed to be binding as originals. This First Amendment is established in the English language. Any translation in another language shall be deemed for convenience only and shall never prevail over the original English version.

4. Except as otherwise provided herein, the Agreement shall remain unchanged and in full force and effect.

5. From and after the execution of this First Amendment by the Parties, any reference to the Agreement shall be deemed to be a reference to the Agreement as amended by this First Amendment.

6. The provisions of Article 19 and Sections 20.2 to 20.13 of the Agreement apply to this First Amendment mutatis mutandis, except that in accordance with paragraph 5 above references to “Agreement” shall be read as references to this First Amendment.

[SIGNATURE PAGE FOLLOWS]

‌Hogan Lovells

IN WITNESS WHEREOF, the Parties have executed this First Amendment as of the day and year first written above.


BIOPROJET SOCIÉTÉ CIVILE DE RECHERCHE


By:		/s/ Jeanne-Marie Lecomte
Name:		Jeanne-Marie Lecomte
Title:		Chairman

HARMONY BIOSCIENCES, LLC


By:		/s/ Jeffrey M Dayno, MD
Name:		Jeffrey M Dayno, MD
Title:		President & Chief Executive Officer

EX-10.2 3 hrmy-20240331xex10d2.htm EX-10.2

AMENDMENT NO. 2

LICENSE AND COMMERCIALIZATION AGREEMENT

This Amendment No. 2, dated as of April 6, 2024 (this “Second Amendment”), to the License and Commercialization Agreement, dated as of July 28, 2017, and amended on August 27, 2018 (the “First Amendment”, collectively the “Agreement”), is entered into between Bioprojet Société Civile de Recherche, an independent (privately) owned research company organized under the laws of France and having its principal place of business at 30, rue des Francs-Bourgeois, 75003 Paris, France (“Bioprojet SCR”) and together with its Affiliates, including Bioprojet Pharma SARL and Bioprojet Europe Ltd., “Bioprojet”), and Harmony Biosciences, LLC, a limited liability company organized under the laws of Delaware and having its principal place of business at 630 W. Germantown Pike, Suite 215, Plymouth Meeting, Pennsylvania 19462 USA (“Partner”). Capitalized terms used, but not otherwise defined, in this Second Amendment shall have the meanings ascribed to them in the Agreement. Bioprojet and Partner may be referred to herein, together, as the “Parties” and, individually, as a “Party.”

WHEREAS, the Parties have previously entered into the Agreement and the First Amendment;

WHEREAS, the Parties have agreed to expand their collaboration by entering into a co-development agreement with respect to an orexin program in-licensed from Teijin; and

WHEREAS, in accordance with the Agreement, the Parties desire to further amend the Agreement, upon the terms and subject to the conditions set forth herein.

NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the adequacy and receipt of which hereby are acknowledged, the Parties hereby agree as follows:

1. The Parties hereby agree that Section 1.20 (“Field Products”) of the Agreement is hereby deleted in its entirety.

2. The Parties hereby agree that Section 8.3 (“Exclusivity of Efforts”) of the Agreement is hereby deleted in its entirety.

3. This Second Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Signatures to this Second Amendment delivered by facsimile or similar electronic transmission will be deemed to be binding as originals. This Second Amendment is established in the English language. Any translation in another language shall be deemed for convenience only and shall never prevail over the original English version.

4. Except as otherwise provided herein, the Agreement shall remain unchanged and in full force and effect.

5. From and after the execution of this Second Amendment by the Parties, any reference to the Agreement shall be deemed to be a reference to the Agreement as amended by this Second Amendment.

6. The provisions of Article 19 and Sections 20.2 to 20.8, 20.10 and 20.11 of the Agreement apply to this Second Amendment mutatis mutandis, except that in accordance with paragraph 5 above references to “Agreement” shall be read as references to this Second Amendment.

[SIGNATURE PAGE FOLLOWS]

‌Hogan Lovells

IN WITNESS WHEREOF, the Parties have executed this Second Amendment as of the day and year first written above.


BIOPROJET SOCIÉTÉ CIVILE DE RECHERCHE


By:		/s/ Jeanne-Marie Lecomte
Name:		Jeanne-Marie Lecomte
Title:		Chairman

HARMONY BIOSCIENCES, LLC


By:		/s/ Jeffrey M Dayno, MD
Name:		Jeffrey M Dayno, MD
Title:		President & Chief Executive Officer

EX-31.1 4 hrmy-20240331xex31d1.htm EX-31.1

Exhibit 31.1

Certification of Principal Executive Officer

I, Jeffrey M. Dayno, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Harmony Biosciences Holdings, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: April 30, 2024	By:	/s/ Jeffrey M. Dayno
		Jeffrey M. Dayno
		President, Chief Executive Officer and Director (Principal Executive Officer)

EX-31.2 5 hrmy-20240331xex31d2.htm EX-31.2

Exhibit 31.2

Certification of Principal Financial Officer

I, Sandip Kapadia, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Harmony Biosciences Holdings, Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: April 30, 2024	By:	/s/ Sandip Kapadia
		Sandip Kapadia
		Chief Financial Officer and Chief Administrative Officer (Principal Financial Officer and Principal Accounting Officer)

EX-32.1 6 hrmy-20240331xex32d1.htm EX-32.1

Exhibit 32.1

Certification of Principal Executive Officer

Pursuant To 18 U.S.C. Section 1350,

as Adopted Pursuant to

Section 906 of The Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Harmony Biosciences Holdings, Inc. (the “Company”) for the quarter ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to such officer’s knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: April 30, 2024	By:	/s/ Jeffrey M. Dayno
		Jeffrey M. Dayno
		President, Chief Executive Officer and Director (Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as a part of the Report or on a separate disclosure document.

EX-32.2 7 hrmy-20240331xex32d2.htm EX-32.2

Exhibit 32.2

Certification of Principal Financial Officer

Pursuant To 18 U.S.C. Section 1350,

as Adopted Pursuant to

Section 906 of The Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Harmony Biosciences Holdings, Inc. (the “Company”) for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to such officer’s knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: April 30, 2024	By:	/s/ Sandip Kapadia
		Sandip Kapadia
		Chief Financial Officer and Chief Administrative Officer (Principal Financial Officer and Principal Accounting Officer)

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as a part of the Report or on a separate disclosure document.

EX-101.SCH 8 hrmy-20240331.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - INVESTMENTS - Carrying Value and Amortized Cost of Available-For-Sale Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - INVENTORY (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Debt - Balances of Long-term Debt, Net (Details) calc 2 link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - INTANGIBLE ASSETS - Schedule of Future Annual Amortization Expense for Unamortized Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - INTANGIBLE ASSETS - Schedule of Gross Carrying Amount and Net Book Value of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40904 - Disclosure - LEASES - Future payments (Details) (Calc2) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - DEBT - Balances of Long-term Debt, Net (Details) link:presentationLink link:calculationLink link:definitionLink 41103 - Disclosure - DEBT - Future Minimum Payments (Details) link:presentationLink link:calculationLink link:definitionLink 41104 - Disclosure - DEBT - Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 41202 - Disclosure - LEASES - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 41204 - Disclosure - LEASES - Future Payments (Details) link:presentationLink link:calculationLink link:definitionLink 41701 - Disclosure - INCOME TAXES - Schedule of Difference Between Statutory Federal Income Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - ACQUISITION (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - FAIR VALUE MEASUREMENTS - Assets Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - INTANGIBLE ASSETS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - DEBT - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41503 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in SARs Granted (Details) link:presentationLink link:calculationLink link:definitionLink 41504 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in RSUs Granted (Details) link:presentationLink link:calculationLink link:definitionLink 41505 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Assumptions Used to Value Awards (Details) link:presentationLink link:calculationLink link:definitionLink 41506 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 41603 - Disclosure - EARNINGS PER SHARE - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 41801 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 41901 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - ACQUISITION link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - INVENTORY link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 11601 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 11701 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 11801 - Disclosure - RELATED-PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 11901 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 20302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - INVENTORY (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 31503 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 31603 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 31703 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 41203 - Disclosure - LEASES - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 41502 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in Stock Options Granted (Details) link:presentationLink link:calculationLink link:definitionLink 41601 - Disclosure - EARNINGS PER SHARE - Summary of Computation of Basic and Diluted Net Income (Loss) per Share (Details) link:presentationLink link:calculationLink link:definitionLink 41602 - Disclosure - EARNINGS PER SHARE - Summary of Securities Outstanding Included in Computation above, Utilizing Treasury Stock Method (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 hrmy-20240331_cal.xml EX-101.CAL EX-101.DEF 10 hrmy-20240331_def.xml EX-101.DEF EX-101.LAB 11 hrmy-20240331_lab.xml EX-101.LAB Cover [Abstract] Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address Postal Zip Code Entity Address, Postal Zip Code Entity Address Address Line1 Entity Address, Address Line One Entity Address Address Line2 Entity Address, Address Line Two Entity Address Address Line3 Entity Address, Address Line Three Entity Address City Or Town Entity Address, City or Town Entity Address State Or Province Entity Address, State or Province City Area Code City Area Code Local Phone Number Local Phone Number Security12b Title Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Current Fiscal Year End Date Current Fiscal Year End Date Entity Shell Company Entity Shell Company Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Amendment Flag Amendment Flag UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Table] Statement [Line Items] Statement Assets [Abstract] ASSETS Assets acquired Assets Current [Abstract] CURRENT ASSETS: Cash And Cash Equivalents At Carrying Value Cash and cash equivalents Short-Term Investments Investments, short-term Accounts Receivable Net Current Trade receivables, net Inventory Net Inventory, net Total inventory, net Prepaid Expense Current Prepaid expenses Other Assets Current Other current assets Assets Current Total current assets Assets Noncurrent [Abstract] NONCURRENT ASSETS: Property Plant And Equipment Net Property and equipment, net Restricted Cash Noncurrent Restricted cash Long-Term Investments Investments, long-term Intangible Assets Net Excluding Goodwill Intangible assets, net Net Book Value Deferred Income Tax Assets, Net Deferred tax asset Other Assets Noncurrent Other noncurrent assets Assets Noncurrent Total noncurrent assets Assets TOTAL ASSETS Liabilities And Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities Current [Abstract] CURRENT LIABILITIES: Accounts Payable Current Trade payables Accrued Employee Benefits Current Accrued compensation Carrying value as of the balance sheet date of accrued liabilities other than accrued compensation. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Liabilities, other than Accrued Compensation, Current Accrued expenses Long-term Debt, Current Maturities Less current portion Current portion of long-term debt Other Liabilities Current Other current liabilities Liabilities Current Total current liabilities Liabilities Noncurrent [Abstract] NONCURRENT LIABILITIES: Long Term Debt Noncurrent Long-term debt, net Other Liabilities Noncurrent Other noncurrent liabilities Liabilities Noncurrent Total noncurrent liabilities Liabilities TOTAL LIABILITIES Commitments And Contingencies COMMITMENTS AND CONTINGENCIES (Note 13) Stockholders Equity [Abstract] STOCKHOLDERS' EQUITY: Common Stock Value Common stock-$0.00001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 56,791,214 and 56,769,081 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively Additional Paid In Capital Common Stock Additional paid in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive (loss) income Retained Earnings Accumulated Deficit Accumulated deficit Accumulated deficit Stockholders Equity Ending balance Beginning balance TOTAL STOCKHOLDERS' EQUITY Liabilities And Stockholders Equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Common Stock Par or Stated Value Per Share Common stock, par value Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME Revenue From Contract With Customer Excluding Assessed Tax Net product revenue Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Cost Of Goods And Services Sold Cost of product sold Cost, Product and Service [Extensible Enumeration] Gross Profit Gross profit Operating Expenses [Abstract] Operating expenses: Research And Development Expense. Research and development Selling And Marketing Expense Sales and marketing General And Administrative Expense. General and administrative Operating Expenses Total operating expenses Operating Income Loss Operating income Other Nonoperating Income Expense Other (expense) income, net Interest Expense Interest expense Investment Income, Nonoperating Interest income Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Income before income taxes Income Tax Expense Benefit Income tax expense Net income Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Unrealized loss on investments Unrealized (loss) income on investments Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income EARNINGS PER SHARE EARNINGS PER SHARE: Denominator Earnings Per Share Basic Basic Net income per share of common stock - basic Earnings Per Share Diluted Diluted Net income per share of common stock - diluted Weighted Average Number Of Shares Outstanding Basic Weighted average number of shares of common stock - basic Weighted Average Number Of Diluted Shares Outstanding Weighted average number of shares of common stock - diluted UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement Equity Components [Axis] Equity Component Common Stock Additional paid-in capital Accumulated other comprehensive (loss) income Accumulated Deficit Accumulated deficit Shares Outstanding Ending balance, shares Beginning balance, shares Value of stock issued as a result of the exercise of stock options and restricted stock units. Stock Issued During Period, Value, Stock Options and Restricted Stock Units Exercised Exercise of options and restricted stock units Number of share options and restricted stock units exercised during the current period. Stock Issued During Period, Shares, Stock Options and Restricted Stock Units Exercised Exercise of options and restricted stock units, Shares Stock Issued During Period Value Stock Options Exercised Exercise of stock options Stock Issued During Period Shares Stock Options Exercised Number of Awards, Awards exercised Exercise of stock options , Shares Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Stock-based compensation UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided By Used In Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Profit Loss Net income Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net income to net cash used in operating activities: Depreciation Depreciation Amortization Of Intangible Assets Intangible amortization Amortization expense Share Based Compensation Stock-based and employee stock purchase compensation expense Stock appreciation rights market adjustment. Stock Appreciation Rights Market Adjustment Stock appreciation rights market adjustment Amount of amortization expense attributable to debt issuance costs. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Adjustment for Amortization of Debt Issuance Costs Debt issuance costs amortization Deferred Income Taxes and Tax Credits Deferred taxes Accretion (Amortization) of Discounts and Premiums, Investments Amortization of premiums and accretion of discounts on Investment securities Other Noncash Expense Other non-cash expenses Increase Decrease In Operating Capital [Abstract] Change in operating assets and liabilities: Increase Decrease In Accounts Receivable Trade receivables Increase Decrease In Inventories Inventory Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid expenses and other assets Increase Decrease In Accounts Payable Trade Trade payables Increase (Decrease) in Other Operating Liabilities Other liabilities Net Cash Provided By Used In Operating Activities Net cash provided by operating activities Net Cash Provided By Used In Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Payments to Acquire Debt Securities, Available-for-Sale Purchase of investment securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Proceeds from maturities and sales of investment securities Payments To Acquire Property Plant And Equipment Purchase of property and equipment Net Cash Provided By Used In Investing Activities Net cash used in investing activities Net Cash Provided By Used In Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Repayments of Long-term Debt Principal repayment of long term debt Proceeds From Stock Options Exercised Proceeds from exercised options Net Cash Provided By Used In Financing Activities Net cash (used in) provided by financing activities Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CASH, CASH EQUIVALENTS, AND RESTRICTED CASH-End of period CASH, CASH EQUIVALENTS, AND RESTRICTED CASH-Beginning of period Total cash, cash equivalents, and restricted cash shown in the statements of cash flows Supplemental Cash Flow Information [Abstract] Supplemental Disclosure of Cash Flow Information: Interest Paid Net Cash paid during the year for interest ORGANIZATION AND DESCRIPTION OF BUSINESS Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] ORGANIZATION AND DESCRIPTION OF BUSINESS Liquidity and capital resources. LIQUIDITY AND CAPITAL RESOURCES Liquidity and capital resources. Liquidity And Capital Resources [Text Block] LIQUIDITY AND CAPITAL RESOURCES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES ACQUISITION Asset Acquisition [Text Block] ACQUISITION INVESTMENTS Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] INVESTMENTS FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] FAIR VALUE MEASUREMENTS INVENTORY Inventory Disclosure [Text Block] INVENTORY INTANGIBLE ASSETS Intangible Assets Disclosure [Text Block] INTANGIBLE ASSETS License and asset purchase agreements. LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS Disclosure of license and asset purchase agreements. License and Asset Purchase Agreements [Text Block] LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS ACCRUED EXPENSES Accounts Payable And Accrued Liabilities Disclosure [Text Block] ACCRUED EXPENSES DEBT Debt Disclosure [Text Block] DEBT LEASES Lessee, Operating Leases [Text Block] LEASES COMMITMENTS AND CONTINGENCIES. Commitments And Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY Stockholders Equity Note Disclosure [Text Block] STOCKHOLDERS' EQUITY STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION Disclosure Of Compensation Related Costs Share Based Payments [Text Block] STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION Earnings Per Share [Text Block] EARNINGS PER SHARE INCOME TAXES Income Tax Disclosure [Text Block] INCOME TAXES RELATED-PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] RELATED-PARTY TRANSACTIONS SUBSEQUENT EVENTS Subsequent Events [Text Block] SUBSEQUENT EVENTS Basis Of Accounting Policy Policy [Text Block] Basis of Presentation Reclassification, Comparability Adjustment [Policy Text Block] Reclassifications Significant risks and uncertainties. Significant Risks And Uncertainties Policy [Text Block] Significant Risks and Uncertainties Use Of Estimates Use of Estimates Segment Reporting Policy Policy [Text Block] Operating Segments Fair Value Of Financial Instruments Policy Fair Value of Financial Instruments Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy Cash, Cash Equivalents and Restricted Cash Investment, Policy [Policy Text Block] Investments EX-101.PRE 12 hrmy-20240331_pre.xml EX-101.PRE XML 14 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2024	Apr. 26, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-39450
Entity Registrant Name	HARMONY BIOSCIENCES HOLDINGS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-2279923
Entity Address, Postal Zip Code	19462
Entity Address, Address Line One	630 W.
Entity Address, Address Line Two	Germantown Pike
Entity Address, Address Line Three	Suite 215
Entity Address, City or Town	Plymouth Meeting
Entity Address, State or Province	PA
City Area Code	484
Local Phone Number	539-9800
Title of 12(b) Security	Common Stock, par value $0.00001 value per share
Trading Symbol	HRMY
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Current Fiscal Year End Date	--12-31
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		56,791,861
Entity Central Index Key	0001802665
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Amendment Flag	false

XML 15 R2.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 332,981	$ 311,660
Investments, short-term	39,369	41,800
Trade receivables, net	79,719	74,140
Inventory, net	5,857	5,363
Prepaid expenses	12,894	12,570
Other current assets	8,683	5,537
Total current assets	479,503	451,070
NONCURRENT ASSETS:
Property and equipment, net	213	371
Restricted cash	270	270
Investments, long-term	81,244	72,169
Intangible assets, net	131,147	137,108
Deferred tax asset	147,639	144,162
Other noncurrent assets	6,969	6,298
Total noncurrent assets	367,482	360,378
TOTAL ASSETS	846,985	811,448
CURRENT LIABILITIES:
Trade payables	15,144	17,730
Accrued compensation	7,317	23,747
Accrued expenses	91,699	99,494
Current portion of long-term debt	15,000	15,000
Other current liabilities	25,093	7,810
Total current liabilities	154,253	163,781
NONCURRENT LIABILITIES:
Long-term debt, net	174,996	178,566
Other noncurrent liabilities	2,342	2,109
Total noncurrent liabilities	177,338	180,675
TOTAL LIABILITIES	331,591	344,456
COMMITMENTS AND CONTINGENCIES (Note 13)
STOCKHOLDERS' EQUITY:
Common stock-$0.00001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 56,791,214 and 56,769,081 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	1	1
Additional paid in capital	620,507	610,266
Accumulated other comprehensive (loss) income	(171)	2
Accumulated deficit	(104,943)	(143,277)
TOTAL STOCKHOLDERS' EQUITY	515,394	466,992
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 846,985	$ 811,448

XML 16 R3.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	56,791,214	56,769,081
Common stock, shares outstanding	56,791,214	56,769,081

XML 17 R4.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
Net product revenue	$ 154,615	$ 119,126
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	us-gaap:ProductMember	us-gaap:ProductMember
Cost of product sold	$ 27,484	$ 20,780
Cost, Product and Service [Extensible Enumeration]	us-gaap:ProductMember	us-gaap:ProductMember
Gross profit	$ 127,131	$ 98,346
Operating expenses:
Research and development	22,189	13,289
Sales and marketing	27,233	22,572
General and administrative	25,676	22,062
Total operating expenses	75,098	57,923
Operating income	52,033	40,423
Other (expense) income, net	(141)	2
Interest expense	(4,535)	(5,731)
Interest income	4,428	3,086
Income before income taxes	51,785	37,780
Income tax expense	(13,451)	(8,295)
Net income	38,334	29,485
Unrealized (loss) income on investments	(173)	120
Comprehensive income	$ 38,161	$ 29,605
EARNINGS PER SHARE:
Basic	$ 0.68	$ 0.49
Diluted	$ 0.67	$ 0.48
Weighted average number of shares of common stock - basic	56,771,251	59,732,157
Weighted average number of shares of common stock - diluted	57,597,627	61,221,511

XML 18 R5.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock	Additional paid-in capital	Accumulated other comprehensive (loss) income	Accumulated deficit	Total
Beginning balance at Dec. 31, 2022	$ 1	$ 675,118	$ (151)	$ (272,130)	$ 402,838
Beginning balance, shares at Dec. 31, 2022	59,615,731
Net Income (Loss)				29,485	29,485
Unrealized loss on investments			120		120
Exercise of stock options		3,395			3,395
Exercise of stock options , Shares	338,887
Stock-based compensation		7,203			7,203
Ending balance at Mar. 31, 2023	$ 1	685,716	(31)	(242,645)	443,041
Ending balance, shares at Mar. 31, 2023	59,954,618
Beginning balance at Dec. 31, 2023	$ 1	610,266	2	(143,277)	466,992
Beginning balance, shares at Dec. 31, 2023	56,769,081
Net Income (Loss)				38,334	38,334
Unrealized loss on investments			(173)		(173)
Exercise of options and restricted stock units		(153)			$ (153)
Exercise of options and restricted stock units, Shares	22,133
Exercise of stock options , Shares					14,120
Stock-based compensation		10,394			$ 10,394
Ending balance at Mar. 31, 2024	$ 1	$ 620,507	$ (171)	$ (104,943)	$ 515,394
Ending balance, shares at Mar. 31, 2024	56,791,214

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2

+ Details

XML 19 R6.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 38,334	$ 29,485
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation	163	103
Intangible amortization	5,961	5,961
Stock-based and employee stock purchase compensation expense	10,394	7,203
Stock appreciation rights market adjustment	40	(642)
Debt issuance costs amortization	180	416
Deferred taxes	(3,477)	(3,442)
Amortization of premiums and accretion of discounts on Investment securities	(594)	(636)
Other non-cash expenses	467	369
Change in operating assets and liabilities:
Trade receivables	(5,579)	2,165
Inventory	(494)	207
Prepaid expenses and other assets	(3,439)	592
Trade payables	(2,586)	2,628
Other liabilities	(8,229)	(1,850)
Net cash provided by operating activities	31,141	42,559
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of investment securities	(25,106)	(47,776)
Proceeds from maturities and sales of investment securities	18,925	45,986
Purchase of property and equipment	(5)
Net cash used in investing activities	(6,186)	(1,790)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal repayment of long term debt	(3,750)	(500)
Proceeds from exercised options	116	3,909
Net cash (used in) provided by financing activities	(3,634)	3,409
NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	21,321	44,178
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH-Beginning of period	311,930	244,534
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH-End of period	333,251	288,712
Supplemental Disclosure of Cash Flow Information:
Cash paid during the year for interest	$ 4,585	$ 5,017

XML 20 R7.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND DESCRIPTION OF BUSINESS

3 Months Ended

Mar. 31, 2024

ORGANIZATION AND DESCRIPTION OF BUSINESS

ORGANIZATION AND DESCRIPTION OF BUSINESS

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

The Company

XML 21 R8.htm IDEA: XBRL DOCUMENT

LIQUIDITY AND CAPITAL RESOURCES

3 Months Ended

Mar. 31, 2024

LIQUIDITY AND CAPITAL RESOURCES

LIQUIDITY AND CAPITAL RESOURCES

2. LIQUIDITY AND CAPITAL RESOURCES

XML 22 R9.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2024

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Reclassifications

Significant Risks and Uncertainties

Use of Estimates

Operating Segments

Fair Value of Financial Instruments

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.

Cash, Cash Equivalents and Restricted Cash


	As of
	March 31,		December 31,
	2024		2023
Cash and cash equivalents	$	332,981	$	311,660
Restricted cash		270		270
Total cash, cash equivalents, and restricted cash shown in the statements of cash flows	$	333,251	$	311,930

Restricted cash includes amounts required to be held as a security deposit in the form of letters of credit for the Company’s credit card program and the fleet program.

Investments

Concentrations of Risk

The Company depends on a single supplier for its product and a single supplier for its active pharmaceutical ingredient.

Share Repurchases

Business Combinations

Recently Issued Accounting Pronouncements

In November 2023, the FASB issued Accounting Standards Update (“ASU”) No. 2023-07, Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 is intended to improve

XML 23 R10.htm IDEA: XBRL DOCUMENT

ACQUISITION

3 Months Ended

Mar. 31, 2024

ACQUISITION

ACQUISITION

4. ACQUISITION

5. INVESTMENTS

XML 24 R11.htm IDEA: XBRL DOCUMENT

INVESTMENTS

3 Months Ended

Mar. 31, 2024

INVESTMENTS

INVESTMENTS

The carrying value and amortized cost of the Company’s available-for-sale debt securities, summarized by type of security, consisted of the following:


	March 31, 2024
		Amortized	Unrealized	Unrealized		Fair
		Cost	Gains	Losses		Value
Short-term:
Commercial paper	$	23,038	10	(7)	$	23,041
Corporate debt securities		16,316	16	(4)		16,328
Total short-term investments	$	39,354	26	(11)	$	39,369

Long-term:
Corporate debt securities		51,062	61	(50)		51,073
U.S. government securities		30,368	—	(197)		30,171
Total long-term investments	$	81,430	61	(247)	$	81,244


	December 31, 2023
		Amortized	Unrealized	Unrealized		Fair
		Cost	Gains	Losses		Value
Short-term:
Commercial paper	$	23,832	36	(3)	$	23,865
Corporate debt securities		15,968	28	—		15,996
U.S. government securities		1,940	—	(1)		1,939
Total short-term investments	$	41,740	64	(4)	$	41,800

Long-term:
Commercial paper	$	744	—	—	$	744
Corporate debt securities		42,688	81	(28)		42,741
U.S. government securities		28,795	7	(118)		28,684
Total long-term investments	$	72,227	88	(146)	$	72,169

XML 25 R12.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS

3 Months Ended

Mar. 31, 2024

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS

6. FAIR VALUE MEASUREMENTS

The Company’s assets measured at fair value consisted of the following:


	March 31, 2024				December 31, 2023
		Total	Level 1	Level 2		Total	Level 1	Level 2
Assets
Cash equivalents	$	264,079	264,079	—	$	244,569	243,685	884
Commercial paper		23,041	—	23,041		24,609	—	24,609
Corporate debt securities		67,401	—	67,401		58,737	—	58,737
U.S. government securities		30,171	—	30,171		30,623	—	30,623
Total	$	384,692	264,079	120,613	$	358,538	243,685	114,853

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 26 R13.htm IDEA: XBRL DOCUMENT

INVENTORY

3 Months Ended

Mar. 31, 2024

INVENTORY

INVENTORY

7. INVENTORY

Inventory, net consisted of the following:


	As of
	March 31,		December 31,
	2024		2023
Raw materials	$	1,009	$	1,060
Work in process		1,748		2,020
Finished goods		3,100		2,283
Total inventory, net	$	5,857	$	5,363

XML 27 R14.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS

3 Months Ended

Mar. 31, 2024

INTANGIBLE ASSETS

INTANGIBLE ASSETS

8. INTANGIBLE ASSETS

The Company expects the future annual amortization expense for the unamortized intangible assets to be as follows:


Years ending December 31,
2024 (excluding the three months ended March 31, 2024)	$	17,884
2025		23,845
2026		23,845
2027		23,845
2028		23,845
Thereafter		17,883
Total	$	131,147

The gross carrying amount and net book value of the intangible asset is as follows:


	As of
	March 31,		December 31,
	2024		2023
Gross Carrying Amount	$	215,000	$	215,000
Accumulated Amortization		(83,853)		(77,892)
Net Book Value	$	131,147	$	137,108

XML 28 R15.htm IDEA: XBRL DOCUMENT

LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS

3 Months Ended

Mar. 31, 2024

LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS

LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS

9. LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS

License Agreements

Agreement Related to Intellectual Property

XML 29 R16.htm IDEA: XBRL DOCUMENT

ACCRUED EXPENSES

3 Months Ended

Mar. 31, 2024

ACCRUED EXPENSES

ACCRUED EXPENSES

10. ACCRUED EXPENSES

Accrued expenses consist of the following:


	As of
	March 31,		December 31,
	2024		2023
Royalties due to Bioprojet	$	24,738	$	40,419
Rebates and other sales deductions		48,165		38,842
Interest		3,125		3,354
Sales and marketing		2,999		2,354
Research and development		7,898		9,835
Professional fees, consulting, and other services		1,918		2,195
Other expenses		2,856		2,495
	$	91,699	$	99,494

XML 30 R17.htm IDEA: XBRL DOCUMENT

DEBT

3 Months Ended

Mar. 31, 2024

DEBT

DEBT

11. DEBT

Term Loan A Credit Agreement

Long-term debt, net consists of the following:


	March 31,		December 31,
	2024		2023
Principal amount	$	192,500	$	196,250
Unamortized debt discount associated with debt financing costs		(2,504)		(2,684)
Total debt, net		189,996		193,566
Less current portion		(15,000)		(15,000)
Long-term debt, net	$	174,996	$	178,566

Future minimum payments relating to total debt, net as of March 31, 2024, for the periods indicated below consists of the following:


Years ending December 31,
2024 (excluding the three months ended March 31, 2024)	$	11,250
2025		16,250
2026		20,000
2027		20,000
2028		125,000
Thereafter		—
Total	$	192,500


	Three Months Ended
	March 31,
	2024		2023
Interest on principal balance	$	4,355	$	5,315
Amortization of deferred financing costs		180		416
Total term loan interest expense	$	4,535	$	5,731

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

XML 31 R18.htm IDEA: XBRL DOCUMENT

LEASES

3 Months Ended

Mar. 31, 2024

LEASES

LEASES

12. LEASES

The Company recorded operating lease costs of $509 and $378 for the three months ended March 31, 2024, and 2023, respectively.

As of March 31, 2024, the weighted-average remaining lease term for operating leases was 1.8 years and the weighted-average discount rate for operating leases was 7.32%.

Supplemental balance sheet information related to operating leases was as follows:


Leases	Classification		March 31, 2024		December 31, 2023
Assets
Operating lease right-of-use assets	Other noncurrent assets	$	3,046	$	2,344
Liabilities
Operating lease liability, current portion	Other current liabilities	$	1,793	$	1,437
Operating lease liability, long-term	Other long-term liabilities		1,276		1,082
Total operating lease liabilities		$	3,069	$	2,519

Supplemental cash flow information related to operating leases was as follows:


		March 31, 2024		March 31, 2023
Operating cash flows from operating leases	$	561	$	428
Right of use assets obtained in exchange for operating lease obligations	$	1,198	$	526

Future payments under noncancelable operating leases with initial terms of one year or more as of March 31, 2024, consisted of the following:


Years ending December 31,
2024 (excluding the three months ended March 31, 2024)	$	1,564
2025		1,239
2026		473
2027		3
2028		-
Thereafter		-
Total lease payments		3,279
Less: imputed interest		(210)
Total lease liabilities	$	3,069

XML 32 R19.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2024

COMMITMENTS AND CONTINGENCIES.

COMMITMENTS AND CONTINGENCIES

13. COMMITMENTS AND CONTINGENCIES

Litigation

XML 33 R20.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY

3 Months Ended

Mar. 31, 2024

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY

14. STOCKHOLDERS’ EQUITY

Common Stock

Share Repurchase Program

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

XML 34 R21.htm IDEA: XBRL DOCUMENT

STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION

3 Months Ended

Mar. 31, 2024

STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION

STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION

15. STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION

2020 Stock Incentive Plan

2017 Stock Incentive Plan

Stock Options

The following table summarizes stock option activity for the three months ended March 31, 2024:


				Weighted-
		Weighted-		Average
		Average		Remaining
	Number of	Exercise		Contractual
	Awards	Price		Term
Awards outstanding—December 31, 2023	6,316,422	$	32.47	7.17
Awards issued	1,071,750	$	30.69
Awards exercised	(14,120)	$	8.22
Awards forfeited	(11,529)	$	39.31
Awards outstanding—March 31, 2024	7,362,523	$	32.25	7.35

Stock Appreciation Rights

The following table summarizes SARs activity for the three months ended March 31, 2024:


				Weighted-
		Weighted-		Average
		Average		Remaining
	Number of	Exercise		Contractual
	Awards	Price		Term
Awards outstanding—December 31, 2023	43,208	$	9.38	5.32
Awards issued	—	$	—
Awards exercised	—	$	—
Awards forfeited	—	$	—
Awards outstanding—March 31, 2024	43,208	$	9.38	5.08

Restricted Stock Units

The following table summarizes RSU activity for the three months ended March 31, 2024:



		Weighted-
		Average
	Number of	Grant Date
	Awards	Fair Value
Awards outstanding—December 31, 2023	330,000	$	31.53
Awards issued	387,500	$	30.69
Awards vested	(15,000)	$	29.03
Awards forfeited	(350)	$	30.69
Awards outstanding—March 31, 2024	702,150	$	31.08

As of March 31, 2024, and December 31, 2023, stock awards issued under the 2017 and 2020 Plans of 3,596,040 and 3,298,284 shares of common stock, respectively, were vested.

Value of Stock Options and SARs

The assumptions used to value the awards are summarized in the following table.


	As of
	March 31,		December 31,
	2024		2023
Dividend yield	0.00	%	0.00	%
Expected volatility	72.60 - 72.60	%	74.87 - 80.78	%
Risk-free interest rate	4.06 - 4.20	%	3.42 - 4.62	%
Lack of marketability discount	0.00	%	0.00	%
Expected term (years)	2.01 - 6.11		2.26 - 10.77

Value of RSUs

The fair value of RSUs is equal to the value of the Company’s common stock on the grant date.

The weighted average per share fair value of awards issued under the 2017 Plan and 2020 Plan was $21.13 and $20.64 on March 31, 2024, and December 31, 2023, respectively.

Stock-Based Compensation Expense


	Three Months Ended March 31,
	2024		2023
Research and development expense	$	1,371	$	976
Sales and marketing expense		1,994		1,073
General and administrative expense		7,069		4,512
	$	10,434	$	6,561

Employee Stock Purchase Plan

XML 35 R22.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE

3 Months Ended

Mar. 31, 2024

EARNINGS PER SHARE

EARNINGS PER SHARE

16. EARNINGS PER SHARE

The following table sets forth the computation of basic and diluted net income per share:


	Three Months Ended March 31,
	2024		2023
Numerator
Net income	$	38,334	$	29,485
Denominator
Net income per share of common stock - basic	$	0.68	$	0.49
Net income per share of common stock- diluted	$	0.67	$	0.48
Weighted average number of shares of common stock - basic		56,771,251		59,732,157
Weighted average number of shares of common stock - diluted		57,597,627		61,221,511

Securities outstanding that were included in the computation above, utilizing the treasury stock method are as follows:

Potential shares of common stock issuable that were excluded from the computation of diluted weighted-average shares outstanding excluded from the numerator, are as follows:

XML 36 R23.htm IDEA: XBRL DOCUMENT

INCOME TAXES

3 Months Ended

Mar. 31, 2024

INCOME TAXES

INCOME TAXES

17. INCOME TAXES

A reconciliation between the statutory federal income tax rate and the Company’s effective income tax rate for the three months ended March 31, 2024, and 2023 is as follows:


	Three Months Ended March 31,
	2024		2023
Federal income tax rate	21.0	%	21.0	%
Stock-based compensation	—		(2.8)
State taxes	5.1		6.3
Credits	(1.0)		(2.9)
Other	0.4		0.4
Valuation allowance	0.5		—
Total	26.0	%	22.0	%

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

XML 37 R24.htm IDEA: XBRL DOCUMENT

RELATED-PARTY TRANSACTIONS

3 Months Ended

Mar. 31, 2024

RELATED-PARTY TRANSACTIONS

RELATED-PARTY TRANSACTIONS

18. RELATED-PARTY TRANSACTIONS

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

XML 38 R25.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2024

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

19. SUBSEQUENT EVENTS

XML 39 R26.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2024

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Basis of Presentation

Reclassifications

Reclassifications

Significant Risks and Uncertainties

Significant Risks and Uncertainties

Use of Estimates

Use of Estimates

Operating Segments

Operating Segments

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.

Cash, Cash Equivalents and Restricted Cash

Cash, Cash Equivalents and Restricted Cash


	As of
	March 31,		December 31,
	2024		2023
Cash and cash equivalents	$	332,981	$	311,660
Restricted cash		270		270
Total cash, cash equivalents, and restricted cash shown in the statements of cash flows	$	333,251	$	311,930

Restricted cash includes amounts required to be held as a security deposit in the form of letters of credit for the Company’s credit card program and the fleet program.

Investments

Investments

Concentrations of Risk

Concentrations of Risk

The Company depends on a single supplier for its product and a single supplier for its active pharmaceutical ingredient.

Share Repurchases

Share Repurchases

Business Combinations

Business Combinations

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

In November 2023, the FASB issued Accounting Standards Update (“ASU”) No. 2023-07, Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 is intended to improve

XML 40 R27.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2024

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Schedule of reconciliation of cash, cash equivalents, and restricted cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet and the statements of cash flows.


	As of
	March 31,		December 31,
	2024		2023
Cash and cash equivalents	$	332,981	$	311,660
Restricted cash		270		270
Total cash, cash equivalents, and restricted cash shown in the statements of cash flows	$	333,251	$	311,930

XML 41 R28.htm IDEA: XBRL DOCUMENT

INVESTMENTS (Tables)

3 Months Ended

Mar. 31, 2024

INVESTMENTS

Schedule of carrying value and amortized cost of available-for-sale debt securities

The carrying value and amortized cost of the Company’s available-for-sale debt securities, summarized by type of security, consisted of the following:


	March 31, 2024
		Amortized	Unrealized	Unrealized		Fair
		Cost	Gains	Losses		Value
Short-term:
Commercial paper	$	23,038	10	(7)	$	23,041
Corporate debt securities		16,316	16	(4)		16,328
Total short-term investments	$	39,354	26	(11)	$	39,369

Long-term:
Corporate debt securities		51,062	61	(50)		51,073
U.S. government securities		30,368	—	(197)		30,171
Total long-term investments	$	81,430	61	(247)	$	81,244


	December 31, 2023
		Amortized	Unrealized	Unrealized		Fair
		Cost	Gains	Losses		Value
Short-term:
Commercial paper	$	23,832	36	(3)	$	23,865
Corporate debt securities		15,968	28	—		15,996
U.S. government securities		1,940	—	(1)		1,939
Total short-term investments	$	41,740	64	(4)	$	41,800

Long-term:
Commercial paper	$	744	—	—	$	744
Corporate debt securities		42,688	81	(28)		42,741
U.S. government securities		28,795	7	(118)		28,684
Total long-term investments	$	72,227	88	(146)	$	72,169

XML 42 R29.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Mar. 31, 2024

FAIR VALUE MEASUREMENTS

Schedule of assets measured at fair value

The Company’s assets measured at fair value consisted of the following:


	March 31, 2024				December 31, 2023
		Total	Level 1	Level 2		Total	Level 1	Level 2
Assets
Cash equivalents	$	264,079	264,079	—	$	244,569	243,685	884
Commercial paper		23,041	—	23,041		24,609	—	24,609
Corporate debt securities		67,401	—	67,401		58,737	—	58,737
U.S. government securities		30,171	—	30,171		30,623	—	30,623
Total	$	384,692	264,079	120,613	$	358,538	243,685	114,853

XML 43 R30.htm IDEA: XBRL DOCUMENT

INVENTORY (Tables)

3 Months Ended

Mar. 31, 2024

INVENTORY

Schedule of inventory net

Inventory, net consisted of the following:


	As of
	March 31,		December 31,
	2024		2023
Raw materials	$	1,009	$	1,060
Work in process		1,748		2,020
Finished goods		3,100		2,283
Total inventory, net	$	5,857	$	5,363

XML 44 R31.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Tables)

3 Months Ended

Mar. 31, 2024

INTANGIBLE ASSETS

Schedule of future annual amortization expense for unamortized intangible assets

The Company expects the future annual amortization expense for the unamortized intangible assets to be as follows:


Years ending December 31,
2024 (excluding the three months ended March 31, 2024)	$	17,884
2025		23,845
2026		23,845
2027		23,845
2028		23,845
Thereafter		17,883
Total	$	131,147

Schedule of gross carrying amount and net book value of intangible assets

The gross carrying amount and net book value of the intangible asset is as follows:


	As of
	March 31,		December 31,
	2024		2023
Gross Carrying Amount	$	215,000	$	215,000
Accumulated Amortization		(83,853)		(77,892)
Net Book Value	$	131,147	$	137,108

XML 45 R32.htm IDEA: XBRL DOCUMENT

ACCRUED EXPENSES (Tables)

3 Months Ended

Mar. 31, 2024

ACCRUED EXPENSES

Schedule of accrued expenses

Accrued expenses consist of the following:


	As of
	March 31,		December 31,
	2024		2023
Royalties due to Bioprojet	$	24,738	$	40,419
Rebates and other sales deductions		48,165		38,842
Interest		3,125		3,354
Sales and marketing		2,999		2,354
Research and development		7,898		9,835
Professional fees, consulting, and other services		1,918		2,195
Other expenses		2,856		2,495
	$	91,699	$	99,494

XML 46 R33.htm IDEA: XBRL DOCUMENT

DEBT (Tables)

3 Months Ended

Mar. 31, 2024

DEBT

Schedule of long-term debt, net

Long-term debt, net consists of the following:


	March 31,		December 31,
	2024		2023
Principal amount	$	192,500	$	196,250
Unamortized debt discount associated with debt financing costs		(2,504)		(2,684)
Total debt, net		189,996		193,566
Less current portion		(15,000)		(15,000)
Long-term debt, net	$	174,996	$	178,566

Schedule of future minimum payments relating to long term debt

Future minimum payments relating to total debt, net as of March 31, 2024, for the periods indicated below consists of the following:


Years ending December 31,
2024 (excluding the three months ended March 31, 2024)	$	11,250
2025		16,250
2026		20,000
2027		20,000
2028		125,000
Thereafter		—
Total	$	192,500

Schedule of interest expense related to long term debt


	Three Months Ended
	March 31,
	2024		2023
Interest on principal balance	$	4,355	$	5,315
Amortization of deferred financing costs		180		416
Total term loan interest expense	$	4,535	$	5,731

XML 47 R34.htm IDEA: XBRL DOCUMENT

LEASES (Tables)

3 Months Ended

Mar. 31, 2024

LEASES

Schedule of supplemental balance sheet and cash flow information related to operating leases

Supplemental balance sheet information related to operating leases was as follows:


Leases	Classification		March 31, 2024		December 31, 2023
Assets
Operating lease right-of-use assets	Other noncurrent assets	$	3,046	$	2,344
Liabilities
Operating lease liability, current portion	Other current liabilities	$	1,793	$	1,437
Operating lease liability, long-term	Other long-term liabilities		1,276		1,082
Total operating lease liabilities		$	3,069	$	2,519

Supplemental cash flow information related to operating leases was as follows:


		March 31, 2024		March 31, 2023
Operating cash flows from operating leases	$	561	$	428
Right of use assets obtained in exchange for operating lease obligations	$	1,198	$	526

Schedule of future payments under noncancelable operating leases

Future payments under noncancelable operating leases with initial terms of one year or more as of March 31, 2024, consisted of the following:


Years ending December 31,
2024 (excluding the three months ended March 31, 2024)	$	1,564
2025		1,239
2026		473
2027		3
2028		-
Thereafter		-
Total lease payments		3,279
Less: imputed interest		(210)
Total lease liabilities	$	3,069

XML 48 R35.htm IDEA: XBRL DOCUMENT

STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION (Tables)

3 Months Ended

Mar. 31, 2024

STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION

Summary of changes in stock options granted

The following table summarizes stock option activity for the three months ended March 31, 2024:


				Weighted-
		Weighted-		Average
		Average		Remaining
	Number of	Exercise		Contractual
	Awards	Price		Term
Awards outstanding—December 31, 2023	6,316,422	$	32.47	7.17
Awards issued	1,071,750	$	30.69
Awards exercised	(14,120)	$	8.22
Awards forfeited	(11,529)	$	39.31
Awards outstanding—March 31, 2024	7,362,523	$	32.25	7.35

Summary of changes in SARs granted

The following table summarizes SARs activity for the three months ended March 31, 2024:


				Weighted-
		Weighted-		Average
		Average		Remaining
	Number of	Exercise		Contractual
	Awards	Price		Term
Awards outstanding—December 31, 2023	43,208	$	9.38	5.32
Awards issued	—	$	—
Awards exercised	—	$	—
Awards forfeited	—	$	—
Awards outstanding—March 31, 2024	43,208	$	9.38	5.08

Summary of changes in RSUs granted

The following table summarizes RSU activity for the three months ended March 31, 2024:



		Weighted-
		Average
	Number of	Grant Date
	Awards	Fair Value
Awards outstanding—December 31, 2023	330,000	$	31.53
Awards issued	387,500	$	30.69
Awards vested	(15,000)	$	29.03
Awards forfeited	(350)	$	30.69
Awards outstanding—March 31, 2024	702,150	$	31.08

Summary of assumptions used to value awards


	As of
	March 31,		December 31,
	2024		2023
Dividend yield	0.00	%	0.00	%
Expected volatility	72.60 - 72.60	%	74.87 - 80.78	%
Risk-free interest rate	4.06 - 4.20	%	3.42 - 4.62	%
Lack of marketability discount	0.00	%	0.00	%
Expected term (years)	2.01 - 6.11		2.26 - 10.77

Summary of stock-based compensation expense


	Three Months Ended March 31,
	2024		2023
Research and development expense	$	1,371	$	976
Sales and marketing expense		1,994		1,073
General and administrative expense		7,069		4,512
	$	10,434	$	6,561

XML 49 R36.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE (Tables)

3 Months Ended

Mar. 31, 2024

EARNINGS PER SHARE

Summary of computation of basic and diluted net income (loss) per share

The following table sets forth the computation of basic and diluted net income per share:


	Three Months Ended March 31,
	2024		2023
Numerator
Net income	$	38,334	$	29,485
Denominator
Net income per share of common stock - basic	$	0.68	$	0.49
Net income per share of common stock- diluted	$	0.67	$	0.48
Weighted average number of shares of common stock - basic		56,771,251		59,732,157
Weighted average number of shares of common stock - diluted		57,597,627		61,221,511

Securities outstanding that were included in the computation above, utilizing the treasury stock method are as follows:

Summary of antidilutive securities excluded from computation of earnings per share

Potential shares of common stock issuable that were excluded from the computation of diluted weighted-average shares outstanding excluded from the numerator, are as follows:

XML 50 R37.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Tables)

3 Months Ended

Mar. 31, 2024

INCOME TAXES

Schedule of reconciliation between statutory federal income tax rate and the Company's effective income tax rate


	Three Months Ended March 31,
	2024		2023
Federal income tax rate	21.0	%	21.0	%
Stock-based compensation	—		(2.8)
State taxes	5.1		6.3
Credits	(1.0)		(2.9)
Other	0.4		0.4
Valuation allowance	0.5		—
Total	26.0	%	22.0	%

XML 51 R38.htm IDEA: XBRL DOCUMENT

LIQUIDITY AND CAPITAL RESOURCES (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
LIQUIDITY AND CAPITAL RESOURCES
Accumulated deficit	$ 104,943	$ 143,277
Cash, cash equivalents and investments	$ 453,594

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References + Details

XML 52 R39.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Cash and cash equivalents	$ 332,981	$ 311,660
Restricted cash	270	270
Total cash, cash equivalents, and restricted cash shown in the statements of cash flows	$ 333,251	$ 311,930	$ 288,712	$ 244,534

XML 53 R40.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2024 segment Institution customer product	Mar. 31, 2023 customer	Dec. 31, 2023 customer
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Line Items]
Number of approved commercial products \| product	1
Number of operating segments \| segment	1
Number of reportable segments \| segment	1
Number Of financial institutions \| Institution	5
Three Customers \| Accounts Receivable \| Customer Concentration Risk
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Line Items]
Number of customers \| customer	3		3
Concentration risk percentage	100.00%		100.00%
Three Customers \| Product Revenues \| Customer Concentration Risk
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Line Items]
Number of customers \| customer	3	3
Concentration risk percentage	100.00%	100.00%
Accredo Health Group, Inc \| Accounts Receivable \| Customer Concentration Risk
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Line Items]
Concentration risk percentage	36.00%		39.00%
Accredo Health Group, Inc \| Product Revenues \| Customer Concentration Risk
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Line Items]
Concentration risk percentage	33.00%	32.00%
Caremark LLC \| Accounts Receivable \| Customer Concentration Risk
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Line Items]
Concentration risk percentage	41.00%		32.00%
Caremark LLC \| Product Revenues \| Customer Concentration Risk
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Line Items]
Concentration risk percentage	42.00%	35.00%
PANTHERx Specialty Pharmacy LLC \| Accounts Receivable \| Customer Concentration Risk
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Line Items]
Concentration risk percentage	23.00%		29.00%
PANTHERx Specialty Pharmacy LLC \| Product Revenues \| Customer Concentration Risk
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Line Items]
Concentration risk percentage	25.00%	33.00%

XML 54 R41.htm IDEA: XBRL DOCUMENT

ACQUISITION (Details) $ / shares in Units, $ in Thousands	1 Months Ended
ACQUISITION (Details) $ / shares in Units, $ in Thousands	Oct. 31, 2023 USD ($) Right $ / shares
ACQUISITION
Transaction costs \| $	$ 2,645
Zynerba Acquisition
ACQUISITION
Cash consideration per Common Stock \| $ / shares	$ 1.1059
Aggregate consideration \| $	$ 60,000
Number of contingent value right per Common Stock \| Right	1
Contingent consideration per Common Stock \| $ / shares	$ 2.5444

XML 55 R42.htm IDEA: XBRL DOCUMENT

INVESTMENTS - Carrying Value and Amortized Cost of Available-For-Sale Debt Securities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Minimum
Investment securities
Non current investment maturity term	1 year
Maximum
Investment securities
Non current investment maturity term	2 years
Short-term
Investment securities
Amortized Cost	$ 39,354	$ 41,740
Unrealized Gains	26	64
Unrealized Losses	(11)	(4)
Fair Value	39,369	41,800
Short-term commercial paper
Investment securities
Amortized Cost	23,038	23,832
Unrealized Gains	10	36
Unrealized Losses	(7)	(3)
Fair Value	23,041	23,865
Short-term corporate debt securities
Investment securities
Amortized Cost	16,316	15,968
Unrealized Gains	16	28
Unrealized Losses	(4)
Fair Value	16,328	15,996
Short-term U.S. government securities
Investment securities
Amortized Cost		1,940
Unrealized Losses		(1)
Fair Value		1,939
Long-term
Investment securities
Amortized Cost	81,430	72,227
Unrealized Gains	61	88
Unrealized Losses	(247)	(146)
Fair Value	81,244	72,169
Long-term commercial paper
Investment securities
Amortized Cost		744
Fair Value		744
Long-term corporate debt securities
Investment securities
Amortized Cost	51,062	42,688
Unrealized Gains	61	81
Unrealized Losses	(50)	(28)
Fair Value	51,073	42,741
Long-term U.S. government securities
Investment securities
Amortized Cost	30,368	28,795
Unrealized Gains		7
Unrealized Losses	(197)	(118)
Fair Value	$ 30,171	$ 28,684

XML 56 R43.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS - Assets Measured at Fair Value (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Assets
Assets	$ 384,692	$ 358,538
Cash equivalents
Assets
Assets	264,079	244,569
Commercial paper
Assets
Assets	23,041	24,609
Corporate debt securities
Assets
Assets	67,401	58,737
U.S. government securities
Assets
Assets	30,171	30,623
Level 1
Assets
Assets	264,079	243,685
Level 1 \| Cash equivalents
Assets
Assets	264,079	243,685
Level 2
Assets
Assets	120,613	114,853
Level 2 \| Cash equivalents
Assets
Assets		884
Level 2 \| Commercial paper
Assets
Assets	23,041	24,609
Level 2 \| Corporate debt securities
Assets
Assets	67,401	58,737
Level 2 \| U.S. government securities
Assets
Assets	$ 30,171	$ 30,623

XML 57 R44.htm IDEA: XBRL DOCUMENT

INVENTORY (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
INVENTORY
Raw materials	$ 1,009	$ 1,060
Work in process	1,748	2,020
Finished goods	3,100	2,283
Total inventory, net	$ 5,857	$ 5,363

XML 58 R45.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended				3 Months Ended
	Mar. 31, 2022	Feb. 28, 2022	Oct. 31, 2020	Aug. 31, 2019	Mar. 31, 2024	Mar. 31, 2023
Intangible Assets
Net product revenue					$ 154,615	$ 119,126
Amortization expense					$ 5,961	$ 5,961
WAKIX
Intangible Assets
Useful life of intangible asset	7 years 7 months 6 days
Remaining useful life					5 years 6 months
Final payment paid	$ 40,000
WAKIX \| United States
Intangible Assets
Net product revenue		$ 500,000
WAKIX \| Daytime Sleepiness
Intangible Assets
License agreement milestone payments paid				$ 75,000
Useful life of intangible asset				10 years
Remaining useful life					5 years 6 months
NDA for WAKIX. \| Cataplexy
Intangible Assets
License agreement milestone payments paid			$ 100,000
Useful life of intangible asset			9 years
Remaining useful life					5 years 6 months

XML 59 R46.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS - Schedule of Future Annual Amortization Expense for Unamortized Intangible Assets (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Future annual amortization expense
2024 (excluding the three months ended March 31, 2024)	$ 17,884
2025	23,845
2026	23,845
2027	23,845
2028	23,845
Thereafter	17,883
Total	$ 131,147

XML 60 R47.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS - Schedule of Gross Carrying Amount and Net Book Value of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
INTANGIBLE ASSETS
Gross Carrying Amount	$ 215,000	$ 215,000
Accumulated Amortization	(83,853)	(77,892)
Net Book Value	$ 131,147	$ 137,108

XML 61 R48.htm IDEA: XBRL DOCUMENT

LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS (Details) - USD ($) $ in Thousands	1 Months Ended								3 Months Ended
	Mar. 31, 2023	Jul. 31, 2022	Mar. 31, 2022	Aug. 31, 2021	Jan. 31, 2021	Oct. 31, 2020	Nov. 30, 2019	Aug. 31, 2019	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Feb. 28, 2019
License Agreements and Asset Purchase Agreements
Cost of product sold									$ 27,484	$ 20,780
Accrued Sales Based Trademark and Royalties									24,738		$ 40,419
All Countries Excluding Greater China \| HBS-102 \| Asset Purchase Agreement with ConSynance Therapeutics
License Agreements and Asset Purchase Agreements
Consideration transferred				$ 3,500
Payment for intellectual property upon preclinical milestones				1,000
Payment for intellectual property upon developmental milestones				19,000
Payment for intellectual property upon regulatory milestones				44,000
Payment for intellectual property upon sales milestones				$ 110,000
All Countries Excluding Greater China \| HBS-102 \| Asset Purchase Agreement with ConSynance Therapeutics \| Research and development expense
License Agreements and Asset Purchase Agreements
Payment related to achievement of preclinical milestone.	$ 750,000
Bioprojet
License Agreements and Asset Purchase Agreements
Licensing agreement milestone fees								$ 2,000
License agreement milestone payments paid							$ 75,000	2,000
License agreement, additional milestone payment due								102,000
Bioprojet \| Upon Acceptance by FDA of Pitolisant's
License Agreements and Asset Purchase Agreements
License agreement, milestone payment due												$ 50,000
License agreement, upfront non-refundable licensing fees paid		$ 30,000
License agreement, maximum additional milestone payment due		$ 155,000
Bioprojet \| Upon FDA Approval of WAKIX
License Agreements and Asset Purchase Agreements
License agreement, milestone payment due								77,000
Licensing agreement milestone fees								$ 2,000
License agreement milestone payments paid					$ 100,000	$ 2,000
Bioprojet \| Sales-based, trademark and tiered royalties
License Agreements and Asset Purchase Agreements
Cost of product sold									24,738	$ 19,060
Accrued Sales Based Trademark and Royalties									$ 24,738		$ 40,419
Bioprojet \| United States
License Agreements and Asset Purchase Agreements
Amount of Aggregate Net Sales Attaining			$ 500,000
Bioprojet \| Attaining $500,000 Aggregate Net Sales \| United States \| Upon FDA Approval of WAKIX
License Agreements and Asset Purchase Agreements
Final payment paid			$ 40,000

XML 62 R49.htm IDEA: XBRL DOCUMENT

ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
ACCRUED EXPENSES
Royalties due to Bioprojet	$ 24,738	$ 40,419
Rebates and other sales deductions	48,165	38,842
Interest	3,125	3,354
Sales and marketing	2,999	2,354
Research and development	7,898	9,835
Professional fees, consulting, and other services	1,918	2,195
Other expenses	2,856	2,495
Accrued liabilities	$ 91,699	$ 99,494

XML 63 R50.htm IDEA: XBRL DOCUMENT

DEBT - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jul. 31, 2023	Mar. 31, 2024	Sep. 30, 2023
Term Loans
DEBT
Debt issuance costs		$ 2,997
Net cash received		197,003
Fair value of loan		192,267
Term Loans \| Repayment Of Debt Commencing On December 31 2023
DEBT
Periodic payment principal		3,750
Term Loans \| Repayment Of Debt Beginning On December 31 2025
DEBT
Periodic payment principal		5,000
Term Loans \| Repayment of Debt Due on Maturity Date of July 26, 2028
DEBT
Periodic payment principal		$ 115,000
Term Loans \| Base rate \| Minimum
DEBT
Basis spread on variable rate		2.50%
Term Loans \| Base rate \| Maximum
DEBT
Basis spread on variable rate		3.00%
Term Loans \| SOFR
DEBT
Credit spread adjustment rate		0.10%
Term Loans \| SOFR \| Minimum
DEBT
Basis spread on variable rate		3.50%
Term Loans \| SOFR \| Maximum
DEBT
Basis spread on variable rate		4.00%
TLA Term Loan
DEBT
Term of loan	5 years
Aggregate principal amount	$ 185,000
Incremental Term Loan
DEBT
Aggregate principal amount			$ 15,000

XML 64 R51.htm IDEA: XBRL DOCUMENT

DEBT - Balances of Long-term Debt, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
DEBT
Principal amount	$ 192,500	$ 196,250
Unamortized debt discount associated with debt financing costs	(2,504)	(2,684)
Total debt, net	189,996	193,566
Less current portion	(15,000)	(15,000)
Long-term debt, net	$ 174,996	$ 178,566

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

XML 65 R52.htm IDEA: XBRL DOCUMENT

DEBT - Future Minimum Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Future minimum payments
2024 (excluding the three months ended March 31, 2024)	$ 11,250
2025	16,250
2026	20,000
2027	20,000
2028	125,000
Total	$ 192,500	$ 196,250

XML 66 R53.htm IDEA: XBRL DOCUMENT

DEBT - Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended
DEBT - Interest Expense (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023
DEBT
Interest on principal balance	$ 4,355	$ 5,315
Amortization of deferred financing costs	180	416
Total term loan interest expense	$ 4,535	$ 5,731

XML 67 R54.htm IDEA: XBRL DOCUMENT

LEASES (Details) ft² in Thousands, $ in Thousands	1 Months Ended	3 Months Ended
LEASES (Details) ft² in Thousands, $ in Thousands	Jun. 30, 2018 ft²	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)
LEASES
Operating lease square feet of office space	15
Additional office space leased one	13
Additional office space leased two	7
Lessee, Operating Lease, Existence of Option to Extend [true false]		true
Lessee, Operating Lease, Existence of Option to Terminate [true false]		true
Operating lease costs \| $		$ 509	$ 378
Weighted average remaining lease term		1 year 9 months 18 days
Weighted-average discount rate for operating leases		7.32%
Minimum
LEASES
Lease terms		1 year
Maximum
LEASES
Lease terms		3 years

XML 68 R55.htm IDEA: XBRL DOCUMENT

LEASES - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Assets
Operating lease right-of-use assets	$ 3,046	$ 2,344
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other Assets Noncurrent	Other Assets Noncurrent
Liabilities
Operating lease liability, current portion	$ 1,793	$ 1,437
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other Liabilities Current	Other Liabilities Current
Operating lease liability, long-term	$ 1,276	$ 1,082
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other Liabilities Noncurrent	Other Liabilities Noncurrent
Total operating lease liabilities	$ 3,069	$ 2,519

XML 69 R56.htm IDEA: XBRL DOCUMENT

LEASES - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
LEASES
Operating cash flows from operating leases	$ 561	$ 428
Right of use assets obtained in exchange for operating lease obligations	$ 1,198	$ 526

XML 70 R57.htm IDEA: XBRL DOCUMENT

LEASES - Future Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Years ending December 31,
2024 (excluding the three months ended March 31, 2024)	$ 1,564
2025	1,239
2026	473
2027	3
Total lease payments	3,279
Less: imputed interest	(210)
Total lease liabilities	$ 3,069	$ 2,519

XML 71 R58.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details) $ in Thousands	3 Months Ended
STOCKHOLDERS' EQUITY (Details) $ in Thousands	Mar. 31, 2024 USD ($) Vote shares	Mar. 31, 2023 shares	Oct. 31, 2023 USD ($)
Equity, Class of Treasury Stock [Line Items]
Number of votes for each common stock \| Vote	1
October 2023 Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Repurchase of shares of common stock approved			$ 200,000
Shares of common stock repurchased and retired \| shares	0	0
Remaining authorized repurchase amount	$ 150,000

XML 72 R59.htm IDEA: XBRL DOCUMENT

STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		12 Months Ended
	Apr. 30, 2021	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Stock Incentive Plan and Stock-based Compensation
Weighted average period		2 years 8 months 12 days
Employee Stock Option
Stock Incentive Plan and Stock-based Compensation
Unrecognized stock-based compensation expense		$ 73,718
Restricted Stock Units
Stock Incentive Plan and Stock-based Compensation
Weighted average per share fair value of awards issued (in USD per share)		$ 30.69
Unrecognized stock-based compensation expense		$ 19,399
2020 Plan
Stock Incentive Plan and Stock-based Compensation
Stock options contractual term		10 years
Total number of shares available for issuance		7,890,232
Percentage of increment of common stock outstanding		4.00%
2017 and 2020 Plans \| Restricted Stock Units
Stock Incentive Plan and Stock-based Compensation
Weighted average per share fair value of awards issued (in USD per share)		$ 21.13		$ 20.64
2017 and 2020 Plans \| Common Stock
Stock Incentive Plan and Stock-based Compensation
Stock vested		3,596,040		3,298,284
Employee Stock Purchase Plan
Stock Incentive Plan and Stock-based Compensation
Total number of shares available for issuance	629,805
Percentage of increment of common stock outstanding	1.00%
ESPP permits eligible employees to purchase shares of common stock at discount	15.00%
Shares issued under the ESPP		0	0
Amount of discount on ESSP		$ 80	$ 105

XML 73 R60.htm IDEA: XBRL DOCUMENT

STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in Stock Options Granted (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION
Number of Awards, Awards outstanding, Beginning balance	6,316,422
Number of Awards, Awards issued	1,071,750
Number of Awards, Awards exercised	(14,120)
Number of Awards, Awards forfeited	(11,529)
Number of Awards, Awards outstanding, Ending balance	7,362,523	6,316,422
Weighted-Average Exercise Price, Awards outstanding, Beginning balance	$ 32.47
Weighted-Average Exercise Price, Awards issued	30.69
Weighted-Average Exercise Price, Awards exercised	8.22
Weighted-Average Exercise Price, Awards forfeited	39.31
Weighted-Average Exercise Price, Awards outstanding, Ending balance	$ 32.25	$ 32.47
Weighted-Average Remaining Contractual Term	7 years 4 months 6 days	7 years 2 months 1 day

XML 74 R61.htm IDEA: XBRL DOCUMENT

STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in SARs Granted (Details) - Stock Appreciation Rights (SARs) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Awards, Awards outstanding, Beginning balance	43,208
Number of Awards, Awards outstanding, Ending balance	43,208	43,208
Weighted-Average Exercise Price, Awards outstanding, Beginning balance	$ 9.38
Weighted-Average Exercise Price, Awards outstanding, Ending balance	$ 9.38	$ 9.38
Weighted-Average Remaining Contractual Term	5 years 29 days	5 years 3 months 25 days

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

XML 75 R62.htm IDEA: XBRL DOCUMENT

STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in RSUs Granted (Details) - Restricted Stock Units	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Awards, Awards outstanding, Beginning balance \| shares	330,000
Number of Awards, Awards issued \| shares	387,500
Number of Awards, Awards vested \| shares	(15,000)
Number of Awards, Awards forfeited \| shares	(350)
Number of Awards, Awards outstanding, Ending balance \| shares	702,150
Weighted-Average Grant Date Fair Value, Awards outstanding, Beginning balance \| $ / shares	$ 31.53
Weighted-Average Grant Date Fair Value, Awards issued \| $ / shares	30.69
Weighted-Average Grant Date Fair Value, Awards vested \| $ / shares	29.03
Weighted-Average Grant Date Fair Value, Awards forfeited \| $ / shares	30.69
Weighted-Average Grant Date Fair Value, Awards outstanding, Ending balance \| $ / shares	$ 31.08

XML 76 R63.htm IDEA: XBRL DOCUMENT

STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Assumptions Used to Value Awards (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Expected volatility, minimum	72.60%	74.87%
Expected volatility, maximum	72.60%	80.78%
Risk-free interest rate, minimum	4.06%	3.42%
Risk-free interest rate, maximum	4.20%	4.62%
Lack of marketability discount	0.00%	0.00%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (years)	2 years 3 days	2 years 3 months 3 days
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (years)	6 years 1 month 9 days	10 years 9 months 7 days

XML 77 R64.htm IDEA: XBRL DOCUMENT

STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 10,434	$ 6,561
Research and development expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,371	976
Sales and marketing expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,994	1,073
General and administrative expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 7,069	$ 4,512

XML 78 R65.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE - Summary of Computation of Basic and Diluted Net Income (Loss) per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Numerator
Net Income (Loss)	$ 38,334	$ 29,485
Denominator
Net income per share of common stock - basic	$ 0.68	$ 0.49
Net income per share of common stock - diluted	$ 0.67	$ 0.48
Weighted average number of shares of common stock - basic	56,771,251	59,732,157
Weighted average number of shares of common stock - diluted	57,597,627	61,221,511

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

XML 79 R66.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE - Summary of Securities Outstanding Included in Computation above, Utilizing Treasury Stock Method (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
EARNINGS PER SHARE
Securities outstanding included in the computation - Stock options, SARs, and RSUs to purchase common stock	826,376	1,489,354

XML 80 R67.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
EARNINGS PER SHARE
Potential shares of common stock issuable excluded from computation - Stock options, SARs, and RSUs to purchase common stock	7,281,505	4,661,499

XML 81 R68.htm IDEA: XBRL DOCUMENT

INCOME TAXES - Schedule of Difference Between Statutory Federal Income Tax Rate (Details)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
INCOME TAXES
Federal income tax rate	21.00%	21.00%
Stock-based compensation		(2.80%)
State taxes	5.10%	6.30%
Credits	(1.00%)	(2.90%)
Other	0.40%	0.40%
Valuation allowance	0.50%
Total	26.00%	22.00%

XML 82 R69.htm IDEA: XBRL DOCUMENT

RELATED-PARTY TRANSACTIONS (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Related-party Transactions
General and administrative	$ 25,676	$ 22,062
Amounts due to related parties	$ 0		$ 0
Other Liability, Related Party, Type [Extensible Enumeration]	Related party		Related party
Amounts due from related parties	$ 0		$ 0
Other Receivable, after Allowance for Credit Loss, Related Party, Type [Extensible Enumeration]	Related party		Related party
Related party
Related-party Transactions
General and administrative	$ 73	$ 71

XML 83 R70.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details) - USD ($) $ in Thousands	Apr. 30, 2024	Apr. 11, 2024
Zynerba \| Epygenix
Subsequent Event [Line Items]
Amount of fee payable upon achieving development and regulatory milestones	$ 130,000
Amount of fees payable upon achieving sale-based milestones	515,000
Up front consideration	$ 35,000
Subsequent Events. \| Bioprojet \| Orexin-2 receptor agonist (OX2R)
Subsequent Event [Line Items]
Payment of upfront license fee		$ 25,500
Amount of fee payable upon achieving development and regulatory milestones		127,500
Amount of fees payable upon achieving sale-based milestones		$ 240,000

XML 84 R71.htm IDEA: XBRL DOCUMENT

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ 38,334	$ 29,485

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

XML 85 R72.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Mar. 31, 2024 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	On February 23, 2024, Jeffrey Dierks, Chief Commercial Officer of the Company, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 35,708 shares of the Company’s common stock related to the exercise of options beginning on July 1, 2024 and until December 31, 2024. During the three months ended March 31, 2024, no director or officer of the Company terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
Name	Jeffrey Dierks
Title	Chief Commercial Officer
Rule 10b5-1 Arrangement Adopted	true
Non-Rule 10b5-1 Arrangement Adopted	false
Adoption Date	Feb. 23, 2024
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Aggregate Available	35,708

EXCEL 86 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 87 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 88 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 90 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 168 334 1 false 64 0 false 11 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME Sheet http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME Statements 4 false false R5.htm 00300 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 00400 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 10101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS Sheet http://www.harmonybiosciences.com/role/DisclosureOrganizationAndDescriptionOfBusiness ORGANIZATION AND DESCRIPTION OF BUSINESS Notes 7 false false R8.htm 10201 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES Sheet http://www.harmonybiosciences.com/role/DisclosureLiquidityAndCapitalResources LIQUIDITY AND CAPITAL RESOURCES Notes 8 false false R9.htm 10301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 10401 - Disclosure - ACQUISITION Sheet http://www.harmonybiosciences.com/role/DisclosureAcquisition ACQUISITION Notes 10 false false R11.htm 10501 - Disclosure - INVESTMENTS Sheet http://www.harmonybiosciences.com/role/DisclosureInvestments INVESTMENTS Notes 11 false false R12.htm 10601 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurements FAIR VALUE MEASUREMENTS Notes 12 false false R13.htm 10701 - Disclosure - INVENTORY Sheet http://www.harmonybiosciences.com/role/DisclosureInventory INVENTORY Notes 13 false false R14.htm 10801 - Disclosure - INTANGIBLE ASSETS Sheet http://www.harmonybiosciences.com/role/DisclosureIntangibleAssets INTANGIBLE ASSETS Notes 14 false false R15.htm 10901 - Disclosure - LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS Sheet http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreements LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS Notes 15 false false R16.htm 11001 - Disclosure - ACCRUED EXPENSES Sheet http://www.harmonybiosciences.com/role/DisclosureAccruedExpenses ACCRUED EXPENSES Notes 16 false false R17.htm 11101 - Disclosure - DEBT Sheet http://www.harmonybiosciences.com/role/DisclosureDebt DEBT Notes 17 false false R18.htm 11201 - Disclosure - LEASES Sheet http://www.harmonybiosciences.com/role/DisclosureLeases LEASES Notes 18 false false R19.htm 11301 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.harmonybiosciences.com/role/DisclosureCommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 19 false false R20.htm 11401 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.harmonybiosciences.com/role/DisclosureStockholdersEquity STOCKHOLDERS' EQUITY Notes 20 false false R21.htm 11501 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION Sheet http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensation STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION Notes 21 false false R22.htm 11601 - Disclosure - EARNINGS PER SHARE Sheet http://www.harmonybiosciences.com/role/DisclosureEarningsPerShare EARNINGS PER SHARE Notes 22 false false R23.htm 11701 - Disclosure - INCOME TAXES Sheet http://www.harmonybiosciences.com/role/DisclosureIncomeTaxes INCOME TAXES Notes 23 false false R24.htm 11801 - Disclosure - RELATED-PARTY TRANSACTIONS Sheet http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactions RELATED-PARTY TRANSACTIONS Notes 24 false false R25.htm 11901 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.harmonybiosciences.com/role/DisclosureSubsequentEvents SUBSEQUENT EVENTS Notes 25 false false R26.htm 20302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 26 false false R27.htm 30303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies 27 false false R28.htm 30503 - Disclosure - INVESTMENTS (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureInvestmentsTables INVESTMENTS (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureInvestments 28 false false R29.htm 30603 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurements 29 false false R30.htm 30703 - Disclosure - INVENTORY (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureInventoryTables INVENTORY (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureInventory 30 false false R31.htm 30803 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsTables INTANGIBLE ASSETS (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureIntangibleAssets 31 false false R32.htm 31003 - Disclosure - ACCRUED EXPENSES (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesTables ACCRUED EXPENSES (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureAccruedExpenses 32 false false R33.htm 31103 - Disclosure - DEBT (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureDebtTables DEBT (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureDebt 33 false false R34.htm 31203 - Disclosure - LEASES (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureLeasesTables LEASES (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureLeases 34 false false R35.htm 31503 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationTables STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensation 35 false false R36.htm 31603 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareTables EARNINGS PER SHARE (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureEarningsPerShare 36 false false R37.htm 31703 - Disclosure - INCOME TAXES (Tables) Sheet http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesTables INCOME TAXES (Tables) Tables http://www.harmonybiosciences.com/role/DisclosureIncomeTaxes 37 false false R38.htm 40201 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureLiquidityAndCapitalResourcesDetails LIQUIDITY AND CAPITAL RESOURCES (Details) Details http://www.harmonybiosciences.com/role/DisclosureLiquidityAndCapitalResources 38 false false R39.htm 40301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) Details 39 false false R40.htm 40302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) Details 40 false false R41.htm 40401 - Disclosure - ACQUISITION (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureAcquisitionDetails ACQUISITION (Details) Details http://www.harmonybiosciences.com/role/DisclosureAcquisition 41 false false R42.htm 40501 - Disclosure - INVESTMENTS - Carrying Value and Amortized Cost of Available-For-Sale Debt Securities (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails INVESTMENTS - Carrying Value and Amortized Cost of Available-For-Sale Debt Securities (Details) Details 42 false false R43.htm 40601 - Disclosure - FAIR VALUE MEASUREMENTS - Assets Measured at Fair Value (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails FAIR VALUE MEASUREMENTS - Assets Measured at Fair Value (Details) Details 43 false false R44.htm 40701 - Disclosure - INVENTORY (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureInventoryDetails INVENTORY (Details) Details http://www.harmonybiosciences.com/role/DisclosureInventoryTables 44 false false R45.htm 40801 - Disclosure - INTANGIBLE ASSETS - Additional Information (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails INTANGIBLE ASSETS - Additional Information (Details) Details 45 false false R46.htm 40802 - Disclosure - INTANGIBLE ASSETS - Schedule of Future Annual Amortization Expense for Unamortized Intangible Assets (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails INTANGIBLE ASSETS - Schedule of Future Annual Amortization Expense for Unamortized Intangible Assets (Details) Details 46 false false R47.htm 40803 - Disclosure - INTANGIBLE ASSETS - Schedule of Gross Carrying Amount and Net Book Value of Intangible Assets (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetsDetails INTANGIBLE ASSETS - Schedule of Gross Carrying Amount and Net Book Value of Intangible Assets (Details) Details 47 false false R48.htm 40901 - Disclosure - LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS (Details) Details http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreements 48 false false R49.htm 41001 - Disclosure - ACCRUED EXPENSES (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails ACCRUED EXPENSES (Details) Details http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesTables 49 false false R50.htm 41101 - Disclosure - DEBT - Additional Information (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails DEBT - Additional Information (Details) Details 50 false false R51.htm 41102 - Disclosure - DEBT - Balances of Long-term Debt, Net (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureDebtBalancesOfLongTermDebtNetDetails DEBT - Balances of Long-term Debt, Net (Details) Details 51 false false R52.htm 41103 - Disclosure - DEBT - Future Minimum Payments (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails DEBT - Future Minimum Payments (Details) Details 52 false false R53.htm 41104 - Disclosure - DEBT - Interest Expense (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureDebtInterestExpenseDetails DEBT - Interest Expense (Details) Details 53 false false R54.htm 41201 - Disclosure - LEASES (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureLeasesDetails LEASES (Details) Details http://www.harmonybiosciences.com/role/DisclosureLeasesTables 54 false false R55.htm 41202 - Disclosure - LEASES - Supplemental Balance Sheet Information (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails LEASES - Supplemental Balance Sheet Information (Details) Details 55 false false R56.htm 41203 - Disclosure - LEASES - Supplemental Cash Flow Information (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalCashFlowInformationDetails LEASES - Supplemental Cash Flow Information (Details) Details 56 false false R57.htm 41204 - Disclosure - LEASES - Future Payments (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails LEASES - Future Payments (Details) Details 57 false false R58.htm 41401 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails STOCKHOLDERS' EQUITY (Details) Details http://www.harmonybiosciences.com/role/DisclosureStockholdersEquity 58 false false R59.htm 41501 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Additional Information (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Additional Information (Details) Details 59 false false R60.htm 41502 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in Stock Options Granted (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in Stock Options Granted (Details) Details 60 false false R61.htm 41503 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in SARs Granted (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in SARs Granted (Details) Details 61 false false R62.htm 41504 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in RSUs Granted (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in RSUs Granted (Details) Details 62 false false R63.htm 41505 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Assumptions Used to Value Awards (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Assumptions Used to Value Awards (Details) Details 63 false false R64.htm 41506 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Stock-based Compensation Expense (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Stock-based Compensation Expense (Details) Details 64 false false R65.htm 41601 - Disclosure - EARNINGS PER SHARE - Summary of Computation of Basic and Diluted Net Income (Loss) per Share (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetIncomeLossPerShareDetails EARNINGS PER SHARE - Summary of Computation of Basic and Diluted Net Income (Loss) per Share (Details) Details 65 false false R66.htm 41602 - Disclosure - EARNINGS PER SHARE - Summary of Securities Outstanding Included in Computation above, Utilizing Treasury Stock Method (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfSecuritiesOutstandingIncludedInComputationAboveUtilizingTreasuryStockMethodDetails EARNINGS PER SHARE - Summary of Securities Outstanding Included in Computation above, Utilizing Treasury Stock Method (Details) Details 66 false false R67.htm 41603 - Disclosure - EARNINGS PER SHARE - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails EARNINGS PER SHARE - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 67 false false R68.htm 41701 - Disclosure - INCOME TAXES - Schedule of Difference Between Statutory Federal Income Tax Rate (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails INCOME TAXES - Schedule of Difference Between Statutory Federal Income Tax Rate (Details) Details 68 false false R69.htm 41801 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails RELATED-PARTY TRANSACTIONS (Details) Details http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactions 69 false false R70.htm 41901 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails SUBSEQUENT EVENTS (Details) Details http://www.harmonybiosciences.com/role/DisclosureSubsequentEvents 70 false false R71.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Uncategorized 71 false false R72.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Cover 72 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:OtherLiabilities, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod - hrmy-20240331x10q.htm 9 [ix-0514-Hidden-Fact-Not-Referenced] WARN: 11 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies, us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList, us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList, us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList, us-gaap:OtherLiabilityRelatedPartyTypeExtensibleEnumeration, us-gaap:OtherReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration, us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList, us-gaap:TypeOfCostGoodOrServiceExtensibleList - hrmy-20240331x10q.htm 9 [dq-0712-Presentation-Base-Set-Order] Role '41901 - Disclosure - SUBSEQUENT EVENTS (Details)', a level 4, Detail role, appears before '995410 - Disclosure - Pay vs Performance Disclosure', a level 1, Note role. hrmy-20240331.xsd 225, https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd 30 hrmy-20240331.xsd hrmy-20240331_cal.xml hrmy-20240331_def.xml hrmy-20240331_lab.xml hrmy-20240331_pre.xml hrmy-20240331x10q.htm http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 93 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hrmy-20240331x10q.htm": { "nsprefix": "hrmy", "nsuri": "http://www.harmonybiosciences.com/20240331", "dts": { "schema": { "local": [ "hrmy-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" ] }, "calculationLink": { "local": [ "hrmy-20240331_cal.xml" ] }, "definitionLink": { "local": [ "hrmy-20240331_def.xml" ] }, "labelLink": { "local": [ "hrmy-20240331_lab.xml" ] }, "presentationLink": { "local": [ "hrmy-20240331_pre.xml" ] }, "inline": { "local": [ "hrmy-20240331x10q.htm" ] } }, "keyStandard": 285, "keyCustom": 49, "axisStandard": 23, "axisCustom": 0, "memberStandard": 27, "memberCustom": 36, "hidden": { "total": 23, "http://fasb.org/us-gaap/2023": 19, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 168, "entityCount": 1, "segmentCount": 64, "elementCount": 595, "unitCount": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 558, "http://xbrl.sec.gov/dei/2023": 31, "http://xbrl.sec.gov/ecd/2023": 9, "http://fasb.org/srt/2023": 1 }, "report": { "R1": { "role": "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets", "longName": "00100 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:ShortTermInvestments", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "unique": true } }, "R3": { "role": "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical", "longName": "00105 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_orCFTrOct0-DhD0jYWzZgQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_orCFTrOct0-DhD0jYWzZgQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome", "longName": "00200 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:GrossProfit", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "unique": true } }, "R5": { "role": "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity", "longName": "00300 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8ckcRewAoEGAovTYZhoPHA", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8ckcRewAoEGAovTYZhoPHA", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows", "longName": "00400 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.harmonybiosciences.com/role/DisclosureOrganizationAndDescriptionOfBusiness", "longName": "10101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS", "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.harmonybiosciences.com/role/DisclosureLiquidityAndCapitalResources", "longName": "10201 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES", "shortName": "LIQUIDITY AND CAPITAL RESOURCES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "hrmy:LiquidityAndCapitalResourcesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "hrmy:LiquidityAndCapitalResourcesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "10301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.harmonybiosciences.com/role/DisclosureAcquisition", "longName": "10401 - Disclosure - ACQUISITION", "shortName": "ACQUISITION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.harmonybiosciences.com/role/DisclosureInvestments", "longName": "10501 - Disclosure - INVESTMENTS", "shortName": "INVESTMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurements", "longName": "10601 - Disclosure - FAIR VALUE MEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.harmonybiosciences.com/role/DisclosureInventory", "longName": "10701 - Disclosure - INVENTORY", "shortName": "INVENTORY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssets", "longName": "10801 - Disclosure - INTANGIBLE ASSETS", "shortName": "INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreements", "longName": "10901 - Disclosure - LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS", "shortName": "LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "hrmy:LicenseAndAssetPurchaseAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "hrmy:LicenseAndAssetPurchaseAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.harmonybiosciences.com/role/DisclosureAccruedExpenses", "longName": "11001 - Disclosure - ACCRUED EXPENSES", "shortName": "ACCRUED EXPENSES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.harmonybiosciences.com/role/DisclosureDebt", "longName": "11101 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.harmonybiosciences.com/role/DisclosureLeases", "longName": "11201 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.harmonybiosciences.com/role/DisclosureCommitmentsAndContingencies", "longName": "11301 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquity", "longName": "11401 - Disclosure - STOCKHOLDERS' EQUITY", "shortName": "STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensation", "longName": "11501 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION", "shortName": "STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShare", "longName": "11601 - Disclosure - EARNINGS PER SHARE", "shortName": "EARNINGS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxes", "longName": "11701 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactions", "longName": "11801 - Disclosure - RELATED-PARTY TRANSACTIONS", "shortName": "RELATED-PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.harmonybiosciences.com/role/DisclosureSubsequentEvents", "longName": "11901 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "20302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "30303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.harmonybiosciences.com/role/DisclosureInvestmentsTables", "longName": "30503 - Disclosure - INVESTMENTS (Tables)", "shortName": "INVESTMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsTables", "longName": "30603 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.harmonybiosciences.com/role/DisclosureInventoryTables", "longName": "30703 - Disclosure - INVENTORY (Tables)", "shortName": "INVENTORY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsTables", "longName": "30803 - Disclosure - INTANGIBLE ASSETS (Tables)", "shortName": "INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesTables", "longName": "31003 - Disclosure - ACCRUED EXPENSES (Tables)", "shortName": "ACCRUED EXPENSES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.harmonybiosciences.com/role/DisclosureDebtTables", "longName": "31103 - Disclosure - DEBT (Tables)", "shortName": "DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.harmonybiosciences.com/role/DisclosureLeasesTables", "longName": "31203 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationTables", "longName": "31503 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION (Tables)", "shortName": "STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareTables", "longName": "31603 - Disclosure - EARNINGS PER SHARE (Tables)", "shortName": "EARNINGS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesTables", "longName": "31703 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.harmonybiosciences.com/role/DisclosureLiquidityAndCapitalResourcesDetails", "longName": "40201 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES (Details)", "shortName": "LIQUIDITY AND CAPITAL RESOURCES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:InvestmentsAndCash", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "hrmy:LiquidityAndCapitalResourcesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "unique": true } }, "R39": { "role": "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "longName": "40301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true }, "uniqueAnchor": null }, "R40": { "role": "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "40302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "hrmy:NumberOfApprovedCommercialProducts", "unitRef": "Unit_Standard_product_fXuHjRCoeUmhx1EzCmAcNA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "hrmy:SignificantRisksAndUncertaintiesPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "hrmy:NumberOfApprovedCommercialProducts", "unitRef": "Unit_Standard_product_fXuHjRCoeUmhx1EzCmAcNA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "hrmy:SignificantRisksAndUncertaintiesPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.harmonybiosciences.com/role/DisclosureAcquisitionDetails", "longName": "40401 - Disclosure - ACQUISITION (Details)", "shortName": "ACQUISITION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "Duration_10_1_2023_To_10_31_2023_OfWAaFVF-0qxyH61f5ckHw", "name": "us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:AssetAcquisitionTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_10_1_2023_To_10_31_2023_OfWAaFVF-0qxyH61f5ckHw", "name": "us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:AssetAcquisitionTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails", "longName": "40501 - Disclosure - INVESTMENTS - Carrying Value and Amortized Cost of Available-For-Sale Debt Securities (Details)", "shortName": "INVESTMENTS - Carrying Value and Amortized Cost of Available-For-Sale Debt Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_srt_RangeAxis_srt_MinimumMember_gF3OdgXyIEuZJym04_1Tnw", "name": "hrmy:NonCurrentInvestmentMaturityTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_srt_RangeAxis_srt_MinimumMember_gF3OdgXyIEuZJym04_1Tnw", "name": "hrmy:NonCurrentInvestmentMaturityTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails", "longName": "40601 - Disclosure - FAIR VALUE MEASUREMENTS - Assets Measured at Fair Value (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Assets Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.harmonybiosciences.com/role/DisclosureInventoryDetails", "longName": "40701 - Disclosure - INVENTORY (Details)", "shortName": "INVENTORY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:InventoryRawMaterials", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:InventoryRawMaterials", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "longName": "40801 - Disclosure - INTANGIBLE ASSETS - Additional Information (Details)", "shortName": "INTANGIBLE ASSETS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_hrmy_WAKIXMember_LTgWjqHPZEmBKU28syruDQ", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "unique": true } }, "R46": { "role": "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails", "longName": "40802 - Disclosure - INTANGIBLE ASSETS - Schedule of Future Annual Amortization Expense for Unamortized Intangible Assets (Details)", "shortName": "INTANGIBLE ASSETS - Schedule of Future Annual Amortization Expense for Unamortized Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetsDetails", "longName": "40803 - Disclosure - INTANGIBLE ASSETS - Schedule of Gross Carrying Amount and Net Book Value of Intangible Assets (Details)", "shortName": "INTANGIBLE ASSETS - Schedule of Gross Carrying Amount and Net Book Value of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails", "longName": "40901 - Disclosure - LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS (Details)", "shortName": "LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_8_1_2021_To_8_31_2021_srt_ProductOrServiceAxis_hrmy_Hbs102Member_srt_StatementGeographicalAxis_hrmy_AllCountriesExcludingChinaMember_us-gaap_AssetAcquisitionAxis_hrmy_AssetPurchaseAgreementWithConsynanceTherapeuticsMember_Qd-Umzc2z06x-7KVNwuvRg", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "hrmy:LicenseAndAssetPurchaseAgreementsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "unique": true } }, "R49": { "role": "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails", "longName": "41001 - Disclosure - ACCRUED EXPENSES (Details)", "shortName": "ACCRUED EXPENSES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:AccruedRoyaltiesCurrent", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "hrmy:AccruedRebatesAndOtherSalesDeductionsCurrent", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "unique": true } }, "R50": { "role": "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails", "longName": "41101 - Disclosure - DEBT - Additional Information (Details)", "shortName": "DEBT - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_hrmy_TermLoanMember_TFgsRmKlwEmkttewhAwtQg", "name": "us-gaap:DeferredFinanceCostsGross", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_hrmy_TermLoanMember_TFgsRmKlwEmkttewhAwtQg", "name": "us-gaap:DeferredFinanceCostsGross", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.harmonybiosciences.com/role/DisclosureDebtBalancesOfLongTermDebtNetDetails", "longName": "41102 - Disclosure - DEBT - Balances of Long-term Debt, Net (Details)", "shortName": "DEBT - Balances of Long-term Debt, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "hrmy:UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "unique": true } }, "R52": { "role": "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails", "longName": "41103 - Disclosure - DEBT - Future Minimum Payments (Details)", "shortName": "DEBT - Future Minimum Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.harmonybiosciences.com/role/DisclosureDebtInterestExpenseDetails", "longName": "41104 - Disclosure - DEBT - Interest Expense (Details)", "shortName": "DEBT - Interest Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails", "longName": "41201 - Disclosure - LEASES (Details)", "shortName": "LEASES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Duration_6_1_2018_To_6_30_2018_jwLqIHdwUUO3_blb-HSKVw", "name": "hrmy:OperatingLeaseOfficeSpace", "unitRef": "Unit_Standard_sqft_47Rr5EmEJUu0FqpvX5lMXA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_6_1_2018_To_6_30_2018_jwLqIHdwUUO3_blb-HSKVw", "name": "hrmy:OperatingLeaseOfficeSpace", "unitRef": "Unit_Standard_sqft_47Rr5EmEJUu0FqpvX5lMXA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails", "longName": "41202 - Disclosure - LEASES - Supplemental Balance Sheet Information (Details)", "shortName": "LEASES - Supplemental Balance Sheet Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalCashFlowInformationDetails", "longName": "41203 - Disclosure - LEASES - Supplemental Cash Flow Information (Details)", "shortName": "LEASES - Supplemental Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails", "longName": "41204 - Disclosure - LEASES - Future Payments (Details)", "shortName": "LEASES - Future Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails", "longName": "41401 - Disclosure - STOCKHOLDERS' EQUITY (Details)", "shortName": "STOCKHOLDERS' EQUITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "hrmy:CommonStockNumberOfVotesPerShare", "unitRef": "Unit_Standard_Vote_PsLd_kIObUS6goyGbKhrtg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "hrmy:CommonStockNumberOfVotesPerShare", "unitRef": "Unit_Standard_Vote_PsLd_kIObUS6goyGbKhrtg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails", "longName": "41501 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Additional Information (Details)", "shortName": "STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails", "longName": "41502 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in Stock Options Granted (Details)", "shortName": "STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in Stock Options Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "As_Of_12_31_2023_g_X6IAc5s0yfvQ7okNr-GQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_7iToqDeMDU-vB42izxjQRw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Unit_Standard_shares_7iToqDeMDU-vB42izxjQRw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "unique": true } }, "R61": { "role": "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails", "longName": "41503 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in SARs Granted (Details)", "shortName": "STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in SARs Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember_DCffTsY9w0WM_aQOd_vYzQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Unit_Standard_shares_7iToqDeMDU-vB42izxjQRw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember_5NShCsa6E0SxFvNUjD1sJQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Unit_Standard_shares_7iToqDeMDU-vB42izxjQRw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "unique": true } }, "R62": { "role": "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails", "longName": "41504 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in RSUs Granted (Details)", "shortName": "STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Changes in RSUs Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember__pWp2klH0kuV6Hq6sB0q2g", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_7iToqDeMDU-vB42izxjQRw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember__pWp2klH0kuV6Hq6sB0q2g", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_7iToqDeMDU-vB42izxjQRw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails", "longName": "41505 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Assumptions Used to Value Awards (Details)", "shortName": "STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Assumptions Used to Value Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Unit_Standard_pure_CFtrjG_RrUiRXf3U43sjtQ", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Unit_Standard_pure_CFtrjG_RrUiRXf3U43sjtQ", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails", "longName": "41506 - Disclosure - STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Stock-based Compensation Expense (Details)", "shortName": "STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION - Summary of Stock-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetIncomeLossPerShareDetails", "longName": "41601 - Disclosure - EARNINGS PER SHARE - Summary of Computation of Basic and Diluted Net Income (Loss) per Share (Details)", "shortName": "EARNINGS PER SHARE - Summary of Computation of Basic and Diluted Net Income (Loss) per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true }, "uniqueAnchor": null }, "R66": { "role": "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfSecuritiesOutstandingIncludedInComputationAboveUtilizingTreasuryStockMethodDetails", "longName": "41602 - Disclosure - EARNINGS PER SHARE - Summary of Securities Outstanding Included in Computation above, Utilizing Treasury Stock Method (Details)", "shortName": "EARNINGS PER SHARE - Summary of Securities Outstanding Included in Computation above, Utilizing Treasury Stock Method (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "Unit_Standard_shares_7iToqDeMDU-vB42izxjQRw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "Unit_Standard_shares_7iToqDeMDU-vB42izxjQRw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "longName": "41603 - Disclosure - EARNINGS PER SHARE - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "shortName": "EARNINGS PER SHARE - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_7iToqDeMDU-vB42izxjQRw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_7iToqDeMDU-vB42izxjQRw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails", "longName": "41701 - Disclosure - INCOME TAXES - Schedule of Difference Between Statutory Federal Income Tax Rate (Details)", "shortName": "INCOME TAXES - Schedule of Difference Between Statutory Federal Income Tax Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_pure_CFtrjG_RrUiRXf3U43sjtQ", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_pure_CFtrjG_RrUiRXf3U43sjtQ", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails", "longName": "41801 - Disclosure - RELATED-PARTY TRANSACTIONS (Details)", "shortName": "RELATED-PARTY TRANSACTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_kPM4ddkQc06ln0-ka_siEw", "name": "us-gaap:OtherReceivables", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "unique": true } }, "R70": { "role": "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails", "longName": "41901 - Disclosure - SUBSEQUENT EVENTS (Details)", "shortName": "SUBSEQUENT EVENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "As_Of_4_30_2024_dei_LegalEntityAxis_hrmy_ZynerbaPharmaceuticalsInc.Member_us-gaap_BusinessAcquisitionAxis_hrmy_EpygenixTherapeuticsIncMember_zqtq7_YqF0e1MGmSN5SMQA", "name": "hrmy:LicenseAgreementMaximumAdditionalMilestonePaymentsDueUponAchievementOfDevelopmentAndRegulatoryMilestones", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_4_30_2024_dei_LegalEntityAxis_hrmy_ZynerbaPharmaceuticalsInc.Member_us-gaap_BusinessAcquisitionAxis_hrmy_EpygenixTherapeuticsIncMember_zqtq7_YqF0e1MGmSN5SMQA", "name": "hrmy:LicenseAgreementMaximumAdditionalMilestonePaymentsDueUponAchievementOfDevelopmentAndRegulatoryMilestones", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } }, "R71": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Uncategorized", "order": "71", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_85tcGVGI6UOT6DflWx2I3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true }, "uniqueAnchor": null }, "R72": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Cover", "order": "72", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_7UL5eTV-UkuWZs0-hb4vnQ", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240331x10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]", "terseLabel": "ACCRUED EXPENSES", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r26" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable Current", "terseLabel": "Trade payables", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25", "r747" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r696" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable Net Current", "terseLabel": "Trade receivables, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r269", "r270" ] }, "hrmy_AccredoHealthGroupIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "AccredoHealthGroupIncMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Accredo Health Group, Inc.", "label": "Accredo Health Group, Inc" } } }, "auth_ref": [] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization of premiums and accretion of discounts on Investment securities", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r117" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "totalLabel": "Accrued liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r29" ] }, "hrmy_AccruedLiabilitiesOtherThanAccruedCompensationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "AccruedLiabilitiesOtherThanAccruedCompensationCurrent", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of accrued liabilities other than accrued compensation. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, other than Accrued Compensation, Current", "terseLabel": "Accrued expenses" } } }, "auth_ref": [] }, "us-gaap_AccruedMarketingCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedMarketingCostsCurrent", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Marketing Costs Current", "terseLabel": "Sales and marketing", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "hrmy_AccruedProfessionalFeesConsultingAndOtherServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "AccruedProfessionalFeesConsultingAndOtherServices", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued professional fees, consulting, and other services.", "label": "Accrued Professional Fees Consulting And Other Services", "terseLabel": "Professional fees, consulting, and other services" } } }, "auth_ref": [] }, "hrmy_AccruedRebatesAndOtherSalesDeductionsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "AccruedRebatesAndOtherSalesDeductionsCurrent", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued rebates and other sales deductions.", "label": "Accrued Rebates And Other Sales Deductions Current", "terseLabel": "Rebates and other sales deductions" } } }, "auth_ref": [] }, "hrmy_AccruedResearchAndDevelopmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "AccruedResearchAndDevelopmentCurrent", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued research and development current", "label": "Accrued Research And Development Current", "terseLabel": "Research and development" } } }, "auth_ref": [] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Royalties Current", "terseLabel": "Royalties due to Bioprojet", "verboseLabel": "Accrued Sales Based Trademark and Royalties", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r29", "r715" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive (loss) income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r36", "r37", "r102", "r182", "r574", "r597", "r598" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive (loss) income", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r14", "r37", "r465", "r468", "r506", "r593", "r594", "r856", "r857", "r858", "r865", "r866", "r867" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r798" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid In Capital Common Stock", "terseLabel": "Additional paid in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r94" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r435", "r436", "r437", "r613", "r865", "r866", "r867", "r920", "r945" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r804" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r804" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r804" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r804" ] }, "hrmy_AdjustmentForAmortizationOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "AdjustmentForAmortizationOfDebtIssuanceCosts", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Adjustment for Amortization of Debt Issuance Costs", "terseLabel": "Debt issuance costs amortization" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r66", "r67", "r400" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash used in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r769", "r780", "r790", "r815" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r772", "r783", "r793", "r818" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r804" ] }, "hrmy_AllCountriesExcludingChinaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "AllCountriesExcludingChinaMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to all countries except Greater China.", "label": "All Countries Excluding Greater China" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r811" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r776", "r784", "r794", "r811", "r819", "r823", "r831" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r829" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Allocated Share Based Compensation Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r430", "r438" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureDebtInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtInterestExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Amortization Of Financing Costs", "verboseLabel": "Amortization of deferred financing costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r106", "r363", "r491", "r859" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization Of Intangible Assets", "terseLabel": "Intangible amortization", "verboseLabel": "Amortization expense", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r8", "r51", "r55" ] }, "hrmy_AmountOfAggregateNetSalesAttaining": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "AmountOfAggregateNetSalesAttaining", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of aggregate net sales attaining.", "label": "Amount Of Aggregate Net Sales Attaining", "terseLabel": "Amount of Aggregate Net Sales Attaining" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Potential shares of common stock issuable excluded from computation - Stock options, SARs, and RSUs to purchase common stock", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r241" ] }, "us-gaap_AssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "ACQUISITION" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r915" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Consideration transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r743", "r916", "r917", "r918" ] }, "hrmy_AssetAcquisitionConsiderationTransferredCommonContingentValueRightPaidPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "AssetAcquisitionConsiderationTransferredCommonContingentValueRightPaidPerShare", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionDetails" ], "lang": { "en-us": { "role": { "documentation": "The contingent consideration per Common Stock, per the Tender Offer.", "label": "Asset Acquisition, Consideration Transferred, Common Contingent Value Right Paid Per Share", "terseLabel": "Contingent consideration per Common Stock" } } }, "auth_ref": [] }, "hrmy_AssetAcquisitionConsiderationTransferredNumberOfContingentValueRightPerCommonStock": { "xbrltype": "integerItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "AssetAcquisitionConsiderationTransferredNumberOfContingentValueRightPerCommonStock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of contingent value right per Common Stock, for each holder of Common Stock upon the closing of the Tender Offer.", "label": "Asset Acquisition, Consideration Transferred, Number of Contingent Value Right per Common Stock", "terseLabel": "Number of contingent value right per Common Stock" } } }, "auth_ref": [] }, "hrmy_AssetAcquisitionConsiderationTransferredOnCommonCashAmountPaidPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "AssetAcquisitionConsiderationTransferredOnCommonCashAmountPaidPerShare", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash amount paid per Common Stock, per the Tender Offer.", "label": "Asset Acquisition, Consideration Transferred, on Common Cash Amount Paid Per Share", "terseLabel": "Cash consideration per Common Stock" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred, Transaction Cost", "terseLabel": "Transaction costs", "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r743", "r916", "r917", "r918" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r915" ] }, "us-gaap_AssetAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Line Items]", "terseLabel": "ACQUISITION", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r915" ] }, "us-gaap_AssetAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Table]", "documentation": "Disclosure of information about asset acquisition." } } }, "auth_ref": [ "r915" ] }, "us-gaap_AssetAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisition" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Text Block]", "terseLabel": "ACQUISITION", "documentation": "The entire disclosure for asset acquisition." } } }, "auth_ref": [ "r915" ] }, "hrmy_AssetPurchaseAgreementWithConsynanceTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "AssetPurchaseAgreementWithConsynanceTherapeuticsMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to asset purchase agreement with ConSynance Therapeutics.", "label": "Asset Purchase Agreement with ConSynance Therapeutics [Member]", "terseLabel": "Asset Purchase Agreement with ConSynance Therapeutics" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "TOTAL ASSETS", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r137", "r178", "r209", "r246", "r259", "r263", "r304", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r458", "r462", "r482", "r571", "r641", "r747", "r760", "r882", "r883", "r926" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS", "verboseLabel": "Assets acquired" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets Current", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r171", "r186", "r209", "r304", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r458", "r462", "r482", "r747", "r882", "r883", "r926" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "CURRENT ASSETS:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r71" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets Noncurrent", "totalLabel": "Total noncurrent assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r209", "r304", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r458", "r462", "r482", "r882", "r883", "r926" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets Noncurrent [Abstract]", "terseLabel": "NONCURRENT ASSETS:" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "verboseLabel": "Unrealized Gains", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r278" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Unrealized Losses", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r279" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r275", "r312", "r570" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale", "terseLabel": "Fair Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r276", "r312", "r564", "r871" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r826" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r827" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r822" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r822" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r822" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r822" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r822" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r822" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r825" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r824" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r823" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r823" ] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BaseRateMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Base Rate [Member]", "terseLabel": "Base rate", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "hrmy_BioprojetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "BioprojetMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails", "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Bioprojet.", "label": "Bioprojet" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r456", "r738", "r739" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r69", "r70", "r456", "r738", "r739" ] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Consideration Transferred", "terseLabel": "Up front consideration", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r1", "r2", "r12" ] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business Combinations", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r68" ] }, "hrmy_CaremarkLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "CaremarkLLCMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Caremark LLC.", "label": "Caremark LLC" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r41", "r173", "r712" ] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash equivalents", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy", "terseLabel": "Cash, Cash Equivalents and Restricted Cash", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r42", "r136" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "periodEndLabel": "CASH, CASH EQUIVALENTS, AND RESTRICTED CASH-End of period", "periodStartLabel": "CASH, CASH EQUIVALENTS, AND RESTRICTED CASH-Beginning of period", "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the statements of cash flows", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r41", "r115", "r205" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r115" ] }, "hrmy_CataplexyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "CataplexyMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Cataplexy.", "label": "Cataplexy" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r802" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfTreasuryStockTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfTreasuryStockTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Treasury Stock [Table]", "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": [ "r59", "r60", "r61", "r62" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r803" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r803" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r124", "r754", "r755", "r756", "r757" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies", "terseLabel": "COMMITMENTS AND CONTINGENCIES (Note 13)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r33", "r81", "r572", "r627" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r122", "r326", "r327", "r697", "r879" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Total number of shares available for issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r34" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r750", "r751", "r752", "r754", "r755", "r756", "r757", "r865", "r866", "r920", "r942", "r945" ] }, "hrmy_CommonStockNumberOfVotesPerShare": { "xbrltype": "integerItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "CommonStockNumberOfVotesPerShare", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of votes for each common stock.", "label": "Common Stock, Number of Votes per Share", "terseLabel": "Number of votes for each common stock" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock Par or Stated Value Per Share", "terseLabel": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r93" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r93", "r628" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r93" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r15", "r93", "r628", "r647", "r945", "r946" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock Value", "terseLabel": "Common stock-$0.00001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 56,791,214 and 56,769,081 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r93", "r573", "r747" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r808" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r807" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r809" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r806" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r38", "r188", "r190", "r195", "r565", "r582" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r44", "r46", "r72", "r73", "r268", "r696" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk By Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r44", "r46", "r72", "r73", "r268", "r599", "r696" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk By Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r44", "r46", "r72", "r73", "r268", "r696", "r841" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Credit Risk", "terseLabel": "Concentrations of Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r83", "r153" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Percentage1", "terseLabel": "Concentration risk percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r44", "r46", "r72", "r73", "r268" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r44", "r46", "r72", "r73", "r268", "r696" ] }, "hrmy_ConcentrationsOfRiskNumberOfFinancialInstitutions": { "xbrltype": "integerItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "ConcentrationsOfRiskNumberOfFinancialInstitutions", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number Of financial institutions in which Substantially all of the Company's cash and money market funds are held.", "label": "Concentrations of Risk, Number Of Financial Institutions", "terseLabel": "Number Of financial institutions" } } }, "auth_ref": [] }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Contractual Obligation Fiscal Year Maturity Schedule Table Text Block", "terseLabel": "Schedule of future minimum payments relating to long term debt", "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation." } } }, "auth_ref": [ "r863" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r735", "r737", "r941" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Cost Of Goods And Services Sold", "terseLabel": "Cost of product sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r108", "r549" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails", "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r168", "r213", "r214", "r345", "r373", "r513", "r716", "r718" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r45", "r268" ] }, "hrmy_DaytimeSleepinessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "DaytimeSleepinessMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Daytime Sleepiness.", "label": "Daytime Sleepiness" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "DEBT" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebt" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "DEBT", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r123", "r207", "r341", "r347", "r348", "r349", "r350", "r351", "r352", "r357", "r364", "r365", "r367" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r23", "r89", "r90", "r138", "r139", "r215", "r342", "r343", "r344", "r345", "r346", "r348", "r353", "r354", "r355", "r356", "r358", "r359", "r360", "r361", "r362", "r363", "r492", "r726", "r727", "r728", "r729", "r730", "r861" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Basis Spread On Variable Rate1", "terseLabel": "Basis spread on variable rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureDebtBalancesOfLongTermDebtNetDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtBalancesOfLongTermDebtNetDetails", "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Carrying Amount", "totalLabel": "Total", "verboseLabel": "Principal amount", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r23", "r139", "r368" ] }, "hrmy_DebtInstrumentCreditSpreadAdjustmentRate": { "xbrltype": "percentItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "DebtInstrumentCreditSpreadAdjustmentRate", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of credit spread adjustment rate.", "label": "Debt Instrument Credit Spread Adjustment Rate", "terseLabel": "Credit spread adjustment rate" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Fair Value", "terseLabel": "Fair value of loan", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r355", "r481", "r727", "r728" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "DEBT", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r215", "r342", "r343", "r344", "r345", "r346", "r348", "r353", "r354", "r355", "r356", "r358", "r359", "r360", "r361", "r362", "r363", "r366", "r492", "r726", "r727", "r728", "r729", "r730", "r861" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r31", "r215", "r342", "r343", "r344", "r345", "r346", "r348", "r353", "r354", "r355", "r356", "r358", "r359", "r360", "r361", "r362", "r363", "r492", "r726", "r727", "r728", "r729", "r730", "r861" ] }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Periodic payment principal", "documentation": "Amount of the required periodic payments applied to principal." } } }, "auth_ref": [ "r31" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Table]", "terseLabel": "Debt Instrument [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r31", "r57", "r58", "r74", "r75", "r77", "r82", "r126", "r127", "r215", "r342", "r343", "r344", "r345", "r346", "r348", "r353", "r354", "r355", "r356", "r358", "r359", "r360", "r361", "r362", "r363", "r366", "r492", "r726", "r727", "r728", "r729", "r730", "r861" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Term", "terseLabel": "Term of loan", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285" ] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Finance Costs Gross", "terseLabel": "Debt issuance costs", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r76" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax asset", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r441", "r442" ] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred taxes", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": [ "r117" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r8", "r56" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensation" ], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r398", "r403", "r431", "r432", "r434", "r741" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r764" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r797" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "verboseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "EARNINGS PER SHARE", "terseLabel": "EARNINGS PER SHARE:", "verboseLabel": "Denominator" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share Basic", "terseLabel": "Basic", "verboseLabel": "Net income per share of common stock - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r196", "r221", "r222", "r223", "r224", "r225", "r231", "r233", "r238", "r239", "r240", "r244", "r473", "r474", "r566", "r583", "r720" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share Diluted", "terseLabel": "Diluted", "verboseLabel": "Net income per share of common stock - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r196", "r221", "r222", "r223", "r224", "r225", "r233", "r238", "r239", "r240", "r244", "r473", "r474", "r566", "r583", "r720" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "EARNINGS PER SHARE", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r230", "r241", "r242", "r243" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Continuing Operations", "totalLabel": "Total", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r444" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate", "terseLabel": "Federal income tax rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r210", "r444", "r452" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance", "terseLabel": "Valuation allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r913", "r914" ] }, "hrmy_EffectiveIncomeTaxRateReconciliationCredits": { "xbrltype": "percentItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "EffectiveIncomeTaxRateReconciliationCredits", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to credits.", "label": "Effective Income Tax Rate Reconciliation, Credits", "terseLabel": "Credits" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation Other Adjustments", "terseLabel": "Other", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r913", "r914" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent", "terseLabel": "Stock-based compensation", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r839", "r913" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes", "terseLabel": "State taxes", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r913", "r914" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued Employee Benefits Current", "terseLabel": "Accrued compensation", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r29" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r433" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r433" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "hrmy_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "EmployeeStockPurchasePlanMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Employee Stock Purchase Plan.", "label": "Employee Stock Purchase Plan" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line3", "terseLabel": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r762" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock Shares Outstanding", "verboseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "All Entities [Member]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r762" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r762" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r836" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r762" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r762" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r762" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r762" ] }, "hrmy_EpygenixTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "EpygenixTherapeuticsIncMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Epygenix Therapeutics, Inc., a Wyoming corporation (\"Epygenix\").", "label": "Epygenix Therapeutics Inc [Member]", "terseLabel": "Epygenix" } } }, "auth_ref": [] }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityClassOfTreasuryStockLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Equity, Class of Treasury Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Component", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r15", "r169", "r191", "r192", "r193", "r216", "r217", "r218", "r220", "r226", "r228", "r245", "r305", "r306", "r385", "r435", "r436", "r437", "r448", "r449", "r464", "r465", "r466", "r467", "r468", "r469", "r472", "r483", "r484", "r485", "r486", "r487", "r488", "r506", "r593", "r594", "r595", "r613", "r672" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r805" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r769", "r780", "r790", "r815" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r766", "r777", "r787", "r812" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r811" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r476", "r477", "r478" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r476", "r477", "r478" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Schedule of assets measured at fair value", "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2." } } }, "auth_ref": [ "r71", "r134" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r355", "r389", "r390", "r391", "r392", "r393", "r394", "r477", "r521", "r522", "r523", "r727", "r728", "r735", "r736", "r737" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "FAIR VALUE MEASUREMENTS" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r475" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r355", "r389", "r394", "r477", "r521", "r735", "r736", "r737" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r355", "r389", "r394", "r477", "r522", "r727", "r728", "r735", "r736", "r737" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r355", "r389", "r390", "r391", "r392", "r393", "r394", "r521", "r522", "r523", "r727", "r728", "r735", "r736", "r737" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Of Financial Instruments Policy", "terseLabel": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r11", "r22" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails", "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r307", "r308", "r309", "r310", "r311", "r313", "r314", "r315", "r366", "r383", "r470", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r581", "r725", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r873", "r874", "r875", "r876" ] }, "hrmy_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Finite Lived Intangible Asset Useful Life", "terseLabel": "Useful life of intangible asset", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite Lived Intangible Assets Accumulated Amortization", "negatedLabel": "Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r176", "r322" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r121" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year", "terseLabel": "2024 (excluding the three months ended March 31, 2024)", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r121" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r121" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r121" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r320", "r321", "r322", "r323", "r550", "r551" ] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Future annual amortization expense" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Finite Lived Intangible Assets [Line Items]", "verboseLabel": "Intangible Assets", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r550" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r52", "r54" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite Lived Intangible Assets Net", "totalLabel": "Total", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r120", "r550" ] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Finite Lived Intangible Assets Remaining Amortization Period1", "terseLabel": "Remaining useful life", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r550" ] }, "hrmy_FiveYearSeniorSecuredTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "FiveYearSeniorSecuredTermLoanMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to five-year senior secured term loan (the \"TLA Term Loan\").", "label": "Five-year Senior Secured Term Loan [Member]", "terseLabel": "TLA Term Loan" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r773", "r784", "r794", "r819" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r773", "r784", "r794", "r819" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r773", "r784", "r794", "r819" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r773", "r784", "r794", "r819" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r773", "r784", "r794", "r819" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "General And Administrative Expense.", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r109", "r651" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative expense", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r105" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Gross Profit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r107", "r209", "r246", "r258", "r262", "r264", "r304", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r482", "r722", "r882" ] }, "hrmy_Hbs102Member": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "Hbs102Member", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to HBS 102.", "label": "HBS-102", "terseLabel": "OX2R" } } }, "auth_ref": [] }, "hrmy_IncentiveAwardPlanTwoThousandTwentyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "IncentiveAwardPlanTwoThousandTwentyMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Incentive award plan two thousand twenty.", "label": "2020 Plan" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "totalLabel": "Income before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r103", "r143", "r246", "r258", "r262", "r264", "r567", "r578", "r722" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r324", "r325", "r656" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r325", "r656" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "INCOME TAXES" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r210", "r440", "r445", "r446", "r447", "r450", "r453", "r454", "r455", "r608" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense Benefit", "negatedLabel": "Income tax expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r149", "r156", "r227", "r228", "r250", "r443", "r451", "r585" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase Decrease In Accounts Payable Trade", "terseLabel": "Trade payables", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase Decrease In Accounts Receivable", "negatedLabel": "Trade receivables", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase Decrease In Inventories", "negatedLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfSecuritiesOutstandingIncludedInComputationAboveUtilizingTreasuryStockMethodDetails" ], "lang": { "en-us": { "role": { "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Securities outstanding included in the computation - Stock options, SARs, and RSUs to purchase common stock", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r234", "r235", "r236", "r240", "r402" ] }, "hrmy_IncrementalTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "IncrementalTermLoanMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Incremental Term Loan.", "label": "Incremental Term Loan [Member]", "terseLabel": "Incremental Term Loan" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r776", "r784", "r794", "r811", "r819", "r823", "r831" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r829" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r765", "r835" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r765", "r835" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r765", "r835" ] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "INTANGIBLE ASSETS", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r319" ] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible Assets Gross Excluding Goodwill", "terseLabel": "Gross Carrying Amount", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r175" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 4.0 }, "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetsDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Intangible Assets Net Excluding Goodwill", "terseLabel": "Intangible assets, net", "totalLabel": "Net Book Value", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r50", "r53" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "lang": { "en-us": { "role": { "label": "INTANGIBLE ASSETS" } } }, "auth_ref": [] }, "hrmy_IntellectualPropertyPaymentDueUponAchievementOfDevelopmentalMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "IntellectualPropertyPaymentDueUponAchievementOfDevelopmentalMilestones", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of intellectual property payment due upon achievement of developmental milestones.", "label": "Intellectual Property Payment Due Upon Achievement of Developmental Milestones", "terseLabel": "Payment for intellectual property upon developmental milestones" } } }, "auth_ref": [] }, "hrmy_IntellectualPropertyPaymentDueUponAchievementOfPreclinicalMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "IntellectualPropertyPaymentDueUponAchievementOfPreclinicalMilestones", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of intellectual property payment due upon achievement of preclinical milestones.", "label": "Intellectual Property Payment Due Upon Achievement of Preclinical Milestones", "terseLabel": "Payment for intellectual property upon preclinical milestones" } } }, "auth_ref": [] }, "hrmy_IntellectualPropertyPaymentDueUponAchievementOfRegulatoryMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "IntellectualPropertyPaymentDueUponAchievementOfRegulatoryMilestones", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of intellectual property payment due upon achievement of regulatory milestones.", "label": "Intellectual Property Payment Due Upon Achievement of Regulatory Milestones", "terseLabel": "Payment for intellectual property upon regulatory milestones" } } }, "auth_ref": [] }, "hrmy_IntellectualPropertyPaymentDueUponAchievementOfSalesMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "IntellectualPropertyPaymentDueUponAchievementOfSalesMilestones", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of intellectual property payment due upon achievement of sales milestones.", "label": "Intellectual Property Payment Due Upon Achievement of Sales Milestones", "terseLabel": "Payment for intellectual property upon sales milestones" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Interest Expense", "negatedLabel": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r76", "r145", "r194", "r249", "r490", "r657", "r758", "r944" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureDebtInterestExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtInterestExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense Debt", "totalLabel": "Total term loan interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r111", "r361", "r370", "r729", "r730" ] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureDebtInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtInterestExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense Debt Excluding Amortization", "terseLabel": "Interest on principal balance", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": [ "r113", "r362", "r729", "r730" ] }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Interest Income And Interest Expense Disclosure Table [Text Block]", "terseLabel": "Schedule of interest expense related to long term debt", "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Paid Net", "terseLabel": "Cash paid during the year for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r200", "r203", "r204" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest Payable, Current", "terseLabel": "Interest", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r29" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "INVENTORY" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInventory" ], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORY", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r316" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory Finished Goods", "terseLabel": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r852" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.harmonybiosciences.com/role/DisclosureInventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInventoryDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Inventory Net", "terseLabel": "Inventory, net", "totalLabel": "Total inventory, net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r183", "r713", "r747" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory Raw Materials", "terseLabel": "Raw materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r854" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory Work In Process", "terseLabel": "Work in process", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r853" ] }, "us-gaap_InvestmentIncomeNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeNonoperating", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Investment Income, Nonoperating", "terseLabel": "Interest income", "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations." } } }, "auth_ref": [ "r110" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r584", "r602", "r603", "r604", "r605", "r682", "r683" ] }, "us-gaap_InvestmentsAndCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsAndCash", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "label": "Investments and Cash", "terseLabel": "Cash, cash equivalents and investments", "documentation": "Sum of investments and unrestricted cash as of the balance sheet date." } } }, "auth_ref": [ "r936", "r938" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "INVESTMENTS" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestments" ], "lang": { "en-us": { "role": { "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "INVESTMENTS", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r135", "r146", "r147", "r157", "r271", "r273", "r479", "r480" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of supplemental balance sheet and cash flow information related to operating leases", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r923" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "LEASES" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "LEASES", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r498" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r498" ] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": [ "r499" ] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Existence of Option to Terminate [true false]", "documentation": "Indicates (true false) whether lessee has option to terminate operating lease." } } }, "auth_ref": [ "r499" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Liability Maturity Table [Text Block]", "terseLabel": "Schedule of future payments under noncancelable operating leases", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r924" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetailsCalc2": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Liability Payments Due", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r505" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r505" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r505" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r505" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Liability Payments Remainder Of Fiscal Year", "terseLabel": "2024 (excluding the three months ended March 31, 2024)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r924" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetailsCalc2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r505" ] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease terms", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r922" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeases" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r493" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r28", "r209", "r304", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r459", "r462", "r463", "r482", "r626", "r721", "r760", "r882", "r926", "r927" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r98", "r140", "r576", "r747", "r862", "r877", "r921" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r30", "r172", "r209", "r304", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r459", "r462", "r463", "r482", "r747", "r882", "r926", "r927" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "CURRENT LIABILITIES:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities Noncurrent", "totalLabel": "Total noncurrent liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r23", "r86", "r87", "r88", "r91", "r209", "r304", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r459", "r462", "r463", "r482", "r882", "r926", "r927" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities Noncurrent [Abstract]", "terseLabel": "NONCURRENT LIABILITIES:" } } }, "auth_ref": [] }, "hrmy_LicenseAgreementAdditionalMilestonePaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "LicenseAgreementAdditionalMilestonePaymentsDue", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "License agreement additional milestone payments due.", "label": "License Agreement Additional Milestone Payments Due", "terseLabel": "License agreement, additional milestone payment due" } } }, "auth_ref": [] }, "hrmy_LicenseAgreementFinalPaymentPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "LicenseAgreementFinalPaymentPaid", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "License agreement final payment paid.", "label": "License Agreement Final Payment Paid", "terseLabel": "Final payment paid" } } }, "auth_ref": [] }, "hrmy_LicenseAgreementMaximumAdditionalMilestonePaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "LicenseAgreementMaximumAdditionalMilestonePaymentsDue", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "License agreement maximum additional milestone payments due.", "label": "License Agreement Maximum Additional Milestone Payments Due", "terseLabel": "License agreement, maximum additional milestone payment due" } } }, "auth_ref": [] }, "hrmy_LicenseAgreementMaximumAdditionalMilestonePaymentsDueUponAchievementOfDevelopmentAndRegulatoryMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "LicenseAgreementMaximumAdditionalMilestonePaymentsDueUponAchievementOfDevelopmentAndRegulatoryMilestones", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of license agreement maximum additional milestone payments due upon achievement of development and regulatory milestones.", "label": "License Agreement Maximum Additional Milestone Payments Due Upon Achievement of Development and Regulatory Milestones", "terseLabel": "Amount of fee payable upon achieving development and regulatory milestones" } } }, "auth_ref": [] }, "hrmy_LicenseAgreementMaximumAdditionalMilestonePaymentsDueUponAchievementOfSalesBasedMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "LicenseAgreementMaximumAdditionalMilestonePaymentsDueUponAchievementOfSalesBasedMilestones", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of license agreement maximum additional milestone payments due upon achievement of sales-based milestones.", "label": "License Agreement Maximum Additional Milestone Payments Due Upon Achievement of Sales-based Milestones", "terseLabel": "Amount of fees payable upon achieving sale-based milestones" } } }, "auth_ref": [] }, "hrmy_LicenseAgreementMilestonePaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "LicenseAgreementMilestonePaymentsDue", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "License agreement milestone payments Due.", "label": "License Agreement Milestone Payments Due", "terseLabel": "License agreement, milestone payment due" } } }, "auth_ref": [] }, "hrmy_LicenseAgreementMilestonePaymentsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "LicenseAgreementMilestonePaymentsPaid", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "License agreement milestone payments paid.", "label": "License Agreement Milestone Payments Paid", "terseLabel": "License agreement milestone payments paid" } } }, "auth_ref": [] }, "hrmy_LicenseAgreementPreclinicalMilestonePaymentsRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "LicenseAgreementPreclinicalMilestonePaymentsRecognized", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of preclinical milestone payments recognized under the license agreement.", "label": "License Agreement, Preclinical Milestone Payments Recognized", "terseLabel": "Payment related to achievement of preclinical milestone." } } }, "auth_ref": [] }, "hrmy_LicenseAgreementUpfrontFeePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "LicenseAgreementUpfrontFeePaid", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to license agreement upfront fees paid.", "label": "License Agreement, Upfront Fee Paid", "terseLabel": "Payment of upfront license fee" } } }, "auth_ref": [] }, "hrmy_LicenseAgreementUpfrontNonRefundableFeePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "LicenseAgreementUpfrontNonRefundableFeePaid", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to license agreement upfront non-refundable fees paid.", "label": "License Agreement Upfront Non-Refundable Fee Paid", "terseLabel": "License agreement, upfront non-refundable licensing fees paid" } } }, "auth_ref": [] }, "hrmy_LicenseAndAssetPurchaseAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "LicenseAndAssetPurchaseAgreementsAbstract", "lang": { "en-us": { "role": { "documentation": "License and asset purchase agreements.", "label": "LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS" } } }, "auth_ref": [] }, "hrmy_LicenseAndAssetPurchaseAgreementsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "LicenseAndAssetPurchaseAgreementsLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent License and asset purchase agreements.", "label": "License and Asset Purchase Agreements [Line Items]", "terseLabel": "License Agreements and Asset Purchase Agreements" } } }, "auth_ref": [] }, "hrmy_LicenseAndAssetPurchaseAgreementsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "LicenseAndAssetPurchaseAgreementsTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about license and asset purchase agreements.", "label": "License Agreements and Asset Purchase Agreements [Table]" } } }, "auth_ref": [] }, "hrmy_LicenseAndAssetPurchaseAgreementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "LicenseAndAssetPurchaseAgreementsTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreements" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of license and asset purchase agreements.", "label": "License and Asset Purchase Agreements [Text Block]", "terseLabel": "LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS" } } }, "auth_ref": [] }, "hrmy_LicensingAgreementMilestoneFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "LicensingAgreementMilestoneFees", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Licensing agreement milestone fees", "label": "Licensing Agreement Milestone Fees", "terseLabel": "Licensing agreement milestone fees" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Line Of Credit Facility Maximum Borrowing Capacity", "terseLabel": "Aggregate principal amount", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r27" ] }, "hrmy_LiquidityAndCapitalResourcesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "LiquidityAndCapitalResourcesAbstract", "lang": { "en-us": { "role": { "documentation": "Liquidity and capital resources.", "label": "LIQUIDITY AND CAPITAL RESOURCES" } } }, "auth_ref": [] }, "hrmy_LiquidityAndCapitalResourcesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "LiquidityAndCapitalResourcesTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLiquidityAndCapitalResources" ], "lang": { "en-us": { "role": { "documentation": "Liquidity and capital resources.", "label": "Liquidity And Capital Resources [Text Block]", "terseLabel": "LIQUIDITY AND CAPITAL RESOURCES" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "hrmy_LongTermCommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "LongTermCommercialPaperMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to long term commercial paper.", "label": "Long-term commercial paper" } } }, "auth_ref": [] }, "hrmy_LongTermCorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "LongTermCorporateDebtSecuritiesMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to long term corporate debt securities.", "label": "Long-term corporate debt securities" } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureDebtBalancesOfLongTermDebtNetDetailsCalc2": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.harmonybiosciences.com/role/DisclosureDebtBalancesOfLongTermDebtNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtBalancesOfLongTermDebtNetDetails" ], "lang": { "en-us": { "role": { "label": "Long-term Debt", "totalLabel": "Total debt, net", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r23", "r139", "r354", "r369", "r727", "r728", "r937" ] }, "us-gaap_LongTermDebtByMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtByMaturityAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]", "terseLabel": "Future minimum payments" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureDebtBalancesOfLongTermDebtNetDetailsCalc2": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtBalancesOfLongTermDebtNetDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term Debt, Current Maturities", "negatedLabel": "Less current portion", "terseLabel": "Current portion of long-term debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r179" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2025", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r215", "r359" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2028", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r215", "r359" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2027", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r215", "r359" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r215", "r359" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2024 (excluding the three months ended March 31, 2024)", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r864" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 }, "http://www.harmonybiosciences.com/role/DisclosureDebtBalancesOfLongTermDebtNetDetailsCalc2": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtBalancesOfLongTermDebtNetDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long Term Debt Noncurrent", "terseLabel": "Long-term debt, net", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r180" ] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermInvestments", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-Term Investments", "terseLabel": "Investments, long-term", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [ "r174" ] }, "hrmy_LongTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "LongTermInvestmentsMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of more than one year from the date of the balance sheet.", "label": "Long-term" } } }, "auth_ref": [] }, "hrmy_LongTermUsGovernmentSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "LongTermUsGovernmentSecuritiesMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to long term us government securities.", "label": "Long-term U.S. government securities" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Major Customers [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r268", "r734", "r885", "r939", "r940" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails", "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Maximum", "terseLabel": "Maximum", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r328", "r329", "r330", "r331", "r396", "r548", "r592", "r618", "r619", "r680", "r684", "r686", "r687", "r689", "r707", "r708", "r724", "r731", "r740", "r749", "r884", "r928", "r929", "r930", "r931", "r932", "r933" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r803" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r803" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails", "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Minimum", "terseLabel": "Minimum", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r328", "r329", "r330", "r331", "r396", "r548", "r592", "r618", "r619", "r680", "r684", "r686", "r687", "r689", "r707", "r708", "r724", "r731", "r740", "r749", "r884", "r928", "r929", "r930", "r931", "r932", "r933" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r822" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r830" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Customer", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r268", "r734", "r885", "r939", "r940" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r804" ] }, "hrmy_NdaForWakixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "NdaForWakixMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "NDA for WAKIX.", "label": "NDA for WAKIX [Member]", "terseLabel": "NDA for WAKIX." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r202" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r202" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash provided by operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r115", "r116", "r117" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r104", "r117", "r144", "r170", "r187", "r189", "r193", "r209", "r219", "r221", "r222", "r223", "r224", "r227", "r228", "r237", "r246", "r258", "r262", "r264", "r304", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r474", "r482", "r580", "r649", "r670", "r671", "r722", "r758", "r882" ] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Net Income Loss [Abstract]", "terseLabel": "Numerator" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "hrmy_NonCurrentInvestmentMaturityTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "NonCurrentInvestmentMaturityTerm", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Maturity term of non current investments.", "label": "Non Current Investment Maturity Term", "terseLabel": "Non current investment maturity term" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r803" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r773", "r784", "r794", "r811", "r819" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r801" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r800" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r811" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r830" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r830" ] }, "hrmy_NumberOfApprovedCommercialProducts": { "xbrltype": "integerItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "NumberOfApprovedCommercialProducts", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of approved commercial products.", "label": "Number Of Approved Commercial Products", "terseLabel": "Number of approved commercial products" } } }, "auth_ref": [] }, "hrmy_NumberOfMajorCustomers": { "xbrltype": "integerItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "NumberOfMajorCustomers", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of major customers.", "label": "Number Of Major Customers", "terseLabel": "Number of customers" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number Of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r870" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r870" ] }, "hrmy_October2023ShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "October2023ShareRepurchaseProgramMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to October 2023 Share Repurchase Program.", "label": "October 2023 Share Repurchase Program [Member]", "terseLabel": "October 2023 Repurchase Program" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Operating Income Loss", "totalLabel": "Operating income", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r246", "r258", "r262", "r264", "r722" ] }, "hrmy_OperatingLeaseAdditionalOfficeSpaceLeasedOne": { "xbrltype": "areaItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "OperatingLeaseAdditionalOfficeSpaceLeasedOne", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating lease additional office space one, leased.", "label": "Operating Lease Additional Office Space Leased, One", "terseLabel": "Additional office space leased one" } } }, "auth_ref": [] }, "hrmy_OperatingLeaseAdditionalOfficeSpaceLeasedTwo": { "xbrltype": "areaItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "OperatingLeaseAdditionalOfficeSpaceLeasedTwo", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating lease additional office space two, leased.", "label": "Operating Lease Additional Office Space Leased, Two", "terseLabel": "Additional office space leased two" } } }, "auth_ref": [] }, "hrmy_OperatingLeaseAssetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "OperatingLeaseAssetAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Operating Lease, Asset [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating lease costs", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r500", "r746" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Years ending December 31," } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetailsCalc2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 }, "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesFuturePaymentsDetails", "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "terseLabel": "Total lease liabilities", "totalLabel": "Total operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r495" ] }, "us-gaap_OperatingLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability [Abstract]", "terseLabel": "Liabilities" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "verboseLabel": "Operating lease liability, current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r495" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r496" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Operating lease liability, long-term", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r495" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": [ "r496" ] }, "hrmy_OperatingLeaseOfficeSpace": { "xbrltype": "areaItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "OperatingLeaseOfficeSpace", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating lease office space.", "label": "Operating Lease Office Space", "terseLabel": "Operating lease square feet of office space" } } }, "auth_ref": [] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r497", "r501" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r494" ] }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } }, "auth_ref": [ "r496" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate for operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r504", "r746" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r503", "r746" ] }, "hrmy_Orexin2ReceptorAgonistOx2rMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "Orexin2ReceptorAgonistOx2rMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to orexin-2 receptor agonist (OX2R) (the \"Licensed Compound\").", "label": "Orexin-2 Receptor Agonist (OX2R) [Member]", "terseLabel": "Orexin-2 receptor agonist (OX2R)" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "ORGANIZATION AND DESCRIPTION OF BUSINESS" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureOrganizationAndDescriptionOfBusiness" ], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]", "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r85", "r132", "r600", "r601" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities Current", "terseLabel": "Other expenses", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r29" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets Current", "terseLabel": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r185", "r747" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets Noncurrent", "terseLabel": "Other noncurrent assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r177" ] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized loss on investments", "verboseLabel": "Unrealized (loss) income on investments", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r6", "r13", "r133" ] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilities", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Other Liabilities", "terseLabel": "Amounts due to related parties", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r80", "r569", "r622", "r623", "r760", "r943" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities Current", "terseLabel": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r29", "r747" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities Noncurrent", "terseLabel": "Other noncurrent liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r32" ] }, "us-gaap_OtherLiabilityRelatedPartyTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilityRelatedPartyTypeExtensibleEnumeration", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Other Liability, Related Party, Type [Extensible Enumeration]", "documentation": "Indicates type of related party for liability classified as other." } } }, "auth_ref": [ "r925" ] }, "us-gaap_OtherNoncashExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashExpense", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other Noncash Expense", "terseLabel": "Other non-cash expenses", "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other." } } }, "auth_ref": [ "r117" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income Expense", "terseLabel": "Other (expense) income, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r112" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r803" ] }, "us-gaap_OtherReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Other Receivable, after Allowance for Credit Loss, Related Party, Type [Extensible Enumeration]", "documentation": "Indicates type of related party for receivable, after allowance for credit loss, classified as other." } } }, "auth_ref": [ "r925" ] }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivables", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction, Due from (to) Related Party", "terseLabel": "Amounts due from related parties", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": [ "r181", "r636" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r771", "r782", "r792", "r817" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r774", "r785", "r795", "r820" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r774", "r785", "r795", "r820" ] }, "hrmy_PANTHERxSpecialtyPharmacyLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "PANTHERxSpecialtyPharmacyLLCMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "PANTHERx Specialty Pharmacy LLC.", "label": "PANTHERx Specialty Pharmacy LLC" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r799" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "ACCRUED EXPENSES" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Debt Securities, Available-for-Sale", "negatedLabel": "Purchase of investment securities", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r39", "r197", "r272" ] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionDetails" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Productive Assets", "terseLabel": "Aggregate consideration", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r148", "r916", "r917", "r918" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchase of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r114" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r802" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r802" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r801" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r811" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r804" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r800" ] }, "hrmy_PitolisantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "PitolisantsMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Pitolisant's.", "label": "Upon Acceptance by FDA of Pitolisant's" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense Current", "terseLabel": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r184", "r317", "r318", "r714" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r850" ] }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Debt, Net of Issuance Costs", "terseLabel": "Net cash received", "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination." } } }, "auth_ref": [ "r199" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from maturities and sales of investment securities", "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r197", "r198", "r872" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds From Stock Options Exercised", "terseLabel": "Proceeds from exercised options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r5", "r20" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails", "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Product Or Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r265", "r549", "r586", "r587", "r588", "r589", "r590", "r591", "r709", "r732", "r748", "r842", "r880", "r881", "r885", "r939" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails", "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r265", "r549", "r586", "r587", "r588", "r589", "r590", "r591", "r709", "r732", "r748", "r842", "r880", "r881", "r885", "r939" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Profit Loss", "terseLabel": "Net income", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r170", "r187", "r189", "r201", "r209", "r219", "r227", "r228", "r246", "r258", "r262", "r264", "r304", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r457", "r460", "r461", "r474", "r482", "r567", "r579", "r612", "r649", "r670", "r671", "r722", "r744", "r745", "r759", "r858", "r882" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r9", "r568", "r577", "r747" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r799" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r799" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails", "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r328", "r329", "r330", "r331", "r388", "r396", "r426", "r427", "r428", "r524", "r548", "r592", "r618", "r619", "r680", "r684", "r686", "r687", "r689", "r707", "r708", "r724", "r731", "r740", "r749", "r752", "r878", "r884", "r929", "r930", "r931", "r932", "r933" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails", "http://www.harmonybiosciences.com/role/DisclosureLeasesDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r328", "r329", "r330", "r331", "r388", "r396", "r426", "r427", "r428", "r524", "r548", "r592", "r618", "r619", "r680", "r684", "r686", "r687", "r689", "r707", "r708", "r724", "r731", "r740", "r749", "r752", "r878", "r884", "r929", "r930", "r931", "r932", "r933" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r766", "r777", "r787", "r812" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r395", "r510", "r511", "r621", "r622", "r623", "r624", "r625", "r646", "r648", "r679" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "terseLabel": "Related party", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r211", "r212", "r510", "r511", "r512", "r513", "r621", "r622", "r623", "r624", "r625", "r646", "r648", "r679" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "terseLabel": "Related-party Transactions", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r652", "r653", "r656" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "RELATED-PARTY TRANSACTIONS" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r395", "r510", "r511", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r621", "r622", "r623", "r624", "r625", "r646", "r648", "r679", "r925" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED-PARTY TRANSACTIONS", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r507", "r508", "r509", "r511", "r514", "r609", "r610", "r611", "r654", "r655", "r656", "r676", "r678" ] }, "hrmy_RepaymentOfDebtBeginningOnDecember312025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "RepaymentOfDebtBeginningOnDecember312025Member", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to repayment of debt beginning on December 31, 2025.", "label": "Repayment Of Debt Beginning On December 31 2025" } } }, "auth_ref": [] }, "hrmy_RepaymentOfDebtCommencingOnDecember312023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "RepaymentOfDebtCommencingOnDecember312023Member", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to repayment of debt commencing on December 31, 2023.", "label": "Repayment Of Debt Commencing On December 31 2023" } } }, "auth_ref": [] }, "hrmy_RepaymentOfDebtDueOnMaturityDateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "RepaymentOfDebtDueOnMaturityDateMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to repayment of debt Due on Maturity Date of August 9, 2026.", "label": "Repayment of Debt Due on Maturity Date of July 26, 2028" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Long-term Debt", "negatedLabel": "Principal repayment of long term debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r40", "r606" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails", "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r213", "r214", "r345", "r373", "r513", "r717", "r718" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Research And Development Expense.", "terseLabel": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r84", "r439", "r934" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and development expense", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r767", "r778", "r788", "r813" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r768", "r779", "r789", "r814" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r775", "r786", "r796", "r821" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 }, "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Restricted Cash Noncurrent", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r150", "r851", "r860" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLiquidityAndCapitalResourcesDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings Accumulated Deficit", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r95", "r128", "r575", "r596", "r598", "r607", "r629", "r747" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated Deficit", "terseLabel": "Accumulated deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r169", "r216", "r217", "r218", "r220", "r226", "r228", "r305", "r306", "r435", "r436", "r437", "r448", "r449", "r464", "r466", "r467", "r469", "r472", "r593", "r595", "r613", "r945" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Net product revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r247", "r248", "r257", "r260", "r261", "r265", "r266", "r268", "r386", "r387", "r549" ] }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]", "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer." } } }, "auth_ref": [ "r732" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right of use assets obtained in exchange for operating lease obligations", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r502", "r746" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r830" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r830" ] }, "hrmy_SalesBasedTrademarkAndTieredRoyaltiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "SalesBasedTrademarkAndTieredRoyaltiesMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Sales-based, trademark and tiered royalties.", "label": "Sales-based, Trademark and Tiered Royalties [Member]", "terseLabel": "Sales-based, trademark and tiered royalties" } } }, "auth_ref": [] }, "us-gaap_SalesRevenueProductLineMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueProductLineMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Product Revenues", "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources." } } }, "auth_ref": [ "r840" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Scenario", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r229", "r397", "r837", "r868" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAccruedExpensesTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Accrued Liabilities Table [Text Block]", "terseLabel": "Schedule of accrued expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Summary of antidilutive securities excluded from computation of earnings per share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Investment securities", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of carrying value and amortized cost of available-for-sale debt securities", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Debt Table [Text Block]", "terseLabel": "Schedule of long-term debt, net", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "terseLabel": "Summary of computation of basic and diluted net income (loss) per share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r869" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]", "terseLabel": "Schedule of reconciliation between statutory federal income tax rate and the Company's effective income tax rate", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r131" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r65" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Summary of stock-based compensation expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r65" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule Of Finite Lived Intangible Assets [Table]", "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r52", "r54", "r550" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Finite Lived Intangible Assets Table [Text Block]", "terseLabel": "Schedule of gross carrying amount and net book value of intangible assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r52", "r54" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInventoryTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Inventory Current Table [Text Block]", "terseLabel": "Schedule of inventory net", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r24", "r99", "r100", "r101" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule Of Related Party Transactions By Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r78", "r79", "r652", "r653", "r656" ] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Restricted Cash And Cash Equivalents [Text Block]", "terseLabel": "Schedule of reconciliation of cash, cash equivalents, and restricted cash", "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": [ "r21", "r136", "r938" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r399", "r401", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]", "terseLabel": "Summary of changes in RSUs granted", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r64" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Share Based Compensation Stock Appreciation Rights Award Activity Table [Text Block]", "terseLabel": "Summary of changes in SARs granted", "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock appreciation rights awards that were outstanding at the beginning and end of the year, and the number of stock appreciation rights awards that were granted, exercised or converted, forfeited, and expired during the year." } } }, "auth_ref": [ "r64" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Summary of changes in stock options granted", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r18", "r19", "r64" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]", "terseLabel": "Summary of assumptions used to value awards", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r130" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]", "terseLabel": "Schedule of future annual amortization expense for unamortized intangible assets", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r54" ] }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "SOFR", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": [ "r919" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security12b Title", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r761" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r763" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Geographical", "documentation": "Geographical area." } } }, "auth_ref": [ "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r266", "r267", "r615", "r616", "r617", "r681", "r685", "r688", "r690", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r710", "r733", "r752", "r885", "r939" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Policy Policy [Text Block]", "terseLabel": "Operating Segments", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r251", "r252", "r253", "r254", "r255", "r256", "r266", "r723" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Selling And Marketing Expense", "terseLabel": "Sales and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense [Member]", "terseLabel": "Sales and marketing expense", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r105" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation", "terseLabel": "Stock-based and employee stock purchase compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r7" ] }, "hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscount", "crdr": "debit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of discount from fair value on purchase date that participants pay for shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount", "terseLabel": "Amount of discount on ESSP" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Purchase Date", "terseLabel": "ESPP permits eligible employees to purchase shares of common stock at discount", "documentation": "Discount rate from fair value on purchase date that participants pay for shares." } } }, "auth_ref": [ "r63" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period", "negatedLabel": "Number of Awards, Awards forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r420" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Awards forfeited", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r420" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period", "terseLabel": "Number of Awards, Awards issued", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r418" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average per share fair value of awards issued (in USD per share)", "verboseLabel": "Weighted-Average Grant Date Fair Value, Awards issued", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r418" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number", "periodEndLabel": "Number of Awards, Awards outstanding, Ending balance", "periodStartLabel": "Number of Awards, Awards outstanding, Beginning balance", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r415", "r416" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-Average Grant Date Fair Value, Awards outstanding, Ending balance", "periodStartLabel": "Weighted-Average Grant Date Fair Value, Awards outstanding, Beginning balance", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r415", "r416" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of Awards, Awards vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r419" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted-Average Grant Date Fair Value, Awards vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r419" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate", "terseLabel": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r427" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum", "terseLabel": "Expected volatility, maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum", "terseLabel": "Expected volatility, minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount": { "xbrltype": "percentItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award fair value assumptions lack of marketability discount.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Lack Of Marketability Discount", "terseLabel": "Lack of marketability discount" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum", "terseLabel": "Risk-free interest rate, maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum", "terseLabel": "Risk-free interest rate, minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "verboseLabel": "Stock Incentive Plan and Stock-based Compensation", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r399", "r401", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Number of Awards, Awards outstanding, Ending balance", "periodStartLabel": "Number of Awards, Awards outstanding, Beginning balance", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r16", "r17" ] }, "hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the non-option equity plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price, Awards outstanding, Ending balance", "periodStartLabel": "Weighted-Average Exercise Price, Awards outstanding, Beginning balance" } } }, "auth_ref": [] }, "hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity instruments other than options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted-Average Remaining Contractual Term" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period", "negatedLabel": "Number of Awards, Awards forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r413" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Number of Awards, Awards issued", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r411" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Number of Awards, Awards outstanding, Ending balance", "periodStartLabel": "Number of Awards, Awards outstanding, Beginning balance", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r407", "r408" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price, Awards outstanding, Ending balance", "periodStartLabel": "Weighted-Average Exercise Price, Awards outstanding, Beginning balance", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r407", "r408" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period", "terseLabel": "Shares issued under the ESPP", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r63" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInRsusGrantedDetails", "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Awards exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r412" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Awards forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r413" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Awards issued", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r411" ] }, "hrmy_ShareBasedCompensationPercentageOfIncrementInCommonStockOutstandingAnnually": { "xbrltype": "percentItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "ShareBasedCompensationPercentageOfIncrementInCommonStockOutstandingAnnually", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of increment in common stock outstanding .", "label": "Share Based Compensation, Percentage of Increment in Common Stock Outstanding Annually", "terseLabel": "Percentage of increment of common stock outstanding" } } }, "auth_ref": [] }, "us-gaap_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [] }, "us-gaap_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Domain]", "documentation": "Name of the share repurchase program." } } }, "auth_ref": [] }, "hrmy_ShareRepurchasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "ShareRepurchasesPolicyTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for Share Repurchases.", "label": "Share Repurchases Policy [Text Block]", "terseLabel": "Share Repurchases" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period", "verboseLabel": "Stock options contractual term", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r742" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1", "terseLabel": "Expected term (years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r425" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Weighted-Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r129" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "hrmy_ShortTermCommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "ShortTermCommercialPaperMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to short term commercial paper.", "label": "Short-term commercial paper" } } }, "auth_ref": [] }, "hrmy_ShortTermCorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "ShortTermCorporateDebtSecuritiesMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to short term corporate debt securities.", "label": "Short-term corporate debt securities" } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Short-Term Investments", "terseLabel": "Investments, short-term", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r141", "r142", "r855" ] }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestmentsMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Short-term", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": [ "r691", "r692", "r693", "r711" ] }, "hrmy_ShortTermUsGovernmentSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "ShortTermUsGovernmentSecuritiesMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to short term us government securities.", "label": "Short-term U.S. government securities" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r118", "r206" ] }, "hrmy_SignificantRisksAndUncertaintiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "SignificantRisksAndUncertaintiesPolicyTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Significant risks and uncertainties.", "label": "Significant Risks And Uncertainties Policy [Text Block]", "terseLabel": "Significant Risks and Uncertainties" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r15", "r35", "r169", "r191", "r192", "r193", "r216", "r217", "r218", "r220", "r226", "r228", "r245", "r305", "r306", "r385", "r435", "r436", "r437", "r448", "r449", "r464", "r465", "r466", "r467", "r468", "r469", "r472", "r483", "r484", "r485", "r486", "r487", "r488", "r506", "r593", "r594", "r595", "r613", "r672" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Statement Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r158", "r167", "r266", "r267", "r615", "r616", "r617", "r681", "r685", "r688", "r690", "r695", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r710", "r733", "r752", "r885", "r939" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r216", "r217", "r218", "r245", "r549", "r602", "r614", "r620", "r621", "r622", "r623", "r624", "r625", "r628", "r631", "r632", "r633", "r634", "r635", "r637", "r638", "r639", "r640", "r642", "r643", "r644", "r645", "r646", "r648", "r650", "r651", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r672", "r753" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Statement Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r229", "r397", "r837", "r838", "r868" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r216", "r217", "r218", "r245", "r549", "r602", "r614", "r620", "r621", "r622", "r623", "r624", "r625", "r628", "r631", "r632", "r633", "r634", "r635", "r637", "r638", "r639", "r640", "r642", "r643", "r644", "r645", "r646", "r648", "r650", "r651", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r672", "r753" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r770", "r781", "r791", "r816" ] }, "hrmy_StockAppreciationRightsMarketAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "StockAppreciationRightsMarketAdjustment", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Stock appreciation rights market adjustment.", "label": "Stock Appreciation Rights Market Adjustment", "terseLabel": "Stock appreciation rights market adjustment" } } }, "auth_ref": [] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInSarsGrantedDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "hrmy_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsExercised", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of share options and restricted stock units exercised during the current period.", "label": "Stock Issued During Period, Shares, Stock Options and Restricted Stock Units Exercised", "terseLabel": "Exercise of options and restricted stock units, Shares" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInStockOptionsGrantedDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Number of Awards, Awards exercised", "terseLabel": "Exercise of stock options , Shares", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r15", "r92", "r93", "r128", "r412" ] }, "hrmy_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercised", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options and restricted stock units.", "label": "Stock Issued During Period, Value, Stock Options and Restricted Stock Units Exercised", "terseLabel": "Exercise of options and restricted stock units" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r15", "r35", "r128" ] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Repurchase of shares of common stock approved", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Remaining authorized repurchase amount", "documentation": "Amount remaining of a stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased And Retired During Period Shares", "terseLabel": "Shares of common stock repurchased and retired", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": [ "r15", "r92", "r93", "r128" ] }, "hrmy_StockVestedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "StockVestedDuringPeriodShares", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock vested during period shares.", "label": "Stock Vested During Period Shares", "terseLabel": "Stock vested" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders Equity", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "TOTAL STOCKHOLDERS' EQUITY", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r93", "r96", "r97", "r119", "r630", "r647", "r673", "r674", "r747", "r760", "r862", "r877", "r921", "r945" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "STOCKHOLDERS' EQUITY:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDERS' EQUITY", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r125", "r208", "r371", "r372", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r384", "r385", "r471", "r675", "r677", "r694" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r489", "r516" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Events.", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r489", "r516" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r489", "r516" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r489", "r516" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r489", "r516" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r515", "r517" ] }, "hrmy_SummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Line Items]" } } }, "auth_ref": [] }, "hrmy_SummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "SummaryOfSignificantAccountingPoliciesTable", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Disclosure of Cash Flow Information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r810" ] }, "hrmy_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "TermLoanMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Term Loans.", "label": "Term Loan [Member]", "terseLabel": "Term Loans" } } }, "auth_ref": [] }, "hrmy_ThreeCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "ThreeCustomersMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Three customers.", "label": "Three Customers" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r802" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r809" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r829" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r831" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails", "http://www.harmonybiosciences.com/role/DisclosureInvestmentsCarryingValueAndAmortizedCostOfAvailableForSaleDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments", "terseLabel": "Financial Instruments", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r366", "r383", "r470", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r581", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r873", "r874", "r875", "r876" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r832" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r833" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r831" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r831" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r834" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r832" ] }, "hrmy_TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Two thousand seventeen equity incentive plan and two thousand twenty incentive award plan.", "label": "2017 and 2020 Plans" } } }, "auth_ref": [] }, "us-gaap_TypeOfCostGoodOrServiceExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfCostGoodOrServiceExtensibleList", "presentation": [ "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Cost, Product and Service [Extensible Enumeration]", "documentation": "Indicates type of cost from product sold and service rendered." } } }, "auth_ref": [ "r886" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "United States" } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government securities", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r719", "r735", "r935" ] }, "hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing", "crdr": "debit", "calculation": { "http://www.harmonybiosciences.com/role/DisclosureDebtBalancesOfLongTermDebtNetDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtBalancesOfLongTermDebtNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Unamortized debt discount associated with exit fee, debt financing costs and discount with warrant financing.", "label": "Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing", "negatedLabel": "Unamortized debt discount associated with debt financing costs" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r828" ] }, "hrmy_UponAchievementOfAggregateNetSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "UponAchievementOfAggregateNetSalesMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Upon achievement of aggregate net sales.", "label": "Attaining $500,000 Aggregate Net Sales" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use Of Estimates", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r47", "r48", "r49", "r151", "r152", "r154", "r155" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "hrmy_WAKIXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "WAKIXMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.harmonybiosciences.com/role/DisclosureLicenseAgreementsAndAssetPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "WAKIX.", "label": "Upon FDA Approval of WAKIX", "terseLabel": "WAKIX" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number Of Diluted Shares Outstanding", "terseLabel": "Weighted average number of shares of common stock - diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r232", "r240" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.harmonybiosciences.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number Of Shares Outstanding Basic", "terseLabel": "Weighted average number of shares of common stock - basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r231", "r240" ] }, "hrmy_ZynerbaAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "ZynerbaAcquisitionMember", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureAcquisitionDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to Zynerba Acquisition.", "label": "Zynerba Acquisition [Member]", "terseLabel": "Zynerba Acquisition" } } }, "auth_ref": [] }, "hrmy_ZynerbaPharmaceuticalsInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.harmonybiosciences.com/20240331", "localname": "ZynerbaPharmaceuticalsInc.Member", "presentation": [ "http://www.harmonybiosciences.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Zynerba Pharmaceuticals, Inc.", "label": "Zynerba Pharmaceuticals, Inc.", "terseLabel": "Zynerba" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-3" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//940-320/tableOfContent" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942-320/tableOfContent" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//946-320/tableOfContent" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "(b)", "Publisher": "SEC" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "2", "Publisher": "SEC" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Footnote": "4", "Publisher": "SEC" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "(m)", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r837": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r838": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "SubTopic": "740", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(S-X 210.12-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 94 0001558370-24-006203-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-006203-xbrl.zip M4$L#!!0 ( Y GECR/*)B(A@ *GZ 1 :')M>2TR,#(T,#,S,2YX M7]V M=7YY1IACNA9W%N_/?#EO_?7L;S__SY]^^M]6Z]>;<9]8KNFOF".)*1B5S")? MN5R2J;M>4X?<,R&X;9,;P:T%(^3J\OS->?O\-6FU?E9-W% /JK@.46VUSZ^B M@D[8FNN\(Z\NKB\OVI?M5^3JW=6K=Z]>$>,^HKL'SN8\C_#)L]YYYI*M*)%4 M+)@IF7=NNBO5XN7U]=49 MH5(*/O,ENW/%ZI;-J6]+T(KSAT]MQ08HRV:HCCV"6#%HU_'> 3]['7^]/G?% M CJZO+KX];X_4:Q&Q+[76E"ZWE:84V^FR,,"Y.\Z(O:$;,G-FGE)\FW17H6G MF; MN:7&GQ$OKR^"PHC4H=ST]BD]9IXOW,<+5;37KLV=+WLRQEN^OL#B&8 ? MXSN5X[TV35\(@&63SD-4NE>%/9G+='(LV==$@N40EJNW;]]>J-(MM]Q,;Q0* M]CEV?4>*+(:#PKT*@&D&?%')/MQR+3(X@9($T%R#"'<\2<'F(WI+B@-6]NI M\0468Q_MUN5U"\='4',I5IMRXRK$RO%7[31+;%\"6I(Y'I_9K(5D3% )#LIK MM=%!;54G7#M#=:ID3Q^"S3.U\>8"2G=VH=':K_VX6< (RV!A6[2/MA29;;^] M@-+MT&,+=(<:8FS\(B2+:A5P5Y$_XOG^J)6P$+86S"S"UXYR)Y#,%T;N>N+I M5@X%>PJUM JU=@I5GHVGNKTW@=OC6[,TK0P/8EK[OL:T6IX_RR3&PJ#"SW\B M1$U*U'%5.:!S>&>$@;+DJ$9\1IQ:;]/N+>D,![?=P23X:S+L]VX- M?'QC](U!ITLF'[O=Z:3!^!B,MV3><#Y<1W,BCE5W!'6L672,R4=RUQ]^;EQ([K3OKU94;(;S"5\X M$/:9U)&&J18?L*@? 8I0V<,8S_)M-IR/F>DZ)K>YDC: %/_K_N'S1VHCSN ) MQLR#X-)$FX"R6R8IMY/APS?L6F-OL,JXO$J$(0_W]\;X-S2F2>_#H'?7ZQB# M*3$ZG>'#8-H;?" CL+U.KSM!XI!%XL[)/I/X!-GX4?V?Q#C]D4"<0W;,!@0_ MA/S^N;';'+OM.8^@.^57.E2(#5C,)VK[#"S 6+E"\G^C&_+D<&X\@D8IK UA MG3,!Y=^RF9PPTQ<@ /,R;//4S6OM[W72_GJ#3]W)-'!H+1*Q0!0/RG*V7!!D M ^ULRT@+.&DA*P1Y(3MF&O,J95Z.=,5&8Q][Y5J _Y(.\& Z!!?3@%(4%#3G MM@]A5".L1:+&<1QB\RT) M[:O"'PETL<.8H/I)NX$Z=_Q)ZBQP1\_P/%AI[J* .U]"N>$X/K5#)Z@D[#ZM M,?8$WP?Q:.0<#YO)',W/VEM9H^H-IL;@0^^FWR7&9-*='L88 5,DX(K$V2(A M7V3N"A+CC.Q8(P%OC=LY@2U^$*ZWC0\ !XA<(4" 7_CNE_47#V<'VV"QW22 M8WG792U/\;(+1P)N5#R"7@X9"D,4H&U,KKK)]1GUF!>,\Q'=J#A4-\'ETFL- MX>WEJT-#Z'>-B5K;A+YF'38:F\E^4"TW6.9A"4M:X3,K],Q9XS^#2H?;U64R MK(0%ZOBA>TNZOXYPEV32C+F31I=5 DL]AE8BX, MT8M:V\;8#6SEPIF)OUX'^4_4CA\C]AQ8K:R48!E@EJZOA;B==+G;<"?>1^2! MB>J%Q+IIH#]%)%LBB,T#-#=^;7QMA64O'N!.Z5/\#.:6S^<,$^G8#9-?&7/P ME,['C= [9C%![6VM,959OOF$+6OM(G7;%<^$R=3X-7%RLV. A!R0+0LDY($$ M3!#@@B ;C3D]0S[*B (*;XTUG"SI8")= M\\O2M6'X>7A\*C>5LP]2FM):Q?6Q:0B3Z;#SR\=A_[8[GOP?Z?[CH3?]K;&, MO("! S0 Z 83BNB:0R V9I[K"S-S[Z1(%>T&6#LY4?1[ !=@_5N06&2,>E.C M3\;=R?!AW&GV54Z>86)8EF(3Y_F\Y< )6LS)!TDL$$KE@^QZ;A8-%;=,84![ M7&,"*11:2%^E;97"")_T,'NP@:8P-'>4"W7$U@./HR[43Y->!X5]46H)-A;>';5&$/5D]$R M3KQ4W9QSS)1E7O(/QGYI@W^9S?8C M&]G4@5E,/53W%>!+4##)*=%*+6I/U*S6&E(RS94UX+XXS(;XUM2H;PS4E*D* M6C=&L,EUC_DDZE6KQ@-_4QO:;G9TEA O,Z_G3*CP/@CJ2&8=;TN%FL^QJ42^ M0Q6;"AE1;\P$K!#ND(DQ]DC(36-?W\:^QI[_G/:5TGR.?25.=T]G7^/)0V-? MW\:^8*'GK];XR'L FJD;O%#UE0HK*Q9]KFYR[.WUB>TMQA)!GHATPZVF@*W& M\)[5\-*+]>ECS]9/CNF].;'I*9Y:,W615IRK)HFMM.EUJ7"XL_!&3$R@QNX4 MR@ ;L;CMHZ7L7K;L/IFV;S'K3K@KU+POP]>6#]O)L,#G[DYKB&^2,5W7& ]Z M@P\3,NJ.R>2C,>X>.+D86_%W3B/&R!PX(S'6L%+$' 'NB&*O,5;=1U6=&=F[$]\PRYH++[ATD"6,[J&8D&=\-58@..6 M>:;@ZV!>O/$][C O,=0*U=' >'69D1+)\/U@!WDBRP:IE>>C"/NMVGP;5XJI8F1TN/ MD#XYJX&@^%5(FFN,]!#HKR!J(*B2%5]/=E-$9JJ5\=]"LXROEH>8GH.HA*IAYVB!SNI2'([(8]%B> M(F^T ;ID@D%>1H >LI2M@^01?H-)\4M0-+>8Z)'(N8:DP:!BGD/1! <].J4R M&QJL2N8SY"4RZ+$IDL'00'*2D[?C3N"*G,2UC[Q7X8>HDR95Y3203_%C$14! M#^MJX+X&N),OAI2 .^BB ;O$\5\ZHDD"+6PI[_/$OT;2X'+,F6 Z0CI2+58I M>;I9MUXTN)4]*,P>3?%B+3Y_21]+X8=?&D2JG1YF 9-*I<6GT"<0&IRJ'36E MPY1.I$/IZC*)4O*>^P:DXN=/ZT; M#1 GWUK/6"R5;D +Z4E>I6_0K[C?G@YQ!I46QV*OSS5 E=^$SPK]#@FT\*1& MY;%[P1M@*G_7(?K"1/4AN\W\#R52H+=V-<@'W3"[=++?W+;O. ML2<0D^L"X 5/D\T>RY91$K(:>,F#VO\5L\7]X0\N8SB*!YOV9QU<0NYR%SY:"S<&@Q6K3:E^V7UU>7U_]"T0]?UK9$8GDTH9ZHY@" M"++D_4BHO:5")O9&QM-,V.>N6%RT+R^O@P%QJ,.0O:@)*LQ$*U^O51M7;]^^ MO5!4T(@++@B-XB(2\8QTN1_'9KA14%WS?C M&LIMTUF*W'TZ8W9%D6VL^RS2_G3QY%GOZ'K-8:6!C\('CN,&HTH]PT<@MBLD M<>B*>6MJ[CI5_'K,/%^XCQ?,M(#O]O49\GT-7 M(7,E>K48+]-K1(Y_E.LUB0]W\'=5-[9\&V MD.H>/R<&<:>QAKC'Y*KI,5\LI7=/Q1MW/TB@"6)VG);^5;A&,+TA@_P= MK$ @I!6;GF0K# 1!('_FP4SF8PL?A.NO(U(.)&<0*7M24%.^/YM3&^<7A]LV M[DZ^/Y/"Q^E2$<^"#]^]/[/8C,OH*3U@@[+"CLCCP.-3S#95IY(0.93B'CP%_- MF!C.[^GOKNB 0;HK)KR85%D$<3FX(]F"B9=%JUA2(D1R#/F,BUBZ9LTP+)&. M65KJL%8%B2WY;@GEPO1G2F_/(_L45@%L:Y;W#(TU)F1Z\:&_L=P5YEJJ%4AW46WL372'Z[R6H^6S\TOLU M >+>T^\1M%N?E<%,D7]3R'"0I&,6+-!EGO P"R7EN6/,2\BMH?Q>K-18X M;YGE!^^@=GPA]O M7%:A[O>BE@?XQQ62_QM3<682#Y9Q!C,\S\6M M,V9]YG+9?>(2!$:".^Y GR!RQ_74O3!1#:3[3 6FSVQIXG[P>?NI1S"1J^TA M4%,T&)5@-YS#XI]-<'LUIBD-S:&#A>4I?=F]GVTFF/I8#J:#3;^ZTZ7KP\1@ M3;]"V28QW39ZC]1IJL;M:V^Z& M!>F$T^&-7N0A M^<%+],4+17>SV9&$ ;XRQNTKM+&/;?6I^04WM_%$ALZXC=],#5U\7$/?K,M# M,\(-5&CLI32^T\!NDWC,O2\X%3[ 2!>XG)31[0Z;V)E.B%7I:@?L'G\T5%'@ MZ-P#C^_<1P7\"K#@U(;X"V-O[^S@"$5+F2I6M=.3B@+=>2LPHW-Q"X+8O5&'J6LJ:?D\N1IP8ZF\P MVF13"//IF@$GIK^7:]=2%;7=4;L3V^V48C"\AY#Z0.I^NEO)]G'E7E^U] M60Z>U9)O966QKS=XQA/W]DPPI5#C!(L?*EI\A3NZKI-^J'@J>6Z56C,EVA;7 M$IT[S-)D?8C"K8,K#_"=>A,"/2-8!@=QS%PR\1NCXL[UMT9X7!,:I$NOBS4+ MW/05L2Z,J1K([2*T(X/06$//JZ2=H936$@#.;!M ]E4,@QFLFU &F$H3>\DC MP4P;S,6,;:QO?<&)VGH9@XIVM$ZGJS%;8.:X*S9'JRJCJ?\43<5V>4]@5]FM M_:?H*SC%.59/R5;JII^T+DZFY&FI*H0?D1QE%M6'4WJY;8U1L/ZG"S:< M]QPSN/=+O= %R@]>9-V]3&4X#J!L;W)W+BJV>NSF1#6UA1L9F1F,%KUSQ6?Z MA3\E=NU2RHX,T)X#^5NZD1#43FS&UNK;D0DY,BEJ*$V'2KJVV5-RQSU14D/N M#W,&\'#'#OUE3AI4DO0H7WG48"GI3?NNLY@RL8I= YE 3T-30QP'KA.>#>_X MC7: 4(JXD\@EC>,8L?*R3B^RON4[.I,9?S]'+()V6OU^F4LTL>[)TA40G$SLTH-!DPOOF$=;0!<=8%FL7 M:JN,BMTU #H9M15J*<.185M2!]#27=@O3@?7 ?F7"PK BH>OH:2AIA5%#0 M8N0UE+/CJI2-H)HWG.-!;72F&>8V4;OG;-F*N]X*=8\Y^GS663::+A[6<^$Z M$L+",9O[CH4=WC&6$_UK:WT_"X'#UP3H$U_YJ\HIUP7K/[-^MIM,IUHGYJ8F>[" MP]\UI]JA893*)WV6*:$P_].O M;A6Q5;7ZB1WZM@,NE8/+ M[#@B2[@[_L@P+6+"'.X*M1R T0^10=]-23(N1%W#:?0@W>Z&+;B#+QD.G5MF M*K;Q*OKVZX3 92O67W85\:FW00YDN,X3/K]F#:5'QG%Y)WSU-I;RC),U3&36 M[GJ;,97Q05R\2BV/&[?'I=3.',<:FAIBF"G&=\"[#^&2MF%"F!AYPF\\DEKB.!NT-^Y(IY2&'A%C'DP[%+OW\7? MA2Q5K3:Q8\YRJSN?,Q-?GMI^K0 ](2X<86*P@SO$ H\9UT6I6K5TJD-3NF"@ M.-D=C-.1"KA*V7KA&'4W^()D8\_*YQ8)FU%>)YTP(7!P' 2]^DR"XT0%W M$U/BXE,UF&(;JN1EC:.H=-&2 ,IQ#0X-J%6FNG,/9(PM'BJHKDSCM=OA+BID M:!UI(AYG>$4;KJ%I([^)[A'H,^#MP_QTGB\-6"ZI$Y8%,\5 MS+R1H6S][V63OW)J_P"B#[4+$[TJ'2URXI?R?V9H]LPR'F&8+%BT,3,2?._U M^Y=DXAN,PO([*=]4(6.V"JY)0I>%[/G!2LY[*80T#,6'53V2TR8HPOH7NJ86 MIREG1BFE-?22?V?SN6";6\[$E^3)5VII#:48"KY0>:EIEQJD%=90AGO7XG/. MTJ^J2"NLH0Q#P9ZXTX9%&5M+6+$N7(=[YY/64+Z,=(C">1/_):D2 MNO>2U-%-VBM=QV575.KR>XG53J.171K#,ZH]O9/O1='=]086;OPI?G- VMVW M.70OZ[F"#ZP$WP?X^?\!4$L#!!0 ( Y GEAXUK2+[!0 *(? 0 5 M:')M>2TR,#(T,#,S,5]C86PN>&UL[5UM<^*XLOY^J\Y_\,G]D*&KU\N:R M=GFM5"I!&P^: W4L4Z&-U2[5U3>MH#W+_*(TKNK5JUJUUE#4+VKC2Z.A-)]7 M!9^!OBG.+&E@\^<7\L\K=*D 4-/Y\NG@;Q1KCD["XI];Y0-,ZOW]_17]=E44&L(I3:]@ _<4 MY:MM&6B(I@IMXXN[7*!O%PZ>+PS2-_UL9J,IM&?/EQ4B@6K=1_+?(Q<$273D MQ=2\"0:AMBQS@DR'_N)8!IX023]H!NEN-$/(=2X4TM_+L!,C<*;9<\MFT7K *=E"176&:\85"ZIN/ I+P> M]$^>"]\W3=/3C$!1Z?!O?RZ(#08=!;L<*O!F,X5HR7XIDXS=WVW+61D(0 6V M&"P$*,F#9?VD!J,_/2B7=R*H%.9V$;3H^-HQT);4Y!8UCK/;+@4RS-JVAR:! MYA>A$*P6I371^[;.)4+WU>T9FWCNS3>T;E?8Z6V7!ADL"K)AO13H7T%@6:V6 M:*9&W@)J$:YK1G1;W#&GECVG\UD!X,7[DLUR[\EHES;_DTW[6/N,;J\>\70* MZ@DH'I#[@9!)MK0>62 _H0EL_XU5K2%L=0N9](NC0IB-.DR7GD&5K@O?!:PC M%.[;VQ21&_IT$=28K#[%+NF_6E6K5:6BK#J WU]ZS9?'SKC]J+3ZO<=V;^3_ M-NIW.X]-\O%#L]OLM=K*Z/=V>SP2X CE!W#$L/08<09Q;UKVAE9!G?3N%-O[FK5F^M0; DM0JHW3RL/[6M.1X0"%488"+8NZS!=N5T!!T.JT2*G(<5,1('4 M&K)*;6"CA89#?TSZH$PL>QIRY(<6"/1:5H'VW1FR>5:YVP7C>.MJ];YVA*+D MQ!7(\496.?H(>I:I<^Q5UL5DE:'0=B4##L\2IUR;:BV0[2X'AD8/-%Q3?:N,Z'DR8B4 M%QO/[N3@&Y+XZ3%8F?:G;G@DXO6[94T^L&$P-RK954]&Q+G!RKZW>413!(R8 MK$X65O@88F=7B.-OJ/7K^^,4MB!$GMU.>1NS)R)(?G>R;G2[67K%! MXQ!A73AR+?WGS#* 9H>L$=TE:^+-J";#@5.$QFP4\JEF+A8G+",R,,J^TH_0 MG^Y5V2XHM4P3B4L57QHJV:48^MP'VI(XW/F.(.*%I99F&HWL$P@.@+(+MCU? M&-82H2$R2&0&]VC-K!?GQK7:4,OV;N<6=SZL^]ZE;P4SD4]^!%&B$1KI6F<\ MT\S@*W)7"9D.Y5:RC/,W= )"+QB\[&>/T=#:C/EYN^0)B%L4G>P[=ZJGW%:< M4?J$Y"J"4/8#R@B,S/U[8EFIY2J^H,X =BQNB86E%F@&F>DVF$^V MTBZK-\T.G[^-@WDW,"YNCEC&@CAE'\.P#)QC_W"'I@&@][21J;-]5BDUI);T M+CXL4$*BS@E6=O/%$8#ZB M*=8Q._HLJ^()"3\GV)Q^L:]7&[=.#WT553"E5T1TS)NJ-?&;JJ,Q_'AN]\8C MI?^D] ?M87/<@0)*LT=*/@^&[=^A6N>/MM+IP=_M"UDOLR:P+ M0- J =34LAW-0.OD3\W)?SP_NB\D>D#RV\!(=UT;OWHNJ36V!EK6WG]_O<;' MZYU:;91]C8]#2;9\!@?F#\\"]\#*V2-Y(<+)EZ%*L3)'+_AL-!+>V5S%!P97 MHAZ0"?,F^V)?8FGY1)+HO5"X8'8GFC: MCO:G:VN !9N:O>P -ZF'$VH"HX&TMS#A3:HZ[*7'4U*IPS%(0@-#IT. 8/F0 M"0""-1AC:6L,9B7Y=./0'UHV"]%=%HIC:PJ_Q2C235$.27A,ZQ?MS*I6PQ$DK&0=ZK]=NRPQ#*5PI> M-O$XSLK2A3#7:)8FA.7DTP->*:3(+Q6<]8 M(&;4DEBTJ0+:%FP>H!(N[$:(6B6 \:S9/U&$$:Q8!&:%TY&M($8)-W=#Y"#@ M%$E(]XC>D6'1- _IDDVMO(&5G&A*$"[ HQR&I5K=>/3]*"Z 0<)5)%"$2?L>()!6CL M&@K0:HY^5YZZ_3_E35^=\.94/)O1U@M4D9(#9&.+I-2P24;X1^3_A+]]PP 6 M8J:9;X@D-F]/ITAG39J')N+P1[^$9AB2[QCT[&'YXI!$)*O9N*G##B8M4P)_ M _)9HW(4;.,<>A?NR1XLZUOZ%)??NH!\VK&C;+:%G0%6=F&&QU8Z&0=<1X*1 MDF<@7E[4$NY''M'"1KK_UB-#IM$B9R#,3+BR7S>)OI*W_6H;*S(]M5*<#ZI: MOZN>FMAS,$#V>_LCV*D@^NQW-+,$RY6;6/@,!"\ ?-^7^9/3K]"P^^9B;96& MI#/']T:OHU(WY"I2]82EO#,;9$_6MY5"DEZYA)\M^! S[7U6M1-6B9U8$*C# M;8%+.$;2I95:/EEV?'*BCQPZCD?>.R-.LDT9"]<_86$7PXM ZG<2+=RWW0_; M;]BP X(SJYZP2NS,AD ;[E,]S>4^_K.)+'P9A^W-2ZUSEMJ0A3_TVE2/2 ^" MEW7"J2]P5L"T%\E>S*T@/(W%.5<#[M=/7W-R,R94J?38+[E4:B-QZ=C6)N(3 M3[3R6:H,-R-"%9$V4\(V-JKU*V9EI^ 6:.$L=46,&Z'"R!2Q1!*>(BJ6^&(< M._XH %,)-G2.O;F3_>!+OL;.0',*9$RH1&Q?9PE!R0R&^5AV.,%.:$ ^;9'V M!)N7>[)G_(&9F(Z'L=74@7/V.C7 DV6/8JD!B!.!="0CM"$7@XB,&C N$N0+/M3-D9V>$2>ULY!?PKDC(0'\EO# M@_E.(Z_%839P#LJR&S,RC_K+WHXS&/:$3Z3,T\0S4GPZ1;@&7#!QX&!(,\Y8I?B0Y(0V^2P^-:KVJ*A5E32&Y ?'R M_-P<_IO<:!AUOOD<$"K8DV5.+7D M$T+/;_1?)4+R;XIF3I0UU7Z!?P2$_\]I7I[8QUV(PU^D\@G:5$$8X;:]! U. MS<+-4U<^^U6(T&.WKW+S0?XYK/AWXD]3!X2@Y_3G'6(^BWBW8^I+\C7XKG$2 M_$EN&V[Z#\B,'?5'B;%3D*H8?,32N* M*D!2A="D$**4-55',"6ELS4F@P?-PTR 4 M?]>PZ2V.-C([FO&C)];-]*5FL[5]* M)L8:";W0Z6 :38V/-8 =3)925;]PEL7PS'R8?# D3NZR(_].R M?Y+P4 N&6Z; 8H6/6&+9."2< %?4/Y%T?C.8U4D>FBR1Q0H?L#7<[( VFFQ9T6..2Y\WS1-3S.BL<3!Q1;8YKR86K@UVFQ&;.>08'D[O7&S][WS MT&TKS=&H/=X\S_.I4WSRE"A]2D"@ KMO)4*BLJ91\8D\@DT)F9-=U,7OVRQF M;U.R*AW8.J20DZ!70S37,&B)#1H("J$9_T::+0Z4MV7Y[ Z?R*.6:%]LD'!3 M)0:U!Q9G_(&,=_1LF>Z,M9+?K='STR N#DBXO1-#28;%^,,J1&>"MLY/5=* M2YA4.PG+K(9\M^UN6/6@+U@Y\G:)=H)"K9P.( MQ_L#&P;3T\]3]?#O,<:(HO++BRBYLGP&1D2(&V\NYL4KN^\U;0Y=AZ=$#6F. M94AR0W%^D0?LR@Z&S:L?!6'GNM%1DJ.W2VZZ.;[;-+P@F>.0[+[:V)Q9NNWF MB-ZW"'RRX168R+'8/V@7\DX.7?)J#%IG5R&\"E.L+%?<8EX?X*]>U@.,<9(8 M,!BEY1OFHN)*?(Z1 Z2$#M!4Z"_F)$CS0O*/D<@+?QF71VU9;9V6-A3' GY_ MYR&L/_5>N.^["C;+(%LIK'B1;4',\U(SQP0A5YA.>B$ MJ1U)M"^,L(FGT[O>R=(2KG^D\BL&IX2'1^&KW4&NQO0QF5SX2$6: Y2$1SL! MU-5SOC3O-Y=E3:QRY+(4AK:'0Y@,&YOT1B^/;4VI=Z1"VPW?P4Y& @K)LV>P M5*:=/"$ !+;>,US_-6U_(@A>]4P1(W\C)R#3'<'R'WL<]NTXT05X>J48]%I5 MK=^6[8P6,K@YP/&_.B)+M#WG_E)-"+1O/XQ% NVEW74*1MC_*./MH%>W8SJN M[=&9(W8,R: XK8I\XW*3O]N#41C/O@^!DB?42/ RH3A,X=QT'(L\:84FY WT M]B=V8=(@!59YJ^AJCJP0@AJDW)^ 4C/799(FW[UV>$R*4A(W9#X_H@CI <\S M-O'O*8.L425J;7[!%+?7Z3I!5%Y8FT5QV QN# MUBXT0R0Z?]=FY3,8/()F71$JC ,R'DKQX^R8G$'Y.[5Y5JK#"5]"GZH0R/1X M_#Q-Q=FDJHWKQBEK21IJ"1VVXMA20O'S-7:."L+$+6$8OC"ZE"C\7&V=H8(P M8?/[F0^U70D/K((H"-&-RE:@6[!1"9M=7326?X>RQ0FF J97B:E]3Z]=E'_6FL#OA"% +P\D%&;S\GO@Q'OU@K<>;4U7J][).@PRA)&GP9G?TBL-+\_*+MG+5^ M,!G [^L_3"8-^) \I!!]?NX13Z?()G4>D/N!D#ER-=>C>8P1$$_EEM3H@2D*"M:E( 8Q:=& 7(40L\1+'[]!U#Q.XHQ MLF61YP ]4*U QRR3-:_S-P Z>'MSUU#O0 GKC=M:X_[P_HID:N//!C;=0)PK M^<8*"_%!J&7YK-2.PMTV7/OBDNS^;A[1%+&^8(V#.N#',+MH&4"O<0YW5#K MC;*/?4M1P%TYQA/3([MNCF"3B1Y@_S1I67-RY$X_]?.Y0(4'9*(I=@?(UMF' M5X7W\TL_"^+9;CD_OU[YT@YVV/_\?U!+ P04 " .0)Y87Y_\'#LO ^ MO ( %0 &AR;7DM,C R-# S,S%?9&5F+GAM;.T]VW+;.);O6[7_P,T^[.Z# MXTN2WDZJ,UNR+*>U(UL>2^\PA)B'#P^GMQ=L/SLG)7Y(N+D%(F^# 2?JZ>'N^^]#?]H:#3\[[TW=GIQ=G%^^= M\T_G[S^]?^_T;G9P-Q2S.5(!^BCX]HG][X&.YU *@_#3G3 MT]/;IW=O,5G0YF?GI_^X&4W=)5R!$Q2$$0A<^,:A\)_"Y(\C[((H84^F^?,# M\7<=O#O=CR6$8+^=[,!.V)].SB].WIV_?0Z]-UL4V6>-07;@SR7X+4WG'S]^ M/$V^[D%I1UZTA\WV^^$T_9@%11(L]ASZR[\XSB\$^W "YTXRVJ=HLX:?WX1H MM?89ELG?E@3.:7=DM3EAHCI[E]+\[].("IQITGT 8@]1X?=QX,$@3'X(L8\\ MIA%[L' \GT;8_;;$OD?5=?!GC*+-&X K+"P>8!X=!%5)MA^-;% MJU,&>MK0L FOM&1U>B2?KE#H^CB,"9S&JQ4@&XH06@34"EP01#W7Q7$046N] MHZA3:L.>1ZFBV@K\83#'9)6H[A6, /+#ZNQJ=G037.NY5&0A:H@+O-Y,4#4, M'F$8)0K:!X1LJ B^ C^&O<#KK3")T#^9/H?1>-Y[I%B"!Q]>8S(%/KR"#]$4 MNC&A1,"P 98TCHH)?EX#1!*L;R!@OR?D],(01N'V+UXOV@,UP+6: YK1->KP M%XC*+<6O+0]3;1P3G!@AE\T4O06!6X%1'6>XWL7$78+LEP;X46GC MU9I:6J)7K2V?FD+!B@7E*XN8]@AAGC&-&P7^IL /VD/(ZX+RZ!W[@3'K7<*H M7'^E[O(LKXWT,/#0(_)BX!^'K* ?(9: N#M$MS\6!0[#%7@+8X+7[)\$AU,8 MPOGI%O[T"=&5Y4D ",%/D/!'+%)3E+U/R+X_-N#)]A=*V/G/)^?G)Q>ITA;' MTN!W%2\& H_Z=^J[^G$8X57O&857> 407?'-0>Q'814WK=T93SC:=IU5C3D( M'Q)VQN') H#U5C_H4.POK,OPH"D0>JNRB9>Z2$5"84\'SQ%US2PD, CB%22) MOQZA,*IKUG+=VW> @NC40ZN]?@#?KZ=DF0 ["_I_2-B0]'8\4O1GQAPED!5=#;_Q5%;(!#* MEV $,3E@-S>ZSP[_,*GM =E?#@YP^X??MP'.AS B=#6VZ]P'#]#__(8/]/MY M@0%BL--.:1E'2TA2)&YQX,:$T/6*@"0NK) R(?2.P(/^]4B>5&H:NT[G!*\T MF(HUQHU#VC5>I\&97D)\B6U)Z/IA6*7\1/SQ]R&VCK26.>L::J&/20%;6%ZRDOC"I,-C9SE5L3 M%Q1%#%A0#QZ@.9IN>S ?^I%?"OA#.GB_N/'CV=GSHESZ)G^LNO:#5]&A+TI -KHI4]R8EIB)K3GK8&[4MNJ"E M>/4)]%!T#5RV#]Q(3$L$+M0J60-+R!VQY361FI6J627RBPV/-2D-F>!J&'5N M3V(2LN:D@WKSQA22**-9]+>#5M%??N^SZQV0K-DNDQDYQWA$8"6MD0%V1,X$ MKHNITT6,N)92J2V7\$JMZ]J,ABAP#70Z,Q@Q_LQ0*N/=N;7<@#\P20,3D/"V M.WP@KL+PP3HB))W/=CN=%R*I='E5!\G MZ9;I2?L$A=\N-YV5_2_)C,?6S>@DL,6-((.6A[6'-56@:J MB?GQ2JS%/*P>OS.EE2',=%6%:.<;ACN"O=B-QF0*R2-R1=MK'AAW=2T"[)8< M=D]YBP!?NZ6P,L+XT,=L&Q2LQ1K#=[IQX..[VSI(\>Q!/[4A$LGS(9=".^5,!?:(E&HYYA&+AX!??AR]UK'!(_(6DAU&Q%&WOHECH#:9NJM#=GGGH" MP14PZMSJI"1D;5")NMEI-HB0A_R8U4P]/+TP>';]V(/>-94:\QQQE. \G@\ M">A6+[R#)/4;&WX'LDF[O1'%2X!VQ[1&;LK%@:I910XV/&EWHAFX&E'=3^=M M_J\R7PV2MMTR6$.DMF$;A0E60-+"%7:D#B!I5(;LYT-"2 =7'IW&C$ MR&%[:0?) MQ\/0YK&,>'G?R$?8J&F,$T8- P\^LS=)AF$8[U]U4@1L=9H*-4FWL84LD9J4 M7N/:;&G.W"I*#]?!L7-3U",J5T94FQBC9IIY1W(8T/VBPC1%X$*]DS6PA%RI MV8D;5"*Y.?/2D #6Q:5S,Q(CGS4=.=)F Z'>'_'VU=IK3&[A4^8M8X(#^J.[ M?713$MJLTHK+ Q7G?@F CPXMUI0,5J/6?8"P M&BVYO"T!#=W7D8I7L0]8Y'$PGT,WNH,$8>^ FJBNE$8S[K4/W8:6D"^\[*+7 ML!8+&BHW54U"N"INW=:>TB)F=V-&GPC3*=$H@B.*IE=\8/MRDU898C6$Y6G2 MNCW(4J>K]&$7GP[X*0_<*O92AU^B?AK(>ZXA9GP4SB;2G?6)S$ZE-8@S'-!\ MA.FJ0;$1+ -*8GL\4./$]4$$%YB@?P+EXE3=4)-X4=/C0YP2:>"JV!@(=);1 MSP[VV)OG!PTL^%ZI;JODA M;WOTG%=)9+@R?MW/;SH$Y>8U/4)L,0FVHNQP=1P-7);5(RI_ MA5:/&!M3D\/+3?9+]4QE3@=5DW<%71AFDG;R\E; %QI$'T!;2E.62T.0M7S MRI9492X9HLSE _IFTY7C$ 4P#/56A )H<>:N&-X26MF/!,K/%I3M*M%?:GET M K-2*+@B1MVG,8M(R&4QZZ!NMF(>NQAT>"KGCK"ZJ"M9T3QA _E-<&$3:XA6 M7YT7-*E(>(,U]'1D4;S7+L&G^TIZ$@)*E]4EB#=F0B%TWR[PXZD'4:I(](># M_M!??A_!!? '0<1/^^= E+1# -,ZYNEP7"TO?N;B7 2HJ[UR'F'^8)VI)A<[ MIHL\K IZ]\MI@1NE;Z8/ P\](B\&?C@._,V;''L%KZ)GVASY MQGD6G=2WNMY!L>@OO]/=6&8X[J&J"FR+M1BLL44P M9/ N#4R(Z=[0>!C*[*P)\=Y@+ZG@+A>O&"HK7AY49^+E#6Z7>'D8RJ9&L1M5 M>]"GIZ>W=-.TPL'F >'019!%R]^Z>)7ZTGW1H?L Q!Z*6!DPZC:#I!Y8$&(? M>2SNMP<+M\^W+['O[:^T:7G>L[-W9V?.B;/OBOY\?]N[OQK.!E=.?WQ[-;B= MIC]-QZ/A58_]>3JC_]P,;F=39WQ-?QOW__KK>'0UF$S_PQG\[7XX^XV.LO*# M,$?P7I(7=-"$>0]TM[AW\]W$%G9DSEBQ3U$TH0!T:@;%5(JL9@P.%/>7%&UV M!&@9N+8!+FE+XL8/\&2_@2G*KD\I(J5?V&TA+X] M,NAY'DI'O@/(&P9]L$81\*7R4+3I4C871\I&08I%85K)0BXS_?9=RN_=L?+3)\NH^"8PHA1 ;U=,3BHK$7"7@GE_I&!$--AC M48>"H13/(?U1N6C+ +8C"N#[VJN $M;D*K8S\07#ETYN.9< .#\-Q M'(41"TX'"]D1;Q[.@@E%4P)EW.T1P"V,T@EMA$.1JRK 6#!AZ#&^@+<]3! MAV![9A9=91:IPA']="GUGX]>$5>CS7H!E[6VIH2E'74IXH\MB%A*G#TRSE0* MFV%!+#$AY:'X1- $IKG,,'W=$:9D3Z"+%ZF\$B47!F#;'K;3^/K9,0K4/B^4 MZO;+:2N'RUZ('P9T6;Q* MJWVS.)Q_X)SLC)DN8LXNG!/G,# [<+Z_N>E-?DL.D(=?;H?7PW[O=N;T^OWQ M_>UL>/O%N1N/AOWA8$J!#R@X&1R<_]QB\5]M'3<+5F%:;..=,%=OWH#?492T M2XL>45VGVQ_".V06 1D_5:XKC%WQ.AY1+<>1%;)@9:?&\QQ>PHJ"$EBS!\MR MI=HQ7X)^"QNG&?T*]_B(,ZGX< 9/A;6T8K^CX:/? C_[=.*C9O=M-.J+F;J&[!WS:'/'5D? W4B55Z>5P3AX-9;K$&,X98>N48.(I MH%'Z[W%S2 M9>N2F: D[TW=K/M%RD5SBQ1],NTY_B[CNL-4FB*G;F9'MIRNHLK%5Z3-= H0 M4\20[E A>F0ZJ,KX$8!;D#RGJWV%7!\!06;C?,"'%*='&,3L2JT7NTG 0BH; M11L+4A;J"$A!E67N3O64DK1%]]/5NTZFJP.%%L]4#,EJDU2VA;7S4U$?I:+* M4F16.ML5;0E#>4JWJI6-@>,P&FJ.L(T/C&\P>C1L8+3H,X^D4W@&I,D9TQ39KP&!N-/30N-1U[; MV52Y&36D.-!)=8?/-0I P.Q^&(01BN($A!ODKMZ)P2S)1IQD#9+;%N5N^/RY MDVP6*T(:3%5L=.8JTF6/ZRLM8._HS$K_ !;P7.#\Y$T,9ADVY?[D!)K/$,G6 MV:Z4\?'^[+R8\='K_^U^.!W.AN/;]C,WFB[Y+JL7((#M.(I[7!E^"](YM%@O M*UN?TF$VEG[\2P&V1))D"J5^/*"56?[_-@$D#R SF/C\5@QK00A(KB;[.5U, M@U5*+HH#:< ;N^^JI$&FXI:%U;>=V"S2V1.ZUMO@UGHWDBEKD-3V7E57OW8[.OJ=[2Q@UY=-T1++CQV[Q*Z!)OCX?7I2SSN$@?AZ)[XK5[L^"^ M[U$+.VU"S4=F#@_PAGU R(9J:J*FO<"CBQ$2H7\R/0ZC\7Q_I_T:$Y9*P0=L2O%#J=E7NSY!LNIT2=[0R2 M569^D*>,2AI8$"EK0_GSI9G$Y+>16+4;+I-8 JA[DSQUH6AA@8S4.G=(EU)0 MTR[+R1K3I5UA :3%>FE+"Z);]40@I:I-4=R'7_ C) '#LY(DY TM"$;5$82< MJ!;D,,+!0F>.4 %;H/AMS0\JTEN4BO;4H&A@<&;0T[(2G[N;% XC5IP3-!N: MSH.MP_NN9X/=R%4G [UVIA-:JTN@Q6F@3BV*"7LH15 .)//-^ 7;FGO^ AEF MV,M5\M)7\^4\2KJ0XZ Q%;VA[%C%*R$7"]\-E_'@2'Q?B2:/:/>,!,]R1N:_ M&Z[B(6-D'E&SH1AW";W8A^4(_,%-E4XGBM&9:GV8*Q]?A]9L'$;+>[^\"O/R MLY?<0Z'YT6^$!R&]P&!P&?$?*'\O635 MIZG./]?3!MV^;8B6M*PBNJQX^7K#"MRWI3>%OBW( C*F-P56V*LWV0/^+&F: MJB%N;D'"3^/2%U/;^KTU'/1CPIX,.,0);D#$QM^PF O_J%N8T$:3FT9:9)H M/@'G&B"2)+G<0,!^3T(\:0[I]B]>+]H#54NS^:F<9G/=&TZJ R&'#;C-PK$^DV;,HI:,7>",$'I"_C7ZE1(V#"5,;5LB; M E#U(+M?DY6?+-VFP?X[3LK9(7ZYV?_X*X*$VN-R,X*/T)?EZ&@VMB9EIW$U MR"7V:'+#Z!3.=2AE=*6)/!7[L"13IY*B<^6J1ZX=XAT&ZS@*$[K.I:DYTA86 MY'W44EBN^'@$6B>LB\K"NK @8-JJL"[L$-9+S5Y5B:J5J? UQ_4UQ_5EY[@F M%RX#C_W#WC-]I)M*59:KO(D%:YR!ABN"Z/.=U+ 6C"_MB[ %G*CCI>< M?O:49AL+#B7:EV1[F5;'2O1^>LA!ZBU@X)9BHE+AZC>WX!"A;3GK,\..K%&-S(@C2'5GC%W60=O_1_@:4(V:HRMF+UKJVY6O*RX71K&$0@6"#J2;;J>OPCD#_S[H[/>K=? MAI>C@=.;3@K#F3JB[20J1-GV9[GL60H'U FCT])C^(JMJ+-0&UJIJN*7(^U7X?_$%^ER7VV8!ZMJ7O[O)$R6<. M59W?6=@6;AN3[3/;@JM*?#!KSGKJ33%BPDR)X1!$@?QC& 6L^3M.,GTJ\)Q' M0 L.Y@IL(DK U(=P33=^H>1.I!#4\)TGI7;L78J0@E9>+X[ VH?/&S%#2R"& M[SSI,[*$>>^HE>JUY[Z8BL:X'T+W[0(_GB:O/I!-*H#M+P?^;__P^_VTP.SL!\.N M6JD?C*U9?&W=I2H/([2:FCMCJ$!9KI)5!2\EVQH9*V,^HI-:$,+>@L!DS!OD MPS#" =S5;&;%5WESM69#N_==7-E6(<^>V+Z8ROL0SF-_A.;"9'VMIA8D"=2U M4CT"7X(LPPED_&(G5>E-W"1.?PWKRD_ M6%%L=J#U=Q0M=Z^,#9Y=/_88&90J^I\GOH):JR<+KAS6%7XM>MN^=%B<4%A: MB[^=3'3GV'(;"RX=-C*]EBFSQQ"S?F(\+](H.CI7-#+XC-ZQYJ4BS?PY>E&[ M6 GP>XN)NX29+]4.TW_6#Y-'PW[@]OIP.E]F0RVMT-[MU?IR;IS=S_I_]K+ M?VW]3%WN?X2J6FIP742^B*8PU%6AK?G0ETSK]B79] EJ^X3T$N$UP7_ 2!QG+X&8+M)6 M597VZX@2)2TO&W2#\%-JY8"BH@K Y^&,'Y >X:($))GU43M<[H-P#5TT1] 3 MA]_%L.9]D%2Q]B(04]"VT[E?4YZX2T1W7@S+\;RWH.JRH$C?PH@5()$3TZ/%#1CBA^X'/$MB>$GN\G2SB" M8+@/N/67* #BB4#=QG ^B!:7-4EY3=V3>_CWC7EX/D5FG?MK E\WZ]([%&$? MA4#ZV H'Z,5D\'%P_U'3VX]*X.LTB3W9 5R",'GCU(,K0+Y1#&<($NA-\ ;X MBH>9JC0W>&Q?30*5J&I!*+\^A.=G_')3G.\&S\:KL36/MOGKIYF'?R57U_B@ MW:]"/C2R"I%3995,I/?+1,!V7".3J9=,"BU>)N K2)*,@(-PPPI;P-D2TLT$ MC"/D2GQ^W9XLN%\F5['\._$U*#1J/L/ Q2NXCW",V"!RSR9MT;V#^ZE1!R<>7F>Y_%4MS@.3M#.[V MFY*JG,!NDD19:FH)CVM8>D=$KXG! $ S0I'0UG72[DN^'5,KH'Z$P32=QJLG MH4,AH[JN3=6#P<3XIF6F(O4U)[YB3GS3 FHS+5X0L5BQ8TM.PDHOBM)K,]SH MA$8K@QGOQXI%ASQ[[BNPIQG'\R\8>]GP\!3[17O2:="EU'YN3&HZE-DCL)[K MT@7^X9!C^PJ7* @K@NY25!\;%Y60K*XGH?LUI2F(;G$P@?,X\))7U"#4G8^D MS3L-09RU.S=)">U\89X^07W\ZD^SHTX%V5( HR+)%OG+PH$".Q] E%5)+&U7 M8)Q T72GW[Q3*3<7T*A.:-?F>D>@2UNQ!+J2LDV@BQ_=5QUYU>^I4E*V$ M0:K3W+94AT$$?1^Z44PW*02O(8DV6SRHQRCEP//0YH:TFNFW4XDW'%QIA@.6 MR3]S@-&P!@A[[E0'&@[6-,4#R[1@ A?LD6],-HVJ +_;3N7?<"RH$098)OST MZE.3,9"\2 M<"&[W6#E49 D,_$ C==9T&!Y=I?$H\&>AP'RV"E? !"#VY&M)-8LL4BR5+0P MA6@->FJN:C4S MR&J)=$'J =LZ%(CT0BL")+EUW18LA($W*+0!9,F6)]R;*[ MB+A15F\GE#%[T!0MEM'V*=1@P3"A.?N:;\5(KFC-( 6W#I>H8(ERK*'TU?Z.^I @Y=AK3SQO*CE6\ M$G*Q\-UT1;FRQ'=L+"#:/2/3XW8Q(_/?#=^@ES$RC^AKL;V*)4TJ>-+7XGIM M>MQCB^NUL,&?P'4:]V<'>P]1'Z]6,%F]C(,KZ"86]^Z<24.\[:_D25MK5 M]2I3UKZ +N$"!4$9A0_:\E'V8+KV55WQ* EK7SI7,1P'-R"*F;.\$NV0*K4T M7%:EMC2$!%ETRC%2O"4EA.[\+JDF_N*SC>ULW_WUT(;/,R%9Z1UG)H 6!!'J M2RRAP)YD6(;Z>-XGT$/1-7"13[':KLPO,2'XB14>!&OZ)=H(1%2M"X.>KX;P MJM%FCUCS)*;/$R%W=Q6,(+K>62>N0FUSXL8&KY\>;8=BJMK.>'W$8L;^R4")O>:'?UN UTPJRJ4B4K?9U"4(4IBB/@VQ\6?2FFGYS@[=1 MC[8Q&5TVB3*]QI!&^"&[\Q=^(3@4+Q^%\ ;OJ-82EI 0>Z1S1[ +H1>RU]@8 M;;>0[D2&81CO41:(2:>AP=NI->2E0Y$]@LL3=@T0^0K\TB4Z);3!6ZE'^[\, M&>93:T<0A+#:>V7G%YSWR@:]Z:"#5\B.WM>PIQE3HJ]@Z!*4L%N6."MM\0,? MX IB%AH,YASDOI[=OI[=OI[=OI[=MN[I54%@92MCP6!->G)1*IDOMJ5VX'B= M7!T/%@F>X_D:NKL%N: +MLCMOL>S\?I](L'R;ZZ@DPE?5@0!VY(M!(B7YR$F6*B MH'Q84[\;"T+([*H F'R "V((-<0%X\26P7R=\@N64"O]TC_ MNN!,#*(SMNK=6!!K/EJ8.G2^$%&SN#,KG,I.#.\@<<4U+:MW8[*28ENRYA)J M_N!A&F'WVQ+[E!?AX,^8Y0U6.H1X7SZ$F,[&_;_^.AY=#2;3_W &?[L?SGZS M_TBB[X,P',]GA,HN)IN$+[(#"0E\Q_<(J:"I)UEO2]'<$?9^[4IR/)14QZH5G>Q(ZKS6J54TNGQ?L58S?"U,4S:?#'%F>(:S>U MX,ZSCG(=(C.ZA!FUEW0&XMF^ZL1 JZ6Q4X,*=.4JG(N=H"WG!NQ^#@X2S&YC MID'C^5<AY@ZEBR7H<6G&@T:MQZ5%NR:1\&+(: 'N&=#P+V K[8_+$ M.IV&V!.2Z5.AQ]?K_"#8XCO#V_[@=C;\.G#N1KU;IW=[E7XXN>Q-!U=.?WQS M-[B=]F;#\>T++NXY=9?0BWTXGB?>H,QA0E@J3E+]]7)S@-G>7>D] >+) @D- M]M]Q\C?5.U:<4!)JR(-8$UQH7*2Y1/ )5-+-C0*D2E),&>.6E?G&>[C*=S, [8K"L[OI"WL:8*:ZN+# 43[)%P 3_I MXD, :\<:1$M5LR(24&./:#+12FE140ZRJ&<#*]ETI4T<:"G5]74E5PPFX7 M+V)!Z92AJD/7Z-A8VD)S7,FY^>;6#;*%W NHLY?0]J#F[T.1_,'S&J4O_:;G ME#+E:Z;_E^"GZFEC9%,7#,DC]*XQN8ZCF,!=@1KU MUD^W'POB8^TH2@U>M'T?E4_H-KL<+*B'W3^R- PR^(_C*(Q X+&3[B"(Z4Q0 MK![9?/<6I(HTJQ?-LZAU=6$C?Z6K,(U\()T&%J1_M"%2.='V./G:M._.;7:5 ML,)QM(1DM@1!NM<*O] NHG"XG=@*%UF2CZRXM*IJF$7X67 _M\75BQT\ML
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
(_9^=TJ,8D4&/%\F"WSFL8K?-=]+KR MJJYOG2Y=1/$FNT17.]YD-=?SO$Z5ZUF+SF<;/0UV5P9A21)_8.XU%'?MO6OO M%0HPWJ2^#8$;#<%\:%2&%7;Z*//\8R?*K]11&3VZH]BY4M(%M<+&VKBN[&=@@K MU\1(/B9SP8P5/6,= 7AZ")=\LH@#".1V^725.TQDA ]T0_3OJY0$ZIA*" MC$NQMZ@DNP>JRNY M,W4GQCMN0@!=\'\-4%J37 A#JINR/I>,F#2#8!X0K^$R2$KGY4F!6(KK6ENL M".F!Q%&'=H6Q"$9(3I0"8#6AHHDQP2?6G/Z.A[3PX,2F!/ M7IK?H5DQ#Y[Q)J7:?^PM*5=2)+&W*=?>"HY4:BI6LIMJ5I]-);*=*ON-B5;U M/@Y4_L9\ ZNQ]3W;OSL[W0CQ@!#:]<*3;$ L$+=<#&(].D _ M .9KR:HIV;KUI!O-+6$@ON70!280_"(#.:V9VUZJ) ZU[ BC[SE=.U*PE"Q) MRX)%&4)-BU=%H^=KF^G'LUF';ZT#8;$470[A]^I;TQ.-O+C.9&O68N%-%T:Z MEU$Z2:K.->#=PFCT\IT=VR( ;X'*Y8!$:@RP;DNB'=CW0V!?)0=B_0+O\478 MGE*![IBG7*<_QG7'YEF]Z:3:/!&7AD,+<]>3W%6XWAYDIL5\NJ%/]:I23GMN MORVUN%__1MO3"*['AEO21/&;?@C\N73;[,UX:LVL2*YG \>3 =_ZH#(/M%(? MD[#5M"9:Q79UH#";YE786NV/!]98Z9)3*1W71PEMK*IN V[!GV-L:/UA<] 0 MM7L6TB.FP+@%F.A@5\D@QB;"C=K.J ,YD&P8$0:-0X"CE&)S%4948(TQ&SY" M!%WFK$E]): M/.LT6B.N<)!&I3XL:>!5NM.: RNMU,S]">$[68L3>\+6:8FSTL0N#P65PGI) MN5:95SBPSR$>(QS'?Z#5OSZO@J#SFB9@DT-=*2'4>[#J]R M?-UM456)F3)4\TI@GA]#+/T98A?\$"54MA;A6%^/MD>FZH)=UU*U)0TI MKF[%_I)@V\ 1"/OA;O'9,/OO&'C,7SI0>V106K5LKB@@#F!3'$[>L,W1XL4N\ZE-FUML!)4KBG& M_?)BQ0I I+!'/$K][\;\3SE?$+4J)PI3U=AHSYOM-'#KU$5,M94/@]&3)&<=LL)_1EV#""($-I@"#A.=> MW"M!:P9B7L_8 1N[P)8Y 6' KMA0'>@$AVY,=QQ/@CMCV0JS'I?)_'W89;6S MFM.0/+&CT>NW;%[ M [XD&>7AQA ZO84?]"9A3P0.;"P!Y3]Y5_E.F46N;XGEYW M/[X?K-N6K*J*DP4>$LZ@JH+M:R&4*43<2+K2E56KT5(2;4'UJSQGDWK'F\*] M8)(%>T'RF:1IE, ^KP0H]3E484[;=H$B*D@M% 5A$H)-WVY?&%[6B$',0_B0 MH*X7Y=11=CW4H*@@,9C72-+MV%(R/'4W]D 7P8>5 ]PJN%NE+B,MMZ9M^V_- M CIU()DB96*0U!1B,Q!L7F>3,Z:G3[(;F8,R03P0S*FV/497F"#HQCU 2ME0 M)1L618V/2BU(:%LO@$CY++ +03V5-6W+#^ACU,G_.@#3W-6$0RQWR_Z]K<[: M6U0(XDF@0BU-C0=8G=((O/BW9/C2VME6%21P MR2>^_*\4&]M0G?Z[74M'EN\\5Y@1?@1\-@QEH.JGH7::KK,KW9'^W6/Z*NW:>4]] MV99IBL)JQAT7KTPS6*[F5A93AM=270Z,/'FF7MJL M-G&Y7L/T=9GM59?T?%C41.+TF6*_L7+QICT6*" M2NH\MK8&BJLT,-Y=<,"Z8<O+TT9BIJ MQ1P4^37=:R^TR72ER3X8>?+VL3&LC&9"8XQUO59%U$;-A%J#D HG;X\W.[[6 M<#OSZ7J8W-0J-;XA$PV1/AVYZDTSI% L)Z:2SXL50:%,O<*)S.G(@N\P,EM< M-7C":N'2F&]S. [[,IV,K H)A6SV,8G/,66:&#B4)_!PY,G:R9Y'KV:KW'2: MPWM=Q^^.UP0)VZT=KEUD&$56L20C,@D@6!1&LV*"(A) NB22)50YR0S9XV=[ MA42U,"?G%M8J;JJKM=FGEXT&D)137F7Q<3_.>ZR@KT5'6&=)41[[@/^G=)WQ M2G%D-8GI DOW,(%>CU(=/TJFY$8OG>.JW'3*E$QU@W<&NM3SHR1%8W)V(]VI MI:8MM]JAVGBW4%SX45Q=-#* C7RAB2V*JC?T*6[$++4HKE:ZA%I9]DR,CY>X M*9'.)XBZX4=Q535F]5+:2$]X7?1IL5OMK:B&'\75#+5)9GQ*FT\7WL)EE':* M\U4M:(UW.%*HK7FAJK0'..4U9N-5 M,@6;ZAS24U1I=B@10\ [>:B*5()0Q 04@B2C)'"*(H<8S1P_VQB8ZRI.IRRA M1%1*\?[&QD>E1I1-*23Z=E$#3E+0<2[?515SE@"Z&L'5I>^V/'9$%OEX/E7L MMZM-CA>X**U>65*_+1 @>)AEBE;<4]/Q9JL1I=6).=_@O!K+":HUGO;,DNG0 MTTBM'DZ$TM!FR^JTMC2S9&;9MQMT XP\>;LD&VUZ2+8'TS55:#3&S9SFK.$S M3]X^7ZC)JLI/TEA.X(7Y6.M35"52IK"D5C#&+D=BNM;F/3(YR BE2)G"TAE_ MT6MZ::&+6_9$+4B:4X!-ED_F211\HE=BVYS@"6NRIB<=1<[#D=MY@F J+-]$ M6XZ72SW#$LZ+%Z*VPM/_X%P,^=73:M2>4<@[=';6QM3U!E!K4B=,S;],?>D+ M.W?@F,L6B'_0Q@'N5QZ"C?M>50'<'XPLPT"5);\O4X!\.JN#$.;C-<>HUGP7 MG@:7"$!H:DAS1_V]_6%_9G B820'@QHY"(:VH3@*'27/M;8?!'$C^N0@O-R[ MAQ"..8W>77L[L3U@^U_ON'1'LB]=:=F+U/:>#S>-(\#++=6VO\?AC8O?03 . MJRU?#8)#9J 7;X=*0\];/![GDK_IRW,'U^[29)W/MP"'_#$G0\WP ?L M$7^QB\V=$7?#]+/X<#=,-\$'8)CN$=/Y&/'^+A$O!ZR?BNK^23>R7[; Y\!E M/USP2RCLP7'.Z7\/D=G/A5A/OFCSKHU(?WB^]0P=[DQ_-].96V;ZMK+Z1;[? MK=JU!?Q=*SYA\SM)<#9;=[WF5W^J%C"U^45LWQ<4#>:+BP9Y#O-XY8: ]:,+ MHV>3]!_8Z!#N9:^\['-T%0JS5#\1=^%B?<".:N EVU[#KLM(Y2)Z"8V7.E9I MDR5WJB^QGBOXOM2GX1DH&111T1$ULG?-O6MND,;YB9I[N1Y@[U3==&XSK8TP MLLHO:)ULI5B\/)["0@<&JB[S0$3<7/A*6RS!?*K"156\BN[(J-6$Y#B6K*,2 M7G0K%_UUM+V@$!3Y?OU ^C,MTG?LD+R-+FZV(3(T47]]C>@"7:_;4\AMGS>H MCMQ.&[M &?F5[F95%0[871E"-?T0 RK\!AS7!>9-,I_&1!@X05OTM&193_&U M>#9>UE;5]-J"%5*H>3J-G78Y_/NN]7>M#R*3'ZCU%X)T^6RU7R>T!6XZDPZV M&(RZ:[ZIUC$7%MNBINE,XD6U_Y*ID;8%&P_M*O_N^ZLOO;^ZPK+O>92SYU%@ M12Z\YP8M6H21&@KU03)'CU2!\55)25K5_JH,:[)AWB21?$@F+P+M>M#VI7.%G7C97X/C9Q"]"U4=Y%_*!9EY2_=O/ MNY3A/7\YZ#X?F\/(#[#LOK'ZHANKZT4C/W ']BG1R// $-EAI9R@4_D$IA+< MINA;=8^RX$51\MG.LO>,R5VQ[ZF5&PDVGM=LL35.#,A::C[-U1M6S]'HTB8/ M-9MYBV9_R:1(Q)7(+[R!NK;J/K=?NC:FTR?6E%Q[J=??,GU*>%*U3/E9.R;, M>FF6:HXQ+%?JZAEY5/(R"2YH4("SU'=+F]RU_NKU*-=>ZO6U_G-BEQ?5GBTH MI6I'R*9XHKALF5V!=]P25'L8OK")MZ1,MHAUMXD&=Z%N%H[M_H:MH"!-/,FH M#8$3XWW+/_&VFQ\<@^-!/F8>/'&TK>]$1I8_D>,?FHA=TLW=1]I MXLZ6.UON;'D36\A'[&FFG!&L3==B+V8 MN;B:,+Q'&NX4N*QM^C(D^)@9N&;>9Y\6 5HSW*C$_E)7LN$A_4>-]L>V"O8_ MX"%C9!? ?N5P9W.>8SJH"+="C%O1C2L1Y:6TT F5SI(A"XS ;:TT3(#MK_4+ M9[[#5(RN.CM8/J8 [-KH*7T3D2PCRU)*R"CK%:_6<';0Z\G* MP.=$ N7(\?->Z[IFH+0SA_3=RW\5"KS+;)WO3L>G!#!W0Q4:JH)9!9-J^Y!L M%1231%BIFLDS](A4")Y0+6VE=7*E.;6].'[FRZ>W&L# 6:_M65,E"J[BDFJF\R-?2FE\NY.F-B/GA+50LLO3J:X=C[%<) M1KZ "?O.]NING#[5.,$4481YLC/K82O)S)+"K%U-5>Q\7.\UN> BVH7,TZT$ M*SN+E?C"(<<7,&*W%9C5%\MD2))7ZAV*CSM,N9]>$?$.IH6W M6XCH(O@O'(FUQZJM(DC&KQ*-? 53=K-W5UXAV6<>%-XPD:*L(<+F)OYYCZK/ M D-]3:C&NSU^@'4+^2L!0(WMO@;,19?JYK\A(R7/3:\95)\_:#IG;T@K8DQ MR)?:/8V/>_WJ4$OW>WZ.$Q-O:^-Z^0+[5VJB#PW"ATJB]R5T!/X'!/ S*_6W M?"N$ /$%4[9F*F]L(R+,>SGRO4K\Q$+;.NT<94FAC=UJ9946N3 MQHT4ZF\7$U.#U005^JJ""O3':BQMS0"AU\@CL_\X,>/T#N=#3(=E^;#Z!7Q/ M-\'_CYX)6WJ"S^'S/%/R%!V^ #!*@7]%/Z%P!+W7<<$_P64!:Q2SYFK 0B<& MM!F,G,UM=0R^IB]5^$[ D? /=V3-9Y$UX]@CCB7P!'X$UKYGQR^%IDG_5+"T MVZYM)AZ)GPG9==ML>0W>Z- MF/E.?3DCMNIKVY7SXDH_5^L4A21]5@E(/++4]Q* /T10I:_>0.YTR;O#&,N, MS7?@JD/)D$Q9/9M-O*TU7Z.''GEE2)'+'.PGK]3C])4G]U6>%#-];$SH2Z+-E[+EP7#ICC2=_7CASA^H MO% JV7BS-FT)-;*=6F)%)T5:(? 9_4#B+ZG\E]OQ[=,"UF$HZDBU;56Y ([K M;6WN/C-JN16X@@M>V@CCF*]5LORE@YI]S86M3/;1'B.L6C%=<=/KEM?":HVL M-LXWF#13X+9(:1=!E[_T+OT&%3Z,67Z PH=1S%WA/RVD>:?"NY.N4+.+IC9- M)SM=?H$S*L ^+=7,E%WEV-)68^F!68;/LFFX$N&[T TOB;[VU M]=EW5@X+X3Y^@^7XMAG\'3)--STI6.]77=F%+YI!E%Y5K04WGDRMK$J.ZIQ> M)RLJ)8IN93P= ]OP3K/;HDM:00L4 ]!853CWA7$B'(9?\/+9Y[+D/N_[O._S MOL_[/N_[O._SOL_[/N_[O._S_F+S/JGO/,JGP F%&02<>(R5>:[%MZZ%[G@\ MHX(9*WJF&B,P//&PWS(CADI<44<,UXH!TEO;G5W,@%L[A&PIS>>VM=)GDJL: MZ[>F1YS%R!4IMFG3_(PO"AZ67*?9X7[].])'KJJ:)SD20%C+E$,)X]CCC=TU(4'&&<E9D;+AEXMUMGVQ&L(-;&_F=967;$F =EPQ[K]#N& MO_\(.D8T.4=T')7$NE\4QT6^-<.-17ZUQKL-0$='7;Y'PYX1[(<84*6Y*L.[ MOL;Z 9$[4+!#_2J8(?!5 .>[;R#!6M%50=UUP%=U!ZE4I'*]IE&P6Q'@$7@< M?(%NH]-:!X)P69XVWAIH@@[4/?ACV"DHL,4[@&*@A4M="8PSA+X&J][]#0B0 M%!0](%POH*=#R=&#SD3P;S'-EA0OZ&($V7%H7 #_K>V:I-C(V)+7 S[7 JY6 MA?.5@-P""GJP+=)PC2CC2/!/MCH'](83@@0/W@E'RH;D./I(!^,A?O(1\1YO MQ4O6CGP?.BV(6Z,X6"F8N*.Z(1F/QAFZA*(0'2[9AMVI9$LSP:042'L5T1VA M0P?$B2TEPU-W3: "$.HC#GL.$C//AK;71JVFX"4+R[91PZ@8-/$@R @8!3M7 MQ="9/YC#M@K &@52@!,AP%OP*Y 8P*E@GJ;EHKG:RM,IMETOCJ=QO;.,%\>;W)QKG%HHQ;./+-1+.>OF=B'H-]@G>,\HE4K] M9L)NH=$N;@I63:.7.\=(?8@YL;@;X'P0* M,V!1M\$"E"9KCCP:,'SG/Y?8/Q(;6A:01Q.=$[R!!#RTXRH0\]JHAF;8MGAD MF/WOD3(:MT$AF-OE08K M8P461+58E\&K1,8WA,X0K-+=CCU9Z,X=W8[=WG=@3_;LR$BCJFXHJ?_G2]=_ M''(9UL)%AE5CHM0I2JE>42@M.N2RQ323<2B]-)8\#:J@3[LT52Y[ZOU&JJSK M1F/4]^LMK+;J9[MFQH-^/*C#_&_)\*6ULZVK3#Z2VPK;W[NJ$!(I._9(TO^) M[?T,J7%"2MA;OTRJBQG.,#2X(=CZP6Q9K:6,_):7J8Z[7$ MW)(5\ :T.L"3>2B2FMK>>3W,@#!]C M])S(]N';F>.1%6V3KSN,6Q86W*"S9#EC/IM"S-23>6[J=:W.->61D$Y-U16= MFWCY!06N\090'O%Z4"R.O M*&M<70,CZ9.11%65"'DF8R6JHAI9>C'HK^"MSI.W-VC>XGDFD1 (BDL[JT)- MZ65@%?7)R&E&H5>#1C8N+%KXN#>+MY-T%8X\F>>DE\?T3+V(3^.MKEE=]YL4 MFVJ D2?SI"@Z-6^S\SE/V$T6+V',A.UQ(G/Z]MG$J2;ILAH72FV37R7&4C$M M:R)[.K)-%5),6[15/CW*L_9L7,_K90Z,/)EGHK AFYZR8:9,6N@4^7RC[Y3@ MR,-YBD.53DB*2HG#$4.*%*NPHB0E"9%-D E<8?$AF3Q963HINM(ZWZOSBRJE M;T8I;"1D.>@;CT=: KF6B^V,)-2ZDU$ED;2U$@U'GE)K-K!R;I>8\D2Z,FOH M+"OE\UJ4]'5Y?:C*4[?'+UHE@TVE2VV"@7)ZHB4V3H^:#EQN,Y!RC2B);BY3E>*TQ-K3F>"Y0UZ>IU9Q M**+6)(@ 943HCHBDT!J9 R8&< ! M>H23C,HR)#U2CY\M.2.N6EMP/2Q7-[1B!ZMOW(D695.L%.7&2Y59@F?JW7EV M-23G<: M$72M)X1A>3%,\H*7P<9JD\O[>15RX(2K"XY;^>:(] 2FF*^R7KJ^ M)IU(:BTWBY;'J U1(-9\+B>FVLZDYD?I:K\D2HE5O;'DU86(E?0!3:7\1I2N MMI*33F-<4',8DTFOG7AW5L\UM"B],C+MC.XO\PSFV3G&V_34NB-R0>7PXVO6^%:L@(I^Q M1ACE+P7YW7#:7##KTZP&OI_6R+!S6E^LBM-6MUR;M/)^0B1 X(\_)DXVN"C1 M@4+Z2.HHNB-#- 24@GN5+*]MI^:>K8KIK&M/+1=\TE9X^S;F3[F"=3]I+'U"9?22) MD_W5?QYCGU.O&FX(G\$]R'?7I6F56LVPW&A9$?RUMK(U_]-+3X_5M>7-Y\8N M[;N?DXWI9L!6*%5[. B14B@Y(D]?$GLWHG\%OF"/^+WWLHWR!80@[R(D7CGRU7X@CVR])TM-\>6 MNQ6[3;90C\F[T[\87][>H>+#T?*-]4X-2UO.U#_WU9CTQE:?#@NF9+3-.QOD M*G[]#C:WW(T[#,6^3?_AJ(;M9VQ*_5J$=.FFU*?BLGU'&BQ@:.LOO.6PI?4Y MN\/<=>PM@<*WT;&,*J-BO6U2_<,-OU]QW#?65N4EDG"H4O:\GOO&EG^B1'\ M-/)'AN9VR?*I'ON:O87?8D&N+R^!L_[Q\G+7FCT?_&.TY@MLGU\5DS=<3OD* M&^7WJ0,L!XCKJWC X=]Y](]H#BF*UA0>P_0"2_I]JUH;J]R+.X*/7/9]O82R MYHY!Y&=:INS9\![6C@^A_)W7;%VQ3=H)E\[1,.[5DX_OT/WM_74;?U#XWH0+ MK(T$1T4Q>$3C-[^7)Z1!GZA."9=?8;62RI5[L!2/_/4O^8!1+[7)O=E$P2VZ MV.^IL:]E^;^/QN+$[JZ*)O:8 B?3#K8>+1NL-:W:\=RY;O"\KK++E)I5+"7+ M\Z4V7>1\NI/G>!^H+//K7^*!I*BS=+;^/NF'\M-MW!^3@_C6FZ=WF;D?E(.X M+3+<$PQW';F]C,-%R/ =TPG;'A;KA]AV,SN'\!OP]/EG9!4(LER-2_,AP<]Z MO"0,1OBX2S2NEE7885[7N$*>85M2+U.!T(9L4MI.STM0?<&&UZ= MIL5&P>--6]S";3VP2?*>6+BK[#VQ\'F)A3?H;$$N-TT]2:A8O$ZQ>$9N:B-6 M"Q"S\ >*9']>9N&%L,BP3"T.[T+^B(Q"=(Q4G/.NA>&]I9">\\K4RV0;N:YV MM1AIQY)/B))>!;:Y*3# 6_!4S^9%;IANWS9RJ^X.*2,< 2?XM4&?TC?3VL)+= MF<32C=,M^\;8[YH769F:=6B M?*7#J[UVCU#)C,=C7 VAC]@B=/> -\KU7:@'?OSG-LJNN@$Y0#^+\!P?:&[ M[/GTY\8RWC;HBK&%-F!&467#[&.-I_4*K48*9WU3B=:CN MJ'J'QE]2]\LBK4:H[%X#HH\H[%6;),F2,X[!N^-?JT'2]E;ZV=LC,^4 M$"',>]^;7Z>!Q;VOR VRA7HD\3M?;HXOQ"-Q;_)V>VRY6[';9 MU=_H7Y,N? M9R-?CPL_>?"3W6;9W3/Y5I[=(^3FQD6[.3+,_Y=.VV[W2<*7>,G-!-K?03LL77 M1'"KAXB?$:ECRN*XQF3)3; ENZ?I6CHQ^C M\->Q[3>F\)\)3OB"PL\7V48WGQ]K?+I:)4 O%M6#RH;!F+?OM9\6=!J?H#0?/8FM3%MM$WB:RYG8NC@)TBI.]859%N!A:BQ>1AA EU3PO9T$#[,"/!^3ZI@='<,PBO=!1-% M4'\(*- R502$!W'M9Y8- S+P<9!EJAR!" )N.1!L7H%?A)AY044-M#Q?M*8& M/25!/6+)^UG:S9UQ$H_T_>CY]MB"/])W )@;9 O^R-[Y7T$?:N:<$:Q+;+!T1G3V4YP7[;B%R?$/O['(1;(&?:7+YO"[[BE?LW,W.Z: M/Z;"MW)&PJ WP$ \]I>ZD@T/Z2Z,PMVQK:H@>#?=,=)I$)\?1NY_GTV-;X48 MUTLHT3?7S>-,5P?9:P,%?,/+@B]F([;G0P&@/=@KUT99'>:2H'..:N*CBI/I ML&$GL9F781KE0BVE8 V1"'HWT,QYV@-?/7K9V3GZ.P0?US)15X^WODRH<;= M3L93JV ^;1]2K(+BB C[,V)H?S[(3YK"NM!;-FE#EJ>^'R *X \$^>H%QZ\? M>C'W0.H;!U+G-ESW:.HZM@S&3VW?BC!AN;:;=>)J%\<6=:*Q<7.]ML,T1 J: M,(I]J7/I5PR@V'L =0^@[@'4)QH=F(B),CNY!D-Q1B\Q959,LX6W%X5L,6R9 M?'ZC'$O>HZ1XU?9^H*?Z%HX+V6+55:>2J]CTV^ ,%O-T+K6?7QMN] M>'@)U;PMTQJTB0SJWK>U7G=?^HU]Z=6.Z7[374/$9D$:+IW^:NAU>$G7 M)"X]:*MMWQ<30=M(@CU/FO4Y>;A^W0HDW>^8/IM[+KH.!&(5U7&_7;BR][WW ME"5][^CE^A2Z^:CGA&:QO[Z1:11,17=DX(> [O,K&0SE9O"WJ*3*HC_ Q)&L M3TN4-,J:5A+/,IJ8A':2P+$3*_GW>\RD:\U?M9$W%CJ\5.ZW'T@:9T?-O<>3 M+\:3U^[0>[W:H6NO_'O'F&^_CV86\IS0&5,J[S57\RS)Z_.EZ(LX]I96Y)?M M37QTT>GEVNU@W,XM$^^("HZNTL'?(:MTTY."]7[5E5VX6_3QM#\^T0M?_$M; MLYGNHGT59RIIQ%M--67@YC(@I# LQ[,C[OS5N2E/48OQF)\-5:R"-SJ#K*]= MYL[?B6-^_H(?3C[&TK5*I="N\-5V*\95,^#W:KM0S?'5=(%OG8_WP:_P.;]U M$"7H\MOF23)184?PG @\MS 0*8.X(^C>L(L];N$Z)>PGY>HS%78/A_\^H+IJ M(%) >M& !BV<=8>^^QDBP#X8+/EL?[45G,'ZOH46"(K<:FP-F:#S%] M]/21HJHSL#>>V]80W;B$7^>$ MR'IJS(?_,:T8' J)OEV@98?KLSS7@:X/K/$Q]BGMWS_+"US8)+5<8&G&0/!5 MV^$7'D)/XH*H K@J5>'<%\:)_J.&"[@5$A(BEMV2ZH$$)10RJN!Q, MTX'31*8"/$)WC0 7X8WA;0<(J5AWRHHX+=2&0HO1K'5N6!K;KO:G\6VAFCT( M<"'V* QRX05#1S6W"C2V9^O? <41P8&&#F%Y/)R94U?MUA@L;1?G8H'Z5"7; M%O46R]4+@S0VG4T<+4TP=;G6\W_]:YGJ28@;6X+'H1Y#J@3LH@,?&ANKAA(# MM)$, UI$%](5&'\06H3@$E+PM? "?&C+0Q%W L*'_ BL_7/,42Q@=-W86%I" M^PV\A3?S@GN5\ 70GZ M"WA*_HWLM559U<.G*?I2!^*C.)#X!ABIQ(;KR!D/ M+3&YIX]MQS@+/>\ M(WSYW%9'*H2(@]YD.Y-P.?#!<,R>4PG'PSFBA1UXR=T\#Y8^EASHLL 7U=D< MT2QX.FI1 +:O#D($"5]HQRR$(0MFZBQX"/H0N3S>G<$YP\=#! M0L]BFX_V67V^&;K M?QW!"L-V/:3".%U$3']:7[@\;J4[(HQ$Q) .\#O10ROH^KPX MKN:IA>68?;Z&=4=\R^BXB>['\WLH]#F=EN>.+1M(DA*X/6HI#HR]5:CH,%J3.P!V/236.@A]G2E&#))=Y#;0SM+UP:"'+)@I*IA M7/.*<(#@:0WWHX[GS-&5Y ?4<@CLC%WX,VHVI.@C'4JCBR("M/^& @1_";:Q MCS&P#WOS+><'--M (]XH.H%DBJS>MA89M9(1XLL41>B;U:31]-_5C^S!6/H9:5(X4VD"2P6BGX#&(*S6+07-R8D,K=MX M,L7,"6&)J8;!C8F:.ZCE&[_^O3RICS;?YR;UI$>EY7YIHDQSQ,S*%;*)@I^X M*JE[:IJJ=2;KQK2FS14==XPZDP.D-JV(//WQKN89:XO2/$]V6=DFC63 S9/= M073&*#3M\+8R5,HG>WVX+=D9**3-3Z\,LO.N(>>M68K">2:=F5===3XF=6#G<3K:SH<) MO-/C#PD]4V1IEDBJC"3BR20E4DD)$Y,*+HET,BDGDG02P]3$KR"LE+:G2W6J M4YG4A[WTM%;+=EKXB%:)K ]4EST>F:AC\42"B2\%B9/BNI 8"%,.]CFGCDZU^,;&YM?><)E(8"I&CV&OQ9-GQLV" MB)O>)(.UBNR M5WJF4AI,!"+M,"HCU['4 (X\>7L&LRK+_ I7L)R44I9#;\Q,&SX8>?+V4E^P M6AHU]'EO($M=1G'6/.6#A9Z^G=ADEW4Y4>.E4JE-%=>%M>Z?'7@ MJ?F!X-'\<-/KUKJE+!QY\G9LI"14*JYV!4*K3K;#KGL$''GR]D1NBD^T4H812M2&X+MCW2:7$!KUY)E9*IXT>@.C MRN>2LW&)+#6G<@:./'GFE+>$=GK"4<),G)2))9F3)9H3$Z?/M'.C3H-A!%*H M#?6)ZHWM1C8)"^I.GCEJ#26_/ -2WJW&L946SW3LNB\F3Y^9]YAI.]?+-Z>> M-4_%)_UDLVC D:=2YZ?[):'<%P7"+YJLFB]4? Z=O9X\%/-EHE5M5 TL)XRY M=;<+YM#FX-#M4R^3"Y*5G%A=+33-';TN%M)8]-A&CM6J*;Y:KO0X6/U,E=%9W'H M#_$4U^+AN5RESE=;7+M0JW[1[#:0$2S(;<<*)DPDP91:W9!NZI0.;'LY3P/? M@\$(=GA$)RG6'&TL8%0##ZWV$[&[C6_P';38IV5R/MPHP\4>;'[1*/CI=IO[ M #>L**$%-Z$-'; ]EVQ]NW?;K2W^6T@0S%DH,>K M6_GN%O1X9#87R'A"JV: MLTL-P#D BQ5?>(#M:+<7_:7JWI<>8BVN"5X)RWZ!F7.W7WIXRB5#XBY!,&2Z M$>-01/GTZ&9+.)Q/F T.YF$CCL6'04@,12',]=Z P+<.2(4.G(,(&X@SB"ZE M_41VT '8/6!N<+80.T@HPJU+7%_%@V/2WWGTCYAJK76CP(R[0FW$43U>KHR: M&2[R&/;/S=E+B4PVM M8LX<$ C)6W@J#V@&;&AP6HX47M+@X0'@P@-*0,AC75VBW]$)!7P.BNF!L ,! M ^)FAX.!Q'AS0/<0H@+M?L#L+"/VEP1/6T9;%(NCM\X!1_Y^C$%I_*)3?[6( MX/R9@.#3(G< M\D^3&=A2QYL+1')2+I3X?DN*@RT_^Y!(8@\$2;QYHW]X4*>'+XTR$($S,-'A MZEZ>%IWMA>D[^'4@$U'6!>SS+4 A6"AJ(#]G!VW&P42*$MA7VNL8#I^*#E=1 MA_$PX1ND#=0%TF8+/=6 ->%H#G_I?[]5CL#^6!736=>>Y,2F+>C-WH@4*-*9 MN.]#"CF'4)4$QA6'8ZDM2*.)7^A/!SC5/A"JMR0)T+GW4X"]'X+751O.1=) M:%Z M(8J73#WA*_V=*+*F8#^@"L[28L3>Z+64IC%O),?9<%&S)N.>Z[54=I MU*C'TWS!?[9!Q9.P1<4H!P*X?[0+/MQVEP4V8_MUZ+Y4]/=MY_F_=/WO/>%0 MU"!9_)YCZS.Z[4^.O7'V2\7>.!L9>T/V'0>]R'4]0= O*4O=L>R3*#BLBYM+NK(W+WE/M6(S8+B\O1()$%EZ MSU=X1%M==VQ;GC8.XF^(>0 +#OQ05AA/QQ^ M'GQSNY&']EN#@4P0,P2@$N&V1-&#N!5B3.Q9A"#&#F:U\RRZ^U6U-U#QQ.)A5 BW@R, 0]P#M0I)H6+VFU;7ST<_'V5PM6/EZI^42@5 MAGFDR#L(P6LES%? [$CI^Y5HT> >BZF5#G3\E0.*E6RK1%'FI MD\GS8%YG:67R:D!^V5L[[Y60$P+]4)&Y*,3;RS'GMS<0KT5WMZ41GZ4 +T96 M/\MFOA;0W!@UNN@W58D?+O\>.-R8%_B*=N%K10]W,3E[0"5;!OSP__TB?GV0 M7HE'[*(B]#G6]&9=ZVV)RX]PN!Q8GJ2I=W?[@^SHW=W>Q>3N;C_)EMZ=[=W9 M;@5D=Y/X[F[O=O2K^]\SZT;01B[(?5FC\]G0'R0H/\[A\BO5EG7G[G'O'O<9 M"8$MU\++B7>?>].F]&L=JX3>]7I0-.?>NJ"+'U_$ZUY+5,[E7[^-U-1M7?XJ MSO=KV9? S7X;06FK]NP<_O>V8(P"H[E_@0Y=1"3^V=ZJ#42"Q!^"'V [L[.9 MU]LBQ?DJ>D+'^ET@+]_=3P$G=FTK-;''%#B9=K#U:-E@K6G5CN<:'V^&$'T? MD;-MV'$"7EE/K4\:2"$9#V\K[EUB#W;KQ\T2VK(X-O#-0.DG9EA)'PT*G8HU M]DA-9&!_-.:!Q)D'BCAME_!-M>(:.&?XS8'?G0/&+*AS^^I6(8-:)*'NF:%= ML.QTMFW79!>+9\89;-+O;@9:=&OD]]@%XCI685MO$!Z$;-,S*$R,L!6]#+MN M<;:C"JUYW.(+3:&\<1O 5M"__B6)1XJ]D)U(W)J&G,U[AF'CK:O).Z[@HT[. M>[(OC?.C69OD/;Z;BVMJN[%NT5WMM &PXMFP?4FDL ]?%_;ANX5]=[:SEW*" M82^Q$_>2[#N%DC1:\#4MD\H:E%&4?.@:66 XV$>ED)_0DOV-O32N%=OF4".6@AFT_\[9EG/2_1MVP)T*&VQDI>EIKMD9 M64I=K:4(3F1A=(L_8"S^P-*G?9J^@_Q?*Y3]%G'KEU+VCP6I?ZSN9PU9G7=I M^SO#5JF^R!6)\<; 2IG4JIT8Y3*\#=M@P[ 5>WP1K_=FTZ.?':->426>6=KQ M K]1AE(-)?I\D=AM+?-[9Q]/EAO[Z^N':[!A6 'M#DYA5_8[I&V-L1)AB(6D MH9,Z/Z1Y;QV?:I@L"YL4Q Z T1CU@!.GH=C?WU0#[IG&>Z;QIP5Q6]/PT3AN MW317Z;H;SV#I9J:GUOJ)4M:!Y@/$<8G'BYU2W+./WR;8NWYD![1MI )VW'-L M-U6=]3-CNC],P64#6?;L)XL>8;5EO*F0F=5R@N7X=-[.4/F::C3$) KZ\ >: M.-U^GR_H^X$1WK<(Y^ZQVXW%;A&Z_L[HC:6&S) 15%=(UXQTEF_(.;/+ 3L MLW#)1Q*_9^'N6;C;"+"?K1.LP"[HIT6"U#=-4GQ"FNXPY"-!R*=8'FS6?@,Q MWV=6$3X9_FF]0BG*M"%CC&%B\:DD.CK_!XA*GU%$F,59HUVJ>*GIC*\*#F8E M2CVW ;$V"0BZ1#($B//(>Q7A/;=WS^V]KXKP/7;A:Q01%O/*Q.*FFP7/9 6W MS2VG"]]'MB*H(B3H>Q[O&^3Q_JR*\(V;H2]01"@H!E%N3%LB[U%RWNK2;;,P M18C5014A2;]21?@_"+SFWY-1ET;?0?*Z!UKV(:]VO#+46GJO?[9L '9!^1Z' M;]Y%@O"E%VB@_>P=*8+:JNANQ7CBN"OV?QWT_M[I&\02LNS?VY!U;U%ASW$" M*:"FQH/6XM((O/BW9/C2V@D7R8(=\#8!^GL7]9*(!Q@0DO_$]GZ&U#@A)<0I MVB/8 511^+5#M*+MAZ^T. _YXEKSWP3^B&0$_!HNC,(?6?HRG#J21/*)+_\K MQ<8VM!K_W:ZE(R]:PY]?1,9%^%T03 WJ+4Q_[*16^G>/Z<])ZB&EHP@8P-"+ M&$/B[&@DB02ILB+%)$=BD@"QP%#!",)'"0T&(AL-UNB#1_8XI-G+NN912W?J_H" MH\V4QKCE)Y-E#HP\>::[J%IIWZ=;0E>@>#)N\7W;]$4*[@X.1Q*.5YKWTJ2) ME:@DA5<;O-?%.##RY.V*P!B^I\7%IC-'# 5<1*PTP\N3M:4EK\]/Q3!?4 MWJ(7+UB+O#_V1?KT[;2-=5I*O$MA,TM221(S].*L 4:>O-TPF'&CD-#K&)/H MV.*R45-T!S[SY.UCA9^F*#_=Y+LI.\UTK%YA ];.B-CQ2)V66D5K-L,P8CU* M%$B=6QD2''GR]ASI$T)[F+9)I. MF-E&4!ER.)*W^RVJJ1DM0'FQES!]9RRWX3-/YLEZ4GF36UCB5#=[S)K?U">N MH 7'Q8 PXW"D3#6X7'6IE81%:9GF:RW55BKPF2?S'+&^G)O5?$-8L]U2=\/5)+&O M!8G1PY'9PJ*;;I488DI,^:RH$$.E.>-@+'$R4:&XL)=X M;X;3E38@EUGPLCYA3-FL%J7Y?;OMR)FNB0G=66_9'%:&TDCDHO2Y+!.K1,WC M/4&JK4VEP'CM";H^\5696F?EKH]/@HO19Z\_YF1%/I#"B M,\C763J3-BN16NHE1G$NGRYU,*+%+5*\TFNN)EJ4[OESOE?H;QK<5#62-,NP M+<;"(S5*=.QZF:=: I:S4PZ3G5$,V,!%Z4FY6JC6-M.,)Q"X%6_U_.F&77%1 MTN^TI8FQ%&ISOF3,LJ7BC,JGLWZD3,]6%C-3\Y.U((GUJC^0FDPV%R'34$+- M]D:HK,TB/Z,20/VU.=UD-;BW.!Z9+\[6^%KMS?@U79=:9&'=7F:@#ST9F9PZ M;)_-Z"U!2A ;+E5OV.-)I+NU*WYK6AORZ;XCC*E/.X34H]2?/%!LB-(//N/8_J:<6TS5L:T/\OAF1(C0WYV0J9NFV71:4RN" M.JS0K#"3-HJF@9'D\<@A+0^-1*\5GZH3S,:2KE7EVE#G3BP/L?!4S$CZFO#_ MV7O3YM21;%WX^_T5BCJG;U1% "T08]5]*P)CC/$ -H.Q]Q="0 (R0L(:&/SK MW[4R4Q.3APT&;)TXW>T-0E)FKGEX5JEYFZQEE44IUT5.6GEZLW6I54O#[+,! M_#'K32[4VN"IM98[]8HVU_)QK7Q;;UU-,T,Q^KJH6-EZ^3YS.V,=TDO2KC#O=D:JO2@F MQ->'>&UX)Y]5L3]R9472X'EA5HH=8_32K@TOG[JYQZON_3K94/C5>[F6\\VA M:#\L>K4K\WF!6BR]NJ*LU7RHF/%NME@:E#/G5YEW5\6^U5<;.;%@ M-%_;9J]4>!BME3?-O#2 M?F$]@:ODD$[B7?'@RFP'-Q_ V[6BC/:TFGL2QW95>KO6K%_5AT,9+XW^X MXY9[>>NMJQ.[>;R4FF4 MI%01+ ^;7'7/$V H'^&$99P_'DY6#B&HV&]V+.%DY>,\EY!=CO-8 MPLG*1W@LX63EHSR6<++R41Y+.%EYG\=RCI]X@ MD7"R\L^3HZ&Z#+;)@28K M\\["-J6SQF)"\G/%=#_=T$]8S]?JMY3ZVN>%?K]A/N5F8NNV+=]7>^WIT^LA MH+,KNL9 I8HO-EBI9;@VZE4%0T32*2-KV_U_.L%3DI M11)B-L18##$60XS%3T]JWK^<>0](X] 8+_8L8CX(VDA(^JKP6K>GS8)A3.K% M\^2U5>&3GW,Q:5]B)X1L/!W(QN7!S[_+2M?9EC68O4A7S=+XXNY,'#1R>B'_ M)N;CU_/.)@Q(T^6>[$NK%4T]YJZ*Y,*R*_.+:$'NW/-!TJF8E @'21_O'(]O M/DB:^VG?X:3"B2LGT3CQ]609C@#9S4%M6-HW'@$2#N+];L&J7>N[XSK/,"SR MT\(BNU:4QW62W]K?WJLZ/;SN#$>='F6YQ.&E3.@EGJP^_,YD&7J))Z#6CLL\ M"0=%?ID;&0Z*7!X(][L)EE2E/BR8342AMKAOSIMR M9K2XCSZU&MV'TN.%,WLR+(H(O?_O[/U_Q>#)_B-V^G6J-KFOV:"C^2H^RCV_/P3S& MFHC+Q/1\<)J;M/;S1)C0#Q*%T@%(%-*4$]=31S2;RWHR]'W^T] M0TG.*H/*W%2?HLUTOCPV'Y6&G>G>'^%0DEJ]&?=,$C]7RK:E.Q^PD23T MDR\>6Y))QN*)'PG*O+GM\R#@V#BF/#R'PY]#/!&+Q\.#./Q!A QQ'.<0![\S M/(?#GT,FEDV'Y["S<_A@LNA-.^G+%OUEH!1O">!]MT&O^H)?BT+QEB&P=\2: M[32PLB,_A2CV.O)@NZ[[?DS^EE8Y,)%_9 ]"B7YHYOW"P_ZV8CTDA&/ ZLO% M$GNM3?M=VV\NI,]%W3&6 !\1X.FZ0L5:OU8)A:TB,QE#F!<5F1=>FL!32V]C=TS.O!\DS M\:)0E,G+5$LE2^VSR8PAGDJ2& $!MX\R^Z/@JD.T\T@'[B[X9S?].RQ1=M)B MY$L037]7D+RG<^<+QGE(3D;C=/;V[#': MF%P\Y1FTJ12/I:0M\N7X7;==PS%^211BK[;%Z4B SQ@2O]6 M%T:G. MJ%\JRM?2^?-5L:XO\/''9U90OC?+VAV6>)DLWX/0 :,DD8N)WR*(L4M T=./8QPO M@FAH?NQ/5%PX/+#% C':CXHTGCZJXGA^7QJ.4]'"[.&^G:/1C=0^S8^?8&N< MIF$16A'?WHK@HL&&+?N,"?&BS]-BM'4_'Y'9@SBJRQ?WA6@>I,8WCVM\*7CK M47AI7Q#[. &TUN.!:MTN?I[$?*)T3H$3.L.JCDND]EY MMZK<&>)UXB&3K-4+I8OS&<=JS8B)2'R->?)=V"X,CH3!D?UBL?ZN(#D..^:W MJCD*3V6S_SP=)$;D5]VN7H )E3KD+4U'9CIC>&N@V;V:N3*18X$Q<'%>N=E2G! M'^6UGN_*Q@R^\2Z@9(]7<4;T\%Z!F)$%V V1CW0-.2+ U/#Q6-/9LB[I8D"[.[;E:*O6,3T0K&"PLWI@%(&&30("RL +E77.9P2JR8;07IJ5> MEJ:97V+BM?>D-^>C=F*>!^Z*I'+IB)A#TB/=_J)LF$)_&J1;-['.ZTDJ. MF_71W87V:Y*M+JKLJ)!ANW0UC-DC GPX(8@R2M1%1)@1@_#D<4PX4=A:JFUPH0RTEBLJ2M;U M?,WK;#D"Z8P(L$ASLK80IOC:<$!+KRO8)D6'A2O/5+"IHO7N4%?="Z,3T'=X MP5CO$34F^.^(EYN":??[< F\C3!4X- --.60"/":*!Z^ M\+4QVQR5"E"8K& MZ!9N3V]H$/@WB=!W<.X-) )T;!&_CNTT%K0@!2\SW7]S6P"L[VQA\/%@<0GZ3!,L0^ZY"\ -)3'A0C?!0?F6ML:RI8 .P'7+7![ M^$\GJJQHT2ELLZK*SJ_Y"["U(JVM6X)B\G.T03+2[QFWX;NA, '? &XM]&V, M90E4/IN,# W%'$7["%>L8*L1;)A@X G!'7TK[2S@B/KP-8AJ/&A\0C-6AUL8 M1#9M8R$L%*+VA*YM3/%. G@2\'H"+)/B(2,9P'L,:+\FWV^Z%QYD,EXRH2(5 MZ&0R,?0Y)5T5J!AWRGGJVJ.CMXH)>= R!5]F+O-X$FL$/MPH5E/)?: M-:.IU![[4C,IF<_6Q^*CF_"SO]@W<"W[/%B*8T9+1;Y)YWR/:K#/K@:+)GPJ MC)PI\IUZ.;XJUA-S,243??0HS_[X=]4@^8]'@YP"^_ -HW2_2$(^TH #6$B M*T PLCETSXK)EIX.0D;3+7Z6GEQ1^'U!S)F$4$1J1M"Q0VD*KAQD;VM!$2!M MZDQ1>,0)2S-\N.$];S$!9/'8H3#;_21#-;*31X=E,%+SUK@!LCW75Z3K_DOU M6K1KPTHU?2O=IT;Y/4*V?^28C@P'_8M!SM.96&KKB,AOBYWZQD0GW^_>3P2[ MA!;.;ITK&Q[+H2#0MX^N#,_E0(CHN5"*'=^QA.QRI.<2:I<]'LM'A^V^98(= M:@^^#G7Q#7+<.]K6/K?$19Y)?A9Y1A)CJ>PQ0\^LV;ZM"$7F>K2VD&^.C&\^ M?N[[!*!_RY8X,BI?5]BV,U2N[=;N+G8B/.5WG?(&O*E=@=%]A6+\I(1;V8P] M#B0(1?U/%/7?QN!A]F ?>N"X)K*?!_+).SOMXUKDSKG\&,N+ M_0L^OJ* Y%$7!32Z;4E\;:86N]3ORJ-QJTD]AO 'N[IV:#W-$) MA/_L23'^>)99KCF5AY?]<4,JVL56*3H@C?M%/=4:G!3// [(\+:4L^RF(K_6 M6HG<%8G'9\ SR?WQS#'JE_^% MU:VB*6-[O+[X;WA;EC)9>?XXNHYF'W.=4GF2:]__\6\F$4NOZ4B(AL;46[LM MSS?O=G$RSCU?ZY=]L3HL->Y+-Y?/O\ALTVZ?0)#A4!;4SY) )V@M?4 $=?-J M;5I?U-6F?%>Y[#W.)J5T&D50,I;-'$($G?YV;Y-!5W>EP<7EPLPT"^>->_U, MKFJ)7/Z/?[-B++.MR_-TS9_?MDB/R\"NK>_F^*;NQ(_SO4,#RQ%N2.@70.=E M3N9O:I).LG(Q%.W;^Z8L*KU\Y65L7-Z">96,B>G0EOWP5F_5(NV+3OU2CQWQ$*Z.=1[B]?4L ;& MKA1+)D);=[K4:O:'%T.K%'JI43507IUK[^I^73*T=@;&7NS M^P)<,R*6S#+10D\QN["[UG?P3+YW6.0T[2L&!+)+P85T7.W?^JGXG!/QND12 M(1$OD6)#-YJM[*_G?"R(;YBX0M(_1Z/JI'N$GT"Q, MPVK74(10F"_\%W>?.+S7X$*J]@:/BW+1_G6U&(O)=KRAS0)""Y;0_;MG&TA2 M:QV0SMM2J_.18'L#*#CN\S-2!>O)>'RME)JEW."!S":%H34$/R,1$^/+>(B> M2[>;S6+^#]^LYL-C^6E(6JJ8'I>>9LHT)<8O!\>U64^)VW*REVU-1]?]1%Q\ M60QS3V/8K'0LOK)9WS1N%(J']ULP;\F'T5EZ4KZYO[L6TXDS8I>K9[WR)']< M)!_/F[7GF1K/BNE1VR[/B\6Y>G:/\B&1_CWY\([="@@(N?52OFCEJZ6B_/"D M7.2D_J]%Z\@$Q.BR?IT9S%.R:'=2XFLEWR##<]BMN!C+9/8@(0YE0&SCH161 M\6D0["_ YE6T*(<6@%<.B+[-[0;XY7N7 2_-\0=E;MS3!GT?"D%7!6+%@Q[^ M$X1]DO Y>X AV-A;DD@ZI^<>73RWC"WP?P(("B[A(U LU'ZV+]'*U/*5G>AU]_XA]] NVFHQ/3V7BTU3 MN0?#5%R^=7L/,T'3WCERM/U4KG3J+N/)VD[JMBU:Y-BH7>9484L].D?GG?3JX^W;B.7Y:GQL(N1G.MV_GP MZGJNB?EV:O7*ZO/E56U(>Y&* M-;WZ>',Q8W/NZ95+XLE!RFO:T49[6DT\B6.[*[U]^/T]L&:X-B+_'40ES* (.I^NP[TU0^[[ !9,M32GFP=#FAR MW5)G',M?D!F8/Z*G,@#II5W8"A6/<-M!O'AA)IO"_Y[81*FO!29_>/K5[1"M M61%;9V=WHY0TU![.CW#NPV^.YF81C//J_6#PT(\W%;-$SB[CSX_:(@\>2CP6 M7YV!24GI2XAG$S3]\5,/J>0NKOJ)]O4HG>NJDG(]>AFECG#ZV2ZH9U"R2T;Y M_#$+)]MYNI=-Z_KQ":E'C*77X-\#K;QS"H8?$7^'8OE+U28EQ2@]&,%_> +Z MOYI)#@F"[[X>PW3N^E^/L-?SL+N'6'$*>M,:@J[5$*5]W2FR@T/M8I N^B$N M"K*MR78/1W!2I':\-_V+0@+(#+6>3X"@LQ%TT'2R!\"/[V:0(?Q,H>#C\&^R MBJ^L*AI\"G*+J"T+J#)I^ [_":W;I7]5^#79GH"%*-..\@FY: MYBK>FIJ4Q2M[\6]84ZLD*\Y6/ 6\Y(,2F$7MP:Y0D1,<-C\8XE MN76>;G@L!SF67"P3'LOQ'4LB)N7"8SFZ8P$AMG5<>W@LAQ)BX;'L[5@^.J7\ M+;LX1'@\+G2[S4" 2XAW+OYUZK/XUXDD2[9_%V# !@V*W+*@2-$+BFS%D WY M*>2G(#\E/LM/\7@L\9WX::?PJMLMZ"-;^1<3S?>B&6D7 O:X:D1KQ"0TO$ZG M)9(I4?4)QL:=N/P)%[[MI<[M-^-2Q[4+_[N#=;' SG&5-?Y&2Q0FDK,IJUMZ M*)73S6HC?=Y76_-$6?I<^4&9)I#,W/"^SG$ZF+)C7>N<> _*T'4_SEA.= M&Z(GVJFB7:Y.SLX[T0^+/=)*SD=DA==N7F6+MJ M2*+<>2FE%F8U^O"0QX7_\6\\(F7B^VD:1!5[7*QS$ &2.K9=V)$ .7FZ;]4?Q.ZX&;UZZ;8? MKLIGE=( %I[^X]]<9A4]YX3=V3HLG145,& !+!S8M57UTR3@UAS2Z314O94- M^XX"[CMA#/GII'N=QJE=H)1"".4Q)L3<2OK\MFH]6O<.1]5"]W6 M"%'ZTR@)Q,QJM?/WBBN5B$8,6:7FC]P;*YIB6@9-:H:1I:^*+!TN]/K5EM3Q M+?[(1.YO&%^LIYZ]>0HL>@K%X_JQ:AO'B! E=-T96JV M;B^*8WML_+K6:N*@-FNGT ++1,1T+@Q0?7F ZH?(H:-<_)')H=\P_=XGA_J7 MZFALSHPGL?"4ZU_6U$FVD#B _;?H50=/XP>C52RDZJE>9I!I/UUBBS#8?\E( M*KX-&/3D(EV'D#4_-/H5%"<2B).>;F-?RQ$(TQVF$P^\RB.3FA_&'_T:&?;R01P0TPVB5&DE(8[MJI9?7]6?\(5GEDK+]D,)T_ MB<.$,DTTBM<7-[\Z4ZL_4#('<+,D\GHQ;H_;1*P_Z^9TJ,GB]26R/I@WZ4@J MO:T.8/]048?J, U??O=]X;07 N%<=4&?>'W:'(WEG2@DBHFMW*K-V\0I(LM0 M5^%G+E@+H0@&K+E<%E3%@8''OO1ZOF8NWT-'@ ,!2#?:M0T#*^:-\N$]>4&>-HGKUNR"O_D.,)8/ M"ZR\V:[VWPV\XO:OXZLR: CNN+43F?+K\"QW/RIT2C?J9*$U[P:?+U!X5Z-\ M1=>FQ$0<"HIJT\ M]7^/S?(5W7HBEM=&ORP,*3+%:U/,Q^WGF2D6;(.,HME) MMC'/__%O1HIDXJO#SMX#;++G@]B.8?(DYCN-F7)_)9(GDJH]7K],C-;G+[:NFE+I>;2H=EO)>NVR_=B9(4!>1,JMQO\HAW.,IB4!LX0,(C2&( 3D M,<*'"S-%584.$7S\MX'GUX-/+&%/8%,8R)UU.$R*WL.+=P\R\4XTSKV='D.D MN- -_A%>YT?HS&9RT;NX%#T;C?.%&T.]7;3;"8)\9]B_>Z._AG_YR^J..4> MB ?4T(NU7'ZF ]TCGYXK(!(LW3 1@"@_,115D$2JN>,H08B =T:^'H/(%0BL M1D'WAO"7,M'2F3BOQ#"MW@4P)UN"S,/9^YK^D&Q+(HJ4.,H7[Q^;$:\"ZM[9 M9Q]ZU>RZ]9*-ZY5FL_":ZKTVTOI5YC+_Y>A5SDR("T,?L[J".Q JQ'EA1*9: M/_DI6LGD4T_]F[-B2QT_C!(YT<:8*"7UX%CU4E9A [6T@:N0C$V/.X##W&IE,(9"A=@ MAP.;P(LBF X;PD!7Z2/MH:';@Z% (66CECP7)O+"@*OAQ'LVW2B3,0DS;^&X M.VQO."/ ?T +X8UA 6C^4V/9
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end XML 96 hrmy-20240331x10q_htm.xml IDEA: XBRL DOCUMENT 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2024-03-31 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2023-10-31 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2024-01-01 2024-03-31 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2023-01-01 2023-03-31 0001802665 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001802665 us-gaap:RetainedEarningsMember 2024-03-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001802665 us-gaap:RetainedEarningsMember 2023-12-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001802665 us-gaap:RetainedEarningsMember 2023-03-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001802665 us-gaap:RetainedEarningsMember 2022-12-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001802665 us-gaap:CommonStockMember 2024-03-31 0001802665 us-gaap:CommonStockMember 2023-12-31 0001802665 us-gaap:CommonStockMember 2023-03-31 0001802665 us-gaap:CommonStockMember 2022-12-31 0001802665 srt:MinimumMember 2023-01-01 2023-12-31 0001802665 srt:MaximumMember 2023-01-01 2023-12-31 0001802665 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001802665 us-gaap:RestrictedStockUnitsRSUMember hrmy:TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember 2024-01-01 2024-03-31 0001802665 us-gaap:RestrictedStockUnitsRSUMember hrmy:TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember 2023-01-01 2023-12-31 0001802665 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001802665 country:US hrmy:WAKIXMember 2022-02-01 2022-02-28 0001802665 hrmy:TermLoanMember 2024-01-01 2024-03-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001802665 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001802665 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001802665 hrmy:IncrementalTermLoanMember 2023-09-30 0001802665 hrmy:FiveYearSeniorSecuredTermLoanMember 2023-07-31 0001802665 srt:MinimumMember 2024-03-31 0001802665 srt:MaximumMember 2024-03-31 0001802665 us-gaap:RelatedPartyMember 2024-01-01 2024-03-31 0001802665 us-gaap:RelatedPartyMember 2023-01-01 2023-03-31 0001802665 hrmy:WAKIXMember 2022-03-31 0001802665 hrmy:CataplexyMember hrmy:NdaForWakixMember 2020-10-31 0001802665 hrmy:DaytimeSleepinessMember hrmy:WAKIXMember 2019-08-31 0001802665 hrmy:DaytimeSleepinessMember hrmy:WAKIXMember 2024-03-31 0001802665 hrmy:CataplexyMember hrmy:NdaForWakixMember 2024-03-31 0001802665 hrmy:WAKIXMember 2024-03-31 0001802665 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0001802665 us-gaap:EmployeeStockOptionMember 2024-03-31 0001802665 hrmy:FiveYearSeniorSecuredTermLoanMember 2023-07-01 2023-07-31 0001802665 hrmy:RepaymentOfDebtDueOnMaturityDateMember hrmy:TermLoanMember 2024-01-01 2024-03-31 0001802665 hrmy:RepaymentOfDebtCommencingOnDecember312023Member hrmy:TermLoanMember 2024-01-01 2024-03-31 0001802665 hrmy:RepaymentOfDebtBeginningOnDecember312025Member hrmy:TermLoanMember 2024-01-01 2024-03-31 0001802665 hrmy:TermLoanMember 2024-03-31 0001802665 srt:MinimumMember hrmy:TermLoanMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-01-01 2024-03-31 0001802665 srt:MinimumMember hrmy:TermLoanMember us-gaap:BaseRateMember 2024-01-01 2024-03-31 0001802665 srt:MaximumMember hrmy:TermLoanMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-01-01 2024-03-31 0001802665 srt:MaximumMember hrmy:TermLoanMember us-gaap:BaseRateMember 2024-01-01 2024-03-31 0001802665 hrmy:BioprojetMember hrmy:SalesBasedTrademarkAndTieredRoyaltiesMember 2024-01-01 2024-03-31 0001802665 hrmy:BioprojetMember hrmy:SalesBasedTrademarkAndTieredRoyaltiesMember 2023-01-01 2023-03-31 0001802665 hrmy:PANTHERxSpecialtyPharmacyLLCMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001802665 hrmy:PANTHERxSpecialtyPharmacyLLCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001802665 hrmy:CaremarkLLCMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001802665 hrmy:CaremarkLLCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001802665 hrmy:AccredoHealthGroupIncMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001802665 hrmy:AccredoHealthGroupIncMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001802665 hrmy:PANTHERxSpecialtyPharmacyLLCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001802665 hrmy:CaremarkLLCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001802665 hrmy:AccredoHealthGroupIncMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001802665 hrmy:PANTHERxSpecialtyPharmacyLLCMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001802665 hrmy:CaremarkLLCMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001802665 hrmy:AccredoHealthGroupIncMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001802665 hrmy:IncentiveAwardPlanTwoThousandTwentyMember 2024-03-31 0001802665 hrmy:EmployeeStockPurchasePlanMember 2021-04-30 0001802665 2023-03-31 0001802665 2022-12-31 0001802665 hrmy:EpygenixTherapeuticsIncMember hrmy:ZynerbaPharmaceuticalsInc.Member 2024-04-30 2024-04-30 0001802665 hrmy:LongTermCommercialPaperMember 2023-12-31 0001802665 hrmy:LongTermUsGovernmentSecuritiesMember 2024-03-31 0001802665 hrmy:ShortTermUsGovernmentSecuritiesMember 2023-12-31 0001802665 us-gaap:ShortTermInvestmentsMember 2024-03-31 0001802665 hrmy:ShortTermCorporateDebtSecuritiesMember 2024-03-31 0001802665 hrmy:ShortTermCommercialPaperMember 2024-03-31 0001802665 hrmy:LongTermInvestmentsMember 2024-03-31 0001802665 hrmy:LongTermCorporateDebtSecuritiesMember 2024-03-31 0001802665 us-gaap:ShortTermInvestmentsMember 2023-12-31 0001802665 hrmy:ShortTermCorporateDebtSecuritiesMember 2023-12-31 0001802665 hrmy:ShortTermCommercialPaperMember 2023-12-31 0001802665 hrmy:LongTermUsGovernmentSecuritiesMember 2023-12-31 0001802665 hrmy:LongTermInvestmentsMember 2023-12-31 0001802665 hrmy:LongTermCorporateDebtSecuritiesMember 2023-12-31 0001802665 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0001802665 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0001802665 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2024-03-31 0001802665 us-gaap:FairValueInputsLevel1Member us-gaap:CashAndCashEquivalentsMember 2024-03-31 0001802665 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0001802665 us-gaap:FairValueInputsLevel2Member 2024-03-31 0001802665 us-gaap:FairValueInputsLevel1Member 2024-03-31 0001802665 us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0001802665 us-gaap:CommercialPaperMember 2024-03-31 0001802665 us-gaap:CashAndCashEquivalentsMember 2024-03-31 0001802665 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001802665 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001802665 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2023-12-31 0001802665 us-gaap:FairValueInputsLevel2Member us-gaap:CashAndCashEquivalentsMember 2023-12-31 0001802665 us-gaap:FairValueInputsLevel1Member us-gaap:CashAndCashEquivalentsMember 2023-12-31 0001802665 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001802665 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001802665 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001802665 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001802665 us-gaap:CommercialPaperMember 2023-12-31 0001802665 us-gaap:CashAndCashEquivalentsMember 2023-12-31 0001802665 2023-10-01 2023-10-31 0001802665 hrmy:Hbs102Member hrmy:AllCountriesExcludingChinaMember hrmy:AssetPurchaseAgreementWithConsynanceTherapeuticsMember 2021-08-01 2021-08-31 0001802665 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-03-31 0001802665 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001802665 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001802665 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-03-31 0001802665 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001802665 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001802665 hrmy:BioprojetMember hrmy:SalesBasedTrademarkAndTieredRoyaltiesMember 2024-03-31 0001802665 hrmy:BioprojetMember hrmy:SalesBasedTrademarkAndTieredRoyaltiesMember 2023-12-31 0001802665 hrmy:TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001802665 hrmy:TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001802665 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001802665 hrmy:IncentiveAwardPlanTwoThousandTwentyMember 2024-01-01 2024-03-31 0001802665 hrmy:EmployeeStockPurchasePlanMember 2021-04-30 2021-04-30 0001802665 us-gaap:StockAppreciationRightsSARSMember 2024-01-01 2024-03-31 0001802665 us-gaap:StockAppreciationRightsSARSMember 2023-01-01 2023-12-31 0001802665 us-gaap:StockAppreciationRightsSARSMember 2024-03-31 0001802665 us-gaap:StockAppreciationRightsSARSMember 2023-12-31 0001802665 2023-01-01 2023-12-31 0001802665 hrmy:EmployeeStockPurchasePlanMember 2024-01-01 2024-03-31 0001802665 hrmy:EmployeeStockPurchasePlanMember 2023-01-01 2023-03-31 0001802665 2018-06-01 2018-06-30 0001802665 hrmy:ThreeCustomersMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001802665 hrmy:ThreeCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001802665 hrmy:ThreeCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001802665 hrmy:ThreeCustomersMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001802665 srt:MinimumMember 2024-01-01 2024-03-31 0001802665 srt:MaximumMember 2024-01-01 2024-03-31 0001802665 hrmy:BioprojetMember hrmy:WAKIXMember 2019-08-01 2019-08-31 0001802665 hrmy:BioprojetMember hrmy:PitolisantsMember 2022-07-01 2022-07-31 0001802665 hrmy:BioprojetMember hrmy:Orexin2ReceptorAgonistOx2rMember us-gaap:SubsequentEventMember 2024-04-11 2024-04-11 0001802665 hrmy:Hbs102Member hrmy:AllCountriesExcludingChinaMember hrmy:AssetPurchaseAgreementWithConsynanceTherapeuticsMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-03-01 2023-03-31 0001802665 hrmy:BioprojetMember hrmy:WAKIXMember 2021-01-01 2021-01-31 0001802665 hrmy:CataplexyMember hrmy:NdaForWakixMember 2020-10-01 2020-10-31 0001802665 hrmy:BioprojetMember hrmy:WAKIXMember 2020-10-01 2020-10-31 0001802665 hrmy:BioprojetMember 2019-11-01 2019-11-30 0001802665 hrmy:DaytimeSleepinessMember hrmy:WAKIXMember 2019-08-01 2019-08-31 0001802665 hrmy:BioprojetMember 2019-08-01 2019-08-31 0001802665 hrmy:BioprojetMember hrmy:WAKIXMember 2019-08-31 0001802665 hrmy:BioprojetMember hrmy:PitolisantsMember 2019-02-28 0001802665 hrmy:EpygenixTherapeuticsIncMember hrmy:ZynerbaPharmaceuticalsInc.Member 2024-04-30 0001802665 hrmy:BioprojetMember hrmy:Orexin2ReceptorAgonistOx2rMember us-gaap:SubsequentEventMember 2024-04-11 0001802665 hrmy:BioprojetMember hrmy:PitolisantsMember 2022-07-31 0001802665 hrmy:BioprojetMember hrmy:WAKIXMember country:US hrmy:UponAchievementOfAggregateNetSalesMember 2022-03-01 2022-03-31 0001802665 hrmy:WAKIXMember 2022-03-01 2022-03-31 0001802665 hrmy:BioprojetMember 2019-08-31 0001802665 hrmy:Hbs102Member hrmy:AllCountriesExcludingChinaMember hrmy:AssetPurchaseAgreementWithConsynanceTherapeuticsMember 2021-08-31 0001802665 hrmy:TermLoanMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-01-01 2024-03-31 0001802665 hrmy:ZynerbaAcquisitionMember 2023-10-01 2023-10-31 0001802665 hrmy:BioprojetMember country:US 2022-03-01 2022-03-31 0001802665 2023-01-01 2023-03-31 0001802665 2023-12-31 0001802665 2024-03-31 0001802665 2024-04-26 0001802665 2024-01-01 2024-03-31 utr:sqft hrmy:segment shares iso4217:USD iso4217:USD shares hrmy:Right hrmy:Vote hrmy:Institution pure hrmy:product hrmy:customer http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember 0001802665 --12-31 Q1 false http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#RelatedPartyMember http://fasb.org/us-gaap/2023#RelatedPartyMember 0 0 http://fasb.org/us-gaap/2023#RelatedPartyMember http://fasb.org/us-gaap/2023#RelatedPartyMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent P10Y 10-Q true 2024-03-31 2024 false 001-39450 HARMONY BIOSCIENCES HOLDINGS, INC. DE 82-2279923 630 W. Germantown Pike Suite 215 Plymouth Meeting PA 19462 484 539-9800 Common Stock, par value $0.00001 value per share HRMY NASDAQ Yes Yes Large Accelerated Filer false false false 56791861 332981000 311660000 39369000 41800000 79719000 74140000 5857000 5363000 12894000 12570000 8683000 5537000 479503000 451070000 213000 371000 270000 270000 81244000 72169000 131147000 137108000 147639000 144162000 6969000 6298000 367482000 360378000 846985000 811448000 15144000 17730000 7317000 23747000 91699000 99494000 15000000 15000000 25093000 7810000 154253000 163781000 174996000 178566000 2342000 2109000 177338000 180675000 331591000 344456000 0.00001 0.00001 500000000 500000000 56791214 56791214 56769081 56769081 1000 1000 620507000 610266000 -171000 2000 -104943000 -143277000 515394000 466992000 846985000 811448000 154615000 119126000 27484000 20780000 127131000 98346000 22189000 13289000 27233000 22572000 25676000 22062000 75098000 57923000 52033000 40423000 -141000 2000 4535000 5731000 4428000 3086000 51785000 37780000 13451000 8295000 38334000 29485000 -173000 120000 38161000 29605000 0.68 0.49 0.67 0.48 56771251 59732157 57597627 61221511 56769081 1000 610266000 2000 -143277000 466992000 38334000 38334000 -173000 -173000 22133 -153000 -153000 10394000 10394000 56791214 1000 620507000 -171000 -104943000 515394000 59615731 1000 675118000 -151000 -272130000 402838000 29485000 29485000 120000 120000 338887 3395000 3395000 7203000 7203000 59954618 1000 685716000 -31000 -242645000 443041000 38334000 29485000 163000 103000 5961000 5961000 10394000 7203000 40000 -642000 180000 416000 -3477000 -3442000 594000 636000 467000 369000 5579000 -2165000 494000 -207000 3439000 -592000 -2586000 2628000 -8229000 -1850000 31141000 42559000 25106000 47776000 18925000 45986000 5000 -6186000 -1790000 3750000 500000 116000 3909000 -3634000 3409000 21321000 44178000 311930000 244534000 333251000 288712000 4585000 5017000 1. ORGANIZATION AND DESCRIPTION OF BUSINESSThe CompanyHarmony Biosciences Holdings, Inc., and its consolidated subsidiaries (the “Company”) was founded in July 2017 as Harmony Biosciences II, LLC, a Delaware limited liability company. The Company converted to a Delaware corporation named Harmony Biosciences II, Inc. in September 2017 and, in February 2020, the Company changed its name to Harmony Biosciences Holdings, Inc. The Company’s operations are conducted in its wholly owned subsidiary, Harmony Biosciences, LLC (“Harmony”), and Zynerba Pharmaceuticals, Inc. The Company is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders as well as patients living with other neurological diseases who have unmet medical needs. The Company is headquartered in Plymouth Meeting, Pennsylvania.On October 10, 2023, the Company completed a tender offer to acquire all of the outstanding shares of common stock of Zynerba Pharmaceuticals, Inc. (together with its subsidiary, Zynerba Pharmaceutical Pty, Ltd., “Zynerba”). Zynerba is a clinical-stage pharmaceutical company focused on innovative pharmaceutically produced transdermal cannabidiol therapies for orphan neuropsychiatric disorders, including Fragile X Syndrome. 2. LIQUIDITY AND CAPITAL RESOURCESThe unaudited condensed consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of $104,943 and $143,277, as of March 31, 2024, and December 31, 2023, respectively. As of March 31, 2024, the Company had cash, cash equivalents and investments of $453,594.The Company believes that its existing cash, cash equivalents and investments on hand as of March 31, 2024, as well as additional cash generated from operating and financing activities will meet its operational liquidity needs and fund its planned investing activities for the next twelve months from the date of issuance of these unaudited condensed consolidated financial statements. -104943000 -143277000 453594000 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESBasis of PresentationThe unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated balance sheet as of March 31, 2024, the unaudited condensed consolidated statements of cash flows for the three months ended March 31, 2024, and 2023, and the unaudited condensed consolidated statements of operations and comprehensive income and the unaudited condensed consolidated statements of shareholders’ equity for the three months ended March 31, 2024, and 2023, are unaudited. The balance sheet as of December 31, 2023, was derived from audited financial statements as of and for the year ended December 31, 2023. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements as of and for the year ended December 31, 2023, and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of March 31, 2024, and the results of its operations and its cash flows for the three months ended March 31, 2024, and 2023. The unaudited condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC’s rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. ReclassificationsCertain prior period amounts within the unaudited condensed consolidated statements of operations and comprehensive income have been reclassified to conform to current period presentation. In particular, interest expense and interest income were previously classified together as interest expense, net and are now separately classified as interest expense and interest income, respectively. The reclassification of these items had no impact on net income, earnings per share or accumulated deficit in current or prior periods.Significant Risks and UncertaintiesThe Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to, clinical trial results of the Company’s product candidates; the Company’s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company’s products, if approved; the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its product candidates.The Company currently has one commercially approved product, WAKIX, and there can be no assurance that the Company’s research and development efforts will result in successfully commercialized products in addition to WAKIX. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property.Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the unaudited condensed consolidated financial statements, including the notes thereto, and elsewhere in this report. Actual results may differ significantly from estimates, which include rebates due pursuant to commercial and government contracts, accrued research and development expenses, stock-based compensation expense and income taxes. Operating SegmentsThe Company holds all its tangible assets, conducts its operations, and generates its revenue in the United States. Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Makers in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined it operates in a single operating segment and has one reportable segment.Fair Value of Financial InstrumentsThe Company’s unaudited condensed consolidated financial statements include cash, cash equivalents, restricted cash, accounts payable, and accrued liabilities, all of which are short term in nature and, accordingly, approximate fair value.It is the Company’s policy to measure non-financial assets and liabilities at fair value on a nonrecurring basis. These non-financial assets and liabilities are not measured at fair value on an ongoing basis but are subject to fair value adjustments in certain circumstances (such as evidence of impairment), which, if material, are disclosed in the accompanying footnotes.The Company measures certain assets and liabilities at fair value based on the fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value into three levels based on the source of inputs as follows:Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.Money market funds are classified as Level 1 fair value instruments. Investments in available-for-sale debt securities are classified as Level 2 and carried at fair value, which we estimate utilizing a third-party pricing service. The pricing service utilizes industry standard valuation models whereby all significant inputs, including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, bids, offers, or other market-related data, are observable. We validate valuations obtained from third-party services by obtaining market values from other pricing sources. The Company did not classify any assets or liabilities as Level 3 as of March 31, 2024, or December 31, 2023.Cash, Cash Equivalents and Restricted CashCash and cash equivalents and restricted cash consist of cash and, if applicable, highly liquid investments with an original maturity of three months or less when purchased, including investments in Money Market Funds and debt securities that approximate fair value. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet and the statements of cash flows.<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">As of</td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;">Cash and cash equivalents</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"> 332,981</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"> 311,660</td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;">Restricted cash</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 270</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 270</td></tr><tr><td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;">Total cash, cash equivalents, and restricted cash shown in the statements of cash flows</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 333,251</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 311,930</td></tr></table>Restricted cash includes amounts required to be held as a security deposit in the form of letters of credit for the Company’s credit card program and the fleet program.InvestmentsThe Company’s investments consist of debt securities that are classified as available-for-sale. Short-term and long-term investments are carried at fair value and unrealized gains and losses are recorded as a component of accumulated comprehensive income in stockholders’ equity. Interest income earned on cash and investment balances, accretion of the discount on investments in debt securities, amortization of premiums and realized gains and losses, if any, are recorded in interest income on the unaudited condensed consolidated statement of operations and comprehensive income. Realized gains and losses that result from the sale of investments are determined on a specific identification basis. At each reporting period, the Company reviews any unrealized losses position to determine if the decline in the fair value of the underlying investments is a result of credit losses or other factors. If the assessment indicates that a credit loss exists, any impairment is recognized as an allowance for credit losses in our consolidated statement of operations. Concentrations of RiskSubstantially all of the Company’s cash and money market funds are held in five financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. Deposits may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company believes that it is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.The Company is subject to credit risk from its trade receivables related to its product sales. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored, and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. The Company monitors its exposure within accounts receivable and would record a reserve against uncollectible accounts receivable if necessary. As of March 31, 2024, three customers accounted for 100% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 41% of gross accounts receivable; Accredo Health Group, Inc. (“Accredo”), which accounted for 36% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 23% of gross accounts receivable. As of December 31, 2023, three customers accounted for 100% of gross accounts receivable; Accredo, which accounted for 39% of gross accounts receivable, CVS Caremark, which accounted for 32% of gross accounts receivable; and Pantherx, which accounted for 29% of gross accounts receivable.For the three months ended March 31, 2024, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 42% of gross product revenue; Accredo accounted for 33% of gross product revenue; and Pantherx accounted for 25% of gross product revenue. For the three months ended March 31, 2023, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 35% of gross product revenue; Pantherx accounted for 33% of gross product revenue; and Accredo accounted for 32% of gross product revenue.The Company depends on a single supplier for its product and a single supplier for its active pharmaceutical ingredient.Share RepurchasesThe Company accounts for share repurchases as constructive retirements, whereby it reduces common stock and additional paid-in capital by the amount of the original issuance, with any excess purchase price recorded as a reduction to retained earnings. Under this method, issued and outstanding shares of common stock are reduced by the amount of shares of common stock repurchased, and no treasury stock is recognized on the condensed consolidated financial statements.Business CombinationsBusiness combinations and asset acquisitions are accounted for in accordance with FASB ASC 805 Business Combinations. Refer to Note 4, Acquisition, for a more detailed discussion of the Zynerba Acquisition.Recently Issued Accounting PronouncementsIn November 2023, the FASB issued Accounting Standards Update (“ASU”) No. 2023-07, Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 is intended to improve reportable segment disclosures primarily through enhanced disclosure of reportable segment expenses and requires that a public entity that has a single reportable segment provide all the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280. This ASU is effective for annual reporting periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. ASU 2023-07 is required to be applied retrospectively to all prior periods presented in the financial statements. The Company has one reportable segment and is currently evaluating the impact that ASU 2023-07 will have on its condensed consolidated financial statements.In December 2023, the FASB issued Accounting Standards Update (“ASU”) No 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” (“ASU 2023-09”). ASU 2023-09 expands disclosures in the rate reconciliation and requires disclosure of income taxes paid by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that ASU 2023-09 will have on its condensed consolidated financial statements. Basis of PresentationThe unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated balance sheet as of March 31, 2024, the unaudited condensed consolidated statements of cash flows for the three months ended March 31, 2024, and 2023, and the unaudited condensed consolidated statements of operations and comprehensive income and the unaudited condensed consolidated statements of shareholders’ equity for the three months ended March 31, 2024, and 2023, are unaudited. The balance sheet as of December 31, 2023, was derived from audited financial statements as of and for the year ended December 31, 2023. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements as of and for the year ended December 31, 2023, and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of March 31, 2024, and the results of its operations and its cash flows for the three months ended March 31, 2024, and 2023. The unaudited condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC’s rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. ReclassificationsCertain prior period amounts within the unaudited condensed consolidated statements of operations and comprehensive income have been reclassified to conform to current period presentation. In particular, interest expense and interest income were previously classified together as interest expense, net and are now separately classified as interest expense and interest income, respectively. The reclassification of these items had no impact on net income, earnings per share or accumulated deficit in current or prior periods. Significant Risks and UncertaintiesThe Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to, clinical trial results of the Company’s product candidates; the Company’s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company’s products, if approved; the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its product candidates.The Company currently has one commercially approved product, WAKIX, and there can be no assurance that the Company’s research and development efforts will result in successfully commercialized products in addition to WAKIX. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property. 1 Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the unaudited condensed consolidated financial statements, including the notes thereto, and elsewhere in this report. Actual results may differ significantly from estimates, which include rebates due pursuant to commercial and government contracts, accrued research and development expenses, stock-based compensation expense and income taxes. Operating SegmentsThe Company holds all its tangible assets, conducts its operations, and generates its revenue in the United States. Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Makers in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined it operates in a single operating segment and has one reportable segment. 1 1 Fair Value of Financial InstrumentsThe Company’s unaudited condensed consolidated financial statements include cash, cash equivalents, restricted cash, accounts payable, and accrued liabilities, all of which are short term in nature and, accordingly, approximate fair value.It is the Company’s policy to measure non-financial assets and liabilities at fair value on a nonrecurring basis. These non-financial assets and liabilities are not measured at fair value on an ongoing basis but are subject to fair value adjustments in certain circumstances (such as evidence of impairment), which, if material, are disclosed in the accompanying footnotes.The Company measures certain assets and liabilities at fair value based on the fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value into three levels based on the source of inputs as follows:Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.Money market funds are classified as Level 1 fair value instruments. Investments in available-for-sale debt securities are classified as Level 2 and carried at fair value, which we estimate utilizing a third-party pricing service. The pricing service utilizes industry standard valuation models whereby all significant inputs, including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, bids, offers, or other market-related data, are observable. We validate valuations obtained from third-party services by obtaining market values from other pricing sources. The Company did not classify any assets or liabilities as Level 3 as of March 31, 2024, or December 31, 2023. Cash, Cash Equivalents and Restricted CashCash and cash equivalents and restricted cash consist of cash and, if applicable, highly liquid investments with an original maturity of three months or less when purchased, including investments in Money Market Funds and debt securities that approximate fair value. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet and the statements of cash flows.<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">As of</td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;">Cash and cash equivalents</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"> 332,981</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"> 311,660</td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;">Restricted cash</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 270</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 270</td></tr><tr><td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;">Total cash, cash equivalents, and restricted cash shown in the statements of cash flows</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 333,251</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 311,930</td></tr></table>Restricted cash includes amounts required to be held as a security deposit in the form of letters of credit for the Company’s credit card program and the fleet program. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet and the statements of cash flows.<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">As of</td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;">Cash and cash equivalents</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"> 332,981</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"> 311,660</td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;">Restricted cash</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 270</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 270</td></tr><tr><td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;">Total cash, cash equivalents, and restricted cash shown in the statements of cash flows</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 333,251</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 311,930</td></tr></table> 332981000 311660000 270000 270000 333251000 311930000 InvestmentsThe Company’s investments consist of debt securities that are classified as available-for-sale. Short-term and long-term investments are carried at fair value and unrealized gains and losses are recorded as a component of accumulated comprehensive income in stockholders’ equity. Interest income earned on cash and investment balances, accretion of the discount on investments in debt securities, amortization of premiums and realized gains and losses, if any, are recorded in interest income on the unaudited condensed consolidated statement of operations and comprehensive income. Realized gains and losses that result from the sale of investments are determined on a specific identification basis. At each reporting period, the Company reviews any unrealized losses position to determine if the decline in the fair value of the underlying investments is a result of credit losses or other factors. If the assessment indicates that a credit loss exists, any impairment is recognized as an allowance for credit losses in our consolidated statement of operations. Concentrations of RiskSubstantially all of the Company’s cash and money market funds are held in five financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. Deposits may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company believes that it is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.The Company is subject to credit risk from its trade receivables related to its product sales. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored, and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. The Company monitors its exposure within accounts receivable and would record a reserve against uncollectible accounts receivable if necessary. As of March 31, 2024, three customers accounted for 100% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 41% of gross accounts receivable; Accredo Health Group, Inc. (“Accredo”), which accounted for 36% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 23% of gross accounts receivable. As of December 31, 2023, three customers accounted for 100% of gross accounts receivable; Accredo, which accounted for 39% of gross accounts receivable, CVS Caremark, which accounted for 32% of gross accounts receivable; and Pantherx, which accounted for 29% of gross accounts receivable.For the three months ended March 31, 2024, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 42% of gross product revenue; Accredo accounted for 33% of gross product revenue; and Pantherx accounted for 25% of gross product revenue. For the three months ended March 31, 2023, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 35% of gross product revenue; Pantherx accounted for 33% of gross product revenue; and Accredo accounted for 32% of gross product revenue.The Company depends on a single supplier for its product and a single supplier for its active pharmaceutical ingredient. 5 3 1 0.41 0.36 0.23 3 1 0.39 0.32 0.29 3 1 0.42 0.33 0.25 3 1 0.35 0.33 0.32 Share RepurchasesThe Company accounts for share repurchases as constructive retirements, whereby it reduces common stock and additional paid-in capital by the amount of the original issuance, with any excess purchase price recorded as a reduction to retained earnings. Under this method, issued and outstanding shares of common stock are reduced by the amount of shares of common stock repurchased, and no treasury stock is recognized on the condensed consolidated financial statements. Business CombinationsBusiness combinations and asset acquisitions are accounted for in accordance with FASB ASC 805 Business Combinations. Refer to Note 4, Acquisition, for a more detailed discussion of the Zynerba Acquisition. Recently Issued Accounting PronouncementsIn November 2023, the FASB issued Accounting Standards Update (“ASU”) No. 2023-07, Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 is intended to improve reportable segment disclosures primarily through enhanced disclosure of reportable segment expenses and requires that a public entity that has a single reportable segment provide all the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280. This ASU is effective for annual reporting periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. ASU 2023-07 is required to be applied retrospectively to all prior periods presented in the financial statements. The Company has one reportable segment and is currently evaluating the impact that ASU 2023-07 will have on its condensed consolidated financial statements.In December 2023, the FASB issued Accounting Standards Update (“ASU”) No 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” (“ASU 2023-09”). ASU 2023-09 expands disclosures in the rate reconciliation and requires disclosure of income taxes paid by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that ASU 2023-09 will have on its condensed consolidated financial statements. 1 4. ACQUISITIONIn October 2023, the Company completed a tender offer to purchase the outstanding common stock of Zynerba (“Zynerba Common Stock”) for (i) $1.1059 per share of Zynerba Common Stock (the “Common Cash Amount”), the aggregate amount of which was $60,000 and was paid at closing, plus (ii) one contingent value right (each, a “CVR”) per share of Zynerba Common Stock (the “Common CVR Amount”), which represents the right to receive up to approximately $2.5444 per share of Zynerba Common Stock, subject to the achievement of certain clinical, regulatory and sales-based milestones. The Common CVR Amounts are to be paid in cash, subject to any applicable withholding of taxes and without interest. The aggregate amount of consideration to acquire Zynerba Common Stock was $60,000, excluding transaction related fees of $2,645 and was paid by the Company using cash on hand. The Zynerba Acquisition was accounted for as an asset acquisition under ASC Topic 805, Business Combinations, because substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable IPR&D asset, ZYN002, Zynerba’s lead asset. ZYN002 is the first and only pharmaceutically manufactured, synthetic cannabidiol, a non-euphoric cannabidiol, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system and is currently in Phase III clinical trial for the potential treatment of Fragile X Syndrome. The Company recognized the acquired assets and assumed liabilities based on the consideration paid, including transaction costs, on a relative fair value basis, and after first allocating the preliminary excess of the fair value of net assets acquired over the purchase price consideration to certain qualifying assets, principally, the IPR&D asset.5. INVESTMENTS 1.1059 60000000 1 2.5444 60000000 2645000 The carrying value and amortized cost of the Company’s available-for-sale debt securities, summarized by type of security, consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;"></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:44.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2024</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;">Amortized</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;">Unrealized</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;">Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;">Fair</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Cost</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Gains</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Losses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;">Short-term:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.76%;margin:0pt;padding:0pt;">Commercial paper</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 23,038</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 10</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> (7)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"> 23,041</td></tr><tr><td style="vertical-align:bottom;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;">Corporate debt securities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,316</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,328</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;">Total short-term investments</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 39,354</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 26</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (11)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 39,369</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;">Long-term:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;">Corporate debt securities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 51,062</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 61</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> (50)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"> 51,073</td></tr><tr><td style="vertical-align:bottom;width:55.76%;margin:0pt;padding:0pt;">U.S. government securities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 30,368</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (197)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 30,171</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;">Total long-term investments</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 81,430</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 61</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (247)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 81,244</td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:44.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2023</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;">Amortized</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;">Unrealized</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;">Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;">Fair</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Cost</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Gains</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Losses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;">Short-term:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;">Commercial paper</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 23,832</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 36</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> (3)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"> 23,865</td></tr><tr><td style="vertical-align:bottom;width:55.76%;margin:0pt;padding:0pt;">Corporate debt securities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 15,968</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 28</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"> 15,996</td></tr><tr><td style="vertical-align:bottom;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;">U.S. government securities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,940</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,939</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;">Total short-term investments</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 41,740</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 64</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (4)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 41,800</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;">Long-term:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;">Commercial paper</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 744</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"> 744</td></tr><tr><td style="vertical-align:bottom;width:55.76%;margin:0pt;padding:0pt;">Corporate debt securities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 42,688</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 81</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> (28)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"> 42,741</td></tr><tr><td style="vertical-align:bottom;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;">U.S. government securities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 28,795</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (118)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 28,684</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;">Total long-term investments</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 72,227</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 88</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (146)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 72,169</td></tr></table>The Company classifies investments with an original maturity of less than one year as current and investments with an original maturity date of greater than one year as noncurrent on its unaudited condensed consolidated balance sheet. The investments classified as noncurrent have original maturity dates ranging from 1-2 years. The Company did not have any available-for-sale debt security investments in a continuous unrealized loss position of greater than 12 months as of March 31, 2024, and December 31, 2023, respectively. The carrying value and amortized cost of the Company’s available-for-sale debt securities, summarized by type of security, consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;"></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:44.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2024</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;">Amortized</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;">Unrealized</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;">Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;">Fair</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Cost</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Gains</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Losses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;">Short-term:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.76%;margin:0pt;padding:0pt;">Commercial paper</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 23,038</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 10</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> (7)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"> 23,041</td></tr><tr><td style="vertical-align:bottom;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;">Corporate debt securities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,316</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,328</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;">Total short-term investments</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 39,354</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 26</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (11)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 39,369</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;">Long-term:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;">Corporate debt securities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 51,062</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 61</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> (50)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"> 51,073</td></tr><tr><td style="vertical-align:bottom;width:55.76%;margin:0pt;padding:0pt;">U.S. government securities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 30,368</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (197)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 30,171</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;">Total long-term investments</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 81,430</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 61</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (247)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 81,244</td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:44.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2023</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;">Amortized</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;">Unrealized</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;">Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;">Fair</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Cost</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Gains</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Losses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;">Short-term:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;">Commercial paper</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 23,832</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 36</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> (3)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"> 23,865</td></tr><tr><td style="vertical-align:bottom;width:55.76%;margin:0pt;padding:0pt;">Corporate debt securities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 15,968</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 28</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"> 15,996</td></tr><tr><td style="vertical-align:bottom;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;">U.S. government securities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,940</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,939</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;">Total short-term investments</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 41,740</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 64</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (4)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 41,800</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;">Long-term:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;">Commercial paper</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 744</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"> 744</td></tr><tr><td style="vertical-align:bottom;width:55.76%;margin:0pt;padding:0pt;">Corporate debt securities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 42,688</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 81</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> (28)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"> 42,741</td></tr><tr><td style="vertical-align:bottom;width:55.76%;background:#cceeff;margin:0pt;padding:0pt;">U.S. government securities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 28,795</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (118)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 28,684</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.76%;margin:0pt;padding:0pt;">Total long-term investments</td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 72,227</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 88</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (146)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 72,169</td></tr></table> 23038000 10000 7000 23041000 16316000 16000 4000 16328000 39354000 26000 11000 39369000 51062000 61000 50000 51073000 30368000 197000 30171000 81430000 61000 247000 81244000 23832000 36000 3000 23865000 15968000 28000 15996000 1940000 1000 1939000 41740000 64000 4000 41800000 744000 744000 42688000 81000 28000 42741000 28795000 7000 118000 28684000 72227000 88000 146000 72169000 P1Y P2Y 6. FAIR VALUE MEASUREMENTSMoney market funds are classified as Level 1 fair value instruments. Investments in available-for-sale debt securities are classified as Level 2 and carried at fair value, which we estimate utilizing a third-party pricing service. The pricing service utilizes industry standard valuation models whereby all significant inputs, including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, bids, offers, or other market-related data, are observable. We validate valuations obtained from third-party services by obtaining market values from other pricing sources. The Company did not classify any assets or liabilities as Level 3 as of March 31, 2024, or December 31, 2023. The Company’s assets measured at fair value consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:33.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.55%;margin:0pt;padding:0pt;"></td><td colspan="6" style="vertical-align:bottom;width:31.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2024</td><td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"></td><td colspan="6" style="vertical-align:bottom;width:31.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2023</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 1</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 2</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 1</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 2</td></tr><tr><td style="vertical-align:bottom;width:33.55%;background:#cceeff;margin:0pt;padding:0pt;">Assets</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:33.55%;margin:0pt;padding:0pt;">Cash equivalents</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"> 264,079</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"> 264,079</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"> 244,569</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"> 243,685</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"> 884</td></tr><tr><td style="vertical-align:bottom;width:33.55%;background:#cceeff;margin:0pt;padding:0pt;">Commercial paper</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"> 23,041</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"> 23,041</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"> 24,609</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"> 24,609</td></tr><tr><td style="vertical-align:bottom;width:33.55%;margin:0pt;padding:0pt;">Corporate debt securities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"> 67,401</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"> 67,401</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"> 58,737</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"> 58,737</td></tr><tr><td style="vertical-align:bottom;width:33.55%;background:#cceeff;margin:0pt;padding:0pt;">U.S. government securities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 30,171</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 30,171</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 30,623</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 30,623</td></tr><tr><td style="vertical-align:bottom;width:33.55%;margin:0pt;padding:0pt;">Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 384,692</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 264,079</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 120,613</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 358,538</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 243,685</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 114,853</td></tr></table> The Company’s assets measured at fair value consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:33.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.55%;margin:0pt;padding:0pt;"></td><td colspan="6" style="vertical-align:bottom;width:31.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2024</td><td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"></td><td colspan="6" style="vertical-align:bottom;width:31.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2023</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 1</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 2</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 1</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 2</td></tr><tr><td style="vertical-align:bottom;width:33.55%;background:#cceeff;margin:0pt;padding:0pt;">Assets</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:33.55%;margin:0pt;padding:0pt;">Cash equivalents</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"> 264,079</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"> 264,079</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"> 244,569</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"> 243,685</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"> 884</td></tr><tr><td style="vertical-align:bottom;width:33.55%;background:#cceeff;margin:0pt;padding:0pt;">Commercial paper</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"> 23,041</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"> 23,041</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"> 24,609</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"> 24,609</td></tr><tr><td style="vertical-align:bottom;width:33.55%;margin:0pt;padding:0pt;">Corporate debt securities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"> 67,401</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"> 67,401</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"> 58,737</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"> 58,737</td></tr><tr><td style="vertical-align:bottom;width:33.55%;background:#cceeff;margin:0pt;padding:0pt;">U.S. government securities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 30,171</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 30,171</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 30,623</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 30,623</td></tr><tr><td style="vertical-align:bottom;width:33.55%;margin:0pt;padding:0pt;">Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 384,692</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 264,079</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 120,613</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 358,538</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 243,685</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 114,853</td></tr></table> 264079000 264079000 244569000 243685000 884000 23041000 23041000 24609000 24609000 67401000 67401000 58737000 58737000 30171000 30171000 30623000 30623000 384692000 264079000 120613000 358538000 243685000 114853000 7. INVENTORYInventory, net consisted of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">As of</td></tr><tr><td style="vertical-align:bottom;width:72.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:72.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:72.79%;background:#cceeff;margin:0pt;padding:0pt;">Raw materials</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 1,009</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"> 1,060</td></tr><tr><td style="vertical-align:bottom;width:72.79%;margin:0pt;padding:0pt;">Work in process</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> 1,748</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"> 2,020</td></tr><tr><td style="vertical-align:bottom;width:72.79%;background:#cceeff;margin:0pt;padding:0pt;">Finished goods</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,100</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,283</td></tr><tr><td style="vertical-align:bottom;width:72.79%;margin:0pt;padding:0pt;">Total inventory, net</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,857</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,363</td></tr></table> Inventory, net consisted of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">As of</td></tr><tr><td style="vertical-align:bottom;width:72.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:72.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:72.79%;background:#cceeff;margin:0pt;padding:0pt;">Raw materials</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 1,009</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"> 1,060</td></tr><tr><td style="vertical-align:bottom;width:72.79%;margin:0pt;padding:0pt;">Work in process</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> 1,748</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"> 2,020</td></tr><tr><td style="vertical-align:bottom;width:72.79%;background:#cceeff;margin:0pt;padding:0pt;">Finished goods</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,100</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,283</td></tr><tr><td style="vertical-align:bottom;width:72.79%;margin:0pt;padding:0pt;">Total inventory, net</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,857</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,363</td></tr></table> 1009000 1060000 1748000 2020000 3100000 2283000 5857000 5363000 8. INTANGIBLE ASSETSIn August 2019, the Company received FDA approval of WAKIX® (pitolisant) for the treatment of excessive daytime sleepiness (“EDS”) in adult patients with narcolepsy. This event triggered a milestone payment of $75,000 under the provisions of the 2017 LCA (defined below) which the Company capitalized as an intangible asset. The Company determined a useful life of 10 years for such intangible asset, and, as of March 31, 2024, the remaining useful life was 5.5 years.In October 2020, the Company received FDA approval for the New Drug Application (“NDA”) for WAKIX for the treatment of cataplexy in adult patients with narcolepsy. This event triggered a milestone payment of $100,000 under the provisions of the 2017 LCA which the Company capitalized as an intangible asset and paid in January of 2021. The Company determined a useful life of 9 years for such intangible asset, and, as of March 31, 2024, the remaining useful life was 5.5 years. In February 2022, the Company attained $500,000 in life-to-date aggregate net sales of WAKIX in the United States. This event triggered a final $40,000 payment under the provisions of the 2017 LCA which the Company capitalized as an intangible asset and paid in March of 2022. The Company determined a useful life of 7.6 years for such intangible asset, and, as of March 31, 2024, the remaining useful life was 5.5 years.Amortization expense was $5,961 for each of the three months ended March 31, 2024, and 2023 and is recorded in general and administrative expenses on the unaudited condensed consolidated statements of operations and comprehensive income.The Company expects the future annual amortization expense for the unamortized intangible assets to be as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.26%;margin:0pt;padding:0pt;">Years ending December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:84.26%;background:#cceeff;margin:0pt;padding:0pt;">2024 (excluding the three months ended March 31, 2024)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"> 17,884</td></tr><tr><td style="vertical-align:bottom;width:84.26%;margin:0pt;padding:0pt;">2025</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"> 23,845</td></tr><tr><td style="vertical-align:bottom;width:84.26%;background:#cceeff;margin:0pt;padding:0pt;">2026</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"> 23,845</td></tr><tr><td style="vertical-align:bottom;width:84.26%;margin:0pt;padding:0pt;">2027</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"> 23,845</td></tr><tr><td style="vertical-align:bottom;width:84.26%;background:#cceeff;margin:0pt;padding:0pt;">2028</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"> 23,845</td></tr><tr><td style="vertical-align:bottom;width:84.26%;margin:0pt;padding:0pt;">Thereafter</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 17,883</td></tr><tr><td style="vertical-align:middle;width:84.26%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 131,147</td></tr></table>The gross carrying amount and net book value of the intangible asset is as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">As of</td></tr><tr><td style="vertical-align:bottom;width:73.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:73.38%;background:#cceeff;margin:0pt;padding:0pt;">Gross Carrying Amount</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"> 215,000</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"> 215,000</td></tr><tr><td style="vertical-align:bottom;width:73.38%;margin:0pt;padding:0pt;">Accumulated Amortization</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (83,853)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (77,892)</td></tr><tr><td style="vertical-align:bottom;width:73.38%;background:#cceeff;margin:0pt;padding:0pt;">Net Book Value</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 131,147</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 137,108</td></tr></table> 75000000 P10Y P5Y6M 100000000 P9Y P5Y6M 500000000 40000000 P7Y7M6D P5Y6M 5961000 5961000 The Company expects the future annual amortization expense for the unamortized intangible assets to be as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.26%;margin:0pt;padding:0pt;">Years ending December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:84.26%;background:#cceeff;margin:0pt;padding:0pt;">2024 (excluding the three months ended March 31, 2024)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"> 17,884</td></tr><tr><td style="vertical-align:bottom;width:84.26%;margin:0pt;padding:0pt;">2025</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"> 23,845</td></tr><tr><td style="vertical-align:bottom;width:84.26%;background:#cceeff;margin:0pt;padding:0pt;">2026</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"> 23,845</td></tr><tr><td style="vertical-align:bottom;width:84.26%;margin:0pt;padding:0pt;">2027</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"> 23,845</td></tr><tr><td style="vertical-align:bottom;width:84.26%;background:#cceeff;margin:0pt;padding:0pt;">2028</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"> 23,845</td></tr><tr><td style="vertical-align:bottom;width:84.26%;margin:0pt;padding:0pt;">Thereafter</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 17,883</td></tr><tr><td style="vertical-align:middle;width:84.26%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 131,147</td></tr></table> 17884000 23845000 23845000 23845000 23845000 17883000 131147000 The gross carrying amount and net book value of the intangible asset is as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">As of</td></tr><tr><td style="vertical-align:bottom;width:73.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:73.38%;background:#cceeff;margin:0pt;padding:0pt;">Gross Carrying Amount</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"> 215,000</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"> 215,000</td></tr><tr><td style="vertical-align:bottom;width:73.38%;margin:0pt;padding:0pt;">Accumulated Amortization</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (83,853)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (77,892)</td></tr><tr><td style="vertical-align:bottom;width:73.38%;background:#cceeff;margin:0pt;padding:0pt;">Net Book Value</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 131,147</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 137,108</td></tr></table> 215000000 215000000 83853000 77892000 131147000 137108000 9. LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTSLicense AgreementsIn July 2017, Harmony entered into a License Agreement (the “2017 LCA”) with Bioprojet Société Civile de Recherche (“Bioprojet”) whereby Harmony acquired the exclusive right to commercialize the pharmaceutical compound pitolisant for the treatment, and/or prevention, of narcolepsy, obstructive sleep apnea, idiopathic hypersomnia, and Parkinson’s disease as well as any other indications unanimously agreed by the parties in the United States and its territories. A milestone payment of $50,000 was due upon acceptance by the FDA of pitolisant’s NDA, which was achieved in February 2019 and was expensed within research and development for the year ended December 31, 2019. A milestone payment of $77,000, which included a $2,000 fee that is described below, was due upon FDA approval of WAKIX (pitolisant) for treatment of EDS in adult patients with narcolepsy, which was achieved in August 2019. The $2,000 payment and $75,000 milestone payment were paid in August and November 2019, respectively. In addition, a milestone payment of $102,000, which included a $2,000 fee was due upon the FDA approval of the NDA for WAKIX for the treatment of cataplexy in adult patients with narcolepsy. The $2,000 payment was paid in October 2020 and a $100,000 milestone payment was paid in January 2021. A final $40,000 milestone payment was paid to Bioprojet in March 2022 upon WAKIX attaining $500,000 in aggregate net sales in the United States. The 2017 LCA also requires a fixed trademark royalty and a tiered royalty based on net sales, which is payable to Bioprojet on a quarterly basis. The Company incurred $24,738 and $19,060 for the three months ended March 31, 2024, and 2023, respectively, for sales-based, trademark and tiered royalties recognized as cost of product sold. As of March 31, 2024, and December 31, 2023, the Company had accrued $24,738 and $40,419, respectively, for sales-based, trademark and tiered royalties. In July 2022, Harmony entered into a License and Commercialization Agreement (the “2022 LCA”) with Bioprojet whereby Harmony obtained exclusive rights to manufacture, use and commercialize one or more new products based on pitolisant in the United States and Latin America, with the potential to add additional indications and formulations upon agreement of both parties. Harmony paid an initial, non-refundable $30,000 licensing fee in October 2022 and additional payments of up to $155,000 are potentially due under the 2022 LCA upon the achievement of certain future development and sales-based milestones. In addition, there are other payments due upon achievement of development milestones for new indications and formulations as agreed upon by both parties. The 2022 LCA also requires a fixed trademark royalty and a tiered royalty based on net sales upon commercialization, which will be payable to Bioprojet on a quarterly basis. Agreement Related to Intellectual PropertyIn August 2021, the Company entered into an asset purchase agreement with ConSynance Therapeutics, Inc. (the “APA”) to acquire HBS-102 (formerly referred to as “CSTI-100”), a potential first-in-class molecule with a novel mechanism of action. Under the terms of the APA, the Company acquired full development and commercialization rights globally, with the exception of Greater China, for $3,500. The Company accounted for the transaction as an asset acquisition as substantially all of the fair value of the assets acquired was concentrated in a single identified asset. In March 2023, the Company achieved a preclinical milestone, which triggered a $750 payment under the provisions of the APA, which the Company recognized as an IPR&D charge recorded in research and development within the unaudited condensed consolidated statement of operations and comprehensive income for the three months ended March 31, 2023. There are additional payments due under the APA upon the achievement of certain milestones including $1,000 for preclinical milestones, $19,000 for development milestones, $44,000 for regulatory milestones and $110,000 for sales milestones. 50000000 77000000 2000000 2000000 75000000 102000000 2000000 2000000 100000000 40000000 500000000 24738000 19060000 24738000 40419000 30000000 155000000 3500000 750000000 1000000 19000000 44000000 110000000 10. ACCRUED EXPENSESAccrued expenses consist of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">As of</td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:73.04%;background:#cceeff;margin:0pt;padding:0pt;">Royalties due to Bioprojet</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"> 24,738</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"> 40,419</td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;">Rebates and other sales deductions</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"> 48,165</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"> 38,842</td></tr><tr><td style="vertical-align:bottom;width:73.04%;background:#cceeff;margin:0pt;padding:0pt;">Interest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"> 3,125</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"> 3,354</td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;">Sales and marketing</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"> 2,999</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"> 2,354</td></tr><tr><td style="vertical-align:bottom;width:73.04%;background:#cceeff;margin:0pt;padding:0pt;">Research and development</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"> 7,898</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"> 9,835</td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;">Professional fees, consulting, and other services</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"> 1,918</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"> 2,195</td></tr><tr><td style="vertical-align:bottom;width:73.04%;background:#cceeff;margin:0pt;padding:0pt;">Other expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,856</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,495</td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 91,699</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 99,494</td></tr></table> Accrued expenses consist of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">As of</td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:73.04%;background:#cceeff;margin:0pt;padding:0pt;">Royalties due to Bioprojet</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"> 24,738</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"> 40,419</td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;">Rebates and other sales deductions</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"> 48,165</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"> 38,842</td></tr><tr><td style="vertical-align:bottom;width:73.04%;background:#cceeff;margin:0pt;padding:0pt;">Interest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"> 3,125</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"> 3,354</td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;">Sales and marketing</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"> 2,999</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"> 2,354</td></tr><tr><td style="vertical-align:bottom;width:73.04%;background:#cceeff;margin:0pt;padding:0pt;">Research and development</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"> 7,898</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"> 9,835</td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;">Professional fees, consulting, and other services</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"> 1,918</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"> 2,195</td></tr><tr><td style="vertical-align:bottom;width:73.04%;background:#cceeff;margin:0pt;padding:0pt;">Other expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,856</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,495</td></tr><tr><td style="vertical-align:bottom;width:73.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 91,699</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 99,494</td></tr></table> 24738000 40419000 48165000 38842000 3125000 3354000 2999000 2354000 7898000 9835000 1918000 2195000 2856000 2495000 91699000 99494000 11. DEBTTerm Loan A Credit AgreementIn July 2023, the Company entered into a Credit Agreement (the “TLA Credit Agreement”) with JPMorgan Chase Bank, N.A., as “Administrative Agent”, and certain lenders. The TLA Credit Agreement provides for a five-year senior secured term loan (the “TLA Term Loan”) in an aggregate principal amount of $185,000. In September 2023, the Company entered into the First Incremental Amendment (the “First Incremental Amendment”) with the Administrative Agent and Bank of America, N.A., as incremental lender. The First Incremental Amendment provides for an incremental senior secured term loan (the “Incremental Term Loan”) in an aggregate principal amount of $15,000. The First Incremental Amendment amends the TLA Credit Agreement and provides that the Incremental Term Loan will have identical terms as the TLA Term Loan. The repayment schedule for both the TLA Term Loan and the Incremental Term Loan (together, the “Term Loans”) consists of quarterly $3,750 principal payments, which commence on December 31, 2023, increasing to quarterly $5,000 principal payments beginning on December 31, 2025, with a $115,000 payment due on the maturity date of July 26, 2028. The Term Loans bear interest at a per annum rate equal to, at the Company’s option, (i) a base rate plus a specified margin ranging from 2.50% to 3.00%, based on the Company’s senior secured net leverage ratio (as defined in the TLA Credit Agreement) or (ii) Term SOFR plus a credit spread adjustment of 0.10% plus a specified margin ranging from 3.50% to 4.00%, based on the Company’s senior secured net leverage ratio.The net cash received related to the Term Loans as a result of the transactions, less debt issuance costs of $2,997, was $197,003. The debt issuance costs related to the Term Loans will be amortized as additional interest expense over the loan term of the TLA Credit Agreement. The fair value of the Term Loans as of March 31, 2024, was $192,267.Long-term debt, net consists of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:73.37%;background:#cceeff;margin:0pt;padding:0pt;">Principal amount</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"> 192,500</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 196,250</td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;">Unamortized debt discount associated with debt financing costs</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,504)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,684)</td></tr><tr><td style="vertical-align:bottom;width:73.37%;background:#cceeff;margin:0pt;padding:0pt;">Total debt, net</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"> 189,996</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 193,566</td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;">Less current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (15,000)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (15,000)</td></tr><tr><td style="vertical-align:bottom;width:73.37%;background:#cceeff;margin:0pt;padding:0pt;">Long-term debt, net</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 174,996</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 178,566</td></tr></table>Future minimum payments relating to total debt, net as of March 31, 2024, for the periods indicated below consists of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.86%;margin:0pt;padding:0pt;">Years ending December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:83.86%;background:#cceeff;margin:0pt;padding:0pt;">2024 (excluding the three months ended March 31, 2024)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"> 11,250</td></tr><tr><td style="vertical-align:bottom;width:83.86%;margin:0pt;padding:0pt;">2025</td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"> 16,250</td></tr><tr><td style="vertical-align:bottom;width:83.86%;background:#cceeff;margin:0pt;padding:0pt;">2026</td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"> 20,000</td></tr><tr><td style="vertical-align:bottom;width:83.86%;margin:0pt;padding:0pt;">2027</td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"> 20,000</td></tr><tr><td style="vertical-align:bottom;width:83.86%;background:#cceeff;margin:0pt;padding:0pt;">2028</td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"> 125,000</td></tr><tr><td style="vertical-align:bottom;width:83.86%;margin:0pt;padding:0pt;">Thereafter</td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:middle;width:83.86%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 192,500</td></tr></table>Interest expense related to the Company’s long-term debt, net, is included in interest expense within the unaudited condensed consolidated statements of operations and comprehensive income and consists of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.108181%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.79%;margin:0pt;padding:0pt;">Three Months Ended </td></tr><tr><td style="vertical-align:bottom;width:75.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, </td></tr><tr><td style="vertical-align:bottom;width:75.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:75.93%;background:#cceeff;margin:0pt;padding:0pt;">Interest on principal balance</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 4,355</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"> 5,315</td></tr><tr><td style="vertical-align:bottom;width:75.93%;margin:0pt;padding:0pt;">Amortization of deferred financing costs</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 180</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 416</td></tr><tr><td style="vertical-align:bottom;width:75.93%;background:#cceeff;margin:0pt;padding:0pt;">Total term loan interest expense</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,535</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,731</td></tr></table> P5Y 185000000 15000000 3750000 5000000 115000000 0.0250 0.0300 0.0010 0.0350 0.0400 2997000 197003000 192267000 Long-term debt, net consists of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:73.37%;background:#cceeff;margin:0pt;padding:0pt;">Principal amount</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"> 192,500</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 196,250</td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;">Unamortized debt discount associated with debt financing costs</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,504)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,684)</td></tr><tr><td style="vertical-align:bottom;width:73.37%;background:#cceeff;margin:0pt;padding:0pt;">Total debt, net</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"> 189,996</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"> 193,566</td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;">Less current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (15,000)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (15,000)</td></tr><tr><td style="vertical-align:bottom;width:73.37%;background:#cceeff;margin:0pt;padding:0pt;">Long-term debt, net</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 174,996</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 178,566</td></tr></table> 192500000 196250000 2504000 2684000 189996000 193566000 15000000 15000000 174996000 178566000 Future minimum payments relating to total debt, net as of March 31, 2024, for the periods indicated below consists of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.86%;margin:0pt;padding:0pt;">Years ending December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:83.86%;background:#cceeff;margin:0pt;padding:0pt;">2024 (excluding the three months ended March 31, 2024)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"> 11,250</td></tr><tr><td style="vertical-align:bottom;width:83.86%;margin:0pt;padding:0pt;">2025</td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"> 16,250</td></tr><tr><td style="vertical-align:bottom;width:83.86%;background:#cceeff;margin:0pt;padding:0pt;">2026</td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"> 20,000</td></tr><tr><td style="vertical-align:bottom;width:83.86%;margin:0pt;padding:0pt;">2027</td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"> 20,000</td></tr><tr><td style="vertical-align:bottom;width:83.86%;background:#cceeff;margin:0pt;padding:0pt;">2028</td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"> 125,000</td></tr><tr><td style="vertical-align:bottom;width:83.86%;margin:0pt;padding:0pt;">Thereafter</td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:middle;width:83.86%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 192,500</td></tr></table> 11250000 16250000 20000000 20000000 125000000 192500000 Interest expense related to the Company’s long-term debt, net, is included in interest expense within the unaudited condensed consolidated statements of operations and comprehensive income and consists of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.108181%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.79%;margin:0pt;padding:0pt;">Three Months Ended </td></tr><tr><td style="vertical-align:bottom;width:75.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, </td></tr><tr><td style="vertical-align:bottom;width:75.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:75.93%;background:#cceeff;margin:0pt;padding:0pt;">Interest on principal balance</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 4,355</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"> 5,315</td></tr><tr><td style="vertical-align:bottom;width:75.93%;margin:0pt;padding:0pt;">Amortization of deferred financing costs</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 180</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 416</td></tr><tr><td style="vertical-align:bottom;width:75.93%;background:#cceeff;margin:0pt;padding:0pt;">Total term loan interest expense</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,535</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,731</td></tr></table> 4355000 5315000 180000 416000 4535000 5731000 12. LEASESIn June 2018, the Company entered into an operating lease for approximately fifteen thousand square feet of office space in Plymouth Meeting, PA, which expires in May 2024. The Company subsequently entered into two separate operating leases for additional office space in Plymouth Meeting, PA, which include approximately thirteen thousand square feet and seven thousand square feet of additional office space, respectively, and expire in May 2024. In March 2024, the Company amended its existing operating leases for office space in Plymouth Meeting to extend their terms through June 2025. The terms of the lease payments provide for rental payments on a monthly basis and on a graduated scale. The Company also leases a fleet of automobiles that are used by its sales representatives and are classified as operating leases.Operating lease right-of-use assets and operating lease liabilities are recognized based on the present value of the future lease payments using our incremental borrowing rate. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Our leases have remaining lease terms of less than 1 year to 3 years, some of which may include the option to extend or terminate the leases.The Company recorded operating lease costs of $509 and $378 for the three months ended March 31, 2024, and 2023, respectively.As of March 31, 2024, the weighted-average remaining lease term for operating leases was 1.8 years and the weighted-average discount rate for operating leases was 7.32%. Supplemental balance sheet information related to operating leases was as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.21%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.74%;margin:0pt;padding:0pt;">Leases </td><td style="vertical-align:bottom;white-space:nowrap;width:30.37%;margin:0pt;padding:0pt;">Classification</td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2024</td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2023</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.74%;background:#cceeff;margin:0pt;padding:0pt;">Assets</td><td style="vertical-align:bottom;white-space:nowrap;width:30.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.74%;margin:0pt;padding:0pt;">Operating lease right-of-use assets</td><td style="vertical-align:bottom;white-space:nowrap;width:30.37%;margin:0pt;padding:0pt;">Other noncurrent assets</td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"> 3,046</td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;margin:0pt;padding:0pt;"> 2,344</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.74%;background:#cceeff;margin:0pt;padding:0pt;">Liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:30.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.74%;margin:0pt;padding:0pt;">Operating lease liability, current portion</td><td style="vertical-align:bottom;white-space:nowrap;width:30.37%;margin:0pt;padding:0pt;">Other current liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"> 1,793</td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;margin:0pt;padding:0pt;"> 1,437</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.74%;background:#cceeff;margin:0pt;padding:0pt;">Operating lease liability, long-term</td><td style="vertical-align:bottom;white-space:nowrap;width:30.37%;background:#cceeff;margin:0pt;padding:0pt;">Other long-term liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,276</td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,082</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.74%;margin:0pt;padding:0pt;"> Total operating lease liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:30.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,069</td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,519</td></tr></table>Supplemental cash flow information related to operating leases was as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2023</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.56%;background:#cceeff;margin:0pt;padding:0pt;">Operating cash flows from operating leases</td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.31%;background:#cceeff;margin:0pt;padding:0pt;"> 561</td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;background:#cceeff;margin:0pt;padding:0pt;"> 428</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.56%;margin:0pt;padding:0pt;">Right of use assets obtained in exchange for operating lease obligations</td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.31%;margin:0pt;padding:0pt;"> 1,198</td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"> 526</td></tr></table>Future payments under noncancelable operating leases with initial terms of one year or more as of March 31, 2024, consisted of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.09%;margin:0pt;padding:0pt;">Years ending December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;">2024 (excluding the three months ended March 31, 2024)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"> 1,564</td></tr><tr><td style="vertical-align:bottom;width:84.09%;margin:0pt;padding:0pt;">2025</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"> 1,239</td></tr><tr><td style="vertical-align:bottom;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;">2026</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"> 473</td></tr><tr><td style="vertical-align:bottom;width:84.09%;margin:0pt;padding:0pt;">2027</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"> 3</td></tr><tr><td style="vertical-align:bottom;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;">2028</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;">-</td></tr><tr><td style="vertical-align:bottom;width:84.09%;margin:0pt;padding:0pt;">Thereafter</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">-</td></tr><tr><td style="vertical-align:bottom;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;">Total lease payments</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"> 3,279</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.09%;margin:0pt;padding:0pt;">Less: imputed interest</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (210)</td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;">Total lease liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,069</td></tr></table> 15000 13000 7000 P1Y P3Y true true 509000 378000 P1Y9M18D 0.0732 Supplemental balance sheet information related to operating leases was as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.21%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.74%;margin:0pt;padding:0pt;">Leases </td><td style="vertical-align:bottom;white-space:nowrap;width:30.37%;margin:0pt;padding:0pt;">Classification</td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2024</td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2023</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.74%;background:#cceeff;margin:0pt;padding:0pt;">Assets</td><td style="vertical-align:bottom;white-space:nowrap;width:30.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.74%;margin:0pt;padding:0pt;">Operating lease right-of-use assets</td><td style="vertical-align:bottom;white-space:nowrap;width:30.37%;margin:0pt;padding:0pt;">Other noncurrent assets</td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"> 3,046</td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;margin:0pt;padding:0pt;"> 2,344</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.74%;background:#cceeff;margin:0pt;padding:0pt;">Liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:30.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.74%;margin:0pt;padding:0pt;">Operating lease liability, current portion</td><td style="vertical-align:bottom;white-space:nowrap;width:30.37%;margin:0pt;padding:0pt;">Other current liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"> 1,793</td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;margin:0pt;padding:0pt;"> 1,437</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.74%;background:#cceeff;margin:0pt;padding:0pt;">Operating lease liability, long-term</td><td style="vertical-align:bottom;white-space:nowrap;width:30.37%;background:#cceeff;margin:0pt;padding:0pt;">Other long-term liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,276</td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,082</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.74%;margin:0pt;padding:0pt;"> Total operating lease liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:30.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,069</td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,519</td></tr></table>Supplemental cash flow information related to operating leases was as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2023</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.56%;background:#cceeff;margin:0pt;padding:0pt;">Operating cash flows from operating leases</td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.31%;background:#cceeff;margin:0pt;padding:0pt;"> 561</td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;background:#cceeff;margin:0pt;padding:0pt;"> 428</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.56%;margin:0pt;padding:0pt;">Right of use assets obtained in exchange for operating lease obligations</td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.31%;margin:0pt;padding:0pt;"> 1,198</td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"> 526</td></tr></table> 3046000 2344000 1793000 1437000 1276000 1082000 3069000 2519000 561000 428000 1198000 526000 Future payments under noncancelable operating leases with initial terms of one year or more as of March 31, 2024, consisted of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.09%;margin:0pt;padding:0pt;">Years ending December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;">2024 (excluding the three months ended March 31, 2024)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"> 1,564</td></tr><tr><td style="vertical-align:bottom;width:84.09%;margin:0pt;padding:0pt;">2025</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"> 1,239</td></tr><tr><td style="vertical-align:bottom;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;">2026</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"> 473</td></tr><tr><td style="vertical-align:bottom;width:84.09%;margin:0pt;padding:0pt;">2027</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"> 3</td></tr><tr><td style="vertical-align:bottom;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;">2028</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;">-</td></tr><tr><td style="vertical-align:bottom;width:84.09%;margin:0pt;padding:0pt;">Thereafter</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">-</td></tr><tr><td style="vertical-align:bottom;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;">Total lease payments</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"> 3,279</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.09%;margin:0pt;padding:0pt;">Less: imputed interest</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (210)</td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;">Total lease liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,069</td></tr></table> 1564000 1239000 473000 3000 3279000 210000 3069000 13. COMMITMENTS AND CONTINGENCIESLitigationFrom time to time, the Company is subject to claims and suits arising in the ordinary course of business. The Company accrues such liabilities when they are known, if they are deemed probable and can be reasonably estimated. As of March 31, 2024, there were no material claims or suits outstanding. 14. STOCKHOLDERS’ EQUITYCommon StockThe holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of the Company’s stockholders. The holders of common stock do not have any cumulative voting rights. Holders of common stock are entitled to receive any dividends declared by the Company’s board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. The Company’s common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions.Share Repurchase Program In October 2023, the Company’s Board of Directors approved a share repurchase program (the “October 2023 Repurchase Program”) providing for the repurchase of shares of common stock in an aggregate amount of up to $200,000, excluding commissions and transaction fees. The October 2023 Repurchase Program may be suspended, terminated, or modified at any time for any reason. During the three months ended March 31, 2024, and 2023, no shares of common stock were repurchased and cancelled by the Company. As of March 31, 2024 the remaining amount of common stock authorized for repurchases was $150,000. 1 200000000 0 0 150000000 15. STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION2020 Stock Incentive PlanIn August 2020, the Company adopted, and its stockholders approved, the 2020 Incentive Award Plan (the “2020 Plan”), in order to facilitate the grant of cash and equity incentives to directors, employees (including the Company’s named executive officers) and consultants of the Company and its subsidiaries. The 2020 Plan provides for the grant of stock options, including incentive stock options (“ISOs”) and non-qualified stock options (“NSOs”), SARs, restricted stock, dividend equivalents, restricted stock units (“RSUs”) and other stock or cash-based awards.Stock options and stock appreciation rights under the 2020 Plan have a 10-year contractual term and vest over the vesting period specified in the applicable award agreement, at achievement of a performance requirement, or upon change of control (as defined in the applicable plan). RSUs vest over the vesting period specified in the applicable award agreement, at achievement of a performance requirement, or upon change of control (as defined in the applicable plan). As of March 31, 2024, there were 7,890,232 shares of common stock available for issuance under the 2020 Plan. The number of shares that may be issued under the 2020 Plan automatically increases on January 1 of each year in an amount equal to the lesser of (i) 4.0% of the shares of the Company’s common stock outstanding on December 31 of the preceding year or (ii) an amount determined by the Company’s board of directors.2017 Stock Incentive PlanIn August 2017, the Company adopted an equity incentive plan (the “2017 Plan”). Under the 2017 Plan, directors, officers, employees, consultants, and advisors of the Company can be paid incentive compensation measured by the value of the Company’s shares of common stock through grants of stock options, stock appreciation rights (“SARs”), or restricted stock. Following the adoption of the 2020 Plan, no further grants have been, or will be, made under the 2017 Plan. However, the 2017 Plan will continue to govern the terms and conditions of outstanding awards granted under it.Stock OptionsThe following table summarizes stock option activity for the three months ended March 31, 2024:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;">Weighted-</td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;">Weighted-</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;">Average</td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;">Remaining</td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;">Number of</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;">Contractual</td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Awards</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Term</td></tr><tr><td style="vertical-align:bottom;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;">Awards outstanding—December 31, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"> 6,316,422</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> 32.47</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"> 7.17</td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;">Awards issued</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"> 1,071,750</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"> 30.69</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;">Awards exercised</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"> (14,120)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> 8.22</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;">Awards forfeited</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (11,529)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"> 39.31</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;">Awards outstanding—March 31, 2024</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,362,523</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> 32.25</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"> 7.35</td></tr></table>Stock Appreciation RightsThe following table summarizes SARs activity for the three months ended March 31, 2024:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;">Weighted-</td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;">Weighted-</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;">Average</td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;">Remaining</td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;">Number of</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;">Contractual</td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Awards</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Term</td></tr><tr><td style="vertical-align:bottom;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;">Awards outstanding—December 31, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"> 43,208</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> 9.38</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"> 5.32</td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;">Awards issued</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;">Awards exercised</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;">Awards forfeited</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;">Awards outstanding—March 31, 2024</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 43,208</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> 9.38</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"> 5.08</td></tr></table>Restricted Stock UnitsThe following table summarizes RSU activity for the three months ended March 31, 2024:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;">Weighted-</td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;">Average</td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;">Number of</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;">Grant Date</td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Awards</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Fair Value</td></tr><tr><td style="vertical-align:bottom;width:74.12%;background:#cceeff;margin:0pt;padding:0pt;">Awards outstanding—December 31, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"> 330,000</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> 31.53</td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;">Awards issued</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"> 387,500</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 30.69</td></tr><tr><td style="vertical-align:bottom;width:74.12%;background:#cceeff;margin:0pt;padding:0pt;">Awards vested</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"> (15,000)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> 29.03</td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;">Awards forfeited</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (350)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 30.69</td></tr><tr><td style="vertical-align:bottom;width:74.12%;background:#cceeff;margin:0pt;padding:0pt;">Awards outstanding—March 31, 2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 702,150</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> 31.08</td></tr></table>As of March 31, 2024, and December 31, 2023, stock awards issued under the 2017 and 2020 Plans of 3,596,040 and 3,298,284 shares of common stock, respectively, were vested. Value of Stock Options and SARsThe Company values options and SARs using the Black-Scholes option-pricing model. The Company lacks sufficient historical company-specific volatility information. Therefore, the Company estimates expected stock volatility based on historical volatility of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For options with service-based vesting conditions, the expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. For SARs, the expected term is based upon the weighting of certain future events. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for the time periods approximately equal to the expected term of the award. An expected dividend yield of 0% is based on the fact that the Company has never paid cash dividends and does not expect to do so in the foreseeable future.The assumptions used to value the awards are summarized in the following table.<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:30.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">As of</td></tr><tr><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:67.57%;background:#cceeff;margin:0pt;padding:0pt;">Dividend yield</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;"> 0.00</td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;"> 0.00</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;">Expected volatility</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;">72.60 - 72.60</td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;">74.87 - 80.78</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:67.57%;background:#cceeff;margin:0pt;padding:0pt;">Risk-free interest rate</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;">4.06 - 4.20</td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;">3.42 - 4.62</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;">Lack of marketability discount</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"> 0.00</td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"> 0.00</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:67.57%;background:#cceeff;margin:0pt;padding:0pt;">Expected term (years)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;">2.01 - 6.11</td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;">2.26 - 10.77</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr></table>Value of RSUsThe fair value of RSUs is equal to the value of the Company’s common stock on the grant date.The weighted average per share fair value of awards issued under the 2017 Plan and 2020 Plan was $21.13 and $20.64 on March 31, 2024, and December 31, 2023, respectively.Stock-Based Compensation ExpenseStock-based compensation expense for the three months ended March 31, 2024, and 2023, was recorded in the unaudited condensed consolidated statements of operations and comprehensive income in the following line items:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended March 31, </td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;">Research and development expense</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"> 1,371</td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"> 976</td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;">Sales and marketing expense</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"> 1,994</td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> 1,073</td></tr><tr><td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;">General and administrative expense</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,069</td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,512</td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,434</td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,561</td></tr></table>Stock-based compensation expense related to options and RSUs issued under the 2017 Plan and 2020 Plan is included in stockholder’s equity, and a liability for SARs is included in other non-current liabilities, in the Company’s unaudited condensed consolidated balance sheet. As of March 31, 2024, the total unrecognized stock-based compensation expense was $73,718 and $19,399 for stock options and RSUs, respectively. This amount will be recognized in the Company’s consolidated statement of operations over a weighted average period of 2.7 years. Employee Stock Purchase PlanThe 2020 Employee Stock Purchase Plan (“ESPP”) was adopted by the Company’s Board of Directors on April 30, 2021. The ESPP permits eligible employees to purchase shares of the Company’s common stock at a 15% discount from the lesser of the fair market value per share of the Company’s common stock on the first day of the offering period or the fair market value of the Company’s common stock on the purchase date. Funds are collected from employees through after-tax payroll deductions. The total number of shares reserved for issuance under the ESPP was initially 629,805, which automatically increases on January 1 of each year in an amount equal to the lesser of (i) 1.0% of the shares of the Company’s common stock outstanding on December 31 of the preceding year or (ii) an amount determined by the Company’s board of directors. It is intended that the ESPP meet the requirements for an “employee stock purchase plan” under Section 423 of the Internal Revenue Code. There were no shares issued under the ESPP for the three months ended March 31, 2024, and 2023, respectively. The discount on the ESPP was $80 and $105 for the three months ended March 31, 2024, and 2023, respectively, and is recorded within stock-based compensation expense. 7890232 0.040 The following table summarizes stock option activity for the three months ended March 31, 2024:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;">Weighted-</td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;">Weighted-</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;">Average</td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;">Remaining</td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;">Number of</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;">Contractual</td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Awards</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Term</td></tr><tr><td style="vertical-align:bottom;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;">Awards outstanding—December 31, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"> 6,316,422</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> 32.47</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"> 7.17</td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;">Awards issued</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"> 1,071,750</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"> 30.69</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;">Awards exercised</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"> (14,120)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> 8.22</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;">Awards forfeited</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (11,529)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"> 39.31</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;">Awards outstanding—March 31, 2024</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,362,523</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> 32.25</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"> 7.35</td></tr></table> 6316422 32.47 P7Y2M1D 1071750 30.69 14120 8.22 11529 39.31 7362523 32.25 P7Y4M6D The following table summarizes SARs activity for the three months ended March 31, 2024:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;">Weighted-</td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;">Weighted-</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;">Average</td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;">Remaining</td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;">Number of</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;">Contractual</td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Awards</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Term</td></tr><tr><td style="vertical-align:bottom;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;">Awards outstanding—December 31, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"> 43,208</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> 9.38</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"> 5.32</td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;">Awards issued</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;">Awards exercised</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;">Awards forfeited</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;">Awards outstanding—March 31, 2024</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 43,208</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"> 9.38</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"> 5.08</td></tr></table> 43208 9.38 P5Y3M25D 43208 9.38 P5Y29D The following table summarizes RSU activity for the three months ended March 31, 2024:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;">Weighted-</td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;">Average</td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;">Number of</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;">Grant Date</td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Awards</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Fair Value</td></tr><tr><td style="vertical-align:bottom;width:74.12%;background:#cceeff;margin:0pt;padding:0pt;">Awards outstanding—December 31, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"> 330,000</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> 31.53</td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;">Awards issued</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"> 387,500</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 30.69</td></tr><tr><td style="vertical-align:bottom;width:74.12%;background:#cceeff;margin:0pt;padding:0pt;">Awards vested</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"> (15,000)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> 29.03</td></tr><tr><td style="vertical-align:bottom;width:74.12%;margin:0pt;padding:0pt;">Awards forfeited</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (350)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 30.69</td></tr><tr><td style="vertical-align:bottom;width:74.12%;background:#cceeff;margin:0pt;padding:0pt;">Awards outstanding—March 31, 2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 702,150</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> 31.08</td></tr></table> 330000 31.53 387500 30.69 15000 29.03 350 30.69 702150 31.08 3596040 3298284 0 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:30.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">As of</td></tr><tr><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:67.57%;background:#cceeff;margin:0pt;padding:0pt;">Dividend yield</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;"> 0.00</td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;"> 0.00</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;">Expected volatility</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;">72.60 - 72.60</td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;">74.87 - 80.78</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:67.57%;background:#cceeff;margin:0pt;padding:0pt;">Risk-free interest rate</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;">4.06 - 4.20</td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;">3.42 - 4.62</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:67.57%;margin:0pt;padding:0pt;">Lack of marketability discount</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"> 0.00</td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"> 0.00</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:67.57%;background:#cceeff;margin:0pt;padding:0pt;">Expected term (years)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;">2.01 - 6.11</td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.88%;background:#cceeff;margin:0pt;padding:0pt;">2.26 - 10.77</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr></table> 0.0000 0.0000 0.7260 0.7260 0.7487 0.8078 0.0406 0.0420 0.0342 0.0462 0.0000 0.0000 P2Y3D P6Y1M9D P2Y3M3D P10Y9M7D 21.13 20.64 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended March 31, </td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;">Research and development expense</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"> 1,371</td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"> 976</td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;">Sales and marketing expense</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"> 1,994</td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> 1,073</td></tr><tr><td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;">General and administrative expense</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,069</td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,512</td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,434</td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,561</td></tr></table> 1371000 976000 1994000 1073000 7069000 4512000 10434000 6561000 73718000 19399000 P2Y8M12D 0.15 629805 0.010 0 0 80000 105000 16. EARNINGS PER SHAREBasic earnings per share is calculated by dividing net income by the weighted average number of shares of common stock outstanding. Diluted net income per share of common is computed under the treasury stock method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income, the potential dilutive effects of stock options, stock appreciation rights and restricted stock units.The following table sets forth the computation of basic and diluted net income per share:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended March 31, </td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:68.39%;background:#cceeff;margin:0pt;padding:0pt;">Numerator</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;">Net income </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 38,334</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"> 29,485</td></tr><tr><td style="vertical-align:bottom;width:68.39%;background:#cceeff;margin:0pt;padding:0pt;">Denominator</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;">Net income per share of common stock - basic</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 0.68</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"> 0.49</td></tr><tr><td style="vertical-align:bottom;width:68.39%;background:#cceeff;margin:0pt;padding:0pt;">Net income per share of common stock- diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"> 0.67</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#cceeff;margin:0pt;padding:0pt;"> 0.48</td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;">Weighted average number of shares of common stock - basic</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 56,771,251</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"> 59,732,157</td></tr><tr><td style="vertical-align:bottom;width:68.39%;background:#cceeff;margin:0pt;padding:0pt;">Weighted average number of shares of common stock - diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"> 57,597,627</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#cceeff;margin:0pt;padding:0pt;"> 61,221,511</td></tr></table>Securities outstanding that were included in the computation above, utilizing the treasury stock method are as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended March 31, </td></tr><tr><td style="vertical-align:bottom;width:68.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:68.38%;background:#cceeff;margin:0pt;padding:0pt;">Stock options, SARs, and RSUs to purchase common stock</td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"> 826,376</td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"> 1,489,354</td></tr></table>Potential shares of common stock issuable that were excluded from the computation of diluted weighted-average shares outstanding excluded from the numerator, are as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended March 31, </td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:68.39%;background:#cceeff;margin:0pt;padding:0pt;">Stock options, SARs, and RSUs to purchase common stock</td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"> 7,281,505</td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#cceeff;margin:0pt;padding:0pt;"> 4,661,499</td></tr></table> The following table sets forth the computation of basic and diluted net income per share:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended March 31, </td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:68.39%;background:#cceeff;margin:0pt;padding:0pt;">Numerator</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;">Net income </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 38,334</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"> 29,485</td></tr><tr><td style="vertical-align:bottom;width:68.39%;background:#cceeff;margin:0pt;padding:0pt;">Denominator</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;">Net income per share of common stock - basic</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 0.68</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"> 0.49</td></tr><tr><td style="vertical-align:bottom;width:68.39%;background:#cceeff;margin:0pt;padding:0pt;">Net income per share of common stock- diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"> 0.67</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#cceeff;margin:0pt;padding:0pt;"> 0.48</td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;">Weighted average number of shares of common stock - basic</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 56,771,251</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"> 59,732,157</td></tr><tr><td style="vertical-align:bottom;width:68.39%;background:#cceeff;margin:0pt;padding:0pt;">Weighted average number of shares of common stock - diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"> 57,597,627</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#cceeff;margin:0pt;padding:0pt;"> 61,221,511</td></tr></table>Securities outstanding that were included in the computation above, utilizing the treasury stock method are as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended March 31, </td></tr><tr><td style="vertical-align:bottom;width:68.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:68.38%;background:#cceeff;margin:0pt;padding:0pt;">Stock options, SARs, and RSUs to purchase common stock</td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"> 826,376</td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"> 1,489,354</td></tr></table> 38334000 29485000 0.68 0.49 0.67 0.48 56771251 59732157 57597627 61221511 826376 1489354 Potential shares of common stock issuable that were excluded from the computation of diluted weighted-average shares outstanding excluded from the numerator, are as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended March 31, </td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:68.39%;background:#cceeff;margin:0pt;padding:0pt;">Stock options, SARs, and RSUs to purchase common stock</td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"> 7,281,505</td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;background:#cceeff;margin:0pt;padding:0pt;"> 4,661,499</td></tr></table> 7281505 4661499 17. INCOME TAXESA reconciliation between the statutory federal income tax rate and the Company’s effective income tax rate for the three months ended March 31, 2024, and 2023 is as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended March 31, </td></tr><tr><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;">Federal income tax rate</td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"> 21.0</td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"> 21.0</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;">Stock-based compensation</td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> (2.8)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;">State taxes</td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"> 5.1</td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"> 6.3</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;">Credits</td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"> (1.0)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> (2.9)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"> 0.4</td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"> 0.4</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;">Valuation allowance</td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 0.5</td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 26.0</td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 22.0</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;">%</td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended March 31, </td></tr><tr><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;">Federal income tax rate</td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"> 21.0</td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"> 21.0</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;">Stock-based compensation</td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> (2.8)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;">State taxes</td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"> 5.1</td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"> 6.3</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;">Credits</td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"> (1.0)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> (2.9)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"> 0.4</td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"> 0.4</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;">Valuation allowance</td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 0.5</td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 26.0</td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 22.0</td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;">%</td></tr></table> 0.210 0.210 -0.028 0.051 0.063 -0.010 -0.029 0.004 0.004 0.005 0.260 0.220 18. RELATED-PARTY TRANSACTIONSThe Company was party to a management agreement for professional services provided by a related party, Paragon Biosciences, LLC (“Paragon”). Paragon is an entity that shares common ownership with the Company. In addition, the Chairman of the Company’s board of directors is the Founder, Chairman and CEO of Paragon. The Company is also party to a right of use agreement with Paragon whereby it has access to and the right to use certain office space leased by Paragon in Chicago, IL. The Company incurred $73 and $71 for the three months ended March 31, 2024, and 2023, respectively, in expenses to Paragon, which are included in general and administrative expense in the unaudited condensed consolidated statements of operations and comprehensive loss. As of March 31, 2024, and December 31, 2023, there were no amounts due to or due from related parties included in the unaudited condensed consolidated balance sheets. 73000 71000 0 0 19. SUBSEQUENT EVENTSOn April 11, 2024, the Company announced that it entered into a sublicense agreement with Bioprojet for an orexin-2 receptor agonist (OX2R) (the “Licensed Compound”) to be evaluated for the treatment of narcolepsy and other potential indications (the “Sublicense”). Under the Sublicense, the Company obtained the exclusive right to develop, manufacture and commercialize the Licensed Compound in the United States and Latin American territories (the “Licensed Territories”), which are rights that Bioprojet originally licensed from Teijin Pharma, the innovator of the Licensed Compound. The Licensed Compound is currently in pre-clinical development with an Investigational New Drug application currently anticipated in the second half 2025. Under the Sublicense, the Company paid Bioprojet an upfront license fee of $25,500 and will also be obligated to pay up to $127,500 upon achievement of development and regulatory milestones and up to $240,000 upon achievement of sales-based milestones, as well as royalty rates in the mid-teens on any sales of product using the Licensed Compound in the Licensed Territories. On April 30, 2024, the Company announced that its subsidiary, Zynerba, acquired all of the issued and outstanding capital stock of Epygenix Therapeutics, Inc., a Wyoming corporation (“Epygenix”), pursuant to the terms of a stock purchase agreement. In connection with the closing of the transaction, Zynerba paid the former stockholders of Epygenix up front consideration of $35,000 (which amount is subject to adjustment following the closing). In addition, Zynerba will also be obligated to pay up to $130,000 upon the achievement of development and regulatory milestones and up to $515,000 upon the achievement of certain sales-based milestones, in each case to Epygenix’s former stockholders. Epygenix has an exclusive license relating to the use of clemizole for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome. 25500000 127500000 240000000 35000000 130000000 515000000 On February 23, 2024, Jeffrey Dierks, Chief Commercial Officer of the Company, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 35,708 shares of the Company’s common stock related to the exercise of options beginning on July 1, 2024 and until December 31, 2024.During the three months ended March 31, 2024, no director or officer of the Company terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K. 2024-02-23 Jeffrey Dierks Chief Commercial Officer true 35708 false false false

Three Months Ended March 31,

Stock options, SARs, and RSUs to purchase common stock